Runda Medical's 2025 financial statements and audit report issued by Zhonghua Accounting Firm (Special General Partnership)

Zhonghua Accounting Firm (Special General Partnership) Chinese Certified Public Accountant (Project Partner)

Chinese Certified Public Accountant China, Shanghai April 27, 2026 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

1. Basic situation of the company

1. Company registered address, organizational form, headquarters address and registered capital

(1) Registered address: Room 201, Building 1, No. 1018 Weichang Road, Jinshan District, Shanghai

(2) Organizational form: joint stock limited company (listed)

(3) Office address: 8th Floor, Tower 1, Star Center, No. 89 Zhapu Road, Hongkou District, Shanghai

(4) Registered capital: 579,534,079 yuan (Currently, the company’s convertible bonds are still being converted into shares, and the industrial and commercial registered capital will be changed after the share conversion is completed)

2. Company establishment status

Shanghai Runda Medical Technology Co., Ltd. (formerly known as "Shanghai Runda Economic and Trade Co., Ltd.", hereinafter referred to as the "Company" or "the Company" or "Runda Medical") was registered and established on January 6, 1999 in Zhujing Town, Jinshan District, Shanghai.

After the establishment of the company, after several equity transfers and capital increases, as of the end of July 2010, the company's registered capital was RMB 12,182,806. In November 2010, the company held the "Foundation Meeting and First Shareholders' Meeting of Shanghai Runda Medical Technology Co., Ltd.". With July 31, 2010 as the base date, the company was changed to a joint-stock company as a whole. After the change, the company's registered capital was RMB 66 million, and the industrial and commercial change procedures were completed on December 17, 2010.

After the company was changed into a joint-stock company, after several equity transfers and capital increases, as of the end of April 2015, the company's registered capital was RMB 70,526,316. In May 2015, approved by the China Securities Regulatory Commission's "Zhengjian Xu [2015] 842" "Reply on the Approval of the Initial Public Offering of Shanghai Runda Medical Technology Co., Ltd.", the company was listed on the Shanghai Stock Exchange and publicly issued 23.6 million RMB ordinary shares (A shares) to the public, increasing the registered capital by RMB 23.60 million. After the change, the company's registered capital was RMB 94,126,316.

According to the resolution of the company's 2015 Annual General Meeting of Shareholders, the company applied for an additional registered capital of RMB 188,252,632. According to the ratio of 20 shares for every 10 shares, the total amount of shares transferred to all shareholders was RMB 188,252,632 from capital reserves. After the increase, the company's registered capital was RMB 282,378,948. The company completed the industrial and commercial change registration procedures on July 5, 2016.

According to the "Reply on the Approval of the Non-public Issuance of Stocks by Shanghai Runda Medical Technology Co., Ltd." (CSRC License [2016] No. 1783) issued by the China Securities Regulatory Commission, the company's non-public issuance of no more than 39,862,874 new shares was approved; according to the resolutions of the company's board of directors and shareholders' meeting, the company applied for an additional registered capital of RMB 39,862,874. The company used a non-public offering to natural persons Liu Hui, natural person Zhu Wenyi, Dongying Dongchuang Investment Partnership (Limited Partnership), Jiujiang Haocheng Investment Management Center (Limited Partnership) and Guojin Rundahui Employee Stock Ownership No. 1 Directed Asset Management Plan to five specific The target issued 39,862,874 new RMB ordinary shares (A shares), with a face value of RMB 1 per share (increased share capital of RMB 39,862,874), and the issuance price per share was RMB 28.80; as of November 10, 2016 As of today, the number of shares subscribed for the No. 1 Directed Asset Management Plan for Employee Shareholdings of China National Finance Corporation Limited has been adjusted from the original 2,330,445 shares to 2,052,000 shares; therefore, after the company implemented the above-mentioned non-public issuance of A shares, it applied to increase its registered capital by RMB 3,9 584,429 yuan, and applied to increase the share capital by RMB 39,584,429 yuan. The registered capital after the change was RMB 321,963,377 yuan. The company completed the industrial and commercial change registration procedures on December 22, 2016.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

According to the resolution of the company's 2016 Annual General Meeting of Shareholders, the company applied for an additional registered capital of RMB 257,570,702. According to the ratio of 8 shares for every 10 shares, the total amount of shares transferred to all shareholders was RMB 257,570,702 using capital reserves. After the increase, the company's registered capital was RMB 579,534,079. The company completed the industrial and commercial change registration procedures on August 14, 2017.

On August 31, 2019, seven shareholders including Zhu Wenyi, Feng Rong, Wei Ming, Chen Zheng, Hu Zhenning, Shanghai Daenhui Investment Co., Ltd. and Li Qing signed an agreement with Hangzhou Xiacheng District State-owned Investment Holding Group Co., Ltd. (hereinafter referred to as "Xiacheng District State-owned Investment Holding Group Co., Ltd.") and Liu Hui to Capital Holding Group Co., Ltd. and Liu Hui’s Share Transfer Agreement on Shanghai Runda Medical Technology Co., Ltd. and its attachments. The relevant shareholders transferred a total of 116,000,000 shares (accounting for 20.02% of the company’s total share capital) to Xiacheng State Investment Corporation at a price of 12.95 yuan per share. At the same time, the agreement stipulates that Feng Rong and Wei Ming will authorize the voting rights of the remaining shares held by Xiacheng State Investment after the completion of this transaction to Xiacheng State Investment. Xiacheng State Investment holds a total of 27.00% of the voting rights of the company's shareholders' meeting.

The transfer registration procedures for the 116,000,000 shares transferred under this agreement were completed on October 30, 2019, and Xiacheng State Investment became the company’s controlling shareholder. The actual controller of the company was changed from Liu Hui and Zhu Wenyi to the People's Government of Xiacheng District, Hangzhou City. On May 9, 2021, the new Hangzhou Gongshu District People's Government was inaugurated, and the actual controller of the company was changed from the original Hangzhou Xiacheng District People's Government to the Hangzhou Gongshu District People's Government.

Approved by the China Securities Regulatory Commission's Securities Regulatory Commission (2020) No. 586, the company publicly issued 5.5 million convertible corporate bonds on June 17, 2020, with a face value of 100 yuan each. The total amount is 550.00 million yuan. As of December 31, 2025, a total of 315.843 million yuan of convertible bonds have been converted into debt for shares, and the cumulative number of shares converted is 24,144,672 shares.

As of December 31, 2025, the company has issued a total of 603,678,751 shares. The company is registered at: Room 201, Building 1, No. 1018 Weichang Road, Jinshan District, Shanghai. The headquarters address is: 8th Floor, Tower 1, Xinghui Center, No. 89 Zhapu Road, Hongkou District, Shanghai. The actual controller of the company is the People's Government of Gongshu District, Hangzhou City.

3. Company business scope

The main business activities actually engaged in by the company and its subsidiaries are technical services, technology development, technical consulting, technology exchange, technology transfer, and technology promotion; maintenance of electronic and mechanical equipment (excluding special equipment); sales of first-class medical devices; sales of second-class medical devices; leasing services (excluding licensed leasing services); sales of chemical products (excluding licensed chemical products); wholesale of computer software, hardware and auxiliary equipment; sales of instruments and meters; sales of office supplies; with self-owned funds Engaged in investment activities; import and export of goods; technology import and export; software development; information system integration services; information technology consulting services; software sales; general cargo warehousing services (excluding hazardous chemicals and other items requiring license approval); third-category medical device operations; road cargo transportation (excluding dangerous goods); pharmaceutical wholesale (items that require approval according to law can only be carried out with the approval of relevant departments. Specific business items are subject to approval documents or licenses from relevant departments).

4. The company’s business period

1999-01-06 to no fixed period

5. Approval date of this financial report

This financial statement has been approved for issuance by the company's board of directors on April 27, 2026.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Basis for preparation of financial statements

1. Basics of preparation

The Company's financial statements are based on the going concern assumption, based on actual transactions and events, in accordance with the "Accounting Standards for Business Enterprises - Basic Standards" issued by the Ministry of Finance (issued by Ministry of Finance Order No. 33 and revised by Ministry of Finance Order No. 76) and 42 specific provisions promulgated and revised on or after February 15, 2006. The disclosure provisions of the China Securities Regulatory Commission's "Information Disclosure and Preparation Rules No. 15 for Companies that Offer Securities to the Public - General Provisions on Financial Reports" are prepared in accordance with the Corporate Accounting Standards, the Guide to the Application of Accounting Standards for Business Enterprises, Interpretations of Accounting Standards for Business Enterprises and other relevant provisions (hereinafter collectively referred to as the "Accounting Standards for Business Enterprises").

2. Going concern

In the process of preparing financial statements, the Company has comprehensively assessed the Company's ability to continue operating in the next 12 months from the balance sheet date. After making an assessment using all available information, including the recent history of profitable operations and information supported by financial resources such as bank financing, the Company reasonably expects that the Company will have sufficient resources to maintain ongoing operations within the next 12 months from the balance sheet date. Therefore, the Company prepares these financial statements on a going concern basis.

3. Important accounting policies and accounting estimates

1. Statement on compliance with Accounting Standards for Business Enterprises

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status as of December 31, 2025, as well as its operating results, cash flow and other relevant information in 2025. In addition, the company's financial statements comply in all material respects with the disclosure requirements for financial statements and their notes in the "Information Disclosure and Preparation Rules for Companies that Offer Securities to the Public No. 15 - General Provisions on Financial Reports" issued by the China Securities Regulatory Commission.

2. Accounting period

The company's accounting period is divided into annual and interim periods. Accounting interim period refers to the reporting period shorter than a complete accounting year. The company's fiscal year adopts the Gregorian calendar year, that is, from January 1 to December 31 each year. The accounting period for the financial information contained in this financial statement is from January 1, 2025 to December 31, 2025.

3. Business cycle

The normal operating cycle refers to the period from the time when the company purchases assets for processing to the realization of cash. The company uses 12 months as an operating cycle and uses it as the liquidity classification standard for assets and liabilities.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

4. Accounting standard currency

RMB is the currency of the main economic environment in which the Company and its domestic subsidiaries operate. The Company and its domestic subsidiaries use RMB as the functional currency for accounting. The Company's overseas subsidiaries determine the Canadian dollar as their recording currency based on the currency of the main economic environment in which they operate. The currency used by the Company in preparing these financial statements is RMB.

5. Criteria for judging importance

Project Materiality Criteria

Important individual accounts receivable with provision for bad debts Individual balance ≥ 0.10% of total assets

Important goodwill: individual balance ≥ 1.00% of total assets

Non-wholly-owned subsidiaries whose net assets account for ≥10.00% of the company's net assets or whose operating income accounts for a significant amount of the company's total assets

The company’s operating income ≥10.00%

The book value of a long-term equity investment in a single invested unit accounts for ≥10.00% of the company's net assets, or the investment profits and losses under the equity method account for ≥10.00% of the company's net assets.

The company’s consolidated net profit is ≥10.00%

6. Accounting treatment methods for business combinations under the same control and those not under the same control

(1) Business merger under common control

If the enterprises participating in the merger are ultimately controlled by the same party or the same parties before and after the merger and the control is not temporary, it is deemed to be a business merger under the same control.

If the merging party issues equity securities as the merger consideration, the share of the book value of the merged party's owner's equity in the ultimate controlling party's consolidated financial statements on the merger date shall be used as the initial investment cost of the long-term equity investment. The total face value of the shares issued is taken as share capital. The difference between the initial investment cost of the long-term equity investment and the total face value of the shares issued is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

The merging party's intermediary fees such as auditing, legal services, evaluation and consulting, and other related management fees incurred by the company merger shall be included in the current profit and loss when incurred.

(2) Business merger not under common control

If the parties involved in the merger are not ultimately controlled by the same party or the same parties before and after the merger, it is deemed to be a business merger not under the same control.

For a business combination achieved by the purchaser through an exchange transaction, the merger cost shall be the fair value of the assets paid by the purchaser, liabilities incurred or assumed, and equity securities issued by the purchaser to obtain control of the purchased party on the purchase date. The intermediary fees such as auditing, legal services, evaluation consulting and other related management expenses incurred by the buyer for the business merger shall be included in the current profit and loss when incurred; the transaction costs of equity securities or debt securities issued by the buyer as consideration for the merger shall be included in the initial recognition amount of the equity securities or debt securities.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The purchaser's merger costs and the identifiable net assets obtained by the purchaser in the merger are measured at fair value on the purchase date. The difference between the merger cost and the fair value of the acquiree's identifiable net assets obtained in the merger on the purchase date is recognized as goodwill; the difference between the merger cost and the fair value of the acquiree's identifiable net assets obtained in the merger is included in the current profit and loss.

(3) Being able to exercise control over investee units that are not under common control due to additional investment or other reasons

When preparing individual financial statements, the sum of the book value of the original equity investment plus the new investment cost will be used as the initial investment cost to be accounted for using the cost method. Other comprehensive income recognized due to equity method accounting for equity investments held before the acquisition date will be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities when disposing of the investment. If the equity investment held before the purchase date is accounted for in accordance with the relevant provisions of the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", the cumulative fair value changes originally included in other comprehensive income will be transferred to the current profit and loss when the cost method is used.

In the consolidated financial statements, the equity of the purchased party held before the purchase date is remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value is included in the investment income of the current period; if the equity of the purchased party held before the purchase date involves other comprehensive income under equity method accounting, the other comprehensive income related to it shall be converted into the current period income on the purchase date.

7. Judgment criteria for control and preparation method of consolidated financial statements

(1) Scope of consolidation

The consolidation scope of the consolidated financial statements includes the company and its subsidiaries. The scope of consolidation in consolidated financial statements is determined based on control.

(2) Basis for control

If the investor has power over the investee, enjoys variable returns by participating in the investee's relevant activities, and has the ability to use its power over the investee to affect the amount of its returns, the investor is deemed to control the investee. Relevant activities are activities that have a significant impact on the return of the investee.

(3) Decision makers and agents

The agent only exercises decision-making power on behalf of the principal responsible person and does not control the investee. If an investor entrusts the decision-making power of the investee's relevant activities to an agent, the investor shall regard the decision-making power as being directly held by itself.

When determining whether a decision-maker is an agent, the company comprehensively considers the relationship between the decision-maker and the investee and other investors. 1) If there is a single party with substantial rights to unconditionally remove the decision-maker, the decision-maker is the agent;

2. In situations other than 1), comprehensive consideration shall be given to the decision-maker's judgment on the scope of decision-making power of the investee, the substantive rights enjoyed by other parties, the salary level of the decision-maker, the risk of variable returns borne by the decision-maker due to holding other interests in the investee, and other relevant factors.

(4) Investment entities

When the following conditions are met at the same time, it is regarded as an investment entity:

1. The company aims to provide investment management services to investors and obtains funds from one or more investors;

2. The company’s sole business purpose is to provide returns to investors through capital appreciation, investment income, or both;

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. The company considers and evaluates the performance of almost all investments based on fair value.

Investment entities usually meet all of the following characteristics:

1. Own more than one investment;

2. Have more than one investor;

3. The investor is not a related party of the entity;

4. Its owner's equity exists in the form of equity or similar equity.

If the parent company is an investment entity, the parent company will only include the subsidiaries (if any) that provide related services for its investment activities into the scope of consolidation and prepare consolidated financial statements; other subsidiaries will not be consolidated, and the parent company's investments in other subsidiaries will be measured at fair value and their changes will be included in the current profits and losses.

If the parent company of an investment entity is not an investment entity itself, all entities it controls, including those indirectly controlled through the investment entity, will be included in the scope of the consolidated financial statements.

(5) Merger procedure

If the accounting policies or accounting periods adopted by a subsidiary are inconsistent with the Company's, necessary adjustments shall be made to the subsidiary's financial statements in accordance with the Company's accounting policies or accounting periods; or the subsidiary shall be required to prepare separate financial statements in accordance with the Company's accounting policies or accounting periods.

The consolidated balance sheet, consolidated income statement, consolidated cash flow statement and consolidated statement of changes in owners' (shareholders' equity) are based on the balance sheet, income statement, cash flow statement and statement of changes in owners' (shareholders') equity of the company and its subsidiaries respectively, and are prepared by the company after offsetting the impact of internal transactions between the company and its subsidiaries and between subsidiaries on the consolidated balance sheet, consolidated income statement, consolidated cash flow statement and consolidated statement of changes in owners' (shareholders') equity.

Unrealized internal transaction gains and losses arising from the company's sale of assets to subsidiaries are fully offset against "net profits attributable to owners of the parent company". Unrealized internal transaction profits and losses arising from the sale of assets by a subsidiary to the Company are offset and allocated between "net profits attributable to owners of the parent company" and "minority shareholders' profits and losses" in accordance with the Company's distribution ratio to the subsidiary. Unrealized internal transaction profits and losses arising from the sale of assets between subsidiaries shall be allocated and offset between "net profits attributable to owners of the parent company" and "minority shareholders' profits and losses" in accordance with the company's distribution ratio to the selling subsidiary.

The share of the subsidiary's owner's equity that does not belong to the company, as minority shareholders' equity, is listed as "minority shareholders' equity" under the owner's equity item in the consolidated balance sheet. The share of minority shareholders' equity in the current period's net profit and loss of a subsidiary is listed as the "minority shareholders' profit and loss" item under the net profit item in the consolidated income statement. The share of the subsidiary's current comprehensive income that is attributable to minority shareholders' equity is listed under the item "total comprehensive income attributable to minority shareholders" in the consolidated income statement. If there are minority shareholders, the "Minority Shareholders' Equity" column will be added to the consolidated statement of changes in owners' equity to reflect the changes in minority shareholders' equity. If the current losses shared by minority shareholders of a subsidiary exceed the minority shareholders' share of the opening owner's equity of the subsidiary, the balance shall still be offset against the minority shareholders' equity.

If the company adds subsidiaries and businesses during the reporting period due to the merger of enterprises under the same control, when preparing the consolidated balance sheet, the opening balance of the consolidated balance sheet will be adjusted; when preparing the consolidated income statement, the income, expenses and profits of the subsidiaries and business combination from the beginning of the current period to the end of the reporting period will be included Consolidated income statement; when preparing the cash flow statement, the cash flow of the subsidiary and the business combination from the beginning of the current period to the end of the reporting period is included in the consolidated cash flow statement; at the same time, relevant items in the comparative statement are adjusted, and the post-merger reporting entity is deemed to have existed since the time when the ultimate controlling party began to control.

Due to the merger of enterprises not under the same control or the increase of subsidiaries and businesses in other ways, when preparing the consolidated balance sheet, the consolidated assets of Shanghai Runda Medical Technology Co., Ltd. will not be adjusted.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The opening balance of the balance sheet; when preparing the consolidated income statement, include the income, expenses and profits of the subsidiary and the business from the date of purchase to the end of the reporting period into the consolidated income statement; when preparing the consolidated cash flow statement, include the cash flow from the date of purchase of the subsidiary to the end of the reporting period into the consolidated cash flow statement.

The company disposes of subsidiaries and businesses during the reporting period. When preparing the consolidated balance sheet, the opening balance of the consolidated balance sheet will not be adjusted. When preparing the consolidated income statement, the income, expenses and profits of the subsidiary and the business from the beginning of the period to the date of disposal will be included in the consolidated income statement. When preparing the consolidated cash flow statement, the cash flow of the subsidiary and the business from the beginning of the period to the date of disposal will be included in the consolidated cash flow statement.

(6) Accounting treatment of special transactions

1. Purchase equity in a subsidiary owned by minority shareholders of the subsidiary

In the consolidated financial statements, the capital reserve (capital premium or equity premium) is adjusted for the difference between the newly acquired long-term equity investment due to the purchase of minority equity and the share of the subsidiary's net assets calculated continuously from the date of purchase or merger based on the new shareholding ratio. If the capital reserve is insufficient for offset, the retained earnings are adjusted.

2. Dispose of long-term equity investments in subsidiaries without losing control

If a long-term equity investment in a subsidiary is partially disposed of without losing control, in the consolidated financial statements, the difference between the disposal price and the share of the subsidiary's net assets continuously calculated from the date of purchase or merger shall be adjusted in the consolidated financial statements. If the capital reserve is insufficient to offset, the retained earnings shall be adjusted.

3. When the control over the investee is lost due to disposal of part of the equity investment or other reasons, the treatment of the remaining equity

When preparing consolidated financial statements, the remaining equity is remeasured according to its fair value on the date when control is lost. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income in the period when control is lost, and the goodwill shall be offset at the same time. Other comprehensive income related to the equity investment in the original subsidiary will be converted into current investment income when control is lost.

4. The enterprise disposes the equity investment in the subsidiary step by step through multiple transactions until it loses control, and the multiple transactions belong to a package deal

If the various transactions involving the disposal of equity investments in a subsidiary until the loss of control belong to a package transaction, each transaction should be accounted for as a transaction in which the subsidiary is disposed of and control is lost; however, the difference between the price of each disposal and the share of the net assets of the subsidiary corresponding to the disposal investment before the loss of control is recognized as other comprehensive income in the consolidated financial statements, and is transferred to the profit and loss of the current period when control is lost.

The principles for judging whether various transactions from the step-by-step disposal of equity to the loss of control belong to a package deal are as follows:

The terms, conditions and economic impact of various transactions related to the disposal of equity investments in subsidiaries meet one or more of the following circumstances, which usually indicates that multiple transactions are a package deal:

① These transactions were entered into at the same time or with consideration of mutual effects;

② Only these transactions as a whole can achieve a complete business result;

③The occurrence of one transaction depends on the occurrence of at least one other transaction;

④A transaction is uneconomical when viewed alone, but it is economical when considered together with other transactions.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

8. Classification of joint arrangements and accounting treatment of joint operations

A joint arrangement refers to an arrangement that is jointly controlled by two or more parties. The Company divides joint arrangements into joint operations and joint ventures based on the rights enjoyed and obligations assumed in the joint arrangements. Joint operation refers to a joint arrangement in which the company enjoys the relevant assets of the arrangement and assumes the relevant liabilities of the arrangement. A joint venture refers to a joint arrangement in which the Company only has rights to the net assets of the arrangement.

The Company's investment in joint ventures is accounted for using the equity method and is handled in accordance with the accounting policies described in Note 3.19 "Long-term Equity Investment" (2) ② "Long-term Equity Investment Accounted for by the Equity Method".

For joint operations, the company, as a joint venturer, recognizes the assets held separately by the company and the liabilities assumed separately, as well as the assets held jointly and the liabilities borne jointly by the company's share; the income generated from the sale of the company's share of the output of the joint operation is recognized; the income generated by the sale of the output of the joint operation is recognized according to the company's share; the expenses incurred by the company alone are recognized, and the expenses incurred by the joint operation are recognized according to the company's share.

When the company invests or sells assets to a joint operation as a joint venture (the assets do not constitute a business, the same below), or purchases assets from the joint operation, before the assets are sold to a third party, the company only recognizes the portion of the profits and losses arising from the transaction that are attributable to other participants in the joint operation. If such assets suffer asset impairment losses that comply with the provisions of "Accounting Standards for Business Enterprises No. 8 - Asset Impairment" and other regulations, the company will recognize the loss in full if the company invests or sells the assets to the joint operation; if the company purchases assets from the joint operation, the company will recognize the loss based on its share.

9. Determination criteria for cash and cash equivalents

The Company's cash and cash equivalents include cash on hand, deposits available for payment at any time, and investments held by the Company with short maturities (generally due within three months from the date of purchase), strong liquidity, easily convertible into known amounts of cash, and with little risk of value changes.

10. Foreign currency business and foreign currency statement conversion

(1) Conversion method for foreign currency transactions

When the Company's foreign currency transactions are initially recognized, they are converted into the recording currency amount based on the spot exchange rate on the transaction date.

(2) Conversion method for foreign currency monetary items and foreign currency non-monetary items

On the balance sheet date, foreign currency monetary items are converted at the spot exchange rate on the balance sheet date. The resulting exchange differences, except for: ① The exchange differences arising from special foreign currency borrowings related to the acquisition and construction of assets that meet capitalization conditions are capitalized as borrowing costs. and ② For foreign currency monetary items classified as measured at fair value and whose changes are included in other comprehensive income, except for the exchange differences arising from changes in other book balances other than amortized costs (including impairment), which are included in other comprehensive income, they are all included in the current profit and loss.

Foreign currency non-monetary items measured at historical cost are still measured using the accounting standard amount converted at the spot exchange rate on the date of the transaction. Foreign currency non-monetary items measured at fair value are converted using the spot exchange rate on the date when the fair value is determined. The difference between the converted accounting functional currency amount and the original accounting functional currency amount is treated as a change in fair value (including exchange rate changes), and is included in the current profit and loss or recognized as other comprehensive income. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(3) Conversion method of foreign currency financial statements

Foreign currency financial statements for overseas operations are converted into RMB statements according to the following method: assets and liability items in the balance sheet are converted using the spot exchange rate on the balance sheet date; shareholders' equity items, except for "undistributed profits" items, are converted using the spot exchange rate at the time of occurrence. Income and expense items in the income statement are translated using the current weighted average exchange rate on the date of transaction. The undistributed profit at the beginning of the period is the undistributed profit at the end of the period after conversion from the previous year; the undistributed profit at the end of the period is calculated and presented according to the converted profit distribution items; the difference between the asset items after conversion and the total number of liability items and shareholders' equity items is regarded as the translation difference of the foreign currency statement and is recognized as other comprehensive income. When an overseas operation is disposed of and control is lost, the translation differences of foreign currency statements listed under the shareholders' equity items in the balance sheet and related to the overseas operation shall be transferred to the current profit and loss of the disposal in full or in proportion to the disposal of the overseas operation.

Foreign currency cash flows and cash flows of overseas subsidiaries are translated using the weighted average exchange rate of the current period on the date when the cash flows occur. The impact of exchange rate changes on cash is presented separately in the cash flow statement as an adjustment item.

The opening amount and the actual amount of the previous period are presented according to the converted amount of the previous period's financial statements.

When the company disposes of all the owners' equity in overseas operations or loses control of the overseas operations due to the disposal of part of the equity investment or other reasons, the translation differences of the foreign currency statements attributable to the parent company's owners' equity listed under the shareholders' equity item in the balance sheet and related to the overseas operation will all be transferred to the profits and losses for the current period of disposal.

When the proportion of overseas operating equity held is reduced due to the disposal of part of the equity investment or other reasons but the control of the overseas operation is not lost, the foreign currency statement translation difference related to the disposal of the overseas operation will be attributed to the minority shareholders' equity and will not be transferred to the current profit and loss. When disposing of part of the equity of an overseas operation that is an associate or joint venture, the translation difference of foreign currency statements related to the overseas operation shall be transferred to the current profit and loss of the disposal in proportion to the disposal of the overseas operation.

If there are foreign currency monetary items that essentially constitute a net investment in overseas operations, in the consolidated financial statements, the exchange differences arising from exchange rate changes are recognized as other comprehensive income as "foreign currency statement translation differences"; when disposing of overseas operations, they are included in the current profit and loss of disposal.

11. Financial instruments

(1) Classification, recognition and measurement of financial assets

Based on the business model of managing financial assets and the contractual cash flow characteristics of financial assets, the company divides financial assets into: financial assets measured at amortized cost; financial assets measured at fair value with changes included in other comprehensive income; financial assets measured at fair value with changes included in current profits and losses. Financial assets are measured at fair value upon initial recognition. For those measured at fair value with changes included in current profits and losses.

For financial assets, relevant transaction costs are directly included in the current profit and loss; for other types of financial assets, relevant transaction costs are included in the initial recognition amount. For accounts receivable or notes receivable arising from the sale of products or provision of services that do not include or take into account significant financing components, the amount of consideration that the company is expected to be entitled to receive shall be regarded as the initial recognition amount.

1. Financial assets measured at amortized cost

The Company's business model for managing financial assets measured at amortized cost is to collect contractual cash flows as the goal, and the contractual cash flow characteristics of such financial assets are consistent with the basic lending arrangements, that is, the cash flows generated on a specific date are only payments of principal and interest based on the outstanding principal amount. For such financial assets, the Company adopts the actual interest rate method and conducts subsequent measurement at amortized cost. Gains or losses arising from amortization or impairment are included in the current profits and losses.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Financial assets measured at fair value with changes included in other comprehensive income

The Company's business model for managing such financial assets aims at both collecting contractual cash flows and selling them, and the contractual cash flow characteristics of such financial assets are consistent with the basic lending arrangements. The Company measures such financial assets at fair value and changes in them are included in other comprehensive income, but impairment losses or gains, exchange gains and losses and interest income calculated according to the effective interest method are included in the current profit and loss.

In addition, the Company designates certain investments in non-trading equity instruments as financial assets measured at fair value through other comprehensive income. The company includes the relevant dividend income of this type of financial assets in the current profit and loss, and the changes in fair value are included in other comprehensive income. When the financial asset is derecognised, the accumulated gains or losses previously included in other comprehensive income will be transferred from other comprehensive income to retained earnings and will not be included in the current profit or loss.

3. Financial assets measured at fair value and changes included in current profits and losses

The Company classifies financial assets other than the above-mentioned financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income as financial assets measured at fair value through profit or loss for the current period. In addition, at the time of initial recognition, in order to eliminate or significantly reduce accounting mismatches, the Company designated some financial assets as financial assets measured at fair value and whose changes are included in current profits and losses. For such financial assets, the company uses fair value for subsequent measurement, and changes in fair value are included in the current profit and loss.

(2) Classification, recognition and measurement of financial liabilities

Financial liabilities are classified upon initial recognition into financial liabilities measured at fair value through profit or loss and other financial liabilities. For financial liabilities measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss, and the relevant transaction costs of other financial liabilities are included in their initial recognition amount.

1. Financial liabilities measured at fair value and changes included in current profits and losses

Financial liabilities at fair value through profit or loss include trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated at fair value through profit or loss upon initial recognition. Trading financial liabilities (including derivatives belonging to financial liabilities) are subsequently measured at fair value. Except for those related to hedging accounting, changes in fair value are included in current profits and losses.

For a financial liability designated as a financial liability measured at fair value through profit or loss for the current period, changes in the fair value of this liability caused by changes in the company's own credit risk are included in other comprehensive income. When the liability is derecognised, the accumulated changes in its fair value caused by changes in its own credit risk included in other comprehensive income are transferred to retained earnings. The remaining changes in fair value are included in the current profit and loss. If handling the impact of changes in the credit risk of such financial liabilities in the above manner will cause or expand accounting mismatches in profits and losses, the company will include all gains or losses from the financial liabilities (including the amount affected by changes in the company's own credit risk) into the profits and losses of the current period.

2. Other financial liabilities

Except for financial liabilities and financial guarantee contracts formed by the transfer of financial assets that do not meet the conditions for termination of recognition or continued involvement in the transferred financial assets, other financial liabilities are classified as financial liabilities measured at amortized cost, and are subsequently measured at amortized cost. Gains or losses arising from termination of recognition or amortization are included in the current profit and loss.

(3) Recognition basis and measurement method of financial asset transfer

Financial assets that meet one of the following conditions shall be derecognized: ① The contractual right to receive cash flows from the financial asset terminates; ② The financial asset has been transferred, and almost all the risks and rewards of the ownership of the financial asset are transferred to the transferee; ③ The financial asset has been transferred, and although the enterprise neither transfers nor retains almost all the risks and rewards of the ownership of the financial asset, it has given up control of the financial asset. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

If an enterprise neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, and does not give up control of the financial asset, the relevant financial assets will be recognized to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly. The degree of continued involvement in the transferred financial assets refers to the level of risk faced by the enterprise due to changes in the value of the financial assets.

If the overall transfer of financial assets meets the conditions for derecognition, the difference between the book value of the transferred financial assets and the sum of the consideration received for the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income will be included in the current profit and loss.

If the partial transfer of financial assets meets the conditions for derecognition, the book value of the transferred financial assets will be apportioned between the derecognized and non-derecognized parts according to their relative fair values, and the difference between the sum of the consideration received for the transfer and the cumulative amount of changes in fair value originally included in other comprehensive income that should be apportioned to the derecognized part and the apportioned aforementioned book amount shall be included in the current profit and loss.

When the company sells financial assets with recourse, or endorses and transfers financial assets it holds, it needs to determine whether substantially all the risks and rewards of ownership of the financial assets have been transferred. If almost all the risks and rewards of the ownership of the financial asset have been transferred to the transferee, the financial asset will be derecognised; if almost all the risks and rewards of the ownership of the financial asset have been retained, the recognition of the financial asset will not be deactivated; if almost all the risks and rewards of the ownership of the financial asset have neither been transferred nor retained, the company will continue to judge whether the enterprise retains control over the asset, and perform accounting treatment according to the principles described in the previous paragraphs.

(4) Derecognition of financial liabilities

If the current obligation of a financial liability (or part thereof) has been discharged, the Company shall terminate the recognition of the financial liability (or part thereof). The company (borrower) signs an agreement with the lender to replace the original financial liability by assuming a new financial liability, and if the contract terms of the new financial liability are substantially different from the original financial liability, the original financial liability will be terminated and a new financial liability will be recognized at the same time. If the company makes substantial modifications to the contract terms of the original financial liability (or part thereof), it will terminate the recognition of the original financial liability and recognize a new financial liability in accordance with the modified terms.

If a financial liability (or part thereof) is derecognised, the company will include the difference between its book value and the consideration paid (including non-cash assets transferred out or liabilities assumed) into the current profit and loss.

(5) Determination method of fair value of financial assets and financial liabilities

Fair value refers to the price that can be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. If there is an active market for a financial instrument, the company uses the quoted price in the active market to determine its fair value. Quotes in active markets refer to prices that are easily obtained from exchanges, brokers, industry associations, pricing service agencies, etc. on a regular basis, and represent the prices of market transactions that actually occur in fair transactions. If there is no active market for a financial instrument, the Company uses valuation techniques to determine its fair value. Valuation techniques include reference to prices used in recent market transactions between parties who are familiar with the situation and voluntary transactions, reference to the current fair value of other financial instruments that are substantially the same, discounted cash flow methods and option pricing models, etc. When valuing, the Company adopts valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information, selects input values ​​that are consistent with the characteristics of the assets or liabilities considered by market participants in transactions of related assets or liabilities, and gives priority to the use of relevant observable input values ​​whenever possible. Non-inputable values ​​are used when the relevant observable input values ​​cannot be obtained or are impracticable to obtain.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

12. Impairment of financial assets

The financial assets that the company needs to confirm impairment losses are financial assets measured at amortized cost, debt instruments measured at fair value with changes included in other comprehensive income, and lease receivables, which mainly include notes receivable, accounts receivable, receivable financing, other receivables, long-term receivables, etc. In addition, for contract assets and some financial guarantee contracts, impairment provisions are made and credit impairment losses are recognized in accordance with the accounting policies described in this section.

(1) Recognition method of impairment provision

Based on expected credit losses, the Company makes impairment provisions and recognizes credit impairment losses for each of the above items in accordance with its applicable expected credit loss measurement method (general method or simplified method).

Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original actual interest rate, that is, the present value of all cash shortfalls. Among them, for purchased or originated financial assets that have suffered credit impairment, the company discounts them according to the credit-adjusted actual interest rate of the financial assets.

The general method of measuring expected credit losses means that the company evaluates on each balance sheet date whether the credit risk of financial assets (including contract assets and other applicable items, the same below) has increased significantly since initial recognition. If the credit risk has increased significantly since initial recognition, the company measures loss provisions at an amount equivalent to the expected credit losses during the entire duration; if the credit risk has not increased significantly since initial recognition, the company measures loss provisions at an amount equivalent to the expected credit losses within the next 12 months. The Company considers all reasonable and evidence-based information, including forward-looking information, when assessing expected credit losses.

For financial instruments with low credit risk on the balance sheet date, the Company assumes that its credit risk has not increased significantly since initial recognition, and chooses to measure loss provisions based on expected credit losses within the next 12 months.

(2) Criteria for judging whether credit risk has increased significantly since initial recognition

If the default probability of a financial asset within the expected duration determined on the balance sheet date is significantly higher than the default probability within the expected duration determined at initial recognition, it indicates that the credit risk of the financial asset has increased significantly. Except for special circumstances, the Company uses the change in default risk within the next 12 months as a reasonable estimate of the change in default risk throughout the entire duration to determine whether credit risk has increased significantly since initial recognition.

(3) Portfolio method to assess expected credit risk on a combined basis

The Company evaluates the credit risk of financial assets with significantly different credit risks individually, such as: accounts receivable from related parties; accounts receivable that are in dispute with the other party or involved in litigation or arbitration; accounts receivable that have obvious signs that the debtor is likely to be unable to fulfill its repayment obligations, etc.

In addition to financial assets that assess credit risk individually, the Company divides financial assets into different groups based on common risk characteristics and assesses credit risk on a combined basis.

(4) Accounting treatment method for impairment of financial assets

At the end of the period, the Company calculates the estimated credit losses of various financial assets. If the estimated credit losses are greater than the carrying amount of the current impairment provisions, the difference will be recognized as impairment losses; if it is less than the current carrying amount of the impairment provisions, the difference will be recognized as impairment gains.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(5) Methods for determining credit losses of various financial assets

1. Notes receivable

The Company measures loss provisions for notes receivable based on an amount equivalent to the expected credit losses during the entire duration. Based on the credit risk characteristics of notes receivable, they are divided into different combinations:

Project determines the basis for combination

Bank acceptance bill The acceptor is a bank with low credit risk

Commercial acceptance bills are divided into different combinations according to the credit risk characteristics of the acceptor, and the basis is the same as "accounts receivable"

2. Accounts receivable and contract assets

The Company lists the rights of the customer that have not paid the contract consideration but that have fulfilled the performance obligations under the contract and are not unconditional (that is, only dependent on the passage of time) to receive payment from the customer as contract assets in the balance sheet. Accounts receivable represent the company’s unconditional right to receive contract consideration.

For accounts receivable and contract assets that do not contain significant financing components, the Company measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

For accounts receivable, contract assets and lease receivables that contain significant financing components, the Company chooses to always measure loss provisions at an amount equivalent to the expected credit losses during the duration.

In addition to accounts receivable for individual assessment of credit risk, they are divided into different combinations based on their credit risk characteristics:

Project determines the basis for combination

Accounts receivable:

Groups of related parties (within the scope of consolidation) Grouped accounts receivable by related parties (within the scope of consolidation)

In addition to the related party portfolio (within the scope of consolidation) and the accounts receivable for which bad debt provisions are individually provided, the credit period and aging portfolio

The remaining receivables are grouped according to credit period and aging

The credit period and aging combination is a combination of credit risk characteristics based on aging confirmation. The company uses the initial entry time of accounts receivable as the initial starting point for calculating aging.

3. Accounts receivable financing

Notes receivable and accounts receivable measured at fair value through other comprehensive income, with a maturity period within one year (inclusive) from the initial recognition date, are reported as receivables financing. The company measures impairment losses based on the amount of expected credit losses throughout the entire duration. 4) Other receivables

The company measures impairment losses based on whether the credit risk of other receivables has increased significantly since initial recognition, and uses an amount equivalent to the expected credit losses in the next 12 months or the entire duration. In addition to other receivables whose credit risk is assessed individually, they are divided into different combinations based on their credit risk characteristics:

Project determines the basis for combination

Group of related parties (within the scope of consolidation) Other receivables grouped by related parties (within the scope of consolidation)

In addition to related party combinations (within the scope of consolidation) and other receivables for which bad debt provisions are individually provided, its aging combination

Remaining receivables are grouped according to credit period and aging

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The aging portfolio is a combination of credit risk characteristics based on aging recognition. The company uses the overdue time of other receivables as the basis for measuring impairment losses based on the amount of expected credit losses throughout the duration.

5. Long-term receivables

For long-term receivables formed by transactions regulated by "Accounting Standards for Business Enterprises No. 14 - Revenue" and which do not contain significant financing components, the company measures loss provisions at an amount equivalent to the expected credit losses during the entire duration.

For long-term receivables formed by transactions regulated by "Accounting Standards for Business Enterprises No. 14 - Revenue" and containing significant financing components, the Company chooses to always measure loss provisions at an amount equivalent to the expected credit losses during the duration.

For financial lease receivables and operating lease receivables formed by transactions regulated by "Accounting Standards for Business Enterprises No. 21 - Leasing", the Company chooses to always measure loss provisions at an amount equivalent to the expected credit losses during the duration.

For receivables that are not applicable or do not choose simplified treatment methods, the company measures impairment losses on long-term receivables based on whether their credit risk has increased significantly since initial recognition, using an amount equivalent to the expected credit losses in the next 12 months or the entire duration.

In addition to long-term receivables with individual credit risk assessments, they are divided into different combinations based on their credit risk characteristics:

Project determines the basis for combination

Aging Portfolio This portfolio uses aging as a credit risk characteristic

13. Notes receivable

For details on the determination method and accounting treatment method of expected credit losses of notes receivable, please refer to Note 3.11 "Financial Instruments" and Note 3.12 "Impairment of Financial Assets".

14. Accounts receivable

For details on the determination method and accounting treatment method of expected credit losses of accounts receivable, please refer to Note 3.11, "Financial Instruments" and Note 3.12, "Impairment of Financial Assets".

15. Receivables Financing

When notes receivable and accounts receivable meet the following conditions at the same time, the company will classify them as financial assets measured at fair value and whose changes are included in other comprehensive income. For specific accounting treatment methods, see Note 3.11 "Financial Instruments" for details, and list them as receivable financing in the statement: (1) Contract cash flow is the payment of principal and interest based on the outstanding principal amount;

(2) The company’s business model for managing notes receivable and accounts receivable aims at both collecting contractual cash flows and selling them.

16. Other receivables

For details on the determination method and accounting treatment method of expected credit losses of other receivables, please refer to Note 3.11 "Financial Instruments" and Note 3.12 "Impairment of Financial Assets".

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

17. Inventory

(1) Category of inventory

Inventories mainly include raw materials, work-in-progress and self-made semi-finished products, turnover materials, inventory goods, etc. Contract performance costs with an amortization period not exceeding one year or one operating cycle are also reported as inventories.

(2) Valuation method for inventory acquisition and issue

Inventories are valued at actual cost when acquired, and inventory costs include purchase costs, processing costs and other costs. The weighted average method is used for collection and issuance.

(3) Recognition of net realizable value of inventories and method of accruing provision for decline in value

Net realizable value refers to the estimated selling price of inventory in daily activities minus the estimated costs to be incurred to completion, estimated selling expenses and related taxes. When determining the net realizable value of inventories, it is based on the conclusive evidence obtained and the purpose of holding the inventories and the impact of events after the balance sheet date are also considered.

On the balance sheet date, inventories are measured at the lower of cost and net realizable value. When the net realizable value is lower than the cost, the inventory depreciation reserve is withdrawn. Inventory depreciation provisions are usually withdrawn based on the difference between the cost of a single inventory item and its net realizable value.

After the provision for inventory depreciation is accrued, if the factors that previously caused the inventory value to be written down have disappeared, causing the net realizable value of the inventory to be higher than its book value, the amount of the inventory depreciation provision that was originally accrued will be reversed, and the amount reversed will be included in the current profit and loss.

(4) The inventory inventory system is a perpetual inventory system.

(5) Amortization method for low-value consumables and packaging materials

Low-value consumables are amortized using the one-time amortization method when used; packaging materials are amortized using the one-time amortization method when used.

18. Assets held for sale and disposal groups

(1) Recognition standards and accounting treatment methods for non-current assets or disposal groups classified as held for sale

If the company recovers its book value mainly through sale (including non-monetary asset exchange with commercial substance, the same below) rather than continuing to use a non-current asset or disposal group, it will be classified as held for sale. The specific criteria are to meet the following conditions at the same time: a certain non-current asset or disposal group can be sold immediately under the current conditions according to the practice of selling such assets or disposal groups in similar transactions; the company has made a resolution on the sales plan and obtained a firm purchase commitment; the sale is expected to be completed within one year. Among them, a disposal group refers to a group of assets that are disposed of as a whole in a transaction through sale or other means, as well as the liabilities directly related to these assets transferred in the transaction. If the asset group or asset group combination to which the disposal group belongs has allocated the goodwill acquired in the business merger in accordance with the "Accounting Standards for Business Enterprises No. 8 - Asset Impairment", the disposal group shall include the goodwill allocated to the disposal group.

When the company initially measures or re-measures and divides it into non-current assets and disposal groups held for sale on the balance sheet date, if its book value is higher than the net amount of fair value minus selling expenses, the book value will be written down to the net amount of fair value minus selling expenses. The amount of the write-down is indeed Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

If the asset impairment loss is considered, the loss will be included in the current profit and loss, and an impairment provision for assets held for sale will be made at the same time. For the disposal group, the recognized asset impairment loss is first deducted from the book value of the goodwill in the disposal group, and then deducted proportionally from the book value of various non-current assets in the disposal group that are subject to the measurement provisions of "Accounting Standards for Business Enterprises No. 42 - Non-current Assets Held for Sale, Disposal Groups and Discontinued Operations" (hereinafter referred to as the "Held for Sale Standards"). If the net amount of the fair value of the disposal group held for sale less the selling expenses increases on the subsequent balance sheet date, the previously written-down amount shall be restored and reversed within the amount of asset impairment loss recognized for non-current assets after being classified as held-for-sale and subject to the measurement provisions of the held-for-sale standards. The reversed amount shall be included in the current profit and loss, and According to the proportion of the book value of each non-current asset in the disposal group that is subject to the measurement requirements of the held-for-sale standards, except for goodwill, the book value is increased proportionally; the book value of goodwill that has been deducted, and the asset impairment losses recognized before the non-current assets are classified as held-for-sale categories are not reversed.

No depreciation or amortization is provided for non-current assets held for sale or non-current assets in the disposal group, and interest and other expenses on liabilities in the disposal group held for sale continue to be recognized.

When a non-current asset or disposal group no longer meets the classification conditions of the held-for-sale category, the company will no longer classify it as a held-for-sale category or remove the non-current assets from the held-for-sale disposal group, and measure it according to the lower of the following two: 1) The book value before being classified as a held-for-sale category, adjusted for the depreciation, amortization or impairment that would have been recognized if it was not classified as a held-for-sale category; 2) The recoverable amount.

(2) Determination criteria and listing method for discontinued operations

Discontinued operations refer to an individually distinguishable component that meets one of the following conditions, and the component has been disposed of or classified as held for sale: 1) The component represents an independent major business or a separate major operating area; 2) The component is part of an associated plan to dispose of an independent major business or a separate major operating area; 3) The component is a subsidiary acquired specifically for resale.

The company separately lists the profit and loss from continuing operations and the profit and loss from discontinued operations in the income statement. For non-current assets or disposal groups held for sale that do not meet the definition of discontinued operations, their impairment losses, reversal amounts, and disposal gains and losses are reported as continuing operating gains and losses. Impairment losses and reversal amounts from discontinued operations and other operating gains and losses as well as disposal gains and losses are presented as gains and losses from discontinued operations.

19. Long-term equity investment

The long-term equity investment referred to in this section refers to the long-term equity investment in which the company has control, joint control or significant influence on the invested unit. Long-term equity investments that the Company does not have control, joint control or significant influence over the investee are accounted for as financial assets measured at fair value with changes included in current profits and losses. If they are non-trading, the company may choose to designate them as financial assets measured at fair value with changes included in other comprehensive income upon initial recognition. For details of its accounting policies, see Note 3.11, Financial Instruments.

Joint control refers to the company's shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the participants sharing control rights. Significant influence means that the company has the power to participate in decision-making on the financial and operating policies of the investee, but it is not able to control or jointly control the formulation of these policies with other parties.

(1) Determination of investment cost

For long-term equity investments obtained through a business combination under common control, the share of the book value of the owner's equity of the merged party in the consolidated financial statements of the ultimate controlling party on the date of merger shall be regarded as the initial investment cost of the long-term equity investment. Initial investment cost and payment of long-term equity investment in Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The difference between the cash, the transferred non-cash assets and the book value of the debts assumed shall be adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings shall be adjusted. If the issuance of equity securities is used as the merger consideration, the share of the book value of the owner's equity of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date shall be used as the initial investment cost of the long-term equity investment, and the total face value of the issued shares shall be regarded as the share capital. The difference between the initial investment cost of the long-term equity investment and the total face value of the shares issued shall be adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings shall be adjusted. If the equity of the merged party under the same control is acquired step by step through multiple transactions, and the merger of enterprises under the same control is finally formed, it should be dealt with whether it belongs to a "package transaction": if it belongs to a "package transaction", each transaction will be accounted for as a transaction to obtain control. If it does not belong to a "package transaction", the share of the book value of the combined party's owner's equity in the final controlling party's consolidated financial statements on the merger date will be used as the initial investment cost of the long-term equity investment. The difference between the initial investment cost of the long-term equity investment and the book value of the long-term equity investment before the merger plus the book value of the new consideration for further acquisition of shares on the merger date will be adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings will be adjusted. Equity investments held before the merger date are not subject to accounting treatment because they are accounted for using the equity method or recognized as financial assets at fair value with changes included in other comprehensive income.

For long-term equity investments obtained through a business combination not under common control, the initial investment cost of the long-term equity investment shall be the merger cost on the acquisition date. The merger cost includes the sum of the assets paid by the purchaser, liabilities incurred or assumed, and the fair value of the equity securities issued. If the equity of the purchased party is acquired step by step through multiple transactions, eventually forming a business combination not under the same control, it should be treated separately whether it belongs to a "package transaction": if it belongs to a "package transaction", each transaction will be accounted for as a transaction that obtains control. If it does not belong to a "package transaction", the initial investment cost of the long-term equity investment that is accounted for using the cost method shall be the sum of the original book value of the equity investment in the purchased party plus the new investment cost. If the originally held equity is accounted for using the equity method, the related other comprehensive income will not be subject to accounting treatment for the time being.

Intermediary fees such as auditing, legal services, evaluation and consulting, and other related administrative expenses incurred by the merging party or purchaser during a business merger shall be included in the current profit and loss when incurred.

Equity investments other than long-term equity investments formed through business combinations are initially measured at cost. Depending on the way in which the long-term equity investment is acquired, the cost is determined based on the actual cash purchase price paid by the company, the fair value of the equity securities issued by the company, the value stipulated in the investment contract or agreement, the fair value or original book value of the assets exchanged in non-monetary asset exchange transactions, the fair value of the long-term equity investment itself, etc. Fees, taxes and other necessary expenses directly related to obtaining long-term equity investment are also included in the investment cost. For additional investments that can exert significant influence on the investee or implement joint control but do not constitute control, the cost of long-term equity investment is the sum of the fair value of the original equity investment determined in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" plus the cost of the new investment.

(2) Subsequent measurement and profit and loss recognition methods

Long-term equity investments that have joint control (except for joint operators) or significant influence on the investee unit are accounted for using the equity method. In addition, the company's financial statements adopt the cost method to account for long-term equity investments that can control the invested unit.

1. Long-term equity investment calculated using cost method

When accounting using the cost method, long-term equity investment is valued at the initial investment cost, and the cost of long-term equity investment is adjusted when additional investment or withdrawal of investment is made. Except for the actual price paid when acquiring the investment or the cash dividends or profits that have been declared but not yet distributed included in the consideration, the current investment income is recognized according to the cash dividends or profits declared and distributed by the investee.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Long-term equity investment accounted for by equity method

When accounting using the equity method, if the initial investment cost of a long-term equity investment is greater than the fair value share of the investee's identifiable net assets at the time of investment, the initial investment cost of the long-term equity investment will not be adjusted; if the initial investment cost is less than the fair value share of the investee's identifiable net assets at the time of investment, the difference will be included in the current profit and loss, and the cost of the long-term equity investment will be adjusted at the same time.

When accounting using the equity method, investment income and other comprehensive income are recognized respectively according to the share of the net profit or loss and other comprehensive income realized by the invested unit, and the book value of the long-term equity investment is adjusted at the same time. The book value of the long-term equity investment is calculated based on the profit or cash dividend declared by the investee to be distributed, and the book value of the long-term equity investment is reduced accordingly. For other changes in the owner's equity of the investee other than net profit or loss, other comprehensive income and profit distribution, the book value of the long-term equity investment is adjusted and included in the capital reserve. When confirming the share of the investee's net profits and losses, the net profit of the investee is adjusted and recognized based on the fair value of the investee's identifiable assets when the investment is obtained. If the accounting policies and accounting periods adopted by the invested unit are inconsistent with those of the Company, the financial statements of the invested unit shall be adjusted in accordance with the Company's accounting policies and accounting periods, and investment income and other comprehensive income shall be recognized accordingly. For transactions between the company and associates and joint ventures, if the assets invested or sold do not constitute business, the unrealized internal transaction profits and losses shall be offset according to the proportion attributable to the company, and investment profits and losses shall be recognized on this basis. However, if the unrealized internal transaction losses between the company and the investee are impairment losses on the transferred assets, they will not be offset. If the assets invested by the company into a joint venture or associated enterprise constitute a business, and the investor obtains a long-term equity investment but does not obtain control, the fair value of the invested business shall be used as the initial investment cost of the new long-term equity investment. The difference between the initial investment cost and the book value of the invested business shall be fully included in the current profit and loss. If the assets sold by the company to a joint venture or associated enterprise constitute a business, the difference between the consideration obtained and the book value of the business shall be fully included in the current profit and loss. If the assets purchased by the company from associates and joint ventures constitute a business, accounting treatment shall be carried out in accordance with the provisions of "Accounting Standards for Business Enterprises No. 20 - Business Merger", and the gains or losses related to the transaction shall be recognized in full.

When confirming the share of the net losses incurred by the investee, the book value of the long-term equity investment and other long-term interests that essentially constitute the net investment in the investee are reduced to zero. In addition, if the company has an obligation to bear additional losses to the investee, it will recognize estimated liabilities based on the estimated obligations and include them in the current investment losses. If the invested unit realizes net profit in the subsequent period, the company will resume recognition of the income sharing amount after the income sharing amount makes up for the unrecognized loss sharing amount.

3. Acquisition of minority stakes

When preparing consolidated financial statements, the difference between the new long-term equity investment due to the purchase of minority shares and the share of the subsidiary's net assets calculated continuously from the purchase date (or merger date) based on the new shareholding ratio will be adjusted to the capital reserve. If the capital reserve is insufficient for offset, the retained earnings will be adjusted.

4. Disposal of long-term equity investments

In the consolidated financial statements, if the parent company partially disposes of the long-term equity investment in the subsidiary without losing control, the difference between the disposal price and the net assets of the subsidiary corresponding to the disposal of the long-term equity investment will be included in shareholders' equity; if the parent company partially disposes of the long-term equity investment in the subsidiary, resulting in the loss of control over the subsidiary, it shall be handled in accordance with the relevant accounting policies described in Note 3.7 (2) "Method for Preparation of Consolidated Financial Statements".

For the disposal of long-term equity investments under other circumstances, the difference between the book value of the disposed equity and the actual price obtained shall be included in the current profit and loss.

For long-term equity investments accounted for using the equity method, if the remaining equity after disposal is still accounted for using the equity method, the portion of other comprehensive income originally included in shareholders' equity at the time of disposal will be accounted for in proportion and on the same basis as the investee's direct disposal of relevant assets or liabilities. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

reason. Owner's equity recognized due to changes in other owners' equity of the investee other than net profit and loss, other comprehensive income and profit distribution shall be carried forward to the current profit and loss on a proportional basis.

For long-term equity investments accounted for using the cost method, if the remaining equity after disposal is still accounted for using the cost method, other comprehensive income recognized by using the equity method or financial instrument recognition and measurement standards before obtaining control over the investee shall be calculated using the method directly related to the investee. Accounting treatment is carried out on the same basis as the disposal of relevant assets or liabilities, and the profits and losses of the current period are carried forward in proportion; changes in other owners' equity other than net profits and losses, other comprehensive income and profit distribution in the net assets of the investee recognized due to the use of equity method accounting are carried forward to the profits and losses of the current period in proportion.

If the company loses control over the invested unit due to the disposal of part of its equity investment, when preparing individual financial statements, if the remaining equity after disposal can jointly control or exert significant influence on the invested unit, it shall be accounted for according to the equity method instead, and the remaining equity shall be deemed to have adopted equity since the time of acquisition. If the remaining equity after disposal cannot jointly control or exert significant influence on the invested unit, the accounting treatment shall be carried out in accordance with the relevant provisions of the financial instrument recognition and measurement standards, and the difference between its fair value and book value on the date of loss of control shall be included in the current profit and loss. For other comprehensive income recognized due to the use of equity method accounting or financial instrument recognition and measurement standards before the company obtains control of the invested unit, when it loses control of the invested unit, it will be accounted on the same basis as the invested unit's direct disposal of relevant assets or liabilities. Other changes in owner's equity in the net assets of the invested unit recognized due to the use of equity method accounting, except for net profit and loss, other comprehensive income and profit distribution, will be carried forward to the current profit and loss when it loses control of the invested unit. Among them, if the remaining equity after disposal is accounted for using the equity method, other comprehensive income and other owners' equity will be carried forward in proportion; if the remaining equity after disposal is accounted for in accordance with the financial instrument recognition and measurement standards, all other comprehensive income and other owners' equity will be carried forward.

If the company loses joint control or significant influence on the investee due to the disposal of part of its equity investment, the remaining equity after disposal will be accounted for in accordance with the financial instrument recognition and measurement standards, and the difference between its fair value and book value on the date of loss of joint control or significant influence will be included in the current profit and loss. Other comprehensive income recognized due to the use of the equity method for accounting in the original equity investment will be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities when the use of the equity method is terminated. Owner's equity recognized due to changes in the investee's other owner's equity other than net profit and loss, other comprehensive income and profit distribution will all be transferred to the investment income of the current period when the use of the equity method is discontinued.

The company disposes the subsidiary's equity investment step by step through multiple transactions until it loses control. If the above-mentioned transactions are a package deal, each transaction will be accounted for as a transaction that disposes of the subsidiary's equity investment and loses control. Before the loss of control, the difference between the price of each disposal and the book value of the long-term equity investment corresponding to the equity disposed is first recognized as other comprehensive income, and then transferred to the current profit and loss for the loss of control when control is lost.

20. Fixed assets

(1) Fixed assets recognition conditions

Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a useful life of more than one accounting year. Fixed assets are recognized only when the economic benefits related to them are likely to flow into the enterprise and their costs can be measured reliably. Fixed assets are initially measured at cost and taking into account the impact of expected disposal costs.

(2) Depreciation methods for various types of fixed assets

Depreciation is calculated using the straight-line method over the useful life of a fixed asset starting from the month after it reaches its intended usable condition. The useful lives, estimated net residual values and annual depreciation rates of various types of fixed assets are as follows:

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Category Depreciation method Depreciation life (years) Salvage value rate (%) Annual depreciation rate (%) Houses and buildings Average age method 20-45.17 5.00 4.75-2.10 Production and R&D equipment Average age method 3-10 5.00 31.67-9.50 Provide instruments and equipment Average age method 3.5-5 5.00 27.14-19.00 Electronics and other equipment Straight-line method 3-10 5.00 31.67-9.50 Transportation equipment Straight-line method 3-5 5.00 31.67-19.00 Fixed asset decoration expenses Straight-line method 3-10 33.33-10.00 Estimated net residual value refers to the amount currently obtained by the company from the disposal of the asset after deducting the estimated disposal costs, assuming that the fixed asset has reached its expected service life and is in its expected state at the end of its service life.

(3) Impairment testing method and impairment provision accrual method for fixed assets

Please refer to Note 3, 25 "Impairment of Long-term Assets" for details on the impairment testing method and impairment provision method for fixed assets.

(4) Other instructions

Subsequent expenditures related to a fixed asset, if the economic benefits related to the fixed asset are likely to flow in and its cost can be measured reliably, will be included in the cost of the fixed asset, and the book value of the replaced part will be derecognized. Other subsequent expenditures other than these shall be included in the current profits and losses when incurred.

When a fixed asset is in a state of disposal or no economic benefits are expected to be generated through use or disposal, the fixed asset is derecognised. The difference between the disposal income from the sale, transfer, scrapping or damage of fixed assets after deducting their book value and relevant taxes is included in the current profit and loss.

The company will review the service life, estimated net residual value and depreciation method of fixed assets at least at the end of the year. If any changes occur, they will be treated as changes in accounting estimates.

21. Construction in progress

The cost of construction in progress is determined based on actual project expenditures, including various project expenditures incurred during the construction period, capitalized borrowing costs before the project reaches its intended usable state, and other related expenses. Construction in progress will be transferred to fixed assets after reaching the intended usable state.

Please refer to Note 3, 25 "Impairment of Long-term Assets" for details on the impairment testing method and impairment provision accrual method for projects under construction.

22. Borrowing costs

Borrowing costs include borrowing interest, amortization of discounts or premiums, auxiliary expenses, and exchange differences arising from foreign currency borrowings. Borrowing costs directly attributable to the acquisition, construction or production of assets that meet the capitalization conditions shall be capitalized when asset expenditures have been incurred, borrowing costs have been incurred, and the acquisition, construction or production activities necessary to bring the assets to the intended usable or salable state have begun; capitalization shall cease when the assets purchased, constructed or produced that meet the capitalization conditions have reached the intended usable or salable state. The remaining borrowing costs are recognized as expenses in the current period.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The interest expenses actually incurred on special borrowings in the current period shall be capitalized after deducting the interest income from unused borrowed funds deposited in banks or investment income from temporary investments; the capitalization amount of general borrowings shall be determined based on the weighted average of asset disbursements exceeding the part of special borrowings multiplied by the capitalization rate of the occupied general borrowings. The capitalization rate is calculated and determined based on the weighted average interest rate of general borrowings.

During the capitalization period, all exchange differences on special foreign currency borrowings are capitalized; exchange differences on general foreign currency borrowings are included in the current profits and losses. Assets that qualify for capitalization refer to fixed assets, investment real estate, inventories and other assets that require a considerable period of acquisition, construction or production activities to reach the intended usable or salable state.

If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs will be suspended until the acquisition, construction or production activities of the asset are restarted.

23. Right-of-use assets

Right-of-use assets refer to the company's right as a lessee to use the leased assets during the lease period.

(1) Initial measurement of right-of-use assets

On the start date of the lease period, the Company initially measures the right-of-use assets at cost. This cost includes the following four items:

1. The initial measurement amount of the lease liability;

2. The lease payment amount paid on or before the start date of the lease term, if there is a lease incentive, will be deducted from the amount related to the lease incentive that has been enjoyed; 3) The initial direct costs incurred by the lessee;

3. The costs expected to be incurred by the lessee to dismantle and remove the leased assets, restore the site where the leased assets are located, or restore the leased assets to the state agreed upon in the lease terms, except for those incurred for the production of inventory.

(2) Subsequent measurement of right-of-use assets

After the start date of the lease period, the Company adopts the cost model for subsequent measurement of right-of-use assets, that is, the right-of-use assets are measured at cost minus accumulated depreciation and accumulated impairment losses.

If the company remeasures lease liabilities in accordance with the relevant provisions of the lease standards, the book value of the right-of-use assets will be adjusted accordingly.

(3) Depreciation of right-of-use assets

From the start date of the lease term, the Company will provide depreciation on the right-of-use assets. Right-of-use assets are generally depreciated from the month the lease term begins. The depreciation amount accrued shall be included in the cost of the relevant assets or the current profits and losses according to the purpose of the right-of-use assets.

When the Company determines the depreciation method for right-of-use assets, it makes a decision based on the expected realization of the economic benefits related to the right-of-use assets, and depreciates the right-of-use assets using the straight-line method.

When determining the depreciation life of right-of-use assets, the Company follows the following principles: If it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, depreciation will be accrued within the remaining useful life of the leased asset; if it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, depreciation will be accrued during the shorter of the lease term and the remaining useful life of the leased asset.

If the right-of-use asset is impaired, the company will conduct subsequent depreciation based on the book value of the right-of-use asset after deducting the impairment loss. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

24. Intangible assets

(1) Useful life and its determination basis, estimation, amortization method or review procedure

Intangible assets refer to identifiable non-monetary assets without physical form owned or controlled by the company.

Intangible assets are initially measured at cost. Expenditures related to intangible assets are included in the cost of intangible assets if the relevant economic benefits are likely to flow into the company and their costs can be measured reliably. Expenditures on other items other than these are included in the current profits and losses when incurred.

Acquired land use rights are usually accounted for as intangible assets. For self-developed and constructed factories and other buildings, the related land use right expenditures and building construction costs are accounted for as intangible assets and fixed assets respectively. In the case of outsourced houses and buildings, the relevant price will be allocated between the land use rights and the buildings. If it is difficult to reasonably distribute them, all of them will be treated as fixed assets.

The original value of an intangible asset with a limited useful life is amortized using the straight-line method over its estimated useful life from the time it becomes available for use. Intangible assets with indefinite useful lives are not amortized. The service life of intangible assets is determined according to the period during which they can bring economic benefits to the company. If it is impossible to predict the period during which they can bring economic benefits to the company, they are regarded as intangible assets with indefinite service life.

The useful life estimation and amortization method of intangible assets with limited service life are as follows:

Item Useful life Amortization method

Computer software 5 years Straight line method

Land use rights 50 years Straight-line method

Right to use proprietary technology 5 years Straight-line method

Patent rights 5 years Straight line method

Software copyright 8 years Straight line method

At the end of the period, the service life and amortization method of intangible assets with limited service life are reviewed, and any changes are treated as changes in accounting estimates. In addition, the service life of intangible assets with indefinite service life is also reviewed. If there is evidence that the intangible asset will bring economic benefits to the enterprise for a foreseeable period, its service life is estimated and amortized in accordance with the amortization policy for intangible assets with limited service life.

(2) Scope of aggregation of research expenditures and related accounting treatment methods

The Company divides the expenditures on internal research and development projects into expenditures in the research phase and expenditures in the development phase. Expenditures in the research stage are included in the current profits and losses when incurred. Expenditures in the development stage can only be capitalized when the following conditions are met at the same time, namely: it is technically feasible to complete the intangible asset so that it can be used or sold; there is the intention to complete the intangible asset and use or sell it; the intangible asset generates economic benefits in a manner that can prove the use of the intangible asset in production. There is a market for the product or the intangible asset itself exists. If the intangible asset will be used internally, its usefulness can be proven; there is sufficient technical, financial and other resource support to complete the development of the intangible asset, and the ability to use or sell the intangible asset; the expenditures attributable to the development stage of the intangible asset can be measured reliably. Development expenditures that do not meet the above conditions are included in the current profits and losses when incurred.

The scope of the company's R&D expenditures includes: R&D personnel wages, direct material costs, depreciation and amortization costs, entrusted external research and development costs, mold equipment, maintenance and calibration fees, etc.

(3) Impairment testing method and impairment provision accrual method for intangible assets

Please refer to Note 3, 25 "Impairment of Long-term Assets" for details on the impairment testing method and impairment provision method for intangible assets.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

25. Impairment of long-term assets

For non-current non-financial assets such as fixed assets, projects under construction, right-of-use assets, intangible assets with limited useful lives, investment properties measured using the cost model, and long-term equity investments in subsidiaries, joint ventures, and associates, the Company determines whether there are signs of impairment on the balance sheet date. If there is any indication of impairment, the recoverable amount is estimated and an impairment test is performed. Goodwill, intangible assets with indefinite useful lives and intangible assets that have not yet reached a usable state are subject to impairment testing every year regardless of whether there are signs of impairment.

If the impairment test results show that the recoverable amount of the asset is lower than its book value, impairment provisions will be made based on the difference and included in the impairment loss. The recoverable amount is the higher of the asset's fair value less disposal costs and the present value of the asset's expected future cash flows. The fair value of an asset is determined based on the sales agreement price in a fair transaction; if there is no sales agreement but there is an active market for the asset, the fair value is determined based on the buyer's bid for the asset; if there is no sales agreement and there is an active market for the asset, the fair value of the asset is estimated based on the best information available. Disposal costs include legal fees, related taxes, transportation fees and direct costs incurred in bringing the assets to a salable condition. The present value of the estimated future cash flows of an asset is determined by selecting an appropriate discount rate to discount the estimated future cash flows generated during the continued use and final disposal of the asset. Asset impairment provisions are calculated and recognized on the basis of individual assets. If it is difficult to estimate the recoverable amount of an individual asset, the recoverable amount of the asset group to which the asset belongs is determined. An asset group is the smallest combination of assets that can independently generate cash inflows.

For goodwill that is presented separately in the financial statements, when performing impairment testing, the book value of the goodwill is allocated to the asset group or combination of asset groups that are expected to benefit from the synergy effects of the business combination. If the test results show that the recoverable amount of an asset group or combination of asset groups containing amortized goodwill is lower than its book value, the corresponding impairment loss will be recognized. The amount of impairment loss first deducts the book value of the goodwill allocated to the asset group or asset group combination, and then deducts the book value of other assets in proportion to the proportion of the book value of other assets in the asset group or asset group combination except goodwill.

Once the above-mentioned asset impairment losses are recognized, the portion whose value has been restored will not be reversed in subsequent periods.

26. Long-term deferred expenses

Long-term deferred expenses are expenses that have been incurred but should be borne by the reporting period and subsequent periods with an amortization period of more than one year. The company's long-term deferred expenses mainly include laboratory decoration costs for cooperation with hospitals; long-term deferred expenses are amortized on a straight-line basis during the expected revenue period.

27. Contract liabilities

Contract liabilities refer to the company's obligation to transfer goods to customers for consideration it has received or receivable from customers. If the customer has paid the contract consideration or the company has obtained the unconditional right to receive payment before the company transfers the goods to the customer, the company will list the amount received or receivable as a contract liability at the earlier of the actual payment by the customer and the amount due. Contract assets and contract liabilities under the same contract are presented on a net basis, and contract assets and contract liabilities under different contracts are not offset.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

28. Employee compensation

(1) Accounting treatment method for short-term compensation

During the accounting period when employees provide services to the company, the actual short-term compensation is recognized as a liability and included in the current profit and loss or related asset costs. Employee welfare expenses incurred shall be included in the current profit and loss or related asset costs according to the actual amount when they are actually incurred. If employee benefits are non-monetary benefits, they are measured at fair value. Social insurance premiums such as medical insurance premiums, work-related injury insurance premiums, maternity insurance premiums, and housing provident funds paid for employees, as well as labor union funds and employee education funds withdrawn in accordance with regulations, during the accounting period when employees provide services to the company, the corresponding employee salary amounts are calculated and determined based on the prescribed accrual basis and accrual ratio, and the corresponding liabilities are recognized and included in the current profit and loss or related asset costs.

When an employee provides services that increase his or her future paid absence rights, employee benefits related to accumulated paid absences are recognized and measured based on the expected increase in payment amount due to accumulated unexercised rights. Employee benefits related to non-cumulative paid absences are recognized during the accounting period in which the employee is actually absent.

When the profit sharing plan meets the following conditions at the same time, the company will confirm the relevant employee benefits payable:

1. The current legal or constructive obligation to pay employee remuneration due to past events;

2. The amount of employee compensation obligations payable due to the profit sharing plan can be estimated reliably.

(2) Accounting treatment of post-employment benefits

1. Set up a withdrawal plan

During the accounting period when employees provide services to them, the company will recognize the deposit amount payable calculated according to the defined contribution plan as a liability and include it in the current profit and loss or related asset costs. According to the defined contribution plan, if the entire amount of deposits payable is not expected to be paid within twelve months after the end of the annual reporting period in which employees provide relevant services, the company will measure the entire amount of deposits payable as the discounted amount of employee benefits payable.

2. Defined benefit plan

The company's accounting treatment of defined benefit plans includes the following four steps:

① Based on the expected cumulative benefit unit method, unbiased and consistent actuarial assumptions are used to estimate relevant demographic variables and financial variables, measure the obligations arising from the defined benefit plan, and determine the vesting period of the relevant obligations. The company discounts the obligations arising from the defined benefit plan to determine the present value of the defined benefit plan obligations and the current service cost;

② If there are assets in the defined benefit plan, the company will recognize the deficit or surplus formed by the present value of the defined benefit plan obligations minus the fair value of the defined benefit plan assets as a net liability or net asset of the defined benefit plan. If there is a surplus in the defined benefit plan, the company shall measure the net assets of the defined benefit plan at the lower of the surplus of the defined benefit plan and the asset upper limit;

③ Determine the amount that should be included in the current profit and loss;

④ Determine the amount that should be included in other comprehensive income.

The company attributes the welfare obligations generated by the defined benefit plan to the period in which employees provide services based on the formula determined by the expected cumulative welfare unit method, and includes them in the current profits and losses or related asset costs. When an employee's service in subsequent years will result in a significantly higher level of defined benefit plan benefits than in previous years, the accumulated defined benefit plan obligations will be apportioned and recognized using the straight-line method from the period when the employee's provision of services results in the company's first defined benefit plan welfare obligation to the time when the employee's provision of services no longer results in a significant increase in the welfare obligation.

At the end of the reporting period, the company recognizes the employee compensation costs generated by the defined benefit plan as: service costs, net interest on the net liabilities or net assets of the defined benefit plan, and changes caused by re-measurement of the net liabilities or net assets of the defined benefit plan.

Under the defined benefit plan, the company recognizes past service costs as current expenses on the earliest of the following dates:

1. When modifying the defined benefit plan;

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. When the enterprise confirms relevant restructuring expenses or dismissal benefits.

The company recognizes a settlement gain or loss when settling the defined benefit plan.

(3) Accounting treatment method for dismissal benefits

If the company provides dismissal benefits to employees, the employee compensation liabilities arising from the dismissal benefits will be recognized at the earliest of the following two times and included in the current profit and loss: 1) The company cannot unilaterally withdraw the dismissal benefits provided due to the labor relationship termination plan or layoff proposal;

2. When the company recognizes costs or expenses related to restructuring involving payment of termination benefits.

In accordance with the provisions of the dismissal plan, the company reasonably estimates and confirms the employee benefits payable arising from dismissal benefits.

(4) Accounting treatment methods for other long-term employee benefits

Other long-term employee benefits provided by the company to employees that meet the conditions of the defined contribution plan shall be handled in accordance with the relevant policies on defined contribution plans.

Except for the above circumstances, the company recognizes and measures other long-term employee welfare net liabilities or net assets in accordance with the relevant policies on defined benefit plans. At the end of the reporting period, employee compensation costs arising from other long-term employee benefits are recognized as the following components:

1. Service cost;

2. Net interest on other long-term employee benefit net liabilities or net assets;

3. Changes caused by re-measurement of other long-term employee benefit net liabilities or net assets.

In order to simplify the relevant accounting treatment, the total net amount of the above items should be included in the current profit and loss or related asset costs.

If the level of long-term disability benefits depends on the length of the employee's service period, the company shall confirm the obligation to pay long-term disability benefits during the period during which the employee provides services; if the long-term disability benefits have nothing to do with the length of the employee's service period, the company shall confirm the obligation to pay long-term disability benefits in the current period when the event causing the employee's long-term disability occurs.

29. Lease liabilities

(1) Initial measurement of lease liabilities

The Company initially measures lease liabilities based on the present value of the unpaid lease payments at the beginning of the lease period.

Lease payments refer to the amounts paid by the company to the lessor related to the right to use the leased assets during the lease period, including: 1) fixed payments and substantive fixed payments. If there are lease incentives, the amount related to the lease incentives will be deducted;

2. Variable lease payments that depend on an index or ratio, which are determined at initial measurement based on the index or ratio at the beginning of the lease term; 3) The exercise price of the purchase option when the Company is reasonably certain that it will exercise the purchase option;

3. The lease term reflects the amount required to be paid when the company exercises the lease termination option;

4. The amount expected to be paid based on the residual value of the guarantee provided by the company.

Discount rate: When calculating the present value of lease payments, the Company uses the interest rate implicit in the lease as the discount rate. This interest rate refers to the interest rate that makes the sum of the present value of the lessor's lease payments and the present value of the unguaranteed residual value equal to the sum of the fair value of the leased asset and the lessor's initial direct costs. Since the company cannot determine the interest rate implicit in the lease, it uses the incremental borrowing rate as the discount rate. The incremental borrowing rate refers to the interest rate that the company must pay to borrow funds under similar mortgage conditions during a similar period to obtain assets close to the value of the right-of-use assets in a similar economic environment. This interest rate is related to:

1. The company’s own situation, that is, the group’s solvency and credit status;

2. The term of “borrowing”, that is, the lease period;

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. The amount of "borrowed" funds, that is, the amount of the lease liability;

4. "Mortgage conditions", that is, the nature and quality of the underlying assets;

5. Economic environment, including the jurisdiction where the lessee is located, the denomination currency, the time when the contract was signed, etc.

The company derives the incremental borrowing rate based on bank loan interest rates and adjustments taking into account the above factors.

(2) Subsequent measurement of lease liabilities

After the start date of the lease period, the Company conducts subsequent measurement of lease liabilities in accordance with the following principles:

1. When recognizing interest on lease liabilities, increase the carrying amount of the lease liability;

2. When the lease payment is paid, the carrying amount of the lease liability is reduced;

3. When the lease payments change due to revaluation or lease changes, the book value of the lease liability is remeasured. The interest expense of the lease liability for each period during the lease term is calculated based on a fixed periodic interest rate and included in the current profit and loss, except for those that should be capitalized. The periodic interest rate refers to the discount rate used by the Company when initially measuring lease liabilities, or the revised discount rate used by the Company when the lease liabilities need to be remeasured at a revised discount rate due to changes in lease payments or changes in the lease.

(3) Remeasurement of lease liabilities

After the start date of the lease period, when the following circumstances occur, the company will remeasure the lease liability based on the present value calculated by the changed lease payment and the revised discount rate, and adjust the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the company will include the remaining amount in the current profit and loss.

1. The actual fixed payment amount changes;

2. The expected amount payable of the residual value of the guarantee changes;

3. Changes in the index or ratio used to determine lease payments;

4. The evaluation result of the purchase option changes;

5. The evaluation results or actual exercise of the lease renewal option or lease termination option change.

30. Estimated liabilities

When obligations related to contingencies meet the following conditions at the same time, they are recognized as estimated liabilities: (1) The obligation is a current obligation assumed by the company; (2) Fulfillment of the obligation is likely to result in an outflow of economic benefits; (3) The amount of the obligation can be measured reliably.

On the balance sheet date, estimated liabilities are measured based on the best estimate of the expenditure required to fulfill the relevant current obligations, taking into account factors such as risks, uncertainties and the time value of money related to contingencies.

If all or part of the expenses required to settle estimated liabilities are expected to be compensated by a third party, the compensation amount will be recognized separately as an asset when it is basically certain that it will be received, and the recognized compensation amount will not exceed the book value of the estimated liabilities.

31. Share-based payment

(1) Types of share-based payment

According to the settlement method, it is divided into equity-settled share-based payment involving employees and cash-settled share-based payment involving employees. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Method for determining the fair value of equity instruments

For shares granted to employees, their fair value is measured based on the market price of the company's shares, and adjusted by taking into account the terms and conditions on which the shares are granted (excluding vesting conditions other than market conditions). For stock options granted to employees, the fair value of the options granted is estimated through an option pricing model.

(3) Basis for confirming the best estimate of exercisable equity instruments

On each balance sheet date during the waiting period, the company makes its best estimate based on the latest changes in the number of vested employees and other subsequent information, and corrects the number of equity instruments expected to be vested.

(4) Accounting treatments related to the implementation, modification, and termination of share-based payment plans

Equity-settled share-based payments involving employees, if vested immediately after grant, are included in cost expenses and capital reserves based on the fair value of the equity instruments on the date of grant; if vesting is subject to completion of services within the waiting period or meeting specified performance conditions after grant, on each balance sheet date during the waiting period, based on the best estimate of the number of exercisable equity instruments, based on the fair value of the equity instruments on the date of grant, the services obtained in the current period are included in relevant costs or expenses and capital reserves.

If a cash-settled share-based payment involving employees is exercisable immediately after the grant, the fair value of the liability borne by the company on the date of grant will be included in the relevant costs or expenses and corresponding liabilities; if the vesting is subject to completion of services during the waiting period or meeting specified performance conditions after the grant, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation, the services obtained in the current period will be included in the relevant costs or expenses and corresponding liabilities based on the fair value of the liability borne by the company.

32. Income

The company’s overall principles and measurement methods for revenue recognition are as follows:

(1) Identify performance obligations

Income is the total inflow of economic benefits generated by the company in its daily activities that will lead to an increase in shareholders' equity and have nothing to do with the capital invested by shareholders. The company fulfills its performance obligations in the contract, that is, when the customer obtains control of the relevant goods or services, revenue is recognized. Obtaining control over relevant goods or services means being able to direct the use of the goods or the provision of the services and obtain almost all economic benefits from them.

The Company regards the commitment to transfer goods (including services, the same below) to customers as a single performance obligation, and identifies single performance obligations in two situations: First, the Company transfers a commitment to clearly distinguishable goods (or combinations of goods) to customers. The second is the company's commitment to transfer to customers a series of clearly distinguishable goods that are essentially the same and have the same transfer mode.

(2) Determine the transaction price

The Company determines the transaction price based on the amount of consideration that it expects to be entitled to receive for transferring the goods to the customer. On the contract commencement date, the Company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods promised by each individual performance obligation. When determining the transaction price, the impact of variable consideration, significant financing components in the contract, non-cash consideration, consideration payable to customers and other factors was considered.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(3) Income judgment time and basis

For each individual performance obligation in the contract, if one of the following conditions is met, the company will recognize the transaction price allocated to the individual performance obligation as revenue according to the performance progress during the relevant performance period: the customer obtains and consumes the company at the same time that the company performs the contract. The economic benefits brought by the performance of the contract; the customer can control the goods under construction during the company's performance of the contract; the goods produced by the company during the performance of the contract have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period. The progress of contract performance is determined using the input method or the output method according to the nature of the transferred goods. When the progress of contract performance cannot be reasonably determined and the costs incurred by the company are expected to be compensated, revenue will be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined.

If one of the above conditions is not met, the company will recognize revenue at the time when the customer obtains control of the relevant goods based on the transaction price allocated to the individual performance obligation. When judging whether the customer has obtained control of the goods, the company considers the following signs: the company has the current right to receive payment for the goods, that is, the customer has current payment obligations for the goods; the company has transferred the legal ownership of the goods to the customer, that is, the customer already has the legal ownership of the goods; the company has The commodity is physically transferred to the customer, which means that the customer has physically taken possession of the commodity; the enterprise has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity; the customer has accepted the commodity; and other signs indicate that the customer has obtained control of the commodity.

(4) Main person in charge/agent

After the company obtains control of the goods from a third party, it transfers the output of the combination of goods and other goods or services to customers by providing significant services. The company has the right to independently determine the price of the goods or services traded. That is, the company can control the goods or services before transferring the goods or services to the customer. Therefore, the company is the main responsible person and recognizes revenue based on the total amount of consideration received or receivable. Otherwise, the company acts as an agent and recognizes revenue based on the amount of commissions or fees that it is expected to be entitled to receive. This amount should be determined based on the net amount of the total consideration received or receivable after deducting the price payable to other related parties, or based on the established commission amount or ratio.

The Company’s specific accounting policies for various types of revenue recognition are as follows:

(1) Sales contract

The company's business of selling reagents, consumables, and instruments usually only includes the performance obligation to transfer goods. When the goods have been shipped and the customer's receipt is received, the control of the goods is transferred, and the company recognizes the realization of revenue at that point. The company usually gives customers different credit periods based on their actual situation, but they are generally within one year, consistent with industry practice, and there is no major financing component.

(2) Provide labor contract

The company's income from services provided mainly includes software installation and maintenance, laboratory after-sales services, laboratory testing services, etc. According to the contract, if it is a service that performs performance obligations within a certain period of time, the service revenue of each period will be recognized according to the performance progress during the service period stipulated in the contract; for performance obligations that are not performed within a certain period of time, the service revenue will be recognized with the customer at the time when the relevant services are completed.

33. Contract assets

(1) Recognition methods and standards for contract assets

The Company and its subsidiaries present contract assets or contract liabilities in the balance sheet based on the relationship between performance obligations and customer payments.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The Company and its subsidiaries present the right to receive consideration from customers that is unconditional (i.e., dependent only on the passage of time) as receivables and the right to receive consideration for goods transferred to customers that is dependent on factors other than the passage of time as contract assets.

(2) Determination method and accounting treatment method of expected credit loss of contract assets

See III. 11 "Financial Instruments" for details and III. 12 "Impairment of Financial Assets" for details.

34. Contract costs

The Company's assets related to contract costs include contract acquisition costs and contract performance costs. According to their liquidity, they are presented in inventories, other current assets and other non-current assets respectively.

If the company expects to recover the incremental costs incurred to obtain the contract, it is recognized as an asset as the contract acquisition cost, unless the amortization period of the asset does not exceed one year.

The costs incurred by the company to fulfill the contract are not applicable to the scope of relevant standards such as inventories, fixed assets or intangible assets, and if the following conditions are met at the same time, they are recognized as contract performance costs as an asset: (1) The cost is directly related to a current or expected contract, including direct labor, direct materials, manufacturing expenses (or similar expenses), costs clearly borne by the customer, and other costs incurred only because of the contract; (2) The cost increases the company's future resources for fulfilling performance obligations; (3) The cost is expected to be recovered.

The company amortizes assets related to contract costs on the same basis as the revenue recognition related to the assets, and includes them in the current profits and losses.

If the book value of assets related to contract costs is higher than the difference between the following two items, the company will make impairment provisions for the excess and recognize it as asset impairment losses: (1) The remaining consideration that the enterprise expects to obtain for the transfer of goods or services related to the asset; (2) The estimated costs to be incurred for the transfer of the related goods or services.

35. Government subsidies

Government subsidies are recognized when the conditions attached to them can be met and received. If government subsidies are monetary assets, they shall be measured based on the amount received or receivable. If the government subsidy is a non-monetary asset, it shall be measured at fair value; if the fair value cannot be obtained reliably, it shall be measured at the nominal amount.

If the government document stipulates that it will be used to purchase, construct or form long-term assets in other ways, it will be regarded as an asset-related government subsidy; if the government document is not clear, the basic conditions that must be met to obtain the subsidy will be judged.

Government subsidies related to assets are recognized as deferred income and are included in the current profits and losses in installments according to a reasonable and systematic method within the useful life of the relevant assets. If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful lives, the undistributed balance of relevant deferred income will be transferred to the profits and losses of the current period of asset disposal. If government subsidies related to income are used to compensate for relevant costs, expenses or losses in the future period, they are recognized as deferred income, and are included in the current profit and loss or offset the relevant costs and expenses during the period when the relevant costs, expenses or losses are recognized; if they are used to compensate for the relevant costs, expenses or losses that have already occurred, they are directly included in the current profits and losses or offset the relevant costs and expenses.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

36. Deferred income tax assets/deferred income tax liabilities

(1) Current income tax

On the balance sheet date, current income tax liabilities (or assets) formed in the current and previous periods are measured based on the amount of income tax expected to be paid (or refunded) calculated in accordance with the provisions of tax laws. The taxable income based on which the income tax expense for the current period is calculated is calculated based on the relevant tax laws and regulations by making corresponding adjustments to the pre-tax accounting profit for the reporting period.

(2) Deferred income tax assets and deferred income tax liabilities

Deferred income tax assets and deferred income tax liabilities are calculated and recognized based on the difference between the tax basis of assets and liabilities and their book value (including taxable temporary differences and deductible temporary differences). Deductible losses that can be offset against taxable income in subsequent years in accordance with tax laws are deemed to be deductible temporary differences. For temporary differences arising from the initial recognition of goodwill, no corresponding deferred income tax liabilities are recognized.

Except for individual transactions (including lease transactions in which the lessee initially recognizes lease liabilities on the start date of the lease period and includes them in the right-of-use assets, and transactions in which estimated liabilities are recognized and included in the cost of related assets due to the disposal obligation of fixed assets, etc.), for temporary differences arising from the initial recognition of assets or liabilities in other non-business combination transactions that neither affect accounting profits nor taxable income (or deductible losses), the corresponding deferred income tax assets and deferred income tax liabilities are not recognized. For the taxable temporary differences and deductible temporary differences arising from the initial recognition of assets and liabilities in the aforementioned individual transactions, the corresponding deferred income tax liabilities and deferred income tax assets are recognized respectively when the transaction occurs.

On the balance sheet date, deferred income tax assets and deferred income tax liabilities are measured according to the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled. Deferred income tax assets are recognized to the extent that the company is likely to obtain taxable income that can be used to offset deductible temporary differences, deductible losses and tax credits. Deferred income tax assets and deferred income tax liabilities arising from temporary differences related to investments in subsidiaries, associates and joint ventures are recognized. However, if the company can control the time of reversal of temporary differences and the temporary differences are likely not to be reversed in the foreseeable future, they will not be recognized.

(3) Income tax expenses

Income tax expense includes current income tax and deferred income tax.

Except for the current income tax and deferred income tax related to transactions and events recognized as other comprehensive income or directly included in shareholders' equity, which are included in other comprehensive income or shareholders' equity, and the deferred income tax arising from business combinations adjusts the book value of goodwill, the remaining current income tax and deferred income tax expenses or income are included in the current profit and loss.

(4) Offset of income tax

When it has the legal right to settle on a net basis and intends to settle on a net basis or acquire assets and pay off liabilities at the same time, the company's current income tax assets and current income tax liabilities are presented at the net amount after offsetting.

When you have the legal right to settle current income tax assets and current income tax liabilities on a net basis, and the deferred income tax assets and deferred income tax liabilities are related to the income tax levied by the same tax collection and administration department on the same taxable entity or on different taxable entities, but in the future each During the period when significant deferred income tax assets and liabilities are reversed, when the tax payer involved intends to settle the current income tax assets and liabilities on a net basis or to acquire assets and settle liabilities at the same time, the Company's deferred income tax assets and deferred income tax liabilities will be presented at the net amount after offsetting. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

37. Leasing

A lease is a contract in which the Company transfers or acquires the right to control the use of one or more identified assets for a certain period of time in exchange for or payment of consideration. On the commencement date of the intended contract, the Company evaluates whether the contract is a lease or contains a lease.

(1) The company serves as the lessee

The company's leased assets mainly include buildings, instruments and equipment.

1. Initial measurement

On the start date of the lease period, the Company recognizes the right to use the leased asset during the lease term as a right-of-use asset, and recognizes the present value of the unpaid lease payments as a lease liability, except for short-term leases and low-value asset leases. When calculating the present value of lease payments, the company uses the interest rate implicit in the lease as the discount rate; if the interest rate implicit in the lease cannot be determined, the lessee's incremental borrowing rate is used as the discount rate.

2. Subsequent measurement

The company refers to the relevant depreciation provisions of "Accounting Standards for Business Enterprises No. 4 - Fixed Assets" to make depreciation provisions for right-of-use assets (see this note for details)

3. 20 "Fixed Assets"), if it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the Company will accrue depreciation within the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the Company will accrue depreciation during the shorter of the lease term and the remaining useful life of the leased asset.

For lease liabilities, the company calculates the interest expense for each period during the lease term based on a fixed periodic interest rate and includes it in the current profit and loss. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss when actually incurred.

After the start date of the lease period, when the actual fixed payment amount changes, the expected amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment amount changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, the company remeasures the lease liability based on the present value of the changed lease payment amount, and adjusts the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the company will include the remaining amount in the current profit and loss.

3. Short-term leasing and leasing of low-value assets

The company will identify leases with a lease term of no more than 12 months on the start date of the lease period and that do not include a purchase option as short-term leases; leases with a value of no more than 40,000.00 yuan when a single leased asset is a new asset will be identified as low-value asset leases. If the company subleases or anticipates subletting a leased asset, the original lease will not be recognized as a low-value asset lease. The company chooses not to recognize right-of-use assets and lease liabilities for short-term leases and low-value asset leases. The relevant asset costs or current profits and losses are included in each period during the lease term using the straight-line method.

(2) The company serves as the lessor

On the lease commencement date, the Company divides leases into finance leases and operating leases based on the nature of the transaction. A finance lease is a lease that transfers substantially all the risks and rewards associated with ownership of the leased asset. Operating leases refer to leases other than finance leases. 1) Operating lease

The Company uses the straight-line method to recognize lease receipts from operating leases as rental income for each period during the lease term. Variable lease payments related to operating leases that are not included in lease receipts are included in the current profit and loss when they actually occur.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Financial leasing

On the commencement date of the lease period, the Company recognizes the finance lease receivable and derecognizes the finance lease assets. Financing lease receivables are initially measured based on the net lease investment (the sum of the unguaranteed residual value and the present value of the lease payments not yet received at the start of the lease period discounted at the interest rate implicit in the lease), and interest income during the lease period is calculated and recognized based on a fixed periodic interest rate. Variable lease payments obtained by the Company that are not included in the measurement of net lease investment are included in the current profit and loss when actually incurred.

38. Goodwill

Goodwill is the excess of the equity investment cost over the investee's share of the fair value on the date of investment acquisition, or the excess of the cost of a business combination not under common control over the fair value of the acquiree's identifiable net assets acquired in the business combination on the date of purchase.

Goodwill formed by business combinations is presented separately in the consolidated financial statements. The difference between the cost of purchasing equity investment in associates and joint ventures and the share of the fair value of the investee at the time of investment is included in long-term equity investment.

39. Changes in important accounting policies and accounting estimates

There are no significant changes in accounting policies and accounting estimates during this period.

40. Others

The Company has no other important accounting policies and accounting estimates that need to be disclosed during the reporting period.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

4. Taxes

1. Main tax types and tax rates

Type of tax Tax calculation basis Tax rate

Calculate output tax based on taxable sales revenue, and deduct the input 13.00%, 9.00%, 6.00%, and value-added tax that are allowed to be deducted in the current period.

The value-added tax on the difference after the tax amount is calculated and paid: 5.00%, 3.00%, 0.00%. Urban maintenance and construction tax is calculated and paid based on the actual value-added tax paid: 7.00%, 5.00%, 1.00%

27.00%, 25.00%, 20.00%, corporate income tax, turnover tax payable

16.50%, 15.00%

If there are taxpayers with different corporate income tax rates, a description of the disclosure:

Name of tax payer 2025 income tax rate

Shanghai Huizhong Medical Technology Co., Ltd. 15.00% Shanghai Huizhong Biotechnology Co., Ltd. 15.00% Shanghai Huirui Information Technology Co., Ltd. 15.00% Shanghai Runda Rongjia Biotechnology Co., Ltd. 15.00% Beijing Huizhong Medical Equipment Co., Ltd. 15.00% Shanghai Ruimei Computer Technology Co., Ltd. 15.00% Shanghai Yicheng Precision Machinery Co., Ltd. 20.00% Heilongjiang Xinshengrui Medical Technology Co., Ltd. 20% 27.00%Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Tax incentives and approvals

(1) Corporate income tax

1. The company's subsidiary, Shanghai Huizhong Medical Technology Co., Ltd., obtained a high-tech enterprise certificate (valid for three years) through review on November 15, 2023, and will enjoy the preferential corporate income tax rate of 15.00% for high-tech enterprises from January 1, 2023 to December 31, 2025.

2. Shanghai Huizhong Biotechnology Co., Ltd., a subsidiary of the company, obtained a high-tech enterprise certificate (valid for three years) through review on December 25, 2025, and will enjoy the preferential corporate income tax rate of 15.00% for high-tech enterprises from January 1, 2025 to December 31, 2027.

3. The company's subsidiary, Shanghai Wairui Information Technology Co., Ltd., passed the review and obtained the high-tech enterprise certificate (valid for three years) on December 19, 2025. From January 1, 2025 to December 31, 2027, it enjoys the preferential corporate income tax rate of 15.00% for high-tech enterprises.

4. The company's subsidiary, Shanghai Runda Rongjia Biotechnology Co., Ltd., passed the review and obtained the high-tech enterprise certificate (valid for three years) on December 12, 2023. From January 1, 2023 to December 31, 2025, it will enjoy the preferential corporate income tax rate of 15.00% for high-tech enterprises.

5. The company’s subsidiary, Beijing Huizhong Medical Equipment Co., Ltd., passed the review and obtained the high-tech enterprise certificate (valid for three years) on December 2, 2024. From January 1, 2024 to December 31, 2026, enjoy the preferential corporate income tax rate of 15.00% for high-tech enterprises.

6. The company’s subsidiary, Shanghai Ruimei Computer Technology Co., Ltd., obtained the high-tech enterprise certificate through review on December 26, 2024 (valid for three years). From January 1, 2024 to December 31, 2026, enjoy the preferential corporate income tax rate of 15.00% for high-tech enterprises.

7. According to the "Announcement on Relevant Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households" (Announcement No. 12 of the Ministry of Finance and the State Administration of Taxation in 2023): 3. The taxable income of small and low-profit enterprises will be calculated at a reduced rate of 25.00%, and the corporate income tax policy will be paid at a rate of 20.00%, which will continue to be implemented until December 31, 2027. The company's subsidiaries - Shanghai Yicheng Precision Machinery Co., Ltd., Heilongjiang Xinshengrui Medical Technology Co., Ltd., Chongqing Runda Kangtai Medical Equipment Co., Ltd., Guangdong Runda Medical Diagnostic Technology Co., Ltd., Zhejiang Hangrun Private Equity Fund Management Co., Ltd., Fuyang Runda Medical Technology Co., Ltd., and Hangzhou Mingheyuan Medical Technology Co., Ltd. meet the conditions of small and low-profit enterprises, and corporate income tax is calculated and paid in accordance with the above regulations.

8. "Announcement of the Ministry of Finance, State Administration of Taxation, Development and Reform Commission, Ministry of Industry and Information Technology on Corporate Income Tax Policies to Promote the High-Quality Development of the Integrated Circuit Industry and Software Industry" (No. 45, 2020): Starting from January 1, 2020, software companies encouraged by the state will be exempted from corporate income tax from the first to second years starting from the profit-making year, and will be levied corporate income tax at a half statutory rate of 25.00% from the third to fifth years. The company's subsidiary, Shanghai Ruimei Network Technology Co., Ltd., was recognized as a software company in 2022. Starting from the profit-making year of 2022, it will enjoy "two exemptions and three halvings" of corporate income tax. It will enjoy tax exemption from 2022 to 2023 and enjoy a 50% reduction from 2024 to 2026.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Value-added tax

1. According to the "Taxpayer Tax Reduction and Reduction Registration Form" issued by the Shanghai Hongkou District State Taxation Bureau on December 15, 2017, the "VAT exemption for medical and health institutions" registration matter handled by the company's subsidiary, Shanghai Zhongke Runda Medical Testing Laboratory Co., Ltd., has been accepted for filing. VAT exemption is approved for income from medical services provided from July 1, 2017 to December 31, 2019 that qualify for tax exemption. According to the regulations on the official website of the Shanghai Municipal Taxation Bureau of the State Administration of Taxation, starting from November 1, 2019, taxpayers will be required to "judge themselves, declare and enjoy, retain relevant information for future reference, and submit attached information for specific items" to enjoy VAT preferential registration matters. You will continue to enjoy the above discounts in 2025.

2. According to the "Notice of the Ministry of Finance and the State Administration of Taxation on Value-Added Tax Policies for Software Products" (Caishui [2011] No. 100), general VAT taxpayers who sell self-developed and produced software products will be charged VAT at a rate of 13.00%, and the portion of their actual VAT tax burden exceeding 3.00% will be subject to an immediate refund policy. The company's subsidiaries - Shanghai Ruimei Computer Technology Co., Ltd. and its subsidiaries Shanghai Ruimei Information Technology Co., Ltd., Shanghai Ruimei Software Technology Co., Ltd., and Shanghai Ruimei Network Technology Co., Ltd. will implement a policy of immediate refund for the portion of the actual VAT tax burden exceeding 3.00% this year.

3. According to the "Notice of the Ministry of Finance and the State Administration of Taxation on Value-Added Tax Policies for Software Products" (Caishui [2011] No. 100), general VAT taxpayers who sell self-developed and produced software products will be levied a VAT at a rate of 13.00%, and the portion of their actual VAT tax burden exceeding 3.00% will be subject to an immediate refund policy. The company's subsidiary, Shanghai Huirui Information Technology Co., Ltd., will implement a policy of immediate refund for the portion of the actual tax burden exceeding 3.00% of the value-added tax this year.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

5. Notes on Consolidated Financial Statement Items

1. Monetary funds

Item December 31, 2025 Cash on hand as of December 31, 2024 188,860.25 241,546.97 Bank deposits 666,856,850.06 888,769,738.14 Other monetary funds 348,798,466.12 317,513,912.56

Total 1,015,844,176.43 1,206,525,197.67 Including: Total amount deposited abroad 8,736,893.93 41,966,623.89

(1) The details of restricted monetary funds are as follows:

Item December 31, 2025 Bank acceptance bill security deposit on December 31, 2024 132,100,000.00 39,100,000.00 Letter of credit security deposit 70,168,460.06 112,378,640.98 Performance security deposit 13,420,932.72 7,559,007.97 Time deposits or notice deposits used for guarantee 52,912,690.79 93,129,054.11 Other restricted monetary funds 80,196,382.55 65,347,209.50

Total 348,798,466.12 317,513,912.56

2. Trading financial assets

Item December 31, 2025 December 31, 2024 Reasons and basis for designation Measured at fair value with changes included

129,800,000.00 82,200,524.19 \

Financial assets with current profits and losses

Including: equity instrument investment\

Bank financial products 129,800,000.00 82,200,524.19 \

Total 129,800,000.00 82,200,524.19

3. Notes receivable

(1) Classified presentation of notes receivable:

Item December 31, 2025 Bank acceptance notes on December 31, 2024 72,788,675.34 102,444,591.95 Commercial acceptance notes 82,561,069.43 27,164,684.41

Subtotal 155,349,744.77 129,609,276.36Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Item December 31, 2025 December 31, 2024 Less: bad debt provision 9,394,997.75 271,646.84

Total 145,954,747.02 129,337,629.52

(2) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date:

December 31, 2025 December 31, 2024

Project

Amount derecognized at the end of the period Amount not derecognized at the end of the period Amount derecognized at the end of the period Amount not derecognized at the end of the period Bank acceptance notes 60,396,952.98 87,306,435.64

Commercial acceptance notes 55,429,993.94

Total 60,396,952.98 55,429,993.94 87,306,435.64

(3) Notes receivable are classified and disclosed according to the bad debt accrual method:

December 31, 2025

Item Book balance Bad debt provision

Provision ratio Book value amount Ratio (%) Amount

(%)

Notes receivable with provision for bad debts individually

Notes receivable with provision for bad debts on a group basis 155,349,744.77 100.00 9,394,997.75 6.05 145,954,747.02 Of which:

Portfolio 1 bank acceptance notes 72,788,675.34 46.85 72,788,675.34 Portfolio 2 commercial acceptance notes 82,561,069.43 53.15 9,394,997.75 11.38 73,166,071.68 Total 155,349,744.77 9,394,997.75 145,954,747.02

December 31, 2024

Book balance Bad debt provision

Project

Provision ratio Book value amount Ratio (%) Amount

(%)

Notes receivable with provision for bad debts individually

Notes receivable with provision for bad debts on a group basis 129,609,276.36 100.00 271,646.84 0.21 129,337,629.52 Of which:

Portfolio 1 bank acceptance notes 102,444,591.95 79.04 102,444,591.95 Portfolio 2 commercial acceptance notes 27,164,684.41 20.96 271,646.84 1.00 26,893,037.57

Total 129,609,276.36 271,646.84 129,337,629.52Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(4) Bad debt provisions for notes receivable accrued, recovered or reversed in the current period:

Amount of changes in the current period

Project December 31, 2024 December 31, 2025

Provision, recovery or transfer, write-off or write-off

Commercial acceptance notes 271,646.84 9,123,350.91 9,394,997.75

Total 271,646.84 9,123,350.91 9,394,997.75

4. Accounts receivable

(1) Accounts receivable are disclosed based on aging:

Aging December 31, 2025 Within 1 year on December 31, 2024 3,621,982,027.90 4,495,004,036.78 1 to 2 years 902,714,570.55 798,734,125.04 2 to 3 years 386,958,006.43 300,255,335.27 More than 3 years 341,611,191.33 218,445,579.05

Subtotal 5,253,265,796.21 5,812,439,076.14 Less: bad debt provision 788,336,199.64 615,763,066.54

Total 4,464,929,596.57 5,196,676,009.60

(2) Accounts receivable are classified and disclosed according to the bad debt accrual method:

December 31, 2025

Book balance Bad debt provision

Category

Provision ratio Book value amount Ratio (%) Amount

(%)

Accounts receivable with bad debt provisions made individually 28,707,557.69 0.55 28,155,771.94 98.08 551,785.75 Of which:

The individual amount is significant and bad debt allowance has been separately accrued

funds provided

The individual amount is not significant and bad debts have been separately accrued

28,707,557.69 0.55 28,155,771.94 98.08 551,785.75 Amounts prepared

Accounts receivable with provision for bad debts on a group basis 5,224,558,238.52 99.45 760,180,427.70 14.55 4,464,377,810.82 Of which:

Credit period and aging combination 5,224,558,238.52 99.45 760,180,427.70 14.55 4,464,377,810.82

Total 5,253,265,796.21 788,336,199.64 4,464,929,596.57 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2024

Book balance Bad debt provision

Category

Provision ratio Book value amount Ratio (%) Amount

(%)

Accounts receivable with bad debt provisions made individually 15,417,804.91 0.27 14,034,137.84 91.03 1,383,667.07 Of which:

The individual amount is significant and bad debt allowance has been separately accrued

funds provided

The individual amount is not significant and bad debts have been separately accrued

15,417,804.91 0.27 14,034,137.84 91.03 1,383,667.07 Amounts prepared

Accounts receivable with provision for bad debts on a group basis 5,797,021,271.23 99.73 601,728,928.70 10.38 5,195,292,342.53 Of which:

Credit period and aging combination 5,797,021,271.23 99.73 601,728,928.70 10.38 5,195,292,342.53 Total 5,812,439,076.14 615,763,066.54 5,196,676,009.60

1. Accounts receivable for which bad debt provisions are individually made:

December 31, 2025

Accounts receivable (by unit)

Accounts receivable Bad debt provision Proportion (%) Reason for provision

Unit 1 10,146,755.12 10,146,755.12 100.00 Objective evidence, expected to be partially recovered Unit 2 9,072,267.42 8,520,481.67 93.92 Objective evidence, expected to be unrecoverable Unit 3 4,208,139.71 4,208,139.71 100.00 Objective evidence, unit four expected to be unrecoverable 2,020,160.00 2,020,160.00 100.00 Objective evidence, unit five expected to be partially recovered 1,394,500.00 1,394,500.00 100.00 Objective evidence, unit six expected to be unrecoverable 496,216.94 496,216.94 100.00 Objective evidence, Unit VII is not expected to be recovered 468,325.70 468,325.70 100.00 Objective evidence, Unit VIII is not expected to be recovered 398,144.00 398,144.00 100.00 Objective evidence, Unit IX is not expected to be recovered 280,000.00 280,000.00 100.00 Objective evidence, expected to be unrecoverable Unit ten 190,000.00 190,000.00 100.00 Objective evidence, expected to be unrecoverable Others 33,048.80 33,048.80 100.00 Objective evidence, expected to be unrecoverable Total 28,707,557.69 28,155,771.94

2. Accounts receivable for which bad debt provisions are made using the aging analysis method:

December 31, 2025

Aging

Accounts receivable Bad debt provision Provision ratio (%) Within the credit period 2,856,575,495.30 28,565,757.60 1.00 The credit period expires to 1 year (including 1 year) 765,406,532.60 38,270,326.71 5.00 1 to 2 years 902,388,997.43 180,477,799.46 20.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2025

Aging

Accounts receivable Bad debt provision Proportion (%) 2 to 3 years 374,641,338.72 187,320,669.46 50.00 More than 3 years 325,545,874.47 325,545,874.47 100.00 Total 5,224,558,238.52 760,180,427.70

December 31, 2024

Aging

Accounts receivable Bad debt provision Provision ratio (%) Within the credit period 3,418,492,667.63 34,184,926.68 1.00 Credit period expires to 1 year (inclusive of 1 year) 1,076,238,318.28 53,811,915.91 5.00 1 to 2 years 798,038,167.96 159,607,636.38 20.00 2 to 3 years 300,255,335.27 150,127,667.64 50.00 More than 3 years 203,996,782.09 203,996,782.09 100.00

Total 5,797,021,271.23 601,728,928.70

(3) Bad debt provisions for accounts receivable accrued, recovered or reversed in the current period:

Amount of changes in the current period

Category Consolidation scope on December 31, 2024 Recovery or provision on December 31, 2025 Write-off or write-off Other

Impact of changes Reversal

Accounts receivable

615,763,066.54 175,625,375.17 3,053,570.78 1,328.71 788,336,199.64 Bad debt provision

Total 615,763,066.54 175,625,375.17 3,053,570.78 1,328.71 788,336,199.64

(4) Accounts receivable actually written off in this period:

Project 2025 2024

Accounts receivable actually written off 3,053,570.78 319,420.25

Total 3,053,570.78 319,420.25

(5) The top five accounts receivable at the end of the period based on debtors:

December 31, 2025

Unit name Closing balance of total accounts receivable Bad debt provision

Proportion (%) First place 93,710,135.26 6,430,495.01 1.78 Second place 81,027,634.60 14,086,276.27 1.54 Third place 78,189,254.85 5,765,236.72 1.49 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2025

Unit name Closing balance of total accounts receivable Bad debt provision

Proportion (%) Fourth place 69,008,220.69 6,224,447.27 1.31 Fifth place 67,913,663.42 12,062,691.68 1.29

Total 389,848,908.82 44,569,146.95 7.41

5. Advance payments

(1) Prepayments are listed based on aging:

December 31, 2025 December 31, 2024

Aging

Amount Proportion (%) Amount Proportion (%) Within 1 year 520,287,278.68 72.82 773,553,950.28 81.51 1 to 2 years 132,247,491.46 18.51 83,363,009.47 8.78 2 to 3 years 36,507,823.77 5.11 70,447,354.29 7.42 More than 3 years 25,449,752.77 3.56 21,720,376.14 2.29

Total 714,492,346.68 100.00 949,084,690.18 100.00

(2) The top five prepayments at the end of the period by prepayment objects:

Company name December 31, 2025 Proportion of total prepayments (%) First place 53,757,562.71 7.52 Second place 37,720,545.43 5.28 Third place 36,378,275.12 5.09 Fourth place 35,662,320.40 4.99 Fifth place 35,587,233.64 4.98

Total 199,105,937.30 27.86

6. Other receivables

(1) Classification of other receivables:

Project December 31, 2025 December 31, 2024

interest receivable

Dividends receivable 1,126,647.24 18,626,647.24 Other receivables 196,337,002.09 213,225,151.06

Subtotal 197,463,649.33 231,851,798.30 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Project December 31, 2025 December 31, 2024

Bad debt provision 33,446,406.19 26,410,180.45

Total 164,017,243.14 205,441,617.85

(2) Dividends receivable:

1. Dividends receivable:

① Classification of dividends receivable

Project December 31, 2025 December 31, 2024 Henan Runbaida Medical Equipment Co., Ltd. 1,126,647.24 1,126,647.24 Suzhou Runying Medical Equipment Co., Ltd. 17,500,000.00

Subtotal 1,126,647.24 18,626,647.24 Less: Bad debt provision 1,126,647.24 1,301,647.24 Total 17,325,000.00

② Provision for bad debts based on the general expected credit loss model

The first stage The second stage The third stage

Lifetime expectations Lifetime expectations

Provision for bad debts Estimated total credit losses (unincurred) in the next 12 months Credit losses (incurred

period credit loss

credit impairment) credit impairment)

Balance on December 31, 2024 175,000.00 1,126,647.24 1,301,647.24 Balance on December 31, 2024 in the current period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period -175,000.00 -175,000.00 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on December 31, 2025 1,126,647.24 1,126,647.24Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

③ Bad debt provisions accrued, recovered or reversed in the current period

Amount of changes in the current period

Category December 31, 2024 December 31, 2025

Provision Recovery or transfer Write-off or write-off Others

Dividends receivable 1,301,647.24 -175,000.00 1,126,647.24

Total 1,301,647.24 -175,000.00 1,126,647.24

(3) Other receivables:

1. Classification of other receivables according to nature of payment:

Nature of payment December 31, 2025 December 31, 2024

Deposits and security deposits 102,892,866.22 109,833,997.67 Reserve funds 13,421,543.48 13,138,665.45 Advances 4,538,602.13 3,281,784.62 Loans and current accounts 65,031,614.35 74,994,804.19 Others 10,452,375.91 11,975,899.13

Subtotal 196,337,002.09 213,225,151.06 Less: Bad debt provision 32,319,758.95 25,108,533.21 Total 164,017,243.14 188,116,617.85

2. Provision for bad debt provisions for other receivables:

The first stage The second stage The third stage

Lifetime expectations Lifetime expectations

Provision for bad debts Estimated total credit losses in the next 12 months (unissued Credit losses (issued

period credit loss

resulting in credit impairment) resulting in credit impairment)

Balance on December 31, 2024 1,187,468.62 2,652,222.15 21,268,842.44 25,108,533.21 Balance on December 31, 2024 in the current period

--Transfer to the second stage -45,000.00 45,000.00

--Transfer to the third stage -12,119.43 -1,603,307.29 1,615,426.72

--Return to the second stage

--Return to the first stage 100.00 -100.00

Provision for the current period -19,278.63 181,661.56 7,135,163.49 7,297,546.42 Transferred for the current period

Sales in this period

Write-off in this period 87,160.96 87,160.96 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

The first stage The second stage The third stage

Lifetime expectations Lifetime expectations

Provision for bad debts Estimated total credit losses in the next 12 months (unissued Credit losses (issued

period credit loss

resulting in credit impairment) resulting in credit impairment)

Other changes 840.28 840.28 Balance as of December 31, 2025 1,112,010.84 1,275,476.42 29,932,271.69 32,319,758.95

3. Disclosure of other receivables based on age:

Aging December 31, 2025 December 31, 2024

Within 1 year 66,228,058.26 104,426,784.91 1-2 years 52,795,055.66 37,810,844.09 2-3 years 20,323,940.58 17,894,901.25 More than 3 years 56,989,947.59 53,092,620.81

Subtotal 196,337,002.09 213,225,151.06 Less: Bad debt provision 32,319,758.95 25,108,533.21 Total 164,017,243.14 188,116,617.85

4. Bad debt provisions for other receivables accrued, recovered or reversed in the current period:

Amount of changes in the current period

Category December 31, 2024 December 31, 2025

Provision Recovery or transfer Write-off or write-off Others

Other receivables 25,108,533.21 7,297,546.42 87,160.96 840.28 32,319,758.95Total 25,108,533.21 7,297,546.42 87,160.96 840.28 32,319,758.95

5. Other receivables actually written off in this period:

Project December 31, 2025 December 31, 2024

Other receivables actually written off 87,160.96 325,876.14 Total 87,160.96 325,876.14

6. Other receivables with top five closing balances based on debtors:

Accounting for the closing balance of other receivables

Company name December 31, 2025 Bad debt provision Nature of payment Aging

Proportion of total amount (%)

Memorial of Sun Yat-sen at Sun Yat-sen University

17,344,000.00 3,468,800.00 8.83 Loans and current accounts 1-2 years Hospital Shenshan Central Hospital

Loans and current accounts, within the credit period, and beyond 1 year Taizhou Second People’s Hospital 10,809,600.00 3,833,820.00 5.51

Deposit and security deposit Within, 1-2 years, 2-3 years Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Accounting for the closing balance of other receivables

Company name December 31, 2025 Bad debt provision Nature of payment Aging

Proportion of total amount (%)

Zhejiang Runxin Medical Technology Co., Ltd.

7,496,868.00 7,496,868.00 3.82 Loans and current accounts Limited company for more than 3 years

Abbott Trading (Shanghai) has

7,156,286.00 71,562.86 3.64 Deposit and margin Credit period Co., Ltd.

Lease office leasing contract

6,717,941.52 67,179.41 3.42 Deposit and security deposit Same as deposit during the credit period

Total 49,524,695.52 14,938,230.27 25.22

7. Inventory

(1) Inventory classification:

December 31, 2025

Item Inventory impairment provision or contract

Book balance Book value

Provision for impairment of performance costs

Raw materials 62,272,775.87 138,083.40 62,134,692.47 Work in progress 17,628,152.61 17,628,152.61 Inventory goods 1,646,417,193.99 9,090,452.17 1,637,326,741.82 Self-made semi-finished products 14,796,224.43 76,713.00 14,719,511.43 Total 1,741,114,346.90 9,305,248.57 1,731,809,098.33

December 31, 2024

Item Inventory impairment provision or contract

Book balance Book value

Provision for impairment of performance costs

Raw materials 48,316,997.37 1,181,653.20 47,135,344.17 Work in progress 10,638,194.28 10,638,194.28 Inventory goods 1,267,263,174.21 16,973,516.59 1,250,289,657.62 Self-made semi-finished products 15,982,141.60 605,976.00 15,376,165.60

Total 1,342,200,507.46 18,761,145.79 1,323,439,361.67

(2) Provision for inventory depreciation and provision for impairment of contract performance costs:

December 2024 Increase amount in this period Decrease amount in this period Project in December 2025

Provision on the 31st Others Transfer or resale Others Raw materials on the 31st 1,181,653.20 17,636.40 1,061,206.20 138,083.40 Inventory goods 16,973,516.59 -305,317.26 1,768.40 7,579,515.56 9,090,452.17 Self-made semi-finished products 605,976.00 9,030.00 538,293.00 76,713.00Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 2024 Increase amount in this period Decrease amount in this period Project in December 2025

Provision on the 31st Other Transfer or write-off Others Total on the 31st 18,761,145.79 -305,317.26 28,434.80 9,179,014.76 9,305,248.57

Note: The inventory write-off of RMB 9,179,014.76 in this period was all external sales.

8. Non-current assets due within one year

Item December 31, 2025 Long-term receivables due within one year on December 31, 2024 (Note V. 10) 25,657,975.38 37,252,713.75

Total 25,657,975.38 37,252,713.75

9. Other current assets

Project December 31, 2025 December 31, 2024

Value-added tax input tax to be deducted and certified 121,442,853.44 71,552,839.03 Prepaid corporate income tax 3,173,976.71 1,451,657.12 Others 57,887.34

Total 124,616,830.15 73,062,383.49

10. Long-term receivables

(1) Long-term receivables:

December 31, 2025 Discount rate range project

Book balance Bad debt provision Book value (%) Financing lease 18,200,000.00 182,000.00 18,018,000.00 Not applicable Installment collection sales of goods 30,792,358.96 11,905,320.54 18,887,038.42 4.50-4.75 minus: Part due within one year (Note 5, 8) 37,631,689.22 11,973,713.84 25,657,975.38

Total 11,360,669.74 113,606.70 11,247,063.04

December 31, 2024 Discount rate range project

Book balance Bad debt provision Book value (%) Financing lease 31,010,000.00 310,100.00 30,699,900.00 Not applicable Installment collection sales of goods 31,537,139.55 7,182,547.18 24,354,592.37 4.50-4.75 minus: Part due within one year (Note 5, 8) 44,565,544.99 7,312,831.24 37,252,713.75

Total 17,981,594.56 179,815.94 17,801,778.62

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Provision for bad debt provisions for long-term receivables:

The first stage The second stage The third stage Expected for the entire duration Expected bad debt provisions for the entire duration Expected total credit losses in the next 12 months (unissued credit losses (issued credit losses)

Credit impairment) Balance on December 31, 2024 179,815.94 179,815.94 Balance on December 31, 2024 in the current period

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision in this period -66,209.24 -66,209.24 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on December 31, 2025 113,606.70 113,606.70

(3) Bad debt provisions accrued, recovered or reversed in the current period:

Amount of changes in the current period

December 31, 2024 December 31, 2025 Category Consolidation Scope Resale or

Day Provision Recovery or transfer Other Day

Impact of changes Write-off

Long-term receivables 179,815.94 -66,209.24 113,606.70

Total 179,815.94 -66,209.24 113,606.70 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

11. Long-term equity investment

December 31, 2025 December 31, 2024

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Investment in subsidiaries

Investment in associates and joint ventures 1,442,467,014.26 1,442,467,014.26 1,442,616,370.31 1,442,616,370.31

Total 1,442,467,014.26 1,442,467,014.26 1,442,616,370.31 1,442,616,370.31

(1) Investment in associates and joint ventures:

Changes in increases and decreases in the current period Impairment quasi December 31, 2024 Investment unit on December 31, 2025 Other comprehensive Other equity recognized under the equity method Announcement of cash distribution Provision minus its balance at the end of the provision period Additional investment Decrease in investment Daily balance

Investment gains and losses, income adjustment changes, dividend or profit value reserves, other balances

1. Joint ventures

Subtotal

2. Joint ventures

Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd. 461,993,084.84 78,075,018.60 24,896,324.00 515,171,779.44 Yunnan Sailis Biotechnology Co., Ltd. 125,238,462.33 4,508,706.28 129,747,168.61 Shanghai Runda Shenghu Investment Management Center (Limited Partnership) 21,829,737.65 -19,793,977.93 2,035,759.72 Shanghai Runqi Investment Management Center (Limited Partnership) 9,868,551.06 300,000.00 -9,018,571.01 549,980.05 Shanghai Runhu Investment Management Center (Limited Partnership) 95,658,999.91 -15,944,859.70 79,714,140.21 Shanghai Runbo Investment Management Center (Limited Partnership) 40,677,920.09 -13,466,624.90 27,211,295.19 Wuhu Runjie Investment Management Center (Limited Partnership) 63,289,232.92 -276,108.00 63,013,124.92 Fujian Furui Medical Technology Co., Ltd. 29,513,031.05 -2,611,931.47 26,901,099.58 Guangxi Liurun Medical Technology Co., Ltd. 72,165,681.14 2,160,081.37 74,325,762.51 Sichuan Runda Hongwang Medical Technology Co., Ltd. 4,004,812.19 3,651.09 4,008,463.28 Guizhou Runda Kangyi Medical Technology Co., Ltd. 5,402,176.32 191,815.39 5,593,991.71 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Changes in increases and decreases in the current period Impairment quasi December 31, 2024 Investment unit on December 31, 2025 Other comprehensive Other equity recognized under the equity method Announcement of cash distribution Provision minus its balance at the end of the provision period Additional investment Decrease in investment Daily balance

Investment gains and losses Income adjustments Changes Dividends or profits Value provision Others Balance Sichuan Runda Ruitai Biotechnology Co., Ltd. 62,647,135.37 1,804,754.96 64,451,890.33 Henan Runbaida Medical Equipment Co., Ltd. 10,665,004.86 20,846.89 10,685,851.75 Hefei Tianyuan Medical Equipment Co., Ltd. 11,693,979.51 399,627.06 3,274.43 343,000.00 11,753,881.00 Hebei Runda Kangtai Medical Technology Co., Ltd. 6,811,086.38 443,523.06 7,254,609.44 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 4,555,473.13 -28,437.13 4,527,036.00 Shanghai General Runda Medical Technology Co., Ltd. 36,826,182.71 -5,265,826.62 31,560,356.09 Hangzhou Xinxiaomei Health Technology Co., Ltd. 1,250,020.83 -922,260.67 327,760.16 Anhui Runkang Lianchuang Biotechnology Co., Ltd. 17,480,342.91 -864,864.04 16,615,478.87 Hangzhou Runshi Equity Investment Partnership (Limited Partnership) 200,501,498.89 -2,055,103.22 198,446,395.67 Suzhou Runying Medical Equipment Co., Ltd. 160,543,956.21 4,108,221.37 10,500,000.00 154,152,177.58 Shanghai Huiyi Enterprise Management Partnership (Limited Partnership) 0.01 -0.01

Hangzhou Runda Hongtai Medical Technology Co., Ltd.

Hangzhou Huihao Information Technology Co., Ltd.

Fuzhou Xintou Kairuikang Venture Capital Fund Partnership (with

12,062,498.07 -63,647.01 11,998,851.06Limited partnership)

Guangzhou Xiangxue Smart Traditional Chinese Medicine Co., Ltd. 1,960,000.00 -427,437.16 1,532,562.84 Beijing Xiangyue Huibai Medical Technology Co., Ltd. 666,667.00 -45,785.37 620,881.63 Tianjin Taixin Runda Medical Technology Co., Ltd. 200,000.00 -29,961.50 170,038.50 Xizhuo Medical Laboratory (Dalian) Co., Ltd. 2,045,000.00 -2,045,000.00

Shanghai Naixiang Enterprise Management Center (Limited Partnership) 1,542.86 122,135.26 27,000.00 96,678.12

Total 1,442,616,370.31 16,935,707.93 300,000.00 18,977,985.59 3,274.43 35,766,324.00 1,442,467,014.26Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

12. Other equity instrument investments

(1) Investment in other equity instruments:

Project December 31, 2025 December 31, 2024 Wuhan Haijili Biotechnology Co., Ltd. 994,611.82 6,329,115.00 Inner Mongolia Runda Wison Medical Supply Chain Services Co., Ltd.

Shanghai Xiangrun Medical Technology Co., Ltd. 377,061.39 989,778.52 Harbin Runda Hongtai Medical Technology Co., Ltd. 546,901.92 759,411.75 Weiyan Medical Technology (Beijing) Co., Ltd. 11,249,010.00 16,064,506.49 Nanjing Zhongchen Medical Technology Co., Ltd. 5,682,316.64 4,214,479.60 Zhejiang Medical and Health Group Health Management Co., Ltd. 5,915,851.32 8,331,502.83 Hangzhou Runqi Equity Investment Partnership (Limited Partnership) 10,001.00 10,001.00 Zhejiang Medical and Health Group Hangzhou Medical Testing Laboratory Co., Ltd. 999,994.17

Total 25,775,748.26 36,698,795.19

1. Explanation of derecognition in 2025:

None.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Disclosure of non-trading equity instrument investments in the current period by items:

Changes in increases and decreases in the current period are designated as recognized at fair value in the current period and are cumulatively included in other

Items accumulatively included in the measurement of other comprehensive value and its changes. Opening balance. Included in other comprehensive value in the current period. Included in other comprehensive value in the current period. Closing balance. Loss on comprehensive income of shares subscribed.

Additional investment Decrease in investment Gains from other comprehensive income Gains included in other comprehensive income Loss from combined income Profit income loss

Reasons for benefit Wuhan Haijili Biotechnology

6,329,115.00 5,334,503.18 994,611.82 4,005,388.18

Ltd.

Inner Mongolia Runda Wison Medical

Supply Chain Services Co., Ltd. 100,000.00

company

Shanghai Xiangrun Medical Technology Co., Ltd.

Co., Ltd. 989,778.52 612,717.13 377,061.39 1,122,938.61 The company’s equity investment in these enterprises, Harbin Runda Hongtai Medical, is based on Zhan Technology Co., Ltd. 759,411.75 212,509.83 546,901.92 150,865.63 The strategic purpose is to hold for a long time, Weiyan Medical Technology (Beijing) Co., Ltd. is not to be sold in the short term 16,064,506.49 4,815,496.49 11,249,010.00 1,249,010.00 or to obtain investment income

For purposes other than trading Nanjing Zhongchen Medical Technology has

4,214,479.60 1,467,837.04 5,682,316.64 3,182,316.64 equity investment, limited company

And it has no control over Zhejiang Medical Health Group

8,331,502.83 2,415,651.51 5,915,851.32 6,084,148.68 or significant impact. Health Management Co., Ltd.

Hangzhou Runqi Equity Investment Co., Ltd.

10,001.00 10,001.00

Partnership (limited partnership)

Zhejiang Medical and Health Group

Hangzhou Medical Laboratory Laboratory 2,000,001.00 1,000,006.83 999,994.17 1,000,006.83

Ltd.

Total 36,698,795.19 2,000,001.00 1,467,837.04 14,390,884.97 25,775,748.26 4,431,326.64 12,463,347.93

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

13. Fixed assets

(1) Summary of fixed assets:

Project December 31, 2025 December 31, 2024

Fixed assets 985,814,869.67 1,016,086,687.83 Liquidation of fixed assets

Total 985,814,869.67 1,016,086,687.83

(2) Fixed assets:

Projects Houses and buildings Transportation equipment Production and R&D equipment Provision of instruments and equipment Electronics and other equipment Decoration of fixed assets Total

1. Original book value

1. December 31, 2024 198,869,284.01 66,000,452.95 162,123,318.75 2,252,267,255.73 135,132,307.81 104,724,409.80 2,919,117,029.05 2. Increase in the current period 2,217,612.91 5,947,997.19 4,223,299.25 289,296,747.99 7,743,314.31 1,561,621.59 310,990,593.24 (1) Purchase 2,217,612.91 5,947,997.19 2,259,276.53 48,180,593.26 3,792,651.70 921,623.54 63,319,755.13 (2) Transfer of projects under construction

(3) Increase in business mergers

(4) Inventory investment 1,405,657.80 241,116,154.73 3,885,629.16 246,407,441.69 (5) Others 558,364.92 65,033.45 639,998.05 1,263,396.42 3. Reduction amount in the current period 4,714,003.37 3,091,947.16 113,379,587.95 6,831,545.17 438,499.62 128,455,583.27 (1) Disposal or scrapping 4,696,945.37 2,308,400.58 113,379,587.95 6,831,545.17 438,499.62 127,654,978.69 (2) Disposal of subsidiaries

(3) Others 17,058.00 783,546.58 800,604.58 4. December 31, 2025 201,086,896.92 67,234,446.77 163,254,670.84 2,428,184,415.77 136,044,076.95 105,847,531.77 3,101,652,039.02

2. Accumulated depreciation

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

1. December 31, 2024 34,510,525.74 40,800,602.89 98,030,159.76 1,530,305,181.09 91,130,172.17 84,142,276.90 1,878,918,918.55 2. Increase in the current period 6,828,526.41 7,380,556.85 14,234,140.85 239,622,338.39 15,763,451.36 6,887,675.23 290,716,689.09 (1) Provision 6,828,526.41 7,247,295.80 13,811,485.65 239,622,338.39 15,255,625.28 6,313,113.18 289,078,384.71 (2) Increase in business mergers

(3) Others 133,261.05 422,655.20 507,826.08 574,562.05 1,638,304.38 3. Decrease amount in the current period 4,344,348.77 2,216,275.22 65,386,705.55 5,867,572.56 94,958.86 77,909,860.96 (1) Disposal or scrapping 4,344,348.77 1,623,359.82 65,386,705.55 5,867,572.56 94,958.86 77,316,945.56 (2) Disposal of subsidiaries

(3) Others 592,915.40 592,915.40 4. December 31, 2025 41,339,052.15 43,836,810.97 110,048,025.39 1,704,540,813.93 101,026,050.97 90,934,993.27 2,091,725,746.68

3. Impairment provision

1. December 31, 2024 2,639,378.92 18,325,385.89 3,146,657.86 24,111,422.67 2. Increase in the current period

(1) Provision

(2) Increase in business mergers

(3) Others

3. Reduction amount in this period

(1) Disposal or scrapping

(2) Disposal of subsidiaries

(3) Others

4. December 31, 2025 2,639,378.92 18,325,385.89 3,146,657.86 24,111,422.67

4. Book value

1. December 31, 2025 159,747,844.77 20,758,256.88 34,881,259.56 723,643,601.84 31,871,368.12 14,912,538.50 985,814,869.67 2. December 31, 2024 164,358,758.27 22,560,471.14 45,767,773.10 721,962,074.64 40,855,477.78 20,582,132.90 1,016,086,687.83

Note: Others are mainly due to the impact of exchange rate changes, classification adjustments and shareholder inputs.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

14. Construction in progress

(1) Summary of projects under construction:

Project December 31, 2025 December 31, 2024

Construction in progress 3,343,212.54 2,848,562.94 Engineering materials

Total 3,343,212.54 2,848,562.94

(2) Projects under construction:

December 31, 2025 December 31, 2024

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Software project 1,004,035.17 1,004,035.17 Decoration project 3,343,212.54 3,343,212.54 1,844,527.77 1,844,527.77

Total 3,343,212.54 3,343,212.54 2,848,562.94 2,848,562.94Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

15. Right-of-use assets

Production and R&D Electronics and Others

Item Houses and buildings Instruments and equipment Total

equipment equipment

1. Original book value

1. December 31, 2024 159,765,455.32 59,309,517.34 546,085.37 219,621,058.03 2. Increase in the current period 53,844,030.21 2,485,183.37 8,470,447.84 197,698.31 64,997,359.73 (1) Increase in business mergers

(2) Operating lease 53,442,536.01 2,485,183.37 8,470,447.84 190,734.09 64,588,901.31 (3) Others 401,494.20 6,964.22 408,458.42 3. Decrease amount in the current period 75,938,316.35 7,377,151.61 432,645.98 83,748,113.94 (1) Disposal or scrapping 75,302,765.13 7,377,151.61 432,645.98 83,112,562.72 (2) Disposal of subsidiaries

(3) Others 635,551.22 635,551.22 4. December 31, 2025 137,671,169.18 2,485,183.37 60,402,813.57 311,137.70 200,870,303.82

2. Accumulated depreciation

1. December 31, 2024 89,358,929.17 20,025,509.30 385,612.08 109,770,050.55 2. Increase in the current period 36,669,610.06 1,242,591.72 15,269,916.34 95,127.63 53,277,245.75 (1) Provision 36,509,007.92 1,242,591.72 15,269,916.34 90,214.49 53,111,730.47 (2) Increase in business combination

(3) Others 160,602.14 4,913.14 165,515.28 3. Reduction amount in the current period 70,948,057.77 5,762,102.23 422,356.21 77,132,516.21 (1) Disposal or scrapping 69,589,615.61 5,762,102.23 422,356.21 75,774,074.05 (2) Disposal of subsidiaries

(3) Others 1,358,442.16 1,358,442.16 4. December 31, 2025 55,080,481.46 1,242,591.72 29,533,323.41 58,383.50 85,914,780.09

3. Impairment provision

1.December 31, 2024

2. Increase amount in this period

3. Reduction amount in this period

4. December 31, 2025

4. Book value

1. December 31, 2025 82,590,687.72 1,242,591.65 30,869,490.16 252,754.20 114,955,523.73 2. December 31, 2024 70,406,526.15 39,284,008.04 160,473.29 109,851,007.48 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

16. Intangible assets

Use of proprietary technology

Items Computer software Land use rights Patent rights Software copyright Total

right

1. Original book value

1. December 31, 2024 125,169,350.11 26,256,617.40 4,207,407.50 307,735.85 27,069,700.00 183,010,810.86 2. Increase in the current period 17,961,369.21 442,477.88 130,000.00 18,533,847.09 (1) Purchase 17,961,369.21 442,477.88 130,000.00 18,533,847.09 (2) Internal research and development

(3) Increase in business mergers

(4) Shareholder investment

(5) Other transfers

3. Decrease amount in the current period 2,055,845.66 2,650,000.00 4,705,845.66 (1) Disposal 2,055,845.66 2,055,845.66 (2) Other transfers 2,650,000.00 2,650,000.00 4. December 31, 2025 141,074,873.66 26,256,617.40 1,999,885.38 437,735.85 27,069,700.00 196,838,812.29

2. Accumulated amortization

1. December 31, 2024 79,273,303.98 5,632,338.10 2,704,486.54 307,735.85 17,764,490.63 105,682,355.10 2. Increase in the current period 18,230,435.15 526,445.76 103,324.03 2,166.67 3,383,712.50 22,246,084.11 (1) Provision 18,230,435.15 526,445.76 103,324.03 2,166.67 3,383,712.50 22,246,084.11 (2) Increase in business mergers

(3) Other transfers

3. Decrease amount in the current period 211,405.92 1,678,333.41 1,889,739.33 (1) Disposal 211,405.92 211,405.92 (2) Other transfers 1,678,333.41 1,678,333.41 4. December 31, 2025 97,292,333.21 6,158,783.86 1,129,477.16 309,902.52 21,148,203.13 126,038,699.88

3. Impairment provision

1.December 31, 2024

2. Increase amount in this period

(1) Provision

(2) Increase in business mergers

(3) Other transfers

3. Reduction amount in this period

(1) Disposal

(2) Other transfer-out

4. December 31, 2025

4. Book value

1. December 31, 2025 43,782,540.45 20,097,833.54 870,408.22 127,833.33 5,921,496.87 70,800,112.41 2. December 31, 2024 45,896,046.13 20,624,279.30 1,502,920.96 9,305,209.37 77,328,455.76Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

17. Development expenses

Increase amount in this period Decrease amount in this period

December 31, 2024 Projects in December 2025 are confirmed as intangible and transferred to the current period

Day Internal Development Expenditure Other Other 31st

Assets Profit and Loss

Diagnostic reagents 5,789,046.28 3,184,422.45 8,973,468.73 Medical instrument systems 13,887,061.03 4,746,889.65 18,633,950.68 Total 19,676,107.31 7,931,312.10 27,607,419.41

18. Goodwill

(1) Original book value of goodwill:

Increase in this period Decrease in this period

The name of the invested unit or

On December 31, 2024, the business combination formed its Disposal of matters that formed goodwill on December 31, 2025

of him him

Changchun Jinzerui Medical Department

769,062,024.69 769,062,024.69 Technology Co., Ltd.

Hangzhou Yidan Biotechnology

190,912,789.61 190,912,789.61 Co., Ltd.

Beijing Southeast Yueda Medical

178,212,247.37 178,212,247.37 Equipment Co., Ltd.

Shandong Xinhai Runbang Medical

163,253,624.13 163,253,624.13 Supplies Distribution Co., Ltd.

Wuhan Youkeliansheng Technology and Trade

123,857,753.05 123,857,753.05 Co., Ltd.

Wuhan Runda Shangqian Medical

106,575,743.55 106,575,743.55 Technology Co., Ltd.

Hefei Sanli Medical Technology

103,756,422.87 103,756,422.87 Co., Ltd.

Beijing Huizhong Medical Equipment

92,579,264.72 92,579,264.72 Co., Ltd.

Shanghai Runlin Medical Technology

89,984,998.57 89,984,998.57 Co., Ltd.

Shanghai Ruimei Computer Technology

82,221,427.93 82,221,427.93 Co., Ltd.

1077801B.C.LTD. 79,815,840.79 79,815,840.79Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Increase in this period Decrease in this period

The name of the invested unit or

On December 31, 2024, the business combination formed its Disposal of matters that formed goodwill on December 31, 2025

of him him

Changchun Runda Zerui Medical

35,668,871.29 35,668,871.29 Technology Co., Ltd.

Hefei Runda Wantong Medical

31,971,814.32 31,971,814.32 Technology Co., Ltd.

Yunnan Runda Kangtai Medical

10,880,760.61 10,880,760.61 Technology Co., Ltd.

Shanghai Huizhong Biotechnology

1,434,774.73 1,434,774.73 Co., Ltd.

Total 2,060,188,358.23 2,060,188,358.23

(2) Goodwill impairment provision:

Increase in this period Decrease in this period

The name of the invested unit or

December 31, 2024 Other Events that resulted in goodwill on December 31, 2025 Provision Disposal

he him

Beijing Huizhong Medical Equipment

48,380,000.00 1,026,311.43 49,406,311.43 Co., Ltd.

Shandong Xinhai Runbang Medical

20,205,250.16 24,657,000.00 44,862,250.16 Supplies Distribution Co., Ltd.

Wuhan Runda Shangqian Medical

8,923,882.01 97,651,861.54 106,575,743.55 Technology Co., Ltd.

Hefei Sanli Medical Technology

42,339,765.00 42,339,765.00 Co., Ltd.

Hefei Runda Wantong Medical

17,473,047.17 17,473,047.17 Technology Co., Ltd.

Shanghai Runlin Medical Technology

25,894,470.00 25,894,470.00 Co., Ltd.

Total 77,509,132.17 209,042,455.14 286,551,587.31

(3) Relevant information on the asset group or asset group combination where the goodwill is located:

On the balance sheet date, the company recognizes each asset group or combination of asset groups related to goodwill, includes the goodwill and the goodwill attributable to minority shareholders' equity, and adjusts the book value of each asset combination. Relevant information on the asset group or asset group combination where the company's goodwill is located is shown in the following table: Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the asset group or combination of asset groups is related to the purchase

Allocate to this asset group or asset group group

The composition of the asset group or asset group combination in 2025. The allocation method of the book value of goodwill based on the goodwill impairment test in the current and previous years.

The determined asset group or combination of asset groups is consistent Changchun Jinzerui Medical Technology Co., Ltd. No need to allocate It is Hangzhou Yidan Biotechnology Co., Ltd. No need to allocate It is Beijing Southeast Yueda Medical Equipment Co., Ltd. No need to allocate It is Shandong Xinhai Runbang Medical Supplies Distribution Co., Ltd. No need to allocate It is Wuhan Youke Liansheng Technology and Trade Co., Ltd. No need to allocate It is Wuhan Runda Shangjian Medical Technology Co., Ltd. No need to allocate It is Hefei Sanli Medical Technology Co., Ltd. No need to allocate It is Beijing Huizhong Medical Equipment Co., Ltd. No need to share. It is Shanghai Runlin Medical Technology Co., Ltd. No need to share. It is Shanghai Ruimei Computer Technology Co., Ltd. No need to share. It is 1077801B.C.LTD. No need to share. It is Hefei Runda Wantong Medical Technology Co., Ltd. No need to share. It is Yunnan Runda Kangtai Medical Technology Co., Ltd. No need to share. It is Shanghai Huizhong Biotechnology Co., Ltd. No need to share. Yes

(4) Impairment testing process of goodwill:

1. The recoverable amount is determined based on the present value of its estimated future cash flows.

Revenue growth during the forecast period Growth during the stable period Pre-tax discount rate Asset group name Forecast period Profit rate

Growth rate (%) Rate (%) (%) Changchun Jinzerui Medical Based on revenue during the forecast period,

2026-2030 -5.75-3.56 0.00 10.37 Technology Co., Ltd. Calculation of costs, expenses, etc. Hangzhou Yidan Biotechnology Based on revenue,

2026-2030 4.05-10.30 0.00 10.23 Surgery Co., Ltd. Calculation of costs, expenses, etc. Beijing Southeast Yueda Medical Based on revenue,

2026-2030 1.12-2.04 0.00 10.68 Medical Equipment Co., Ltd. Calculation of costs, expenses, etc. Wuhan Youke Lianshengke is based on the revenue during the forecast period,

2026-2030 2.52-4.00 0.00 10.39 Trading Co., Ltd. Calculation of costs, expenses, etc. Hefei Sanli Medical Department Based on income,

2026-2030 8.47-16.28 0.00 10.39 Technology Co., Ltd. Calculation of costs, expenses, etc. Beijing Huizhong Medical Devices is based on revenue during the forecast period,

2026-2030 6.15-15.00 0.00 11.99 Machinery Co., Ltd. Calculation of costs, expenses, etc. Shanghai Runlin Medical Department is based on revenue,

2026-2030 9.41-77.04 0.00 10.68 Technology Co., Ltd. Calculation of costs, expenses, etc. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Revenue growth during the forecast period Growth during the stable period Pre-tax discount rate Asset group name Forecast period Profit rate

Growth rate (%) Rate (%) (%) Shanghai Ruimei Computer Technology Based on revenue during the forecast period,

2026-2030 3.38-7.35 0.00 11.49 Technology Co., Ltd. Calculation of costs, expenses, etc.

Based on revenue during the forecast period,

1077801B.C.LTD. 2026-2030 24.77-36.58 0.00 10.66

Calculation of costs, fees, etc.

Hefei Runda Wantong Medical According to the revenue during the forecast period,

2026-2030 3.19-10.10 0.00 10.39 Medical Technology Co., Ltd. Calculation of costs, expenses, etc.

Yunnan Runda Kangtai Medical According to the revenue during the forecast period,

2026-2030 0.85-2.01 0.00 10.39 Medical Technology Co., Ltd. Calculation of costs, expenses, etc.

Shanghai Huizhong Biotechnology Co., Ltd. is based on revenue during the forecast period,

2026-2030 1.88-7.55 0.00 10.89 Technology Co., Ltd. Calculation of costs, expenses, etc.

The company uses the present value of the expected future cash flows of the asset portfolio as its recoverable amount. The present value of the estimated future cash flows of each asset group or asset group combination adopts key parameters. The key parameters are determined comprehensively with reference to the historical actual situation of each company, the development of companies in the same industry and the market. The discount rate used by the Company is a pre-tax discount rate that reflects the current market time value of money and the risks specific to the underlying asset group.

2. The recoverable amount is determined based on the net amount of fair value minus disposal costs.

Unit (10,000 yuan)

Fair value and disposal costs Asset group name of key parameters Book value Recoverable amount Impairment provision Key parameters

Determination method Determination based on fair value based on asset group

Detailed assets composed of

Shandong Xinhai Runbang adopts market approach and equipment-related conditions respectively.

The equipment is determined using the city’s medical supply distribution method 29,045.45 26,579.75 2,465.70. The replacement cost method is used to determine the disposal replacement value.

Market Inquiry Ltd. Fees are calculated based on the time spent on disposal of the asset group and the newness rate

Relevant taxes and property rights incurred

Transaction service fees, etc. determined

Fair value based on asset group

Detailed assets composed of

Wuhan Runda Shang inspected the situation using market method and equipment related methods respectively.

The equipment is determined by the replacement cost method of Municipal Medical Technology Co., Ltd. 45,134.50 25,372.71 9,765.19, and the replacement value of disposal is

Market inquiry company's fees are based on disposal time and newness rate of the asset group

Relevant taxes and property rights incurred

Transaction service fees, etc. determined

Total 74,179.95 51,952.46 12,230.89 // /Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

19. Long-term deferred expenses

Project December 31, 2024 Increase in the current period Amortization in the current period Other decreases Decoration and renovation project costs on December 31, 2025 39,864,480.96 10,981,321.61 16,790,107.73 34,055,694.84 Testing project costs 89,359,329.46 166,822.64 9,448,509.51 80,077,642.59 Technical service fee 3,337,150.11 2,284,133.11 1,669,951.72 3,951,331.50 Product registration certificate fee 1,249,577.49 555,072.00 569,936.56 1,234,712.93

Total 133,810,538.02 13,987,349.36 28,478,505.52 119,319,381.86

20. Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset:

December 31, 2025 December 31, 2024

Project

Deductible temporary differences Deferred income tax assets Deductible temporary differences Deferred income tax assets Asset impairment provision 796,097,541.03 190,848,894.04 628,698,960.34 147,812,758.11 Internal transactions not realized

74,287,098.54 17,579,892.22 94,501,833.10 21,437,217.30Profit

Estimated liabilities 2,055,145.05 308,271.76 1,402,553.00 210,382.95 Impact of equity method 49,788,704.81 12,447,176.20 16,858,518.84 4,214,629.71 Deductible losses 319,565,040.48 78,744,607.68 281,812,276.55 66,995,194.52 Changes in fair value 11,463,341.10 2,865,835.28 4,278,718.65 1,069,679.66 Lease liabilities-operating

53,211,085.22 13,302,771.29 67,515,385.29 15,742,446.90 Lease

Total 1,306,467,956.23 316,097,448.47 1,095,068,245.77 257,482,309.15

(2) Deferred income tax liabilities without offset:

December 31, 2025 December 31, 2024

Project

Taxable temporary differences Deferred income tax liabilities Taxable temporary differences Deferred income tax liabilities for non-commonly controlled enterprise joint ventures

Consolidated fixed assets and intangible assets 23,317,904.79 5,237,326.50 27,867,861.20 6,036,444.35 Property appraisal added value

Changes in fair value 4,431,326.64 1,107,831.66 9,169,745.29 2,292,436.32 Right-of-use assets 114,955,523.73 27,623,215.56 109,851,007.48 26,261,864.20 Depreciation or amortization difference 36,041,801.15 9,010,450.33 38,755,319.21 9,348,888.14

Total 178,746,556.31 42,978,824.05 185,643,933.18 43,939,633.01Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(3) Details of unrecognized deferred income tax assets:

Item December 31, 2025 Deductible temporary differences on December 31, 2024 97,553,761.92 80,342,071.71 Deductible losses 1,565,951,481.13 1,165,715,086.63 Others 69,352,482.11 54,942,876.98

Total 1,732,857,725.16 1,301,000,035.32

(4) The deductible losses of unrecognized deferred income tax assets will expire in the following years:

Year December 31, 2025 December 31, 2024 Notes 2025 34,296,609.91 2026 69,885,463.04 72,297,368.79 2027 82,031,915.19 79,186,595.28 2028 142,105,482.27 209,116,912.93 2029 369,400,616.34 377,514,968.21 2030 448,865,886.89 34,036,681.20 2031 33,316,505.89 33,100,816.13 2032 69,677,186.72 69,782,061.29 2033 100,978,562.33 105,924,034.62 2034 81,409,217.32 101,324,484.27 2035 109,216,749.34 1,974,471.80 2036 2,858,837.80 2,822,838.20 2037

2038

2039

2040

2041

2042 14,841,408.40 14,654,519.60 2043 6,474,577.20 6,393,046.80 2044 17,603,076.40 23,289,677.60 2045 17,285,996.00

Total 1,565,951,481.13 1,165,715,086.63

Note: For the subsidiary company 1077801B.C.LTD., the period within which its losses can be recovered is 20 years.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

21. Other non-current assets

December 31, 2025 December 31, 2024

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Non-current assets Advance payment 9,574,865.10 9,574,865.10 5,642,694.95 5,642,694.95

Total 9,574,865.10 9,574,865.10 5,642,694.95 5,642,694.95

22. Short-term borrowings

Project December 31, 2025 December 31, 2024

Pledge loans 1,616,930,526.24 1,512,365,155.11 Mortgage loans 31,038,132.26 Guaranteed loans 2,253,365,883.81 2,179,033,719.07 Credit loans 990,949,889.75 1,202,122,864.85

Total 4,861,246,299.80 4,924,559,871.29

23. Trading financial liabilities

Item December 31, 2025 December 31, 2024 Reasons and basis for designation Trading financial liabilities 5,707.45 1,253,592.65 /

Including: foreign exchange options 5,707.45 1,253,592.65

Total 5,707.45 1,253,592.65

24. Notes payable

Category December 31, 2025 December 31, 2024

commercial acceptance bill

Bank acceptance draft 55,000,000.00

Total 55,000,000.00

25. Accounts payable

Item December 31, 2025 Account payable on December 31, 2024 1,163,827,928.54 1,158,573,938.53

Total 1,163,827,928.54 1,158,573,938.53 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

26. Advance payments

(1) List of accounts received in advance:

Project December 31, 2025 Lease payment received in advance on December 31, 2024 12,203,702.05 8,973,556.24

Total 12,203,702.05 8,973,556.24

27. Contract liabilities

Item December 31, 2025 Advance payments for goods received on December 31, 2024 86,687,033.75 97,579,716.33 Less: Included in other current liabilities (Note V. 32) 9,259,180.41 9,190,200.13

Total 77,427,853.34 88,389,516.20

28. Employee benefits payable

(1) List of employee benefits payable:

Item December 31, 2024 Increase in this period Decrease in this period December 31, 2025

1. Short-term salary 76,852,089.36 614,813,463.04 632,929,413.00 58,736,139.40

2. Post-employment benefits-setup

2,194,533.94 64,137,425.51 63,623,375.30 2,708,584.15Defined contribution plan

3. Dismissal benefits 3,463,354.18 2,879,000.96 584,353.22

4. Others due within one year

his welfare

Total 79,046,623.30 682,414,242.73 699,431,789.26 62,029,076.77

(2) Short-term salary presentation:

Item December 31, 2024 Increase in this period Decrease in this period December 31, 2025

1. Salaries, bonuses, allowances and

73,992,324.74 515,602,863.70 533,911,277.47 55,683,910.97 Subsidy

2. Employee welfare fees 364,185.17 22,769,823.69 23,066,184.00 67,824.86

3. Social insurance premiums 1,436,664.94 37,262,839.49 37,184,840.12 1,514,664.31 Including: medical insurance premiums 1,351,959.48 35,031,852.84 35,020,616.79 1,363,195.53Work-related injury insurance premium 70,747.91 1,506,530.42 1,444,469.42 132,808.91

Maternity insurance premium 13,957.55 724,456.23 719,753.91 18,659.87Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Item December 31, 2024 Increase in this period Decrease in this period December 31, 2025

Others

4. Housing provident fund 152,104.00 30,296,451.94 30,062,229.94 386,326.00

5. Union funds and employee education

294,610.53 6,731,990.21 6,637,232.73 389,368.01 Funding

6. Short-term paid absences

7. Short-term profit sharing plan

8. Other short-term remuneration 612,199.98 2,149,494.01 2,067,648.74 694,045.25

Total 76,852,089.36 614,813,463.04 632,929,413.00 58,736,139.40

(3) List of defined contribution plans:

Item December 31, 2024 Increase in this period Decrease in this period December 31, 2025

1. Basic pension insurance 1,317,894.98 61,965,249.79 61,416,828.73 1,866,316.04

2. Unemployment insurance premium 42,238.96 2,157,982.02 2,115,552.87 84,668.11

3. Enterprise annuity payment 834,400.00 76,800.00 757,600.00

4. Others 14,193.70 14,193.70

Total 2,194,533.94 64,137,425.51 63,623,375.30 2,708,584.15

29. Taxes payable

Project December 31, 2025 December 31, 2024

Value-added tax 19,428,013.06 20,243,381.10 Corporate income tax 39,587,083.94 68,654,234.57 Personal income tax 2,328,797.09 2,212,192.44 Urban maintenance and construction tax 1,029,389.63 1,154,110.43 Education fee surcharge 802,449.37 872,938.94 Stamp tax 1,470,862.86 1,359,468.57 Property tax 356,444.70 404,433.89 Land use tax 15,798.44 15,798.44 Others 74,422.32 89,365.69

Total 65,093,261.41 95,005,924.07 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

30. Other payables

(1) Other payable categories:

Project December 31, 2025 December 31, 2024

interest payable

Dividends payable 19,072,120.00 12,971,219.37 Other payables 150,302,347.23 139,541,007.70

Total 169,374,467.23 152,512,227.07

(2) Dividends payable:

Project December 31, 2025 December 31, 2024 Yueshengda (Jinan) Investment Partnership (Limited Partnership) 3,000,000.00 3,000,000.00 Meng Fanyu 11,000,000.00 8,399,099.37 Deqing Hengyi Investment Management Partnership (Limited Partnership) 5,000,000.00 1,500,000.00 Tang Jianfeng 72,120.00 72,120.00

Total 19,072,120.00 12,971,219.37

(3) Other payables:

3. List other payables according to the nature of the payment:

Project December 31, 2025 December 31, 2024

Deposits and security deposits 37,403,949.56 37,027,864.54 Advances, loans and current accounts 76,893,421.90 80,289,193.96 Payables for the purchase and construction of non-current assets 2,494,101.23 1,477,997.19 Accrued expenses 25,152,921.89 13,876,655.14 Others 8,357,952.65 6,869,296.87

Total 150,302,347.23 139,541,007.70

31. Non-current liabilities due within one year

Item December 31, 2025 Long-term borrowings due within one year on December 31, 2024 (Note V. 33) 770,122,951.61 527,771,475.35 Bonds payable due within one year (Note V. 34) 232,955,162.89 308,453,722.78 Long-term payables due within one year (Note 5, 36) 152,950,200.31 141,925,144.16 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Item December 31, 2025 December 31, 2024 Including: Sale and leaseback payment payable 151,758,233.72 140,816,561.57

Installment payment of fixed asset decoration fee 1,191,966.59 1,108,582.59 Lease liabilities due within one year (Note 5, 35) 47,226,549.95 48,375,808.01 Among them: operating lease payable 47,226,549.95 48,375,808.01

Total 1,203,254,864.76 1,026,526,150.30

32. Other current liabilities

Item December 31, 2025 Advance sales received on December 31, 2024 - Output tax to be transferred 9,259,180.41 9,190,200.13

Total 9,259,180.41 9,190,200.13

33. Long-term borrowings

Item December 31, 2025 Pledged loan on December 31, 2024 (Note 1) 61,318,897.90 73,761,160.22 Mortgaged loan (Note 2) 1,719,120.91 1,841,915.20 Guaranteed loan (Note 3) 192,127,946.43 207,104,368.45 Credit borrowings (Note 4) 1,147,780,402.67 906,642,747.02 Less: Long-term borrowings due within one year (Note 5.31) 770,122,951.61 527,771,475.35 Total 632,823,416.30 661,578,715.54 Description of the classification of long-term borrowings in 2025:

Note 1: (1) The company's subsidiary Hangzhou Runday acquired a 65.00% equity interest in Hefei Sanli and obtained a merger and acquisition loan of RMB 87 million from Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch. The loan period is seven years, from August 31, 2021 to August 29, 2028. Subsidiary Hangzhou Runda provided pledge guarantee for the above-mentioned loans with its 65.00% equity interest in Hefei Sanli, and the Company provided guarantee for the above-mentioned matters. As of December 31, 2025, the principal amount of the loan was 55.48 million yuan, of which 22.50 million yuan was included in "non-current liabilities due within one year" and the interest payable was 65,300 yuan.

(2) The company's subsidiary Hangzhou Runday acquired a 65.00% equity interest in Hefei Sanli and obtained a merger and acquisition loan of RMB 6 million from Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch. The loan period is six years, from April 14, 2022 to August 29, 2028. Subsidiary Hangzhou Runda provided pledge guarantee for the above-mentioned loans with its 65.00% equity interest in Hefei Sanli, and the Company provided guarantee for the above-mentioned matters. As of December 31, 2025, the principal amount of the loan was 3.8448 million yuan, of which 1.539 million yuan was included in "non-current liabilities due within one year" and the interest payable was 4.5 million yuan.

(3) The company's subsidiary Hangzhou Runday acquired a 65.00% equity interest in Hefei Sanli and obtained a merger and acquisition loan of RMB 3 million from Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch. The loan period is six years, starting from August 17, 2022 to August 29, 2028. Subsidiary Hangzhou Runda provided pledge guarantee for the above-mentioned loans with its 65.00% equity interest in Hefei Sanli, and the Company provided guarantee for the above-mentioned matters. Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

As of December 31, 2025, the principal amount of the loan was 1.9224 million yuan, of which the amount of "non-current liabilities due within one year" was 769,500 yuan, and the interest payable was 1,900 yuan.

Note 2: (1) The company's subsidiary Chongqing Runda obtained a loan of 1.85 million yuan from the Chongqing Branch of Industrial Bank Co., Ltd., with a loan period of fifteen years, from November 28, 2024 to December 21, 2039. Subsidiary Chongqing Runda provided mortgage guarantees for the above-mentioned loans with real estate held by it, while Chongqing Tianan Cyber ​​City Co., Ltd., Huang Liujin, and Zhang Min provided guarantees for the above matters. As of December 31, 2025, the principal amount of the loan was 1.7171 million yuan, of which 122,700 yuan was included in "non-current liabilities due within one year", and the interest payable was 2,000 yuan.

Note 3: (1) The company's subsidiary Hangzhou Runda obtained a loan of RMB 18.9 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from June 5, 2025 to September 5, 2026. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 18.80 million yuan, including "non-current liabilities due within one year" of 18.80 million yuan in principal and 18,100 yuan in interest payable.

(2) The company's subsidiary Hangzhou Runda obtained a loan of RMB 22 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from July 17, 2025 to October 17, 2026. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 21.89 million yuan, of which 21.89 million yuan in principal and 20,700 yuan in interest payable were included in "non-current liabilities due within one year."

(3) The company's subsidiary Hangzhou Runda obtained a loan of RMB 11.25 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from August 19, 2025 to November 19, 2026. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 11.19 million yuan, including "non-current liabilities due within one year" of 11.19 million yuan in principal and 10,600 yuan in interest payable.

(4) The company's subsidiary Hangzhou Runda obtained a loan of RMB 10 million from Huaxia Bank Co., Ltd. Hangzhou Branch. The loan period is from August 26, 2025 to November 26, 2026. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 9.95 million yuan, including "non-current liabilities due within one year" of 9.95 million yuan in principal and 9,400 yuan in interest payable.

(5) The company's subsidiary Hangzhou Runda obtained a loan of RMB 17.8 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from October 30, 2025 to January 30, 2027. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 17.80 million yuan, of which the principal of "non-current liabilities due within one year" was 200,000 yuan and the interest payable was 16,900 yuan.

(6) The company's subsidiary Hefei Runda obtained a loan of RMB 10 million from the Shanghai Pudong Development Bank Hefei Huangshan Road Branch. The loan period is from January 2, 2025 to July 2, 2026. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 9 million yuan, including "non-current liabilities due within one year" of 9 million yuan in principal and 8,000 yuan in interest payable.

(7) The company's subsidiary Hefei Sanli obtained a loan of RMB 2 million from the Hefei Binhu New District Branch of Shanghai Pudong Development Bank Co., Ltd. The loan period is from March 18, 2025 to March 18, 2027. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 1.80 million yuan, and the interest payable was 2,400 yuan.

(8) The company's subsidiary Hefei Sanli obtained a loan of RMB 4 million from the Hefei Binhu New District Branch of Shanghai Pudong Development Bank Co., Ltd. The loan period is from April 25, 2025 to April 25, 2027. The company provides a joint and several liability guarantee. As of December 31, 2025, the loan principal balance was 3.60 million yuan, and the interest payable was 4,700 yuan.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(9) The company's subsidiary Shanghai Huizhong Biotech obtained a loan of 9.70 million yuan from the Shanghai Branch of China Guangfa Bank Co., Ltd., with the loan period starting from July 24, 2025 to August 24, 2026. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 9.70 million yuan, including "non-current liabilities due within one year" of 9.70 million yuan in principal and 9,200 yuan in interest payable.

(10) The company's subsidiary Huizhong Rongjia obtained a loan of 9.4969 million yuan from Baoshan Branch of Shanghai Rural Commercial Bank Co., Ltd. The loan period is five years, from December 25, 2024 to December 22, 2029. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 8.4969 million yuan, including "non-current liabilities due within one year" of 1.50 million yuan in principal and 9,900 yuan in interest payable.

(11) The company's subsidiary Hangzhou Huizhong Diagnostics obtained a loan of RMB 10 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from February 23, 2024 to February 23, 2027. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 9.70 million yuan, and the interest payable was 14,700 yuan, including "non-current liabilities due within one year" with a principal of 200,000 yuan and interest payable of 2,200 yuan.

(12) Shanghai Huizhong Medical, a subsidiary of the Company, obtained a loan of RMB 4.99 million from the Shanghai Branch of China Guangfa Bank Co., Ltd., with the loan period starting from May 6, 2025 to June 6, 2026. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 4.89 million yuan, including "non-current liabilities due within one year" of 4.89 million yuan in principal and 4.6 million yuan in interest payable.

(13) Shanghai Huizhong Medical, a subsidiary of the Company, obtained a loan of RMB 2.17 million from the Shanghai Branch of China Guangfa Bank Co., Ltd., with the loan period starting from July 7, 2025 to August 7, 2026. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 2.17 million yuan, including "non-current liabilities due within one year" of 2.17 million yuan in principal and 2,100 yuan in interest payable.

(14) Shanghai Huizhong Medical, a subsidiary of the Company, obtained a loan of RMB 1.34 million from the Shanghai Branch of China Guangfa Bank Co., Ltd., with the loan period starting from July 24, 2025 to August 24, 2026. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 1.34 million yuan, including "non-current liabilities due within one year" of 1.34 million yuan in principal and 1,300 yuan in interest payable.

(15) The company's subsidiary Hangzhou Mingheyuan obtained a loan of RMB 10 million from Huaxia Bank Co., Ltd. Hangzhou Branch. The loan period is from June 23, 2025 to June 19, 2028. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 9.90 million yuan, including "non-current liabilities due within one year" of 200,000 yuan in principal and 9,100 yuan in interest payable.

(16) The company's subsidiary Zhongdingdako obtained a loan of 5 million yuan from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from May 19, 2025 to May 16, 2028. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 4.95 million yuan, of which the principal of "non-current liabilities due within one year" was 100,000 yuan and the interest payable was 5,100 yuan.

(17) Zhongdingdako, a subsidiary of the company, obtained a loan of RMB 5 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from June 12, 2025 to June 12, 2028. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 4.95 million yuan, including "non-current liabilities due within one year" of 100,000 yuan in principal and 5,000 yuan in interest payable.

(18) The company's subsidiary Runda Supply Chain Hangzhou obtained a loan of RMB 19 million from Hua Xia Bank Co., Ltd. Hangzhou Branch. The loan period is from May 23, 2025 to May 19, 2028. The company provides a joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 18.80 million yuan, of which 400,000 yuan in principal and 17,800 yuan in interest payable were included in "non-current liabilities due within one year."

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(19) The company's subsidiary Runda Rongjia obtained a loan of 5 million yuan from the Shanghai Branch of Xiamen International Bank Co., Ltd., with the loan period starting from September 25, 2025 to December 25, 2026. The company provides a joint and several liability guarantee. As of December 31, 2025, the principal balance of the loan was 5 million yuan, including "non-current liabilities due within one year" of 5 million yuan in principal and 5,300 yuan in interest payable.

(20) Shanghai Zhongke Laboratory, a subsidiary of the Company, obtained a loan of RMB 8 million from Shanghai Wujiaochang Branch of China Construction Bank Co., Ltd., with the loan period starting from September 15, 2025 to September 15, 2028. Hu Chunying provides joint liability guarantee. As of December 31, 2025, the principal balance of the loan was 8 million yuan, and the interest payable was 17,000 yuan.

(21) Anhui Zefen, a subsidiary of the Company, obtained a loan of RMB 10 million from Shanghai Pudong Development Bank Co., Ltd. Hefei Branch. The loan period is from November 26, 2025 to May 26, 2027. The company provides a joint and several liability guarantee. As of December 31, 2025, the loan principal balance was RMB 10 million, and the interest payable was RMB 9,200.

Note 4: (1) The company obtained a loan of RMB 23.5 million from China CITIC Bank Co., Ltd. Shanghai Branch. The loan period is from June 13, 2025 to June 11, 2027. As of December 31, 2025, the principal balance of the loan was 22.325 million yuan, including "non-current liabilities due within one year" of 2.35 million yuan in principal and 25,200 yuan in interest payable.

(2) The company obtained a loan of RMB 58.65 million from China CITIC Bank Co., Ltd. Shanghai Branch. The loan period is from June 23, 2025 to June 23, 2027. As of December 31, 2025, the principal balance of the loan was 55.7175 million yuan, including "non-current liabilities due within one year" of 5.865 million yuan in principal and 63,600 yuan in interest payable.

(3) The company obtained a loan of RMB 3 million from Hua Xia Bank Shanghai Branch. The loan period is from August 9, 2024 to August 9, 2026. As of December 31, 2025, the principal balance of the loan was 2.91 million yuan, including "non-current liabilities due within one year" of 2.91 million yuan in principal and 3,400 yuan in interest payable.

(4) The company obtained a loan of RMB 63 million from Hua Xia Bank Shanghai Branch. The loan period is from January 10, 2025 to January 10, 2027. As of December 31, 2025, the principal balance of the loan was 61.74 million yuan, of which 1.26 million yuan in principal and 68,600 yuan in interest payable were included in "non-current liabilities due within one year."

(5) The company obtained a loan of RMB 34 million from Hua Xia Bank Shanghai Branch. The loan period is from January 15, 2025 to January 15, 2027. As of December 31, 2025, the principal balance of the loan was 33.32 million yuan, of which the principal of "non-current liabilities due within one year" was 680,000 yuan and the interest payable was 37,000 yuan.

(6) The company obtained a loan of RMB 45 million from the Shanghai Branch of China Guangfa Bank Co., Ltd., and the loan period is from August 16, 2024 to February 16, 2026. As of December 31, 2025, the principal balance of the loan was 43.20 million yuan, including "non-current liabilities due within one year" of 43.20 million yuan in principal and 58,100 yuan in interest payable.

(7) The company obtained a loan of RMB 45 million from the Shanghai Branch of China Guangfa Bank Co., Ltd., and the loan period is from October 22, 2024 to April 22, 2026. As of December 31, 2025, the principal balance of the loan was 40.50 million yuan, including "non-current liabilities due within one year" of 40.50 million yuan in principal and 60,200 yuan in interest payable.

(8) The company obtained a loan of RMB 40 million from the Shanghai Branch of China Guangfa Bank Co., Ltd., and the loan period is from January 14, 2025 to July 14, 2026. As of December 31, 2025, the principal balance of the loan was 39.20 million yuan, including "non-current liabilities due within one year" of 39.20 million yuan in principal and 47,700 yuan in interest payable.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(9) The company obtained a loan of RMB 34 million from the Shanghai Yangpu Branch of Bank of Jiangsu Co., Ltd., and the loan period is from January 16, 2024 to January 15, 2026. As of December 31, 2025, the principal balance of the loan was 28.90 million yuan, including "non-current liabilities due within one year" of 28.90 million yuan in principal and 40,600 yuan in interest payable.

(10) The company obtained a loan of RMB 10 million from the Shanghai Yangpu Branch of Bank of Jiangsu Co., Ltd., and the loan period is from February 2, 2024 to February 1, 2026. As of December 31, 2025, the principal balance of the loan was 8.50 million yuan, including "non-current liabilities due within one year" of 8.50 million yuan in principal and 11,900 yuan in interest payable.

(11) The company obtained a loan of RMB 6 million from the Shanghai Yangpu Branch of Bank of Jiangsu Co., Ltd., and the loan period is from February 2, 2024 to February 1, 2026. As of December 31, 2025, the principal balance of the loan was 5.10 million yuan, including "non-current liabilities due within one year" of 5.10 million yuan in principal and 7,200 yuan in interest payable.

(12) The company obtained a loan of RMB 50 million from the Shanghai Yangpu Branch of Bank of Jiangsu Co., Ltd., and the loan period is from May 15, 2025 to May 14, 2027. As of December 31, 2025, the principal balance of the loan was 47.5 million yuan, of which 5 million yuan in principal and 60,900 yuan in interest payable were included in "non-current liabilities due within one year."

(13) The company obtained a loan of RMB 28 million from the Shanghai Branch of Xiamen International Bank Co., Ltd., and the loan period is from June 26, 2024 to June 25, 2026. As of December 31, 2025, the principal balance of the loan was 23.80 million yuan, including "non-current liabilities due within one year" of 23.80 million yuan in principal and 29,900 yuan in interest payable.

(14) The company obtained a loan of RMB 85 million from the Shanghai Branch of Xiamen International Bank Co., Ltd., and the loan period is from July 9, 2024 to July 8, 2026. As of December 31, 2025, the principal balance of the borrowings was 76.50 million yuan, including "non-current liabilities due within one year" of 76.50 million yuan in principal and 93,500 yuan in interest payable.

(15) The company obtained a loan of RMB 31 million from the Shanghai Branch of Xiamen International Bank Co., Ltd., and the loan period is from October 23, 2024 to October 23, 2026. As of December 31, 2025, the principal balance of the loan was 27.90 million yuan, including "non-current liabilities due within one year" of 27.90 million yuan in principal and 29,800 yuan in interest payable.

(16) The company obtained a loan of RMB 59 million from the Shanghai Branch of Xiamen International Bank Co., Ltd., and the loan period is from October 24, 2024 to October 23, 2026. As of December 31, 2025, the principal balance of the loan was 53.10 million yuan, including "non-current liabilities due within one year" of 53.10 million yuan in principal and 56,800 yuan in interest payable.

(17) The company obtained a loan of RMB 12 million from Xiamen International Bank Co., Ltd. Shanghai Branch. The loan period is from April 7, 2025 to April 7, 2027. As of December 31, 2025, the principal balance of the loan was 11.40 million yuan, including "non-current liabilities due within one year" of 1.20 million yuan in principal and 12,200 yuan in interest payable.

(18) The company obtained a loan of RMB 50 million from the Hangzhou Branch of Macau International Bank Co., Ltd., and the loan period is from October 25, 2024 to October 23, 2026. As of December 31, 2025, the principal balance of the borrowings was 45 million yuan, of which 45 million yuan in principal and 56,900 yuan in interest payable were included in "non-current liabilities due within one year."

(19) The company obtained a loan of RMB 50 million from the Hangzhou Branch of Macau International Bank Co., Ltd., and the loan period is from November 7, 2024 to November 6, 2026. As of December 31, 2025, the principal balance of the loan was 45 million yuan, including "non-current liabilities due within one year" of 45 million yuan in principal and 58,300 yuan in interest payable.

(20) The company obtained a loan of RMB 60 million from Chiyu Bank Xiamen Branch, with the loan period starting from July 4, 2024 to July 3, 2026. As of December 31, 2025, the principal balance of the borrowings was RMB 54 million, including RMB 54 million in principal and RMB 78,000 in interest payable as "non-current liabilities due within one year."

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(21) The company obtained a loan of RMB 27 million from Capital Bank Shanghai Pudong Branch. The loan period is from October 25, 2024 to October 23, 2026. As of December 31, 2025, the principal balance of the loan was 24.30 million yuan, including "non-current liabilities due within one year" of 24.30 million yuan in principal and 30,700 yuan in interest payable.

(22) The company obtained a loan of RMB 63 million from Capital Bank Shanghai Pudong Branch. The loan period is from October 25, 2024 to October 23, 2026. As of December 31, 2025, the principal balance of the loan was 56.70 million yuan, including "non-current liabilities due within one year" of 56.70 million yuan in principal and 71,700 yuan in interest payable.

(23) The company obtained a loan of RMB 21 million from the Hongkou Branch of the Bank of Beijing. The loan period is from October 31, 2024 to October 30, 2026. As of December 31, 2025, the principal balance of the loan was 18.90 million yuan, including "non-current liabilities due within one year" of 18.90 million yuan in principal and 20,200 yuan in interest payable.

(24) The company obtained a loan of RMB 29 million from the Hongkou Branch of the Bank of Beijing. The loan period is from November 26, 2024 to November 25, 2026. As of December 31, 2025, the principal balance of the loan was 26.10 million yuan, including "non-current liabilities due within one year" of 26.10 million yuan in principal and 31,400 yuan in interest payable.

(25) The company obtained a loan of RMB 50 million from the Shanghai Branch of the Bank of East Asia. The loan period is from February 18, 2025 to February 18, 2027. As of December 31, 2025, the principal balance of the loan was RMB 47.5 million, including RMB 5 million in principal and RMB 203,200 in interest payable as "non-current liabilities due within one year."

(26) The company obtained a loan of RMB 50 million from the Shanghai Branch of the Bank of East Asia. The loan period is from March 13, 2025 to February 18, 2027. As of December 31, 2025, the principal balance of the loan was 47.5 million yuan, of which 5.0 million yuan in principal and 78,500 yuan in interest payable were included in "non-current liabilities due within one year."

(27) The company obtained a loan of RMB 20 million from Industrial Bank Shanghai Branch. The loan period is from May 9, 2025 to May 8, 2027. As of December 31, 2025, the principal balance of the loan was 19.90 million yuan, including "non-current liabilities due within one year" of 200,000 yuan in principal and 23,700 yuan in interest payable.

(28) The company obtained a loan of RMB 35 million from Industrial Bank Shanghai Branch. The loan period is from June 6, 2025 to June 5, 2027. As of December 31, 2025, the principal balance of the loan was 34.90 million yuan, of which 200,000 yuan in principal and 40,500 yuan in interest payable were included in "non-current liabilities due within one year."

(29) The company obtained a loan of RMB 70 million from Industrial Bank Shanghai Branch. The loan period is from July 11, 2025 to July 10, 2027. As of December 31, 2025, the principal balance of the loan was 69.90 million yuan, of which 200,000 yuan in principal and 81,200 yuan in interest payable were included in "non-current liabilities due within one year."

(30) The company obtained a loan of RMB 75 million from Industrial Bank Shanghai Branch. The loan period is from July 24, 2025 to July 23, 2027. As of December 31, 2025, the principal balance of the loan was 74.90 million yuan, of which 200,000 yuan in principal and 87,000 yuan in interest payable were included in "non-current liabilities due within one year."

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

34. Bonds payable

(1) Bonds payable:

Item December 31, 2025 Convertible bonds on December 31, 2024 225,172,313.22 Medium-term notes 02

Total 225,172,313.22

1. Increases and decreases in bonds payable (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities)

Profit is accrued based on face value on December 31, 2024. December 31, 2025 Whether the name of the bond, face value, coupon rate, issuance date, bond term, issuance amount, issuance in this period, amortization of premium and discount, repayment in this period, balance on conversion date in this year, balance on interest date, default

0.30% in the first year

0.60% in the second year

Since June 2020

Convertible company 1.00% in the third year

550,000,000.00 17th to June 2026 72 months 550,000,000.00 225,172,313.22 4,470,516.89 8,020,135.45 4,218,336.00 489,466.67 232,955,162.89 No company bonds 1.50% in the fourth year

March 16

1.80% in the fifth year

Sixth year 2.00%

From July 2023

medium term notes

300,000,000.00 6.48% 18th to July 2025 24 months 300,000,000.00 308,453,722.78 10,746,000.00 240,277.22 319,440,000.00 No

March 20

Less: within one year

Expiration part

Closing balance 308,453,722.78 232,955,162.89 No (Note 5.

31)

Total 850,000,000.00 850,000,000.00 225,172,313.22 15,216,516.89 8,260,412.67 323,658,336.00 489,466.67Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Description of convertible corporate bonds:

Item Stock conversion conditions Stock conversion time 2025/1/31 2025/2/28 Due to the company's implementation of profit distribution for 2020, starting from July 16, 2021, the stock conversion 2025/3/31 2025/4/30 price will be adjusted to 13.25 yuan/share. Due to the company's implementation of profit distribution in 2022, since

2025/5/31 Starting from July 18, 2023, the conversion price will be adjusted to 13.10 yuan/share. Because the company is

2025/6/30 Runda Convertible Bonds will implement profit distribution in 2023. From July 19, 2024, the conversion price will be adjusted to

2025/7/31 13.00 yuan/share. Due to the company’s implementation of profit distribution in 2024, starting from July 2025

Starting from 2025/8/31 on the 18th, the conversion price will be adjusted to 12.97 yuan/share.

2025/9/30 2025/10/31 2025/11/30 2025/12/31

As approved by the China Securities Regulatory Commission's Securities Regulatory Commission (2020) No. 586, the company publicly issued 5.5 million convertible corporate bonds on June 17, 2020, with a face value of 100 yuan each, and a total issuance of 550 million yuan. On the bond issuance date, the company calculates the debt component of the bonds issued based on the average interest rate of 5.21% "referring to the Shanghai Stock Exchange & Shenzhen Stock Exchange (Corporate Bonds) 5-7 years summary of similar bonds", and the actual issuance amount after deducting the debt component is regarded as other equity components. The issuance costs are allocated based on the fair value of the debt component and the equity component. The term of the convertible corporate bonds is 6 years from the date of issuance, that is, June 17, 2020 to June 16, 2026. The start and end date of the share conversion period: December 23, 2020 to June 16, 2026. Coupon interest rate: 0.30% in the first year, 0.60% in the second year, 1.00% in the third year, 1.50% in the fourth year, 1.80% in the fifth year, and 2.00% in the sixth year. The initial conversion price of the convertible bonds issued this time is 13.36 yuan/share. Due to the company's implementation of profit distribution in 2020, the conversion price will be adjusted to 13.25 yuan/share starting from July 16, 2021. Due to the company's implementation of profit distribution in 2022, the conversion price will be adjusted to 13.10 yuan/share starting from July 18, 2023. Due to the company's implementation of profit distribution in 2023, the conversion price will be adjusted to 13.00 yuan/share starting from July 19, 2024. Due to the company's implementation of profit distribution in 2024, the conversion price will be adjusted to 12.97 yuan/share starting from July 18, 2025.

As of December 31, 2025, a total of RMB 315.843 million of convertible bonds had been converted into debt-for-equity, and the cumulative number of shares converted was 24,144,672 shares.

35. Lease liabilities

Item December 31, 2025 Operating lease on December 31, 2024 122,563,567.33 122,458,262.27 Less: Lease liabilities due within one year (Note V. 31) 47,226,549.95 48,375,808.01

Total 75,337,017.38 74,082,454.26 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

36. Long-term payables

(1) Classification list:

Item December 31, 2025 Long-term payables on December 31, 2024 92,936,749.51 135,299,458.54 Total 92,936,749.51 135,299,458.54

1. List long-term payables according to the nature of the payment:

Item December 31, 2025 Sale and leaseback payable on December 31, 2024 239,145,165.90 269,459,131.36 Installment fixed asset decoration fee 6,741,783.92 7,765,471.34 Less: Part due within one year (Note 5, 31) 152,950,200.31 141,925,144.16 Sale and leaseback payment payable 151,758,233.72 140,816,561.57 Installment fixed asset decoration fee 1,191,966.59 1,108,582.59

Total 92,936,749.51 135,299,458.54

37. Estimated liabilities

Project December 31, 2025 December 31, 2024 Reasons for formation

Quality deposit for self-produced instruments, used for product quality assurance 2,483,050.16 2,413,396.72

After-sales maintenance services during the warranty period

Total 2,483,050.16 2,413,396.72

38. Deferred income

Project December 31, 2024 Increase in this period Decrease in this period December 31, 2025 Causes Government subsidies 10,870,012.99 664,542.22 3,726,107.63 7,808,447.58 Total government subsidies 10,870,012.99 664,542.22 3,726,107.63 7,808,447.58

Note: For details about government subsidies, please see Note V. 63.

39. Other non-current liabilities

Project December 31, 2025 December 31, 2024

Advances received are deducted from sales of goods in installments 473,308.73 Long-term termination benefits 3,209,641.23 3,534,860.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Project December 31, 2025 December 31, 2024

Total 3,209,641.23 4,008,168.73

40. Share capital

This change increases or decreases (+, -)

Item Issuance on December 31, 2024 Provident Fund Bonus shares on December 31, 2025 Others Subtotal

New shares Conversion

Total number of shares 603,640,279.00 38,472.00 38,472.00 603,678,751.00

41. Other equity instruments

December 31, 2024 Increase in this period Decrease in this period Issued on December 31, 2025

Number of books

Financial instruments Quantity Book value Quantity Book value Quantity Book value

quantity value

Convertible bonds 2,346,570.00 47,022,026.64 5,000.00 100,193.09 2,341,570.00 46,921,833.55Total 2,346,570.00 47,022,026.64 5,000.00 100,193.09 2,341,570.00 46,921,833.55

42. Capital reserve

Item December 31, 2024 Increase in this period Decrease in this period Equity premium on December 31, 2025

(1) Capital reserve invested by investors 1,407,718,895.45 686,728.16 1,408,405,623.61 (2) Merger of enterprises under the same control

-1,332,085.12 -1,332,085.12 impact

(3) Changes in equity interests of minority shareholders of subsidiaries

-159,844,908.36 7,243,494.35 -152,601,414.01 Impact of movement (note)

Subtotal 1,246,541,901.97 7,930,222.51 1,254,472,124.48 Other capital reserves

(1) In addition to net profit and loss of the invested unit

-154,955.20 2,095.87 -152,859.33Other changes in owner’s equity

Subtotal -154,955.20 2,095.87 -152,859.33Total 1,246,386,946.77 7,932,318.38 1,254,319,265.15 Note: Please refer to Note 7.2 for details of the main impact of changes in minority shareholders’ equity of subsidiaries.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

43. Other comprehensive income

Amount incurred this period

Item December 2024 Less: Included in the previous period Less: Included in others in the previous period Before income tax for the current period in December 2025 Less: Income tax expense Attributable to the public after tax Attributable to the public after tax

Other comprehensive income on the 31st. Comprehensive income for the current period. Amount incurred on the 31st. The company's minority shareholders.

Transferred to profit and loss during period and transferred to retained earnings

1. Other comprehensive income that cannot be reclassified into profit and loss 3,668,269.98 -12,923,047.93 -2,980,760.28 -9,502,284.64 -440,003.01 -5,834,014.66 Including: Changes in remeasurement of defined benefit plans

Other comprehensive income that cannot be transferred to profit or loss under the equity method

Changes in the fair value of other equity instrument investments 3,668,269.98 -12,923,047.93 -2,980,760.28 -9,502,284.64 -440,003.01 -5,834,014.66 Changes in the fair value of the enterprise's own credit risk

2. Other comprehensive income that will be reclassified into profit and loss 2,195,869.55 -337,050.54 -308,739.98 -28,310.56 1,887,129.57 Among them: other comprehensive income that can be converted into profit and loss under the equity method

Changes in fair value of other debt investments

The amount of financial assets reclassified and included in other comprehensive income

Credit impairment provisions for other debt investments

Cash flow hedging reserve

Differences in translation of foreign currency financial statements 2,195,869.55 -337,050.54 -308,739.98 -28,310.56 1,887,129.57

3. Total other comprehensive income 5,864,139.53 -13,260,098.47 -2,980,760.28 -9,811,024.62 -468,313.57 -3,946,885.09Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

44. Surplus reserve

Item December 31, 2024 Increase in this period Decrease in this period Statutory surplus reserve on December 31, 2025 115,933,980.61 115,933,980.61

Total 115,933,980.61 115,933,980.61

45. Undistributed profits

Item 2025 Year 2024 Undistributed profits at the end of the previous period before adjustment 2,335,734,634.86 2,340,340,319.09 Total undistributed profits at the beginning of the adjustment period (increase +, decrease -)

Adjusted opening undistributed profit 2,335,734,634.86 2,340,340,319.09 plus: Net profit attributable to owners of the parent company for the period -548,393,978.51 55,280,607.97

Other comprehensive income transferred directly to undistributed profits

Less: Withdrawal from statutory surplus reserve

Withdraw discretionary surplus reserve

Withdraw reserve fund

Withdraw enterprise development funds

Withdraw employee bonus fund

Common stock dividends payable 18,109,927.92 59,886,292.20 Common stock dividends converted into share capital

preferred stock dividends

Other distributions to shareholders

Profits return investment

Other profit distribution

Other comprehensive income carried forward to retained earnings

Insufficient capital reserve for acquiring minority equity to offset retained earnings

Undistributed profit at the end of the period 1,769,230,728.43 2,335,734,634.86Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

46. Operating income and operating costs

2025 2024

Project

revenue cost revenue cost

Main business 6,990,562,484.47 5,500,922,521.84 8,305,933,347.53 6,201,120,412.04 Other businesses 7,967,491.79 705,901.17 5,847,009.86 2,371,786.70

Total 6,998,529,976.26 5,501,628,423.01 8,311,780,357.39 6,203,492,198.74

(1) Breakdown information of operating income and operating costs:

2025

Project

Operating income Operating costs

Reagents and other consumables 6,501,986,844.11 5,114,328,913.14 Instruments 337,804,988.55 325,018,306.39 Software sales and services 150,770,651.81 61,575,302.31 House rental 1,623,417.72 705,901.17 Fund services 6,344,074.07

Total 6,998,529,976.26 5,501,628,423.01

47. Taxes and Surcharges

Project 2025 2024

Urban maintenance and construction tax 11,798,666.67 17,433,673.28 Education surcharge 9,018,253.24 13,773,638.89 Property tax 2,008,577.04 2,168,194.28 Stamp tax 5,533,350.11 6,617,541.69 Land use tax 109,612.37 24,571.68 Consumption tax 2,049.29

Vehicle and vessel use tax 64,410.32

Others 664,777.20 963,727.84 Total 29,199,696.24 40,981,347.66

Note: Please see Note 4, "Taxes" for details on the calculation and payment standards of various taxes and surcharges.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

48. Selling expenses

Project 2025 2024

Employee compensation 346,873,562.96 356,330,005.58 Technical service fee 152,829,058.50 141,822,949.77 Debugging and maintenance fee 83,708,174.04 148,475,307.60 Travel and transportation expenses 44,096,003.77 48,218,859.63 Business entertainment expenses 56,445,116.75 61,876,212.87 Business promotion expenses 11,965,235.72 17,299,885.97 Conference expenses 12,376,661.91 16,883,271.34 Office expenses 14,004,319.15 18,743,772.75 Others 26,302,964.85 31,126,780.47

Total 748,601,097.65 840,777,045.98

49. Administrative expenses

Project 2025 2024

Employee compensation 224,053,952.83 251,300,838.62 Depreciation and amortization expenses 73,592,546.83 80,103,289.53 Inventory scrapping 22,676,102.92 17,681,233.79 Business entertainment expenses 21,958,302.25 26,573,198.36 Travel and transportation expenses 16,406,753.69 20,451,367.83 Office expenses 24,651,732.68 24,606,688.58 Rent and property expenses 20,113,463.10 19,375,764.56 Intermediary agency fees 11,405,288.48 15,959,701.12 Others 23,657,364.06 23,889,106.33

Total 438,515,506.84 479,941,188.72

50. Research and development expenses

Project 2025 2024

Employee compensation 68,477,002.97 71,245,281.15 Direct material expenses 7,870,207.90 11,317,400.18 Depreciation and amortization expenses 14,059,145.81 15,594,988.46 Mold equipment 2,838,158.01 1,783,089.28 Commissioned external research and development expenses 459,224.93 2,509,734.13 Office expenses 752,663.36 1,686,725.07 Maintenance and calibration expenses 4,812,938.98 3,717,253.36 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Project 2025 2024

Others 8,744,420.51 8,301,970.47

Total 108,013,762.47 116,156,442.10

51. Financial charges

Project 2025 2024

Interest expense 278,931,171.45 312,858,681.19 Less: Interest income 10,980,948.03 13,365,461.21 Exchange gains and losses 383,934.89 5,973,701.87 Others 5,181,640.83 7,968,045.52

Total 273,515,799.14 313,434,967.37

52. Other income

2025 2024

Items are included in the current period's non-recurring amounts and are included in the current period's non-recurring amounts.

The amount of sexual gains and losses is related to the daily activities of the enterprise.

31,325,945.44 27,675,819.84 32,901,869.92 26,772,113.26 government subsidies

Withholding personal income tax

721,739.95 760,703.68

Renewal refund

Input tax plus deduction

Total 32,047,685.39 27,675,819.84 33,662,573.60 26,772,113.26

Note: For details of other income generated from government subsidies related to the daily activities of the enterprise, please see Note V. 63.

53. Investment income

Item 2025 Income from long-term equity investments accounted for by equity method in 2024 18,977,985.59 108,488,300.20 Investment income from disposal of long-term equity investments 892,999.21 Income from entrusted loans or financial management 1,816,534.22 439,581.77

Total 20,794,519.81 109,820,881.18 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

54. Credit impairment losses

Item 2025 Bad debt losses on notes receivable in 2024 -9,123,350.91 29,230.64 Bad debt losses on accounts receivable -175,625,375.17 -67,249,184.62 Bad debt losses on other receivables -7,297,546.42 -10,026,658.57 Impairment losses on non-current assets due within one year -4,730,882.60 -4,359,332.31 Bad debt losses on long-term receivables 66,209.24 61,626.21 Impairment losses on other current assets

Bad debt loss on dividends receivable 175,000.00 -169,806.00 Total -196,535,945.86 -81,714,124.65

Note: In the above table, losses are listed with a "-" sign, and gains are listed with a "+" sign.

55. Asset impairment losses

Item 2025 Inventory depreciation losses and contract performance cost impairment losses in 2024 305,317.26 -7,041,000.58 Fixed asset impairment losses

Goodwill impairment losses -209,042,455.14 -29,129,132.17 Total -208,737,137.88 -36,170,132.75

Note: In the above table, losses are listed with a "-" sign, and gains are listed with a "+" sign.

56. Income from asset disposals

2025 2024

Sources of asset disposal income Included in non-recurring current period Included in current non-recurring amount incurred in current period Amount incurred in current period

Amount of sexual gains and losses Gains or losses on disposal of fixed assets -1,886,645.14 -1,886,645.14 8,283,091.88 8,283,091.88 Gains or losses on disposal of right-of-use assets 4,574,490.46 4,574,490.46 3,180,390.28 3,180,390.28 Gains or losses on disposal of intangible assets 431,302.89 431,302.89

Total 3,119,148.21 3,119,148.21 11,463,482.16 11,463,482.16

Note: In the above table, losses are listed with a "-" sign, and gains are listed with a "+" sign.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

57. Non-operating income

2025 2024

Item Included in non-recurring losses for the current period Amount incurred for the current period included in non-recurring losses for the current period

Amount of gain Amount of gain Profit from damage and scrapping of non-current assets 4,867.26 4,867.26 324.89 324.89 Including: Fixed assets 4,867.26 4,867.26 324.89 324.89 Government policies unrelated to the daily activities of the enterprise

313,000.00 313,000.00 62,000.00 62,000.00 Government subsidy

Income from liquidated damages and fines 437,736.58 437,736.58 371,403.62 371,403.62 Others 5,097,425.69 5,097,425.69 188,727.79 188,727.79 Total 5,853,029.53 5,853,029.53 622,456.30 622,456.30

Note: For details of government subsidies included in current profits and losses, please see Note V. 63.

58. Non-operating expenses

2025 2024

Item Included in non-recurring losses for the current period Amount incurred for the current period included in non-recurring losses for the current period

Amount of gain Amount of gain Loss from damage and scrapping of non-current assets 3,575,988.14 3,575,988.14 4,979,067.38 4,979,067.38 Including: fixed assets 3,575,988.14 3,575,988.14 4,979,067.38 4,979,067.38 External donations 2,427,291.78 2,427,291.78 2,351,027.22 2,351,027.22 Extraordinary losses 14,837.98 14,837.98 Fines and late payment fees 5,395,098.15 5,395,098.15 1,372,706.58 1,372,706.58 Others 4,835,840.03 4,835,840.03 422,464.62 422,464.62

Total 16,234,218.10 16,234,218.10 9,140,103.78 9,140,103.78

59. Income tax expenses

(1) Income tax expense schedule:

Item 2025 Current income tax expense in 2024 114,108,840.47 185,653,433.98 Deferred income tax expense -56,595,188.00 -29,569,256.15

Total 57,513,652.47 156,084,177.83Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Adjustment process of accounting profits and income tax expenses:

Item 2025 Total profit in 2024 -460,637,227.99 345,542,198.88 Income tax expense calculated according to statutory/applicable tax rates -115,159,307.00 86,385,549.71 Impact of different tax rates applicable to subsidiaries -3,792,531.20 -2,746,414.84 The impact of adjusting income tax in previous periods -857,807.33 1,320,377.12 The impact of non-taxable income -5,255,137.10 -25,673,330.24 The impact of non-deductible costs, expenses and losses 55,804,828.62 3,983,287.39 The impact of using the deductible losses of deferred income tax assets not recognized in the previous period -1,384,502.29 -15,902,634.51 The deductible temporary differences of deferred income tax assets not recognized in the current period may be

131,847,619.17 108,717,343.20 Effect of deducting losses

Changes in the balance of deferred income tax assets/liabilities at the beginning of the period due to tax rate adjustments -3,689,510.40

Income tax expenses 57,513,652.47 156,084,177.83

60. Cash flow statement items

(1) Cash related to operating activities:

1. Other cash received related to operating activities:

Project 2025 2024

Other transactions and other non-operating income 23,638,491.46 52,846,818.19 Special subsidies and grants 25,769,181.31 23,288,224.37 Interest income 11,790,445.76 18,293,120.83 Impact of restricted monetary funds 54,796,942.31 51,553,332.18 Total 115,995,060.84 145,981,495.57

2. Other cash paid related to operating activities:

Project 2025 2024

Other transactions 38,970,238.21 37,750,448.27 Expenses and non-operating expenses 582,736,948.97 675,609,125.62 Impact of restricted monetary funds 107,431,096.67 35,153,933.31

Total 729,138,283.85 748,513,507.20 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Cash related to investing activities:

1. Cash received related to important investment activities:

Project 2025 2024

Financial management products 493,240,000.00 329,270,000.00 Recovery of investment principal from fund companies 300,000.00

Investment funds received 3,500,000.00 4,985,632.92 Investment funds returned 40,600,000.00 Total 497,040,000.00 374,855,632.92

2. Cash paid for important investment activities:

Project 2025 2024

Financial products 540,840,000.00 353,470,000.00 Investment funds from joint-stock companies 18,935,708.93 219,462,001.00 Total 559,775,708.93 572,932,001.00 3) Other cash received related to investment activities:

Project 2025 2024

Current loans 1,500,550.00 1,515,500.00 Cooperation intention money returned 9,000,000.00 Total 1,500,550.00 10,515,500.00

4. Other cash paid related to investment activities:

Project 2025 2024

Payment of investment equity guarantee 359,124.14 65,347,209.50 Payment of cooperation intention deposit 9,000,000.00 Payment of loan 100,000.00 3,000,000.00 Payment of entrusted loan handling fee 17,600.00 17,600.00 Payment of deposit 166,870.83 281,397.45

Total 643,594.97 77,646,206.95 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(3) Cash related to financing activities:

1. Other cash received related to financing activities:

Project 2025 2024

Security deposit recovered 280,648,095.00 521,646,201.92 Sales and leaseback financing lease payments received 121,600,000.00 279,360,000.00 Current borrowings 12,000,000.00 Total 402,248,095.00 813,006,201.92

2. Other cash paid related to financing activities:

Project 2025 2024

Payment of financing-related expenses 4,464,244.77 3,812,857.49 Payment of loan deposit 256,350,000.00 344,614,000.00 Return of financing 205,782,177.13 353,414,292.45 Return of investment from minority shareholders 28,000,000.00

Total 494,596,421.90 701,841,149.94 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. Changes in various liabilities arising from financing activities

Increase in this period Decrease in this period

Project December 31, 2024 December 31, 2025

Cash changes Non-cash changes Cash changes Non-cash changes

Short-term borrowings 4,924,559,871.29 6,796,169,547.23 186,883,169.19 6,982,763,705.18 63,602,582.73 4,861,246,299.80 Long-term borrowings 1,189,350,190.89 757,300,000.00 55,932,889.45 599,636,712.43 1,402,946,367.91 Lease liabilities 122,458,262.27 55,313,050.32 55,339,969.34 -132,224.08 122,563,567.33 Dividends payable 12,971,219.37 150,760,854.86 144,248,148.97 411,805.26 19,072,120.00 Other payables 57,349,894.50 25,836,158.11 3,311,576.75 27,905,123.93 58,592,505.43 Long-term payables 277,224,602.70 121,600,000.00 12,816,585.68 164,211,329.33 1,542,909.23 245,886,949.82 Bonds payable-mid-term notes 308,453,722.78 10,986,277.22 319,440,000.00

Bonds payable - convertible bonds 225,172,313.22 17,321,617.17 4,218,336.00 4,118,594.39 234,157,000.00 Dividend income tax and handling fees 13,515,814.54 13,515,814.54

Capital contribution from minority shareholders 154,285.71 154,285.71

Other receivables 1,550,000.00 1,150,000.00 400,000.00 Security deposit for financing activities 223,278,654.11 279,718,858.78 11,003,992.56 259,853,992.56 18,095.00 192,427,890.33 Prepayment 1,500,000.00 3,700,000.00 2,200,000.00

Minority shareholders withdraw shares 28,000,000.00 28,000,000.00

Total 7,343,868,731.14 7,981,928,849.83 549,545,827.74 8,601,333,132.28 69,716,048.24 7,137,292,700.62Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

61. Supplementary information to cash flow statement

(1) Supplementary information for cash flow statement:

Supplementary information 2025 2024

1. Reconcile net profit to cash flow from operating activities:

Net profit -518,150,880.46 189,458,021.05 plus: asset impairment provision 208,737,137.88 36,170,132.75 Credit impairment loss 196,535,945.86 81,714,124.65 Depreciation of fixed assets, depletion of oil and gas assets, depreciation of productive biological assets

286,439,547.75 316,869,272.16 Amortization of old and investment properties

Depreciation of right-of-use assets 53,119,679.83 56,295,066.41 Amortization of intangible assets 21,910,565.24 21,140,270.09 Amortization of long-term prepaid expenses 28,163,963.57 27,756,306.35 Losses on disposal of fixed assets, intangible assets and other long-term assets

-3,119,148.21 -11,463,482.16 (Income is listed with "-")

Loss from scrapping of fixed assets (income is listed with "-") 3,571,120.88 4,978,742.49 Loss from changes in fair value (income is listed with "-")

Financial expenses (income is listed with "-") 279,777,407.24 318,059,213.29 Investment losses (income is listed with "-") -20,792,097.98 -109,820,881.18 Decrease in deferred income tax assets (increase is listed with "-") -56,818,983.70 -21,792,264.61 Increase in deferred income tax liabilities (decreases are indicated with "-") 223,795.70 -7,776,991.54 Decrease in inventories (increases are indicated with "-") -521,072,010.81 -72,592,557.32 Decrease in operating receivables (increases are indicated with "-") -70,246,852.02 -115,067,333.81 Increase in operating payables (decreases are listed with "-") 748,943,020.00 -66,980,258.91 Others

Net cash flow generated from operating activities 637,222,210.77 646,947,379.71 2. Major investing and financing activities that do not involve cash receipts and payments:

debt to capital

Convertible corporate bonds due within one year

3. Net changes in cash and cash equivalents:

Closing balance of cash 667,045,710.31 889,011,285.11 Less: Opening balance of cash 889,011,285.11 613,287,701.29 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents -221,965,574.80 275,723,583.82 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Acquisition or disposal of subsidiaries and other business units during the reporting period:

Project 2025 2024 1． Acquire subsidiaries and other business units:

Cash and cash equivalents paid in the current period for the business merger that occurred in the current period 455,000.00 Among them: Anhui Zefen Biotechnology Co., Ltd. 455,000.00 Less: Cash and cash equivalents held by the company on the date of purchase 270,500.10 Among them: Anhui Zefen Biotechnology Co., Ltd. 270,500.10 Plus: Cash and cash equivalents paid in the current period for the business merger that occurred in the previous period

Net cash paid to acquire subsidiaries 184,499.90 2. Disposal of subsidiaries and other business units:

Cash and cash equivalents received from disposal of subsidiaries in the current period

Less: Cash and cash equivalents held by the company on the date of loss of control

Add: Cash and cash equivalents received in the current period from the disposal of subsidiaries in the previous period

Net cash received from disposal of subsidiaries

(3) Composition of cash and cash equivalents:

Project 2025 2024 1. Cash 667,045,710.31 889,011,285.11 Of which: Cash on hand 188,860.25 241,546.97 Bank deposits that can be used for payment at any time 666,856,850.06 888,769,738.14 Other monetary funds that can be used for payment at any time

Central bank deposits available for payment

Deposit funds from other banks

Funds placed with other banks

2. cash equivalents

Including: Bond investments due within three months

3. Closing balance of cash and cash equivalents 667,045,710.31 889,011,285.11 Including: restricted cash and cash equivalents used by the parent company or subsidiaries within the group

(4) Monetary funds that are not cash and cash equivalents:

Not classified as cash and cash items December 31, 2025 December 31, 2024

Reasons for equivalents Bank acceptance bill deposit 132,100,000.00 39,100,000.00 Restricted use Letter of credit deposit 70,168,460.06 112,378,640.98 Restricted use Performance bond 13,420,932.72 7,559,007.97 Use restricted Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Not classified as cash and cash items December 31, 2025 December 31, 2024

Reasons for equivalents used for guaranteed time deposits or notice deposits 52,912,690.79 93,129,054.11 Use restricted Other monetary funds with restricted use 80,196,382.55 65,347,209.50 Use restricted

Total 348,798,466.12 317,513,912.56

62. Foreign currency monetary items

(1) Foreign currency monetary items:

December 31, 2025 Conversion items on December 31, 2025 Conversion exchange rate

Foreign currency balance RMB balance

Monetary funds

Among them: US dollars 4,047,132.42 7.0288 28,446,484.36 Euros 62,221.27 8.2355 512,423.26 Canadian dollars 661,494.00 5.1142 3,383,012.61 Hong Kong dollars 3,906.62 0.9026 3,526.30 Accounts receivable 42,365,030.04 Including: US dollars 4,544,099.16 7.0288 31,939,564.18 Euros 36,985.00 8.2355 304,589.97 Canadian dollars 1,978,975.38 5.1142 10,120,875.89 Other receivables 6,871,423.78 Canadian dollars 1,343,597.00 5.1142 6,871,423.78 Accounts payable 13,408,673.04 Canadian dollars 2,621,851.52 5.1142 13,408,673.04

(2) Description of overseas operating entities:

Accounting standard. Accounting standard currency. Important overseas operations. Overseas major accounting standard currency. Current period.

Accounting standard currency and selection basis. Currency changes. Entity that changes. Business location. Whether there is a change.

Reasons for change Accounting treatment

Huizhong Diagnostic Technology (Hong Kong dollars, the main

Hong Kong No Not applicable Not applicable Hong Kong) Co., Ltd. requires currency in the economic environment

The Canadian dollar, the main currency in which businesses operate

1077801B.C.LTD. Canada No Not applicable Not applicable

money in the economic environment

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

63. Government subsidies

(1) Basic information on government subsidies:

New additions in the current period are included in the operating income in the current period. Included in the deduction in the current period. Asset-related/liability items December 31, 2024 Other changes December 31, 2025

Amount of subsidy Amount of external income Amount of other income Amount of expenses Deferred income related to income 10,870,012.99 664,542.22 3,865,670.08 139,562.45 7,808,447.58

Total 10,870,012.99 664,542.22 3,865,670.08 139,562.45 7,808,447.58

The government subsidy items involved in deferred income are as follows:

December 2024 New subsidy in this period. Included in non-operating in this period. Included in other in this period. Subsidy in this period. December 2025. Other changes in asset-related/liability items.

31st Amount Income Amount Benefit Amount This fee amount 31st Relevant to Benefit NGEN funding for COVID antigen test

8,488,268.00 1,330,412.84 111,468.67 7,269,323.83 Related to assets and manufacturing scaleup

ISCGrant 1,680,068.46 1,705,619.82 25,551.36 Related to income CANEXPORT 151,494.00 264,542.22 252,367.14 2,542.42 166,211.50 Related to income Ranosi2100 fully automatic chemiluminescence immunoanalyzer

400,000.00 100,000.00 500,000.00 Project prototype development related to income

Shanghai Jinshan District Science and Technology Commission-2025

300,000.00 300,000.00 Relevant to income, the first funding from the District’s Little Technology Giant

Runda B2B supply chain management platform 37,500.00 37,500.00 Asset-related clinical laboratory reagents and consumables combined with technological innovation management

112,682.53 39,770.28 72,912.25 Asset-related management platform

Total 10,870,012.99 664,542.22 3,865,670.08 139,562.45 7,808,447.58

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Government subsidies included in current profits and losses:

Accounting accounts 2025 2024

Other income 31,325,945.44 32,901,869.92 Non-operating income 313,000.00 62,000.00Total 31,638,945.44 32,963,869.92

Related to assets/income 2025 2024

Related to income 30,231,262.32 31,481,224.83 Related to assets 1,407,683.12 1,482,645.09

Total 31,638,945.44 32,963,869.92

64. Leasing

(1) The company serves as the lessee

Simplified treatment of short-term leases or lease payments for low-value assets

Items Lease expenses in 2025 Lease expenses in 2024 Short-term lease expenses (simplified treatment applies) 70,581,746.93 84,848,569.49

(2) The company serves as the lessor

Operating lease as lessor

Including: Available items not included in lease receipts Lease income in 2025

Income related to variable lease payments Operating leased fixed assets 20,580,780.69

Total 20,580,780.69

65. Research and development expenditure

(1) Listed by nature of expenses:

Project 2025 2024

Employee compensation 70,607,316.52 74,464,924.49 Direct material expenses 7,870,207.90 12,697,367.84 Depreciation and amortization expenses 18,466,235.62 23,477,683.59 Mold equipment 4,232,066.75 1,783,089.28 Commissioned external research and development expenses 459,224.93 6,924,647.22 Office expenses 752,663.36 1,686,725.07 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Project 2025 2024

Maintenance and calibration fees 4,812,938.98 6,496,141.45 Others 8,744,420.51 8,301,970.47

Total 115,945,074.57 135,832,549.41 Including: expensed R&D expenditures 108,013,762.47 116,156,442.10 Capitalized R&D expenditures 7,931,312.10 19,676,107.31 (2) R&D project development expenditures that meet capitalization conditions

Increase amount in this period Decrease amount in this period

December 2024 December 2025 project confirmed as intangible and transferred to the current period

31st Internal development expenditure Others 31st

Assets Profit and Loss

Diagnostic reagents 5,789,046.28 3,184,422.45 8,973,468.73 Medical instrument systems 13,887,061.03 4,746,889.65 18,633,950.68

Total 19,676,107.31 7,931,312.10 27,607,419.41

6. Changes in consolidation scope

1. Business merger not under common control

As of the date of issuance of these financial statements, the Company has no business combinations involving enterprises not under common control.

2. Merger of enterprises under common control

As of the date of issuance of these financial statements, the Company has no business combinations under common control.

3. Reverse purchase

As of the date of issuance of these financial statements, the Company has no reverse purchases.

4. Disposal of subsidiaries

As of the date of issuance of these financial statements, the Company has no disposal subsidiaries.

5. Changes in consolidation scope due to other reasons

(1) On February 19, 2025, the company canceled its wholly-owned company Zhejiang Runhui Diagnostic Technology Co., Ltd., accounting for 100.00% of the equity. It will be removed from the scope of consolidated statements from the date of cancellation.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) On March 5, 2025, the company established Chongqing Runda Intelligent Medical Technology Co., Ltd., accounting for 61.00% of the equity. From the date of establishment, it will be included in the scope of consolidated statements.

(3) On March 24, 2025, the company canceled its wholly-owned company Nanjing Runda Qianghan Medical Technology Co., Ltd., accounting for 100.00% of the equity ratio. It will be removed from the scope of consolidated statements from the date of cancellation.

(4) On March 25, 2025, the company established a wholly-owned company, Shenzhen Runyi Smart Technology Co., Ltd., accounting for 100.00% of the equity. From the date of establishment, it will be included in the scope of consolidated statements.

(5) On May 29, 2025, the company established a wholly-owned company, Fuyang Huizhong Medical Technology Co., Ltd., accounting for 100.00% of the equity. From the date of establishment, it will be included in the scope of consolidated statements.

(6) On May 30, 2025, the company established Fuyang Runda Medical Technology Co., Ltd., accounting for 80.00% of the equity. From the date of establishment, it will be included in the scope of consolidated statements.

(7) On October 20, 2025, the company canceled Yixian Inspection (Guangdong) Co., Ltd., accounting for 43.35% of the equity. From the date of cancellation, it will be removed from the scope of the consolidated statements.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

7. Interests in other entities

1. Interests in subsidiaries

(1) Composition of enterprise group:

Registered capital Major managers Shareholding ratio (%)

Subsidiary name Registration place Nature of business Obtaining method

(10,000 yuan) Campsite Direct Indirect

Shanghai Runda Industrial Development Co., Ltd. 2,500.00 Shanghai Shanghai Business 36.00 Shanghai Huizhong Medical Technology Co., Ltd., a business combination under the same control 15,000.00 Shanghai Shanghai Production and R&D 100.00 Shanghai Yicheng Precision Machinery Co., Ltd., a business combination under the same control 400.00 Shanghai Shanghai Mechanical parts manufacturing 100.00 Establishment

Shanghai Huizhong Biotechnology Co., Ltd. 500.00 Shanghai Shanghai Production and R&D 100.00 Merger of enterprises not under common control Shanghai Huirui Information Technology Co., Ltd. 100.00 Shanghai Shanghai Software development and services 70.00 Establishment

Huizhong Diagnostic Technology (Hong Kong) Co., Ltd. 50.98 Hong Kong Hong Kong Investment, Business 100.00 Establishment

Beijing Huizhong Medical Devices Co., Ltd. 7,529.63 Beijing Beijing Production and R&D 64.87 Beijing Southeast Yueda Medical Devices Co., Ltd., a business combination not under common control 1,000.00 Beijing Beijing Commercial 60.00 Hangzhou Huizhong Diagnostic Technology Co., Ltd., a business combination not under common control 300.00 Hangzhou Hangzhou Commercial 100.00 Runlan (Shanghai) Biotechnology Co., Ltd., a business combination not under common control 1,000.00 Shanghai Shanghai Business 70.00 Merger of enterprises not under common control Shanghai Runhao Medical Technology Co., Ltd. 1,000.00 Shanghai Shanghai Technology development and services 100.00 Establishment

Shanghai Kangxia Medical Technology Co., Ltd. 500.00 Shanghai Shanghai Commercial 70.00 Purchase equity

Shanghai Runda Rongjia Biotechnology Co., Ltd. 6,000.00 Shanghai Shanghai Business, technology development 51.00 Merger of enterprises not under common control Shanghai Runyi Scientific Instrument Co., Ltd. 1,000.00 Shanghai Shanghai Business 100.00 Establishment

Harbin Runda Kangtai Biotechnology Co., Ltd. 22,200.00 Harbin Harbin Commercial 100.00 Merger of enterprises not under common control Heilongjiang Longwei Precision Medical Testing Laboratory Co., Ltd.

6,000.00 Harbin Harbin Inspection Services 70.00 Establishment

Ltd.

Liaoning Runda Kangtai Biotechnology Co., Ltd. 10,000.00 Tieling Tieling Commercial 100.00 Establishment

Changchun Jinzerui Medical Technology Co., Ltd. 1,000.00 Changchun Changchun Commercial 60.00 Merger of enterprises not under common control Heilongjiang Xinshengrui Medical Technology Co., Ltd. 500.00 Harbin Harbin Commercial 100.00 Establishment

Changchun Ruihe Medical Technology Co., Ltd. 1,000.00 Changchun Changchun Commercial 51.00 Established

Changchun Runda Zerui Medical Technology Co., Ltd. 7,300.00 Changchun Changchun Commercial 100.00 Merger of enterprises not under common control Heilongjiang Runda Taixin Biotechnology Co., Ltd. 1,000.00 Jiamusi Jiamusi Commercial 51.00 Establishment

Suzhou Runda Huichang Biotechnology Co., Ltd. 300.00 Suzhou Suzhou Commercial 51.00 Establishment

Qingdao Yixin Medical Technology Co., Ltd. 10,000.00 Qingdao Qingdao Commercial 100.00 Merger of enterprises not under common control Jinan Runda Biotechnology Co., Ltd. 5,050.00 Jinan Jinan Commercial 70.00 Establishment

Shandong Xinhai Runbang Medical Supplies Distribution Co., Ltd.

8,000.00 Qingdao Qingdao Commercial 100.00 Business Merger Department not under common control

Qingdao Runda Medical Technology Co., Ltd. 5,000.00 Qingdao Qingdao Commercial 100.00 Establishment

Hangzhou Yidan Biotechnology Co., Ltd. 2,000.00 Hangzhou Hangzhou Commercial 57.00 Merger of enterprises not under common control Hangzhou Runda Medical Management Co., Ltd. 50,000.00 Hangzhou Hangzhou Commercial 100.00 Establishment

Runda (Zhejiang) Medical Testing Laboratory Co., Ltd.

10,000.00 Hangzhou Hangzhou Inspection Services 100.00 Establishment

company

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Hefei Sanli Medical Technology Co., Ltd. 500.00 Hefei Hefei Commercial 65.00 Merger of enterprises not under common control Hefei Runda Wantong Medical Technology Co., Ltd. 1,667.00 Hefei Hefei Commercial 40.01 Merger of enterprises not under common control Hefei Runda Medical Laboratory Management Co., Ltd. 1,000.00 Hefei Hefei Inspection Services 100.00 Establishment

Shanghai Zhongke Runda Precision Medical Testing Co., Ltd.

5,000.00 Shanghai Shanghai Inspection Services 56.00 Establishment

Division

Shanghai Zhongke Runda Medical Testing Laboratory Co., Ltd.

3,000.00 Shanghai Shanghai Inspection Services 100.00 Establishment

company

Shanghai Ruimei Computer Technology Co., Ltd. 1,600.00 Shanghai Shanghai Software development and services 60.00 Shanghai Ruimei Information Technology Co., Ltd., a merger of companies not under common control 300.00 Shanghai Shanghai Software development and services 100.00 Shanghai Ruimei Software Technology Co., Ltd., a merger of companies not under common control 300.00 Shanghai Shanghai Software development and services 100.00 Shanghai Ruimei Network Technology Co., Ltd., a merger of companies not under common control 300.00 Shanghai Shanghai Software development and services 100.00 Establishment

Yunnan Runda Kangtai Medical Technology Co., Ltd. 4900.00 Kunming Kunming Commercial 81.6327 Wuhan Runda Shangqian Medical Technology Co., Ltd. 988.84606 Wuhan Wuhan Commercial 88.3721 Wuhan Youkeliansheng Technology and Trade Co., Ltd. 10,929.00 Wuhan Wuhan Commercial 51.00 Merger of enterprises not under common control Guorun Youke Medical Enshi Co., Ltd. 800.00 Enshi Enshi Commercial 100.00 Establishment

Guangdong Runda Medical Diagnostic Technology Co., Ltd. 3,000.00 Guangzhou Guangzhou Commercial 100.00 Establishment

1077801B.C.LTD. Canada Canada Business 92.19 Business merger not under common control ResponseBiomedicalCorp. Canada Canada Production and R&D 100.00 Business merger not under common control Chongqing Runda Kangtai Medical Equipment Co., Ltd. 1,000.00 Chongqing Chongqing Business 61.00 Business merger not under common control Hainan Runda Medical Technology Co., Ltd. 500.00 Chengmai Chengmai Commercial 100.00 Purchase equity

Shanghai Runlin Medical Technology Co., Ltd. 933.33 Shanghai Shanghai Commercial 100.00 Business merger not under common control Runli Supply Chain Management (Shanghai) Co., Ltd. 5,000.00 Shanghai Shanghai Commercial 51.00 Business merger not under common control Chengdu Runli Medical Technology Co., Ltd. 2,000.00 Chengdu Chengdu Commercial 51.00 Business merger not under common control Shanghai Huizhong Rongjia Medical Laboratory Co., Ltd.

2,000.00 Shanghai Shanghai Inspection Services 51.00 Established

company

Runda Medical Supply Chain Management (Hangzhou) Co., Ltd.

10,000.00 Hangzhou Hangzhou Commercial 100.00 Establishment

company

Zhejiang Zhongdingdako Biotechnology Co., Ltd. 1,000.00 Hangzhou Hangzhou Commercial 100.00 Establishment

Hangzhou Mingheyuan Medical Technology Co., Ltd. 1,000.00 Hangzhou Hangzhou Commercial 100.00 Establishment

Hangzhou Runda Jiafu Medical Technology Co., Ltd. 500.00 Hangzhou Hangzhou Commercial 51.00 Establishment

Shandong Runda Kangyuan Supply Chain Service Co., Ltd. 1,000.00 Jinan Jinan Commercial 100.00 Establishment

Zhejiang Hangrun Private Equity Fund Management Co., Ltd. 1,000.00 Hangzhou Hangzhou Investment 65.00 Establishment

Anhui Zefen Biotechnology Co., Ltd. 500.00 Hefei Hefei Commercial 65.00 Merger of enterprises not under common control Fuyang Huizhong Medical Technology Co., Ltd. 1,000.00 Fuyang Fuyang Commercial 100.00 Establishment

Fuyang Runda Medical Technology Co., Ltd. 1,000.00 Fuyang Fuyang Commercial 80.00 Establishment

Shenzhen Runyi Intelligent Technology Co., Ltd. 100.00 Shenzhen Shenzhen Software development and services 100.00 Establishment

Chongqing Runda Intelligent Medical Technology Co., Ltd. 200.00 Chongqing Chongqing Commercial 100.00 Establishment

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Important non-wholly owned subsidiaries

Name of subsidiary company Shareholding ratio of minority shareholders (%) Profit and loss attributable to minority shareholders in the current period Dividends declared to minority shareholders in the current period Balance of minority shareholders’ equity at the end of the period

Beijing Southeast Yueda Medical Equipment Co., Ltd. 40.00 15,566,507.61 44,000,000.00 197,453,281.25 Changchun Jinzerui Medical Technology Co., Ltd. (single) 40.00 49,480,631.17 50,000,000.00 358,520,221.93

(3) Main financial information of important non-wholly owned subsidiaries:

December 31, 2025 December 31, 2024

Subsidiary name

Current assets Non-current assets Total assets Current liabilities Non-current liabilities Total liabilities Current assets Non-current assets Total assets Current liabilities Non-current liabilities Total liabilities Beijing Southeast Yueda Medical Equipment Co., Ltd.

547,231,540.26 44,353,895.44 591,585,435.70 94,636,241.55 3,315,991.02 97,952,232.57 622,720,549.88 51,268,814.58 673,989,364.46 108,455,500.67 816,929.69 109,272,430.36 Co., Ltd.

Changchun Jinzerui Medical Technology Co., Ltd.

818,934,719.80 194,007,632.07 1,012,942,351.87 109,765,037.69 6,876,759.35 116,641,797.04 813,694,318.39 182,505,148.20 996,199,466.59 91,328,130.87 7,272,358.81 98,600,489.68 Company (single entity)

December 31, 2025 December 31, 2024

Subsidiary name

Operating income Net profit Total comprehensive income Cash flow from operating activities Operating income Net profit Total comprehensive income Cash flow from operating activities Beijing Southeast Yueda Medical Equipment Co., Ltd.

746,950,149.21 38,916,269.03 38,916,269.03 80,606,882.58 891,096,414.96 83,528,155.21 83,528,155.21 99,367,643.02Company

Changchun Jinzerui Medical Technology Co., Ltd.

Division (single unit) 654,449,801.12 123,701,577.92 123,701,577.92 166,430,821.77 817,465,535.64 150,871,612.06 150,871,612.06 150,458,020.05 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Transactions in which the owner's equity share in the subsidiary changes and the subsidiary is still controlled

(1) Description of changes in owner’s equity shares of subsidiaries:

1. According to the resolution of the shareholders meeting of Shanghai Zhongke Runda Precision Medical Testing Co., Ltd.: it is agreed that the Shanghai Institute of Advanced Studies of the Chinese Academy of Sciences will reduce its capital and withdraw, and the registered capital will be reduced from 52.65 million yuan to 50 million yuan; after completion, the capital contribution of Runda Medical Company will remain unchanged, and the capital contribution ratio will become 56.00%, and the capital contribution ratio of other shareholders will be adjusted in the same proportion.

2. According to the capital reduction and withdrawal agreement of Wuhan Runda Shangqian Medical Technology Co., Ltd.: Yang Sanqi and Hu Xiao reduced their capital and withdrew, and the registered capital was reduced from 11.49821 million yuan to 988.846060 yuan; after completion, the capital contribution of Runda Medical Company remained unchanged, the capital contribution ratio changed from 76.00% to 88.37%, and the minority shareholder Zeng Qing’s capital contribution ratio changed from 10.00% to 11.63%.

(2) The impact of the transaction on minority shareholders’ equity and owner’s equity attributable to the parent company:

Projects Shanghai Zhongke Runda Precision Medical Testing Co., Ltd. Wuhan Runda Shangqian Medical Technology Co., Ltd. Purchase cost/disposal consideration

--cash

--Fair value of non-cash assets

Total purchase cost/disposal consideration

Less: Calculated based on the proportion of equity acquired/disposed of

293,350.87 6,368,588.34 calculated share of net assets of the subsidiary

Difference -293,350.87 -6,368,588.34 Including: Adjusted capital reserve -293,350.87 -6,368,588.34 Adjusted surplus reserve

Adjust undistributed profits

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. Interests in joint arrangements or associates

(1) Important joint ventures or associates:

Shareholding ratio (%) Name of joint venture or joint venture or associated enterprise Main place of business Registration place Nature of business Investment in joint venture will be direct or indirect

calculation method

Sinopharm Holding Runda Medical Device Development Co., Ltd.

Shanghai Shanghai Business 49.00 Equity Law Exhibition (Shanghai) Co., Ltd.

(2) Main financial information of important associates:

Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd. project

December 31, 2025 December 31, 2024

Current assets 2,539,172,734.88 2,419,835,991.03 Non-current assets 550,548,363.65 559,722,911.37

Total assets 3,089,721,098.53 2,979,558,902.40

Current liabilities 1,773,166,285.67 1,781,673,491.94 Non-current liabilities 13,400,969.89 19,266,340.70

Total liabilities 1,786,567,255.56 1,800,939,832.64

Minority shareholders’ equity 242,036,643.63 228,445,342.30 Equity attributable to shareholders of the parent company 1,061,117,199.34 950,173,727.46 Share of net assets calculated based on shareholding ratio 519,947,427.68 465,585,126.46 Adjustment matters -4,775,648.24 -3,592,041.62 --Goodwill

--Unrealized profits from internal transactions -4,775,648.24 -3,592,041.62 --Others

Book value of equity investments in associates 515,171,779.44 461,993,084.84 Fair value of equity investments in associates with publicly quoted prices

Operating income 4,548,667,927.08 4,672,903,875.81 Net profit 161,752,296.37 161,059,606.91 Net profit from discontinued operations

other comprehensive income

Total comprehensive income 161,752,296.37 161,059,606.91 Dividends received from associates this year 24,896,324.00 19,579,285.92 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(3) Summary financial information of unimportant joint ventures and associates:

Items Balance as of December 31, 2025 Balance as of December 31, 2024 Joint ventures:

Total book value of investments

The total of the following items calculated based on shareholding ratio

--Net profit

--Other comprehensive income

--Total comprehensive income

Associates:

Total book value of investments 927,295,234.82 980,623,285.47 Total of the following items calculated based on shareholding ratio

--Net profit -59,097,033.01 28,451,592.33 --Other comprehensive income

--Total comprehensive income -59,097,033.01 28,451,592.33

(4) Excess losses incurred by joint ventures or associates:

Accumulated unrecognized losses in previous periods (or losses accumulated in the current period) that have not been recognized in the current period (or the accumulated unrecognized names of joint ventures or associates at the end of the period)

Loss (net profit shared during the period)

Hangzhou Runda Hongtai Medical Technology Co., Ltd. -1,054,097.57 531,554.90 -522,542.67 Hangzhou Huihao Information Technology Co., Ltd. -14,703,158.21 -12,021,265.34 -26,724,423.55 Shanghai Runhu Investment Management Center (Limited Partnership) -11,770,678.34 -11,770,678.34 Xizhuo Medical Laboratory (Dalian) Co., Ltd. -10,157,270.28 -10,157,270.28 Shanghai Huiyi Enterprise Management Partnership (Limited Partnership) -3,688.93 -3,688.93

4. Interests in structured entities not included in the scope of consolidated financial statements:

long term equity investment

Name of structured entity Amount of capital contributed by the company

Book value of assets

Shanghai Runda Shenghu Investment Management Center (Limited Partnership) 2,035,759.72

Shanghai Runqi Investment Management Center (Limited Partnership) 3,510,000.00 549,980.05

Shanghai Runhu Investment Management Center (Limited Partnership) 90,100,000.00 79,714,140.21

Shanghai Runbo Investment Management Center (Limited Partnership) 50,000,000.00 27,211,295.19

Wuhu Runjie Investment Management Center (Limited Partnership) 50,000,000.00 63,013,124.92

Hangzhou Runshi Equity Investment Partnership (Limited Partnership) 200,500,000.00 198,446,395.67

Shanghai Huiyi Enterprise Management Partnership (Limited Partnership) 2,000.00 0.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

long term equity investment

Name of structured entity Amount of capital contributed by the company

Book value of assets

Shanghai Naixiang Enterprise Management Center (Limited Partnership) 1,542.86 96,678.12

The above-mentioned structured entities are all limited partnerships. Among them, in Runhu Fund, subsidiary Hangzhou Runda holds a priority partnership share of 63.10 million yuan; subsidiary Zhejiang Hangrun Private Equity Fund Management Co., Ltd. subscribes 1 million yuan as a general partner and manager of Hangzhou Runshi Fund; subsidiary Hangzhou Runda serves as a general partner in Huijian Partnership and is responsible for daily management; subsidiary Shanghai Runhao Medical Technology Co., Ltd. serves as a general partner in Naixiang Partnership and is responsible for daily management. The company occupies an investment committee member or serves as a general partner in the above-mentioned partnerships, and has an important influence on the partnership. Therefore, it is listed in the "long-term equity investment" item in the consolidated statements and is accounted for using the equity method (see notes for details)

5. 11. "Long-term equity investment"). According to the partnership agreement, the company as a general partner bears unlimited joint and several liability; the company's maximum risk exposure as a limited partner is limited to the amount of subscribed capital.

8. Risks related to financial instruments

The Company's financial instruments include: monetary funds, notes receivable, accounts receivable, receivable financing, other receivables, non-current assets due within one year, other current assets, equity investments, other equity instrument investments, loans, notes payable, accounts payable, other payables, non-current liabilities due within one year, bonds payable, long-term payables, etc. For detailed descriptions of each financial instrument, see the relevant items in Note 5 of this note. The risks associated with these financial instruments, and the risk management policies adopted by the Company to mitigate these risks, are described below. The company's management manages and monitors these risk exposures to ensure that the above risks are controlled within limited limits. The company's goal in risk management is to achieve an appropriate balance between risks and returns, reduce the negative impact of risks on the company's operating performance to a minimum, and maximize the interests of shareholders and other equity investors. Based on this risk management objective, the company's basic risk management strategy is to determine and analyze the various risks faced by the company, establish an appropriate risk tolerance bottom line and conduct risk management, and supervise various risks in a timely and reliable manner to control risks within a limited range.

1. Credit risk

Credit risk refers to the risk that one party to a financial instrument fails to perform its obligations, causing financial losses to the other party.

The Company mainly faces customer credit risks caused by credit sales. Before entering into a new contract, the Company conducts an assessment of the credit risk of new customers, including external credit ratings and, in some cases, bank references when this information is available. The company sets a credit sales limit for each customer, which is the maximum amount that does not require additional approval.

The company ensures that the company's overall credit risk is within a controllable range through quarterly monitoring of existing customer credit ratings and monthly review of aging analysis of accounts receivable. When monitoring customer credit risk, group customers according to their credit characteristics. Customers rated as "high risk" will be placed on the restricted customer list, and only with additional approval, the company can sell to them on credit in the future period, otherwise they must be required to pay the corresponding amount in advance.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Liquidity risk

Liquidity risk refers to the risk of a shortage of funds when fulfilling obligations settled by delivery of cash or other financial assets.

The Company's management objectives, policies and procedures, and risk measurement methods for liquidity risk: When managing liquidity risk, the Company maintains cash and cash equivalents deemed sufficient by management and monitors them to meet the Company's operating needs and reduce the impact of cash flow fluctuations. Each subsidiary within the Company is responsible for its own cash flow forecasts. On the basis of summarizing the cash flow forecasts of each subsidiary, the company continues to monitor short-term and long-term funding needs at the company level to ensure that it maintains sufficient cash reserves and securities that can be liquidated at any time; at the same time, it continues to monitor whether it complies with the provisions of the loan agreement and obtains commitments from major financial institutions to provide sufficient reserve funds to meet short-term and long-term funding needs.

As of December 31, 2025, the Company's various financial liabilities are listed as follows based on undiscounted contractual cash flows based on maturity dates:

(Unit: 10,000 yuan) December 31, 2025

Item Total

Within 1 year 1-2 years 2-5 years More than 5 years

Short-term borrowings 492,778.46 492,778.46 Trading financial liabilities 0.57 0.57 Notes payable 5,500.00 5,500.00Accounts payable 116,382.79 116,382.79 Other payables 17,225.06 18.56 20.43 17,264.05Non-current liabilities due within one year 123,617.90 123,617.90Long-term borrowings 58,531.90 5,508.11 131.26 64,171.27Long-term payables 6,136.23 3,640.15 9,776.38Bonds payable

Lease liabilities 5,940.93 2,492.21 35.18 8,468.32 Total 755,504.78 70,627.62 11,660.90 166.44 837,959.74

3. Market risk

Market risk of financial instruments refers to the risk that the fair value or future cash flows of financial instruments fluctuate due to market price changes, including exchange rate risk, interest rate risk and other price risks.

The company uses sensitivity analysis techniques to analyze the possible impact of reasonable and possible changes in market risk-related variables on current profits and losses or shareholders' equity. Since any risk variable rarely changes in isolation, and the correlation between variables will have a significant impact on the final impact of a change in a certain risk variable, the following content is based on the assumption that changes in each variable are independent.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(1) Exchange rate risk

Exchange rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. Exchange rate risk can arise from financial instruments denominated in foreign currencies other than the functional currency of accounting. The company's foreign exchange risks are mainly related to the U.S. dollar, euro, Canadian dollar and Hong Kong dollar. Except for several of the company's subsidiaries that purchase and sell in U.S. dollars, euros, Canadian dollars and Hong Kong dollars, the company's other main business activities are denominated and settled in RMB. Exchange rate risk affects the Company's transactions and the performance of overseas operations.

For the balance of the company’s foreign currency monetary items on December 31, 2025, please refer to Note 5.62 “Foreign Currency Monetary Items” of this note. The sensitivity analysis of exchange rate risk is shown in the table below, which reflects the impact on net profit and shareholders' equity due to changes in the fair value of monetary assets and monetary liabilities when there are reasonable and possible changes in the foreign currency exchange rates listed below, assuming that other variables remain unchanged.

Balance at the end of 2025 Balance at the end of 2024

Project

US dollar Euro Canadian dollar Hong Kong dollar Total US dollar Euro Canadian dollar Hong Kong dollar Total monetary funds 28,446,484.36 512,423.26 3,383,012.61 3,526.30 32,345,446.53 47,659,810.51 1,913,585.34 7,805,884.90 7,172.37 57,386,453.12 Accounts receivable 31,939,564.18 304,589.97 10,120,875.89 42,365,030.04 8,681,165.86 10,790,505.66 19,471,671.52 Other receivables 6,871,423.78 6,871,423.78 6,620,525.14 6,620,525.14

Total 60,386,048.54 817,013.23 20,375,312.28 3,526.30 81,581,900.35 56,340,976.37 1,913,585.34 25,216,915.70 7,172.37 83,478,649.78 Accounts payable 13,408,673.04 13,408,673.04 14,622,891.39 14,622,891.39 Other accounts payable

Total 13,408,673.04 13,408,673.04 14,622,891.39 14,622,891.39Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

On December 31, 2025, with all other variables held constant, if the RMB appreciates or depreciates by 5.00% against the US dollar, euro, Canadian dollar and Hong Kong dollar, the company will reduce or increase its net profit by RMB 2,556,500 (December 31, 2024: RMB 2,582,100). Management believes that 5.00% reasonably reflects the reasonable range of possible changes in the RMB against the US dollar in the next year.

(2) Interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Interest rate risk can arise from both recognized interest-bearing financial instruments and unrecognized financial instruments (such as certain loan commitments).

The Company's interest rate risk arises from interest-bearing debt such as bank borrowings and bonds payable. Financial liabilities with floating interest rates expose the Company to cash flow interest rate risks, while financial liabilities with fixed interest rates expose the Company to fair value interest rate risks. The Company determines the relative proportions of fixed-rate and floating-rate contracts based on the prevailing market environment. The company's floating rate borrowings accounted for 17.71% of external borrowings in 2025.

On December 31, 2025, with other variables held constant, if the borrowing rate calculated on a floating rate basis increases or decreases by 100 basis points, the company's net profit will decrease or increase by RMB 235,200 (December 31, 2024: RMB 285,900). Management believes that 100 basis points reasonably reflects the reasonable range of possible changes in interest rates over the next year.

(3) Other price risks

Other price risks refer to the risk of fluctuations caused by market price changes other than exchange rate risk and interest rate risk, whether these changes are caused by factors related to a single financial instrument or its issuer, or due to factors related to all similar financial instruments traded in the market. Other price risks may arise from changes in commodity prices or equity instrument prices, for example.

During the 2025 reporting period, the company held no equity investments in other listed companies. Therefore, there is no market price risk faced by such investment activities.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

9. Disclosure of fair value

1. Closing fair value of assets and liabilities measured at fair value

Fair value as of December 31, 2025

Item Level 1 fair value Level 2 fair value Level 3 fair value

total

Measurement Measurement Measurement

1. Continuous fair value measurement

(1) Trading financial assets 129,800,000.00 129,800,000.00 1. Measured at fair value with changes included in the current period

129,800,000.00 129,800,000.00 Financial assets for period profit and loss

(1) Bank financial products 129,800,000.00 129,800,000.00

(2) Investment in other equity instruments 25,775,748.26 25,775,748.26 Total assets continuously measured at fair value 129,800,000.00 25,775,748.26 155,575,748.26

(3) Trading financial liabilities

1. Measured at fair value with changes included in the current

5,707.45 5,707.45 Financial liabilities for period profit and loss

(1) Foreign exchange options 5,707.45 5,707.45 Total liabilities continuously measured at fair value 5,707.45 5,707.45

2. Continuous and non-continuous second- and third-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters:

Trading financial assets (bank wealth management products) are bank structured deposits purchased by the company at the end of the period, and their fair value is equal to the purchase price.

All trading financial liabilities are foreign exchange options. The company's second-level fair value measurement items are foreign exchange options in trading financial liabilities, which are measured based on valuation data obtained from banks.

3. Descriptive information on the estimation techniques, inputs and valuation processes used in ongoing and discontinued Level 3 fair value measurements:

For unlisted equity investments in other equity instrument investments, the Company uses valuation techniques to determine their fair value. Valuation techniques include discounted cash flow method and market comparison method. The measurement of its fair value uses important unobservable parameters, such as liquidity discount, volatility, risk adjustment discount and market multiplier. The fair value of unlisted equity investments is not significantly sensitive to reasonable changes in these unobservable inputs.

Level 3 Quantitative information on unobservable input values ​​that are important and reasonably obtainable used in fair value measurement.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

4. Conversion information between various levels of ongoing fair value measurement items, adjustment information of ongoing third-level fair value measurement items, and sensitivity analysis of unobservable parameters

(1) Determine the policies and transition information for transition points between each level:

The company recognizes the transition between levels on the date when the event or change in circumstances that causes the transfer occurs. There is no transition between the first level and the second level this year. The reconciliation information between the opening balance and the closing balance of the continuing third level fair value measurement assets and liabilities is as follows:

Total gain or loss for the current period Transfer-in from purchases, issuance, sales and settlement Transfer-out

End of 2024 End of 2025 For assets held at the end of the reporting period, it is included in the loss item Third Third

Balance Balance Changes in current unrealized gains or losses Level Level

plan

Included in other comprehensive issues and results

buy

Loss, income, sales, calculation of profit

Other rights and interests

36,698,795.19 -12,923,047.93 2,000,001.00 25,775,748.26 Tool investment

Total 36,698,795.19 -12,923,047.93 2,000,001.00 25,775,748.26Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Reasons for transitions between levels during this period:

For ongoing fair value measurement items, there will be no conversion between levels in 2025. (3) Gains and losses of third-level fair value measurement items included in current profits and losses:

There will be no gains or losses included in current profits and losses in 2025.

(4) Gains and losses of third-level fair value measurement items included in other comprehensive income for the current period: Gains included in other comprehensive income for the current period

Items Other comprehensive income items and total losses recognized as gains and losses

Other equity instrument investments -9,502,284.64 Changes in fair value of other equity instrument investments

5. Valuation technology changes and reasons for changes during the period

No changes in valuation technology occurred in 2025.

6. Assets and liabilities not measured at fair value but whose fair value is disclosed

The Company has evaluated the fair value of financial assets and financial liabilities measured at amortized cost such as monetary funds, notes receivable, accounts receivable, other receivables, entrusted loans, long-term receivables due within one year, long-term receivables, short-term loans, notes payable, accounts payable, other payables, non-current liabilities due within one year, long-term loans, long-term payables, etc. The company's management believes that the book value of financial assets and financial liabilities measured at amortized cost in the financial statements is close to the fair value of the corresponding assets and liabilities.

10. Related parties and related transactions

1. Information about the company’s parent company

Parent company to this enterprise Parent company to this enterprise Parent company name Place of registration Nature of business Registered capital

Shareholding ratio (%) Voting rights ratio (%)

Gongshu, Hangzhou City, Zhejiang Province

Hangzhou Gongshu District State-owned

No. 398 Shaoxing Road, District State Investment Management 300,000,000 19.22 22.26 Investment Group Co., Ltd.

Room 1508, Tou Building

2. Information about the company’s subsidiaries

For details in 2025, please see Note 7.1, "Equity in Subsidiaries".

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. Information about the company’s joint ventures and associated enterprises

For details of the Company's important joint ventures and associates in 2025, please see Note 7.3 "Equity in Joint Ventures or Associates". The situation of other joint ventures or associates that have related party transactions with the company in 2025, or other joint ventures or associates that have balances from related party transactions with the company in the previous period are as follows:

Name of the joint venture or associated enterprise Relationship with the enterprise Fujian Furui Medical Technology Co., Ltd. Associated enterprise Guangxi Liurun Medical Technology Co., Ltd. Associated enterprise Guizhou Runda Kangyi Medical Technology Co., Ltd. Associated enterprise Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd. Associated enterprise Hefei Tianyuan Medical Device Co., Ltd. Associated enterprise Henan Runbaida Medical Device Co., Ltd. Associated enterprise Sichuan Runda Hongwang Medical Technology Co., Ltd. Associated enterprise Sichuan Runda Ruitai Biotechnology Co., Ltd. Associates Yunnan Sailis Biotechnology Co., Ltd. Associates Shanghai General Runda Medical Technology Co., Ltd. Associates Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. Associates Hebei Runda Kangtai Medical Technology Co., Ltd. Associates Suzhou Runying Medical Equipment Co., Ltd. Associates Hangzhou Runda Hongtai Medical Technology Co., Ltd. Associates Hangzhou Huihao Information Technology Co., Ltd. Associates Anhui Runkang Lianchuang Biotechnology Co., Ltd. Associates Hangzhou Runshi Equity Investment Partnership (Limited Partnership) Associates

4. Other related parties

Names of other related parties Relationship between other related parties and the enterprise Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. A subsidiary of the associated enterprise Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd. Sinopharm Holding Guorun Medical Supply Chain Service (Anhui) Co., Ltd. A company controlled by the associated enterprise Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd. Jiangsu Yier Medical Equipment Co., Ltd. Binzhou Runda Kangtai Medical Technology Co., Ltd., an enterprise controlled by minority shareholders of Shanghai Runda Industrial Development Co., Ltd. Hangzhou Runda Shengtai Medical Technology Co., Ltd., a wholly-owned subsidiary of the associated enterprise Hebei Runda Kangtai Medical Technology Co., Ltd. Harbin Runda Hongtai Medical Technology Co., Ltd., a wholly-owned subsidiary of the associated enterprise Hebei Runda Kangtai Medical Technology Co., Ltd. Other equity instrument investments

Wuhan Haijili Biotechnology Co., Ltd. Other equity instrument investments

Shanghai Xiangrun Medical Technology Co., Ltd. Other equity instrument investments

Weiyan Medical Technology (Beijing) Co., Ltd. Other equity instrument investments

Beijing Weiyan Medical Equipment Co., Ltd. An enterprise controlled by the joint-stock company Weiyan Medical Technology (Beijing) Co., Ltd. Nanjing Zhongchen Medical Technology Co., Ltd. Other equity instrument investments

Yueshengda (Jinan) Investment Partnership (Limited Partnership) Minority Shareholder of Jinan Runda Biotechnology Co., Ltd.

Shanghai Anbaida Investment Management Consulting Co., Ltd. Shanghai Zhongke Runda Precision Medical Testing Co., Ltd. Minority shareholder Zhejiang Qinggu Bioengineering Co., Ltd. Shanghai Runda Medical Technology Co., Ltd., an enterprise controlled by minority shareholders of Hangzhou Yidan Biotechnology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Names of other related parties Relationship between other related parties and the company Deqing Hengyi Investment Management Partnership (Limited Partnership) Minority shareholder of Hefei Sanli Medical Technology Co., Ltd.

Jiuyisanluling Medical Technology Nanjing Co., Ltd. Xizhuo Medical Laboratory (Dalian) Co., Ltd., a minority shareholder of Runli Supply Chain Management (Shanghai) Co., Ltd. Guangzhou Shiwei Technology R&D Co., Ltd., a company in which Shanghai Runda Rongjia Biotechnology Co., Ltd. holds shares. Zhejiang Medical Health Group Hangzhou Medical Laboratory Co., Ltd., a company in which Shanghai Runda Rongjia Biotechnology Co., Ltd. controls Shanghai Huihao Yisheng Information Technology Co., Ltd., a company controlled by Zhejiang Medical Health Group Health Management Co., Ltd. Shanghai Lekang Technology Partnership (limited partnership), a wholly-owned subsidiary of Hangzhou Huihao Information Technology Co., Ltd., a minority shareholder of Shanghai Huizhong Rongjia Medical Testing Laboratory Co., Ltd., Shanghai Weiyan Shenghong Medical Technology Co., Ltd., an enterprise controlled by the joint-stock company Weiyan Medical Technology (Beijing) Co., Ltd., Zhenjiang Hanhe Medical Equipment Co., Ltd., an enterprise controlled by minority shareholders of Shanghai Runda Industrial Development Co., Ltd., Hangzhou Gongshu State Investment Industrial Development Co., Ltd., a company controlled by the company's controlling shareholder

Ma Junsheng, minority shareholder of Yunnan Runda Kangtai Medical Technology Co., Ltd.

Tang Jinhu, minority shareholder of Shanghai Ruimei Computer Technology Co., Ltd.

Wang Ping, minority shareholder of Yunnan Runda Kangtai Medical Technology Co., Ltd.

Meng Fanyu, minority shareholder of Beijing Southeast Yueda Medical Equipment Co., Ltd.

Qiao Yang, minority shareholder of Beijing Southeast Yueda Medical Equipment Co., Ltd.

Hu Xiao, minority shareholder of Wuhan Runda Shangjian Medical Technology Co., Ltd.

Zeng Qing, minority shareholder of Wuhan Runda Shangjian Medical Technology Co., Ltd.

Huang Liujin Minority shareholder of Chongqing Runda Kangtai Medical Equipment Co., Ltd.

Tang Jianfeng is a minority shareholder of Beijing Huizhong Medical Equipment Co., Ltd. and Shanghai Ruimei Computer Technology Co., Ltd. Peng Huabing is a minority shareholder of Hangzhou Yidan Biotechnology Co., Ltd.

Qian Xueqing, minority shareholder of Shanghai Runda Rongjia Biotechnology Co., Ltd.

Chen Linjun, minority shareholder of Shanghai Huizhong Rongjia Medical Testing Laboratory Co., Ltd.

Minority shareholder and holding subsidiary of Heilongjiang Runda Taixin Biotechnology Co., Ltd. Heilongjiang Runda Tai Zhang Yanxue

General Manager of Xin Biotechnology Co., Ltd.

Hangzhou Gongshu State Investment Innovation Development Co., Ltd. A company controlled by the company’s controlling shareholder

Hefei Runda Wantong Medical Technology Co., Ltd. minority shareholder and holding subsidiary Hefei Runda Medical Technology Co., Ltd. Wang Shuo

General Manager of Laboratory Management Co., Ltd.

Wang Chuangen, minority shareholder of Anhui Zefen Biotechnology Co., Ltd., a subsidiary of the company

Wuhan Youke Liansheng Technology and Trade Co., Ltd. is a minority shareholder and holding subsidiary of Wuhan Youke Liansheng Technology and Trade Co., Ltd. Xiong Donghe

Co., Ltd. General Manager

Yang Hong, minority shareholder of Hefei Runda Wantong Medical Technology Co., Ltd.

Yang Sanqi, minority shareholder of Wuhan Runda Shangjian Medical Technology Co., Ltd.

Zhang Xinming Minority shareholder of Suzhou Runda Huichang Biotechnology Co., Ltd.

Shanghai Cross-Dimensional Exosome Biomedicine Co., Ltd. Shanghai Runda Medical Technology Co., Ltd., a company controlled by Qian Xueqing, a minority shareholder of Shanghai Runda Rongjia Biotechnology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

5. Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services:

1. Purchase of goods/receipt of labor status table

Related parties Related transaction content 2025 2024 Fujian Furui Medical Technology Co., Ltd. Purchased goods 26,702.61 266,703.38 Guizhou Runda Kangyi Medical Technology Co., Ltd. Purchased goods 299,773.46 4,539,740.18 Guorun Medical Supply Chain Service (Shanghai) Co., Ltd. Purchased goods 65,743,146.86 2,954,726.99 Henan Runbaida Medical Equipment Co., Ltd. Purchased goods 2,013.59 Shanghai Xiangrun Medical Technology Co., Ltd. Purchased goods 242,239.47 214,084.90 Sichuan Runda Hongwang Medical Technology Co., Ltd. Purchased goods 36,874,514.40 55,600,493.26 Sichuan Runda Ruitai Biotechnology Co., Ltd. Purchased goods 1,053,877.82 11,798,270.31 Wuhan Haijili Biotechnology Co., Ltd. Purchased goods 1,188,858.96 720,319.25 Yunnan Sailis Biotechnology Co., Ltd. Purchased goods 19,734,654.60 13,410,327.58 Shanghai Anbaida Investment Management Consulting Co., Ltd. Purchased goods 1,374,449.92 602,049.96 Hefei Tianyuan Medical Equipment Co., Ltd. Purchased goods 3,654,207.94 4,043,658.95 Suzhou Runying Medical Equipment Co., Ltd. Purchased goods 146,928.25 5,785,117.97 Hebei Runda Kangtai Medical Technology Co., Ltd. Purchased goods 5,988,090.58 34,832,809.55 Shanghai General Runda Medical Technology Co., Ltd. Purchased goods 15,540,988.15 8,333,834.92 Hangzhou Runda Hongtai Medical Technology Co., Ltd. Purchased goods 38,243,233.09 19,844,494.23 Zhejiang Qinggu Bioengineering Co., Ltd. Purchased goods 3,936,699.06 2,756,067.37 Shanghai Huihao Yisheng Information Technology Co., Ltd. Purchased goods 20,921,803.31 39,818,467.21 Nanjing Zhongchen Medical Technology Co., Ltd. Purchased goods 3,168,751.32 2,481,285.57 Jiuyisanlu Medical Technology Nanjing Co., Ltd. Purchased goods 7,492,035.85 21,239,556.97 Sinopharm Holding Guorun Medical Supply Chain Services (Anhui) Co., Ltd. Purchased goods 540,237.97 432,069.73 Beijing Weiyan Medical Equipment Co., Ltd. Purchased goods 2,775,929.24 594,690.27 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. Purchased goods 53,646,001.72 10,105,834.75 Weiyan Medical Technology (Beijing) Co., Ltd. Purchased goods 1,421,011.82 Hangzhou Huihao Information Technology Co., Ltd. Purchased goods 5,354,410.07

Shanghai Xiangrun Medical Technology Co., Ltd. Accepted labor services 94,339.62 101,886.78 Shanghai General Runda Medical Technology Co., Ltd. Accepted labor services 533,980.58 11,890.00 Jiuyisanlu Medical Technology Nanjing Co., Ltd. Accepted labor services 1,189,437.50 131,768.88 Shanghai Anbaida Investment Management Consulting Co., Ltd. Accepting labor services 159,292.04

Total 289,924,584.39 242,043,174.37 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. List of goods sold/services provided

Related parties Related transaction content 2025 2024 Fujian Furui Medical Technology Co., Ltd. Sales of goods 523,118.28 4,236,506.66 Guangxi Liurun Medical Technology Co., Ltd. Sales of goods 2,725,663.73 2,277,905.67 Guizhou Runda Kangyi Medical Technology Co., Ltd. Sales of goods 456,496.28 1,054,121.22 Guorun Medical Supply Chain Service (Shanghai) Co., Ltd. Sales of goods 525,137,776.42 521,168,376.41 Harbin Runda Hongtai Medical Technology Co., Ltd. Sales of goods 16,982.83 972,476.09 Henan Runbaida Medical Equipment Co., Ltd. Sales of goods -1,165,423.35 40,609,844.83 Shanghai Xiangrun Medical Technology Co., Ltd. Sales of goods 1,990,622.59 2,384,850.94 Sichuan Runda Ruitai Biotechnology Co., Ltd. Sales of goods 6,730,721.27 6,649,496.32 Yunnan Sailis Biotechnology Co., Ltd. Sales of goods 1,503,466.37 2,946,489.70 Hefei Tianyuan Medical Equipment Co., Ltd. Sales of goods 13,038,068.09 24,075,378.44 Suzhou Runying Medical Equipment Co., Ltd. Sales of goods 2,473,802.07 9,797,523.27 Hebei Runda Kangtai Medical Technology Co., Ltd. Sales of goods 23,842,967.74 21,732,642.23 Shanghai General Runda Medical Technology Co., Ltd. Sales of goods 1,583,548.77 3,910,211.78 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. Sales of goods 11,736,448.60 18,231,274.53 Hangzhou Runda Hongtai Medical Technology Co., Ltd. Sales of goods 3,232,795.38 10,485,496.24 Zhejiang Qinggu Bioengineering Co., Ltd. Sales of goods 1,557.55 160,163.74 Binzhou Runda Kangtai Medical Technology Co., Ltd. Sales of goods 400,331.29 Weiyan Medical Technology (Beijing) Co., Ltd. Sales of goods 3,293,722.10 6,902,119.23 Nanjing Zhongchen Medical Technology Co., Ltd. Sales of goods 16,445,787.17 29,851,187.98 Hangzhou Runda Shengtai Medical Technology Co., Ltd. Sales of goods 96,379.96 6,448,677.60 Sichuan Runda Hongwang Medical Technology Co., Ltd. Sales of goods 45,653.09 Xizhuo Medical Testing Laboratory (Dalian) Co., Ltd. Sales of goods 500,507.19 Shanghai Anbaida Investment Management Consulting Co., Ltd. Sales of goods 1,115,044.25 Jiuyisanlu Medical Technology Nanjing Co., Ltd. Sales of goods 2,121,345.14 681,415.93 Guangzhou Shiwei Technology R&D Co., Ltd. Sales of goods 3,513,420.08 Sinopharm Holding Guorun Medical Supply Chain Services (Anhui) Co., Ltd. Sales of goods 373,287.44 43,216.83 Shanghai Huihao Yisheng Information Technology Co., Ltd. Sales of goods 5,854,513.28

Zhejiang Medical and Health Group Hangzhou Medical Testing Laboratory Co., Ltd. Sales of goods 4,458,655.11

Shanghai Kuandimensional Exosome Biomedicine Co., Ltd. Sales of goods 213,497.32

Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. Provided labor services 1,677,473.76 4,980,539.45 Henan Runbaida Medical Equipment Co., Ltd. Provided labor services 12,264.15 1,470,507.55 Fujian Furui Medical Technology Co., Ltd. Provided labor services 11,320.76 5,660.38 Shanghai Xiangrun Medical Technology Co., Ltd. Provision of labor services 402,188.65 126,179.24 Sichuan Runda Ruitai Biotechnology Co., Ltd. Provision of labor services 94,339.62 188,679.24 Yunnan Sailis Biotechnology Co., Ltd. Provision of labor services 12,264.15 24,528.30 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Related parties Related transaction content 2025 2024 Shanghai Anbaida Investment Management Consulting Co., Ltd. Provision of services 22,641.50

Jiangsu Yier Medical Equipment Co., Ltd. Providing labor services 44,233.68 415,938.70 Suzhou Runying Medical Equipment Co., Ltd. Providing labor services 608,260.98 481,422.89 Hebei Runda Kangtai Medical Technology Co., Ltd. Providing labor services 137,547.17 230,125.77 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. Providing labor services 508,264.98 638,775.94 Hangzhou Runda Hongtai Medical Technology Co., Ltd. Providing labor services 32,540.49 73,014.68 Shanghai General Runda Medical Technology Co., Ltd. Providing labor services 71,297.53 227,435.28 Weiyan Medical Technology (Beijing) Co., Ltd. Providing labor services 66,583.44 Nanjing Zhongchen Medical Technology Co., Ltd. Providing labor services 2,160,069.80 1,337,160.23 Hangzhou Runda Shengtai Medical Technology Co., Ltd. Providing labor services 47,169.81 Guangxi Liurun Medical Technology Co., Ltd. Providing labor services 6,226.42 Shanghai Huihao Yisheng Information Technology Co., Ltd. Providing labor services 50,167.81 849.06 Sinopharm Holding Guorun Medical Supply Chain Services (Anhui) Co., Ltd. Provides labor services 31,839.66 Guizhou Runda Kangyi Medical Technology Co., Ltd. Provides labor services 11,320.75 561,320.75 Anhui Runkang Lianchuang Biotechnology Co., Ltd. Provides labor services 75,471.70

Hangzhou Gongshu State Investment Innovation Development Co., Ltd. Provision of labor services 226,534.66

Hangzhou Runshi Equity Investment Partnership (Limited Partnership) Provision of labor services 6,002,445.07

Zhejiang Provincial Medical and Health Group Hangzhou Medical Testing Laboratory Co., Ltd. Provision of labor services 3,193,733.18

Total 642,040,180.53 731,108,288.33

(2) Related entrusted management/contracting and entrusted management/contracting:

None in 2025.

(3) Related leasing situation

1. Our company serves as the lessor

Name of lessee Type of leased assets 2025 2024 Fujian Furui Medical Technology Co., Ltd. Equipment leased 15,929.22 440,040.90 Guizhou Runda Kangyi Medical Technology Co., Ltd. Equipment leased 28,023.60 Guorun Medical Supply Chain Service (Shanghai) Co., Ltd. Equipment leased 925,865.78 782,595.59 Harbin Runda Hongtai Medical Technology Co., Ltd. Equipment rental 10,619.49 10,176.97 Henan Runbaida Medical Equipment Co., Ltd. Equipment rental 335,017.56 Shanghai Xiangrun Medical Technology Co., Ltd. Equipment rental 18,584.08 18,584.08 Sichuan Runda Ruitai Biotechnology Co., Ltd. Equipment rental 13,274.34 Shanghai Anbaida Investment Management Consulting Co., Ltd. Equipment rental 20,648.95 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Name of lessee Type of leased assets 2025 2024 Suzhou Runying Medical Equipment Co., Ltd. Equipment leased 607,816.82 654,984.97 Hebei Runda Kangtai Medical Technology Co., Ltd. Equipment leased 292,035.40 292,035.40 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. Equipment leased 445,307.67 616,384.18 Hangzhou Runda Hongtai Medical Technology Co., Ltd. Equipment rental 5,309.73 5,309.73 Nanjing Zhongchen Medical Technology Co., Ltd. Equipment rental 2,034,108.03 1,299,705.33 Zhejiang Medical Health Group Hangzhou Medical Testing Laboratory Co., Ltd. Equipment rental 353,982.30 16,224.20 Hangzhou Huihao Information Technology Co., Ltd. Equipment rental 247,476.07

Total 4,957,034.59 4,533,005.80 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Our company serves as the lessee

Simplified processing of short-term leases and leasing of low-value assets

Rent paid Interest expense on lease liabilities borne Increased name of lessor of right-of-use assets Rental expenses of type of leased asset

2025 2024 2025 2024 2025 2024 2025 2024 Peng Huabing House rental 1,193,352.00 1,193,352.00 1,193,352.00 1,193,352.00 Hu Xiao House rental 189,586.29 189,586.29 199,065.60 199,065.60Zeng Qing House rental 189,588.57 189,588.57 199,068.00 199,068.00Sinopharm Holdings Guorun Medical Supply Chain Services

Equipment rental

205,214.75 810,794.29 133,209.00 18,395.49 (Anhui) Co., Ltd.

Guorun Medical Supply Chain Services (Shanghai)

Equipment rental 53,097.35 53,097.35 60,000.00

Ltd.

total

1,830,838.96 2,436,418.50 1,651,485.60 1,724,694.60 18,395.49Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(4) Related guarantees

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Harbin Runda Kangtai Shanghai Pudong Development Bank Co., Ltd. Harbin Youyi Branch 10,000,000.00 Guaranteed 2024/11/4 2025/11/3 Runda Medical Harbin Runda Kangtai Shanghai Pudong Development Bank Co., Ltd. Harbin Youyi Branch 30,000,000.00 Guaranteed 2025/4/11 2026/3/23 No Runda Medical Harbin Runda Kangtai Industrial Bank Co., Ltd. Harbin Branch 10,000,000.00 Guarantee 2024/6/4 2025/1/3 Yes Runda Medical Hangzhou Huizhong Diagnostics Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 9,400,000.00 Guarantee 2024/11/19 2025/11/18 Yes Runda Medical Hangzhou Huizhong Diagnostics Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 9,300,000.00 Guaranteed 2025/11/18 2026/11/17 No Runda Medical Hangzhou Huizhong Diagnostics Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guaranteed 2024/3/7 2025/1/21 Yes Runda Medical Hangzhou Huizhong Diagnostics Hua Xia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2024/3/7 2025/7/21 Yes Runda Medical Hangzhou Huizhong Diagnostics Huaxia Bank Co., Ltd. Hangzhou Branch 9,700,000.00 Guarantee 2024/3/7 2027/2/23 Verunda Medical Hangzhou Huizhong Diagnostics Industrial Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guarantee 2024/5/10 2025/5/9 Verunda Medical Hangzhou Huizhong Diagnostics Industrial Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guarantee 2025/5/29 2026/5/28 Verunda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch Xihu Branch 250,000.00 Guarantee 2023/11/9 2025/3/21 Yes Runda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch Xihu Branch 40,250,000.00 Guarantee 2023/11/9 2025/5/6 Yes Runda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch Xihu Branch 100,000.00 Guarantee 2024/4/11 2025/3/21 Yes Runda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch Xihu Branch 100,000.00 Guarantee 2024/4/11 2025/9/21 Yes Runda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch Xihu Branch 17,700,000.00 Guarantee 2024/4/11 2025/10/8 Yes Runda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch High-tech Branch 3,000,000.00 Guarantee 2024/7/1 2025/6/30 Yes Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 17,000,000.00 Guaranteed 2024/7/10 2025/7/11 Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 11,250,000.00 Guaranteed 2024/8/13 2025/8/11 Shirunda Medical Hangzhou Runda High-tech Branch of Huaxia Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guaranteed 2024/8/20 2025/8/22 Shirunda Medical Hangzhou Runda High-tech Branch of Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guaranteed 2025/6/5 2025/11/21 Yes Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guaranteed 2025/6/5 2026/5/21 No Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 18,700,000.00 Guaranteed 2025/6/5 2026/9/5 No Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 110,000.00 Guarantee 2025/7/17 2025/11/21 Is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 110,000.00 Guaranteed 2025/7/17 2026/5/21 Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 21,780,000.00 Guaranteed 2025/7/17 2026/10/17 Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 60,000.00 Guaranteed 2025/8/19 2025/12/21 Runda Medical Hangzhou Runda High-tech Branch of Hangzhou Branch of Hua Xia Bank Co., Ltd. 60,000.00 Guaranteed 2025/8/19 2026/6/21 Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 11,130,000.00 Guaranteed 2025/8/19 2026/11/19 No Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/8/26 2025/12/21 Yes Runda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/8/26 2026/6/21 Fulunda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 9,900,000.00 Guaranteed 2025/8/26 2026/11/26 Fulunda Medical Hangzhou Runda High-tech Branch of Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guaranteed 2025/10/30 2026/3/21 Fulunda Medical Hangzhou Runda High-tech Branch of Hua Xia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guaranteed 2025/10/30 2026/9/21 Fulunda Medical Hangzhou Runda Hua Xia Bank Co., Ltd. Hangzhou Branch Gaoxin Branch 17,600,000.00 Guaranteed 2025/10/30 2027/1/30 Ferunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 73,000,000.00 Guaranteed 2024/3/18 2025/3/12 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 9,000,000.00 Guarantee 2024/4/10 2025/4/9 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 8,000,000.00 Guarantee 2024/4/24 2025/4/9 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 56,000,000.00 Guarantee 2024/4/24 2025/4/16 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 14,760,000.00 Guarantee 2024/5/28 2025/5/27 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 1,350,000.00 Guaranteed 2024/6/25 2025/6/23 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 38,000,000.00 Guaranteed 2024/8/9 2025/8/4 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 33,000,000.00 Guarantee 2024/8/23 2025/8/21 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 7,000,000.00 Guarantee 2024/8/30 2025/8/27 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 8,000,000.00 Guarantee 2024/9/6 2025/8/27 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 8,000,000.00 Guarantee 2024/9/24 2025/9/22 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 50,000,000.00 Guarantee 2024/9/24 2025/9/23 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 14,400,000.00 Guarantee, pledge 2024/7/31 2025/1/27 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 12,000,000.00 Guarantee, pledge 2024/8/19 2025/2/18 Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 23,200,000.00 Guarantee, pledge 2024/9/9 2025/3/12 It is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 18,000,000.00 Guaranteed 2024/10/11 2025/10/9 Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 5,000,000.00 Guaranteed 2024/11/4 2025/10/22 Shirunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 20,000,000.00 Guarantee, pledge 2024/11/26 2025/5/25 Shirunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 80,000,000.00 Guarantee 2025/3/19 2026/3/18 Fulunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 17,000,000.00 Guaranteed 2025/4/16 2026/4/14 Fulunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 57,650,000.00 Guaranteed 2025/4/22 2026/4/20 No Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 40,000,000.00 Guarantee, pledge 2025/1/6 2025/7/8 Yes Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 5,000,000.00 Guarantee, pledge 2025/1/15 2026/1/7 No Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 40,800,000.00 Guarantee, pledge 2025/3/20 2025/9/15 No Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 5,350,000.00 Guarantee, pledge 2025/4/17 2026/4/16 Fulunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 42,400,000.00 Guarantee, pledge 2025/8/22 2026/2/16 Fulunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 56,000,000.00 Guarantee and pledge 2025/9/11 2026/3/16 Fulunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 24,000,000.00 Guarantee and pledge 2025/9/16 2026/3/19 Fulunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 7,000,000.00 Guaranteed 2025/9/18 2026/9/17 Furunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 12,000,000.00 Guaranteed 2025/10/9 2026/9/17 Furunda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 50,000,000.00 Guarantee 2025/10/24 2026/10/23 Fu Runda Medical Hangzhou Runda Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch 16,000,000.00 Guarantee, pledge 2025/10/30 2026/4/27 Fu Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 5,630,000.00 Guarantee, pledge 2021/8/30 2025/2/28 Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 5,630,000.00 Guarantee, pledge 2021/8/30 2025/8/28 Yes Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 55,480,000.00 Guarantee, pledge 2021/8/31 2028/8/29 No Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 384,800.00 Guarantee, pledge 2022/4/14 2025/2/28 Yes Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 384,800.00 Guarantee, pledge 2022/4/14 2025/8/28 Yes Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 3,844,800.00 Guarantee, pledge 2022/4/14 2028/8/29 No Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 192,400.00 Guarantee, pledge 2022/8/17 2025/2/28 No Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 192,400.00 Guarantee, pledge 2022/8/17 2025/8/28 Yes Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 1,922,400.00 Guarantee, pledge 2022/8/17 2028/8/29 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 65,000,000.00 Guaranteed 2024/11/26 2025/11/25 Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 44,000,000.00 Guaranteed 2024/12/11 2025/12/11 Yes Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 65,000,000.00 Guaranteed 2025/11/26 2026/11/26 No Runda Medical Hangzhou Runda Shanghai Pudong Development Bank Co., Ltd. Hangzhou Jianguo Branch 44,000,000.00 Guaranteed 2025/12/4 2026/12/4 Runda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 28,750,000.00 Guaranteed 2024/6/21 2025/6/21 Runda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 5,000,000.00 Guaranteed 2024/6/24 2025/6/24 Yes Runda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 16,250,000.00 Guaranteed 2024/7/11 2025/7/11 Yes Runda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 47,000,000.00 Guaranteed 2024/9/11 2025/9/11 Yes Runda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 42,000,000.00 Guaranteed 2025/7/30 2026/7/30 No Runda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 11,000,000.00 Guaranteed 2025/8/11 2026/8/11 Fulunda Medical Hangzhou Runda Guangfa Bank Co., Ltd. Hangzhou Gongshu Branch 47,000,000.00 Guaranteed 2025/9/18 2026/9/18 Fulunda Medical Hangzhou Runda Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 23,000,000.00 Guaranteed 2024/10/22 2025/10/22 Runda Medical Hangzhou Runda Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 17,000,000.00 Guaranteed 2024/12/12 2025/12/12 Runda Medical Hangzhou Runda Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 23,000,000.00 Guaranteed 2025/10/30 2026/10/30 Fulunda Medical Hangzhou Runda Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 17,000,000.00 Guaranteed 2025/12/12 2026/12/12 Fulunda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 14,000,000.00 Guaranteed 2024/1/19 2025/1/6 Yes Runda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 44,000,000.00 Guaranteed 2024/2/1 2025/1/10 Yes Runda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 18,000,000.00 Guaranteed 2024/11/8 2025/11/7 Yes Runda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 14,000,000.00 Guaranteed 2024/11/13 2025/11/12 Yes Runda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 10,000,000.00 Guaranteed 2024/12/12 2025/12/11 Yes Runda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 37,000,000.00 Guaranteed 2025/1/9 2026/1/8 No Runda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 21,000,000.00 Guaranteed 2025/1/14 2026/1/13 Fulunda Medical Hangzhou Runda Bank of Beijing Co., Ltd. Hangzhou Linping Branch 11,650,000.00 Guaranteed 2025/12/22 2026/12/21 Fulunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 7,500,000.00 Guaranteed 2024/6/21 2025/6/19 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 50,000,000.00 Guaranteed 2024/9/23 2025/3/18 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 70,000,000.00 Guaranteed 2024/12/25 2025/12/24 is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 50,000,000.00 Guaranteed 2024/11/14 2025/5/8 Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 50,000,000.00 Guaranteed 2024/11/14 2025/4/11 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 30,000,000.00 Guaranteed 2024/11/26 2025/5/22 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 30,000,000.00 Guaranteed 2024/12/6 2025/6/2 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guaranteed 2024/12/6 2025/6/3 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 30,000,000.00 Guaranteed 2024/12/18 2025/5/16 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 55,000,000.00 Guaranteed 2024/12/20 2025/6/18 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 40,000,000.00 Guaranteed 2024/12/25 2025/3/3 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 410,000.00 Guarantee 2024/12/25 2025/6/20 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 697,000.00 Guarantee 2024/12/25 2025/6/20 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guarantee, pledge 2025/3/5 2025/9/3 Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guarantee, pledge 2025/4/24 2025/10/22 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 24,000,000.00 Guarantee, pledge 2025/4/28 2025/10/25 Shirunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guarantee, pledge 2025/5/7 2025/10/30 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 40,000,000.00 Guarantee, pledge 2025/5/13 2025/11/4 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 62,000,000.00 Guarantee, pledge 2025/5/21 2025/11/19 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guarantee, pledge 2025/5/27 2025/11/26 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 12,000,000.00 Guarantee and pledge 2025/5/29 2025/11/28 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 16,000,000.00 Guarantee and pledge 2025/5/29 2025/11/28 Yes Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 22,500,000.00 Guarantee 2025/6/24 2026/6/23 No Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 52,000,000.00 Guarantee, pledge 2025/6/16 2025/12/12 No Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 70,000,000.00 Guarantee, pledge 2025/6/27 2025/12/25 Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 21,500,000.00 Guarantee, pledge 2025/9/4 2026/3/4 Falunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guarantee, pledge 2025/10/23 2026/4/22 Falunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 24,000,000.00 Guarantee, pledge 2025/10/28 2026/4/27 No Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 60,000,000.00 Guarantee, pledge 2025/11/4 2026/5/4 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 62,000,000.00 Guarantee, pledge 2025/11/21 2026/5/19 Runda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 20,000,000.00 Guarantee, pledge 2025/11/26 2026/5/26 Fulunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 28,000,000.00 Guarantee, pledge 2025/12/1 2026/6/1 Fulunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 52,000,000.00 Guarantee, pledge 2025/12/15 2026/6/12 Ferunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 70,000,000.00 Guarantee 2025/12/23 2026/12/22 Ferunda Medical Hangzhou Runda Industrial Bank Co., Ltd. Hangzhou Shangcheng Branch 70,000,000.00 Guarantee, pledge 2025/12/25 2026/6/25 No Runda Medical Hangzhou Runda China Minsheng Banking Co., Ltd. Hangzhou Branch 30,000,000.00 Guarantee 2024/3/1 2025/3/1 Yes Runda Medical Hangzhou Runda China Minsheng Banking Co., Ltd. Hangzhou Branch 30,000,000.00 Guarantee 2025/3/7 2026/3/7 No Runda Medical Hangzhou Runda Huzhou Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guaranteed 2024/9/10 2025/9/2 Yes Runda Medical Hangzhou Runda Huzhou Bank Co., Ltd. Hangzhou Branch 16,000,000.00 Guaranteed 2024/10/8 2025/10/8 Yes Runda Medical Hangzhou Runda Huzhou Bank Co., Ltd. Hangzhou Branch 54,000,000.00 Guaranteed 2024/10/8 2025/10/8 Yes Runda Medical Hangzhou Runda Huzhou Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guaranteed 2025/8/18 2026/8/6 Fulunda Medical Hangzhou Runda Huzhou Bank Co., Ltd. Hangzhou Branch 54,000,000.00 Guaranteed 2025/9/18 2026/9/11 Fulunda Medical Hangzhou Runda Huzhou Bank Co., Ltd. Hangzhou Branch 16,000,000.00 Guaranteed 2025/9/18 2026/9/11 No Runda Medical Hangzhou Runda China CITIC Bank Co., Ltd. Hangzhou Hushu Branch 30,000,000.00 Guaranteed 2024/8/23 2025/8/20 Yes Runda Medical Hangzhou Runda China CITIC Bank Co., Ltd. Hangzhou Hushu Branch 20,000,000.00 Guaranteed 2024/9/12 2025/9/10 Yes Runda Medical Hangzhou Runda China CITIC Bank Co., Ltd. Hangzhou Hushu Branch 16,000,000.00 Guaranteed 2025/8/22 2026/8/22 No Runda Medical Hangzhou Runda China CITIC Bank Co., Ltd. Hangzhou Hushu Branch 14,000,000.00 Guaranteed 2025/8/28 2026/8/28 Fulunda Medical Hangzhou Runda China CITIC Bank Co., Ltd. Hangzhou Hushu Branch 20,000,000.00 Guarantee 2025/9/11 2026/9/11 Fulunda Medical Hangzhou Runda China Everbright Bank Co., Ltd. Hangzhou Branch 24,500,000.00 Guarantee, pledge 2025/4/7 2025/10/7 Runda Medical Hangzhou Runda China Everbright Bank Co., Ltd. Hangzhou Branch 21,700,000.00 Guarantee, pledge 2025/5/26 2025/11/26 Runda Medical Hangzhou Runda China Everbright Bank Co., Ltd. Hangzhou Branch 26,600,000.00 Guarantee, pledge 2025/11/20 2026/5/20 Fulunda Medical Hangzhou Runda China Everbright Bank Co., Ltd. Hangzhou Branch 23,100,000.00 Guarantee, pledge 2025/12/1 2026/6/1 Fulunda Medical Hangzhou Runda Hangzhou United Rural Commercial Bank Co., Ltd. Dingqiao Branch 9,000,000.00 Guarantee and pledge 2024/5/10 2025/5/5 Yes Runda Medical Hangzhou Runda Hangzhou United Rural Commercial Bank Co., Ltd. Dingqiao Branch 2,520,000.00 Guarantee and pledge 2024/6/13 2025/6/6 Yes Runda Medical Hangzhou Runda Hangzhou United Rural Commercial Bank Co., Ltd. Dingqiao Branch 10,350,000.00 Guarantee and pledge 2024/7/12 2025/7/7 is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Runda Dingqiao Branch of Hangzhou United Rural Commercial Bank Co., Ltd. 9,000,000.00 Guarantee, pledge 2024/9/19 2025/9/12 Runda Medical Hangzhou Runda Dingqiao Branch of Hangzhou United Rural Commercial Bank Co., Ltd. 4,050,000.00 Guarantee, pledge 2024/9/19 2025/9/12 Yes Runda Medical Hangzhou Runda Hangzhou United Rural Commercial Bank Co., Ltd. Dingqiao Branch 9,000,000.00 Guarantee, pledge 2025/5/23 2026/5/22 No Runda Medical Hangzhou Runda Hangzhou United Rural Commercial Bank Co., Ltd. Dingqiao Branch 2,520,000.00 Guarantee, pledge 2025/6/20 2026/6/15 Fulunda Medical Hangzhou Runda Dingqiao Branch of Hangzhou United Rural Commercial Bank Co., Ltd. 10,350,000.00 Guarantee, pledge 2025/7/14 2026/7/6 Fulunda Medical Hangzhou Runda Dingqiao Branch of Hangzhou United Rural Commercial Bank Co., Ltd. 9,900,000.00 Guarantee, pledge 2025/8/21 2026/8/21 Fulunda Medical Hangzhou Runda Hangzhou United Rural Commercial Bank Co., Ltd. Dingqiao Branch 18,000,000.00 Guarantee, pledge 2025/9/15 2026/9/15 Fulunda Medical Hangzhou Yidan Hua Xia Bank Co., Ltd. Hangzhou Branch 1,000,000.00 Guarantee 2023/12/20 2025/5/21 Runda Medical Hangzhou Yidan Hua Xia Bank Co., Ltd. Hangzhou Branch 94,000,000.00 Guarantee 2023/12/20 2025/12/11 Runda Medical Hangzhou Yidan Hua Xia Bank Co., Ltd. Hangzhou Branch 93,000,000.00 Guarantee 2025/12/17 2026/12/16 Norunda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 20,000,000.00 Guarantee 2024/2/6 2025/2/5 Yesrunda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 20,000,000.00 Guarantee 2024/9/14 2025/3/26 Runda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 15,000,000.00 Guarantee 2024/10/15 2025/5/9 Runda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 20,000,000.00 Guarantee 2024/12/3 2025/4/3 Runda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 10,000,000.00 Guarantee 2025/1/16 2025/10/13 Runda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 10,000,000.00 Guarantee 2025/1/16 2026/1/15 Fulunda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 20,000,000.00 Guarantee 2025/3/20 2026/3/19 Fulunda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 20,000,000.00 Guaranteed 2025/3/26 2026/3/25 Fulunda Medical Hangzhou Yidan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 15,000,000.00 Guaranteed 2025/5/9 2026/5/8 Fulunda Medical, Yang Hong, Wang Shuo Hefei Runda Bank of Dongguan Co., Ltd. Hefei Branch 1,300,000.00 Guaranteed 2024/3/22 2025/3/21 Runda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 5,000,000.00 Guaranteed 2025/7/23 2026/7/22 Verunda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 3,973,452.80 Guarantee 2025/8/21 2026/8/20 Verunda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 5,000,000.00 Guarantee, pledge 2025/8/21 2026/8/21 Fu Runda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 1,026,547.20 Guarantee 2025/8/28 2026/8/27 Fu Runda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 10,000,000.00 Guarantee 2025/9/18 2026/9/17 No Runda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 10,000,000.00 Guarantee 2025/11/25 2026/11/24 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical, Yang Hong, Wang Shuo Hefei Runda Dongguan Bank Co., Ltd. Hefei Branch 10,000,000.00 Guaranteed 2025/12/4 2026/12/3 Fulunda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Branch 10,000,000.00 Guaranteed 2024/1/1 2025/1/1 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Area Branch 10,000,000.00 Guarantee 2024/3/27 2025/3/27 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Area Branch 10,000,000.00 Guarantee 2024/6/7 2025/4/15 Runda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Area Branch 10,000,000.00 Guarantee 2024/12/6 2025/12/6 Runda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Pilot Zone Hefei Branch 10,000,000.00 Guarantee 2025/3/18 2026/3/18 Runda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Pilot Zone Hefei Branch 10,000,000.00 Guarantee 2025/4/21 2026/4/21 Fulunda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Branch 10,000,000.00 Guarantee 2025/10/23 2026/10/23 Ferunda Medical, Yang Hong, Wang Shuo Hefei Runda Huishang Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Area Branch 10,000,000.00 Guaranteed 2025/12/10 2026/12/10 Ferunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 8,000,000.00 Guaranteed 2023/11/23 2025/5/23 Yes Runda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 5,000,000.00 Guarantee 2024/11/20 2025/11/17 Yes Runda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 5,000,000.00 Guarantee 2024/12/24 2025/12/19 Yes Runda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 2,000,000.00 Guarantee 2025/3/6 2026/3/6 No Runda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 10,000,000.00 Guarantee 2025/3/25 2026/3/23 Norunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 1,000,000.00 Guarantee 2025/1/2 2025/7/2 Norunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 1,000,000.00 Guaranteed 2025/1/2 2026/1/2 Fulunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 8,000,000.00 Guaranteed 2025/1/2 2026/7/2 Fulunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 9,000,000.00 Guarantee 2025/9/2 2026/3/23 Fulunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 5,000,000.00 Guarantee, pledge 2025/11/26 2026/11/23 Ferunda Medical Hefei Runda Shanghai Pudong Development Bank Co., Ltd. Hefei Huangshan Road Branch 3,200,000.00 Guarantee, pledge 2025/12/23 2026/12/18 Ferunda Medical, Yang Hong, Wang Shuo Hefei Runda Anhui Maanshan Rural Commercial Bank Co., Ltd. Changfeng Branch 10,000,000.00 Guarantee 2024/10/8 2025/10/8 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda Anhui Maanshan Rural Commercial Bank Co., Ltd. Changfeng Branch 10,000,000.00 Guarantee 2025/11/19 2026/11/19 No Runda Medical, Yang Hong, Wang Shuo Hefei Runda Hua Xia Bank Co., Ltd. Hefei Luyang Branch 10,000,000.00 Guarantee 2024/9/19 2025/9/19 Runda Medical, Yang Hong, Wang Shuo Hefei Runda Hua Xia Bank Co., Ltd. Hefei Luyang Branch 10,000,000.00 Guarantee, pledge 2025/7/24 2026/7/24 No Runda Medical, Yang Hong, Wang Shuo Hefei Runda Hefei Science and Technology Rural Commercial Bank Co., Ltd. Binhu Branch 10,000,000.00 Guarantee 2024/6/28 2025/6/28 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda Hefei Science and Technology Rural Commercial Bank Co., Ltd. Binhu Branch 10,000,000.00 Guaranteed 2024/8/22 2025/8/21 is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical, Yang Hong, Wang Shuo Hefei Runda China Merchants Bank Co., Ltd. Hefei High-tech Zone Branch 5,000,000.00 Guaranteed 2024/11/6 2025/11/6 Runda Medical, Yang Hong, Wang Shuo Hefei Runda China Merchants Bank Co., Ltd. Hefei High-tech Zone Branch 1,680,000.00 Guaranteed 2024/11/13 2025/11/13 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda China Merchants Bank Co., Ltd. Hefei High-tech Zone Branch 10,000,000.00 Guarantee 2024/12/19 2025/12/19 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda China Merchants Bank Co., Ltd. Hefei High-tech Zone Branch 3,320,000.00 Guaranteed 2024/12/23 2025/12/23 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda China Merchants Bank Co., Ltd. Hefei High-tech Zone Branch 50,000.00 Guaranteed 2025/11/26 2026/11/26 No Runda Medical, Yang Hong, Wang Shuo Hefei Runda China Merchants Bank Co., Ltd. Hefei High-tech Zone Branch 4,700,000.00 Guarantee, pledge 2025/12/24 2026/12/24 No Runda Medical Hefei Runda China Everbright Bank Co., Ltd. Hefei Branch 10,000,000.00 Guarantee 2024/9/23 2025/9/18 No Runda Medical Hefei Runda Industrial Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Area Branch 10,000,000.00 Guaranteed 2024/6/13 2025/6/13 Runda Medical Hefei Runda Industrial Bank Co., Ltd. Anhui Free Trade Pilot Zone Hefei Area Branch 10,000,000.00 Guaranteed 2024/6/13 2025/6/12 Yes Runda Medical Hefei Runda Industrial Bank Co., Ltd. Anhui Pilot Zone Hefei Area Branch 10,000,000.00 Guaranteed 2024/7/23 2025/7/23 Yes Runda Medical Hefei Runda Industrial Bank Co., Ltd. Anhui Pilot Zone Hefei Area Branch 121,212.42 Guaranteed 2025/6/13 2029/6/12 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda Guangfa Bank Co., Ltd. Hefei Branch 10,000,000.00 Guarantee 2024/4/24 2025/2/1 Yes Runda Medical, Yang Hong, Wang Shuo Hefei Runda Guangfa Bank Co., Ltd. Hefei Branch 10,000,000.00 Guaranteed 2025/5/22 2026/5/21 Fulunda Medical, Yang Hong, Wang Shuo Hefei Runda China Guangfa Bank Co., Ltd. Hefei Branch 10,000,000.00 Guaranteed 2025/6/10 2026/6/9 Fulunda Medical, Yang Hong, Wang Shuo Hefei Runda Guangfa Bank Co., Ltd. Hefei Branch 10,000,000.00 Guarantee 2025/6/26 2026/6/25 Fe Runda Medical, Hou Zhong, Gong Yuying,

Hefei Sanli Binhu Branch of Hefei Science and Technology Rural Commercial Bank Co., Ltd. 6,000,000.00 Guarantee 2024/6/20 2025/6/20 They are Tang Yong and Zhang Li

Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 5,000,000.00 Guarantee 2024/4/19 2025/4/18 Yes Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 7,500,000.00 Guarantee 2024/9/14 2025/9/13 Yes Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 2,700,000.00 Guarantee 2024/9/20 2025/9/19 Yes Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 4,800,000.00 Guarantee 2024/10/17 2025/10/16 Yes Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 1,500,000.00 Guarantee 2024/11/15 2025/11/14 Yes Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 8,500,000.00 Guarantee 2024/11/19 2025/11/18 Yes Runda Medical Hefei Sanli Industrial Bank Co., Ltd. Hefei Branch 5,000,000.00 Guaranteed 2025/4/18 2026/4/17 Ferunda Medical, Hou Zhong, Gong Yuying Hefei Sanli Dongguan Bank Co., Ltd. Hefei Branch 4,800,000.00 Guaranteed 2024/5/28 2025/5/27 Is Runda Medical, Hou Zhong, Gong Yuying Hefei Sanli Dongguan Bank Co., Ltd. Hefei Branch 8,770,000.00 Guarantee 2024/10/18 2025/10/17 Is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical, Hou Zhong, Gong Yuying Hefei Sanli Dongguan Bank Co., Ltd. Hefei Branch 3,830,000.00 Guaranteed 2024/11/5 2025/11/4 Runda Medical, Hou Zhong, Gong Yuying Hefei Sanli Dongguan Bank Co., Ltd. Hefei Branch 2,600,000.00 Guaranteed 2024/11/22 2025/11/21 Runda Medical, Hou Zhong, Gong Yuying Hefei Sanli Dongguan Bank Co., Ltd. Hefei Branch 4,800,000.00 Guarantee 2025/5/22 2026/5/21 Runda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 1,000,000.00 Guarantee 2023/8/22 2025/2/22 Yesrunda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 7,000,000.00 Guarantee 2023/8/22 2025/8/22 Yesrunda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 1,000,000.00 Guarantee 2023/9/12 2025/3/12 Yesrunda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 7,000,000.00 Guarantee 2023/9/12 2025/9/12 Yesrunda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 200,000.00 Guarantee 2025/3/18 2025/9/18 Yes Runda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 1,800,000.00 Guarantee 2025/3/18 2027/3/18 No Runda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 400,000.00 Guarantee 2025/4/25 2025/10/25 Yes Runda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 3,600,000.00 Guarantee 2025/4/25 2027/4/25 No Runda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 7,000,000.00 Guarantee 2025/8/27 2026/3/23 Fulunda Medical Hefei Sanli Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 7,000,000.00 Guarantee 2025/9/9 2026/3/23 Fulunda Medical Hefei Sanli Hua Xia Bank Co., Ltd. Hefei Luyang Branch 4,000,000.00 Guarantee 2024/4/28 2025/4/28 Yes Runda Medical Hefei Sanli Hua Xia Bank Co., Ltd. Hefei Luyang Branch 7,000,000.00 Guarantee 2024/5/9 2025/5/9 Yes Runda Medical Hefei Sanli Hua Xia Bank Co., Ltd. Hefei Luyang Branch 4,000,000.00 Guarantee 2024/5/10 2025/5/10 Runda Medical Hefei Sanli Hua Xia Bank Co., Ltd. Hefei Luyang Branch 5,000,000.00 Guarantee 2024/7/30 2025/7/30 Runda Medical Hefei Sanli Hua Xia Bank Co., Ltd. Hefei Luyang Branch 10,000,000.00 Guarantee 2025/4/25 2026/4/25 Fulunda Medical Hefei Sanli Hua Xia Bank Co., Ltd. Hefei Luyang Branch 5,000,000.00 Guarantee 2025/7/18 2026/7/18 Fulunda Medical, Tang Yong Hefei Sanli Huishang Bank Co., Ltd. Hefei Chenghuangmiao Branch 8,000,000.00 Guarantee 2024/12/17 2025/12/17 Yes Runda Medical Heilongjiang Longwei China Everbright Bank Co., Ltd. Harbin Fendou Branch 10,000,000.00 Guarantee 2024/9/5 2025/9/4 Yes Runda Medical Heilongjiang Longwei Harbin Fendou Branch of China Everbright Bank Co., Ltd. 10,000,000.00 Guaranteed 2025/9/4 2026/9/3 Ferunda Medical Heilongjiang Longwei Industrial Bank Harbin Branch Sales Department 10,000,000.00 Guaranteed 2025/9/29 2026/9/28 Ferunda Medical Heilongjiang Longwei Shanghai Pudong Development Bank Co., Ltd. Harbin Branch 20,000,000.00 Guarantee 2024/11/8 2025/11/7 Runda Medical, Li Jie, Li Jian Jinan Runda Laishang Bank Co., Ltd. Jinan Licheng Branch 10,000,000.00 Guarantee 2024/2/23 2025/2/23 Yes Runda Medical, Li Jie, Li Jian Jinan Runda Laishang Bank Co., Ltd. Jinan Licheng Branch 10,000,000.00 Guaranteed 2025/2/24 2026/2/24 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Jinan Runda Bank of Beijing Co., Ltd. Jinan Branch 20,000,000.00 Guarantee 2024/6/6 2025/5/22 Yes Runda Medical Jinan Runda Bank of Beijing Co., Ltd. Jinan Branch 18,000,000.00 Guarantee 2024/6/17 2025/5/22 Yes Runda Medical Jinan Runda Bank of Beijing Co., Ltd. Jinan Branch 2,000,000.00 Guarantee 2025/2/24 2025/5/22 Yes Runda Medical Jinan Runda Bank of Beijing Co., Ltd. Jinan Branch 3,850,000.00 Guarantee 2025/5/22 2025/10/9 Yes Runda Medical Jinan Runda Jinan Branch of Bank of Beijing Co., Ltd. 36,150,000.00 Guaranteed 2025/5/22 2026/5/22 Fulunda Medical, Li Jie, Li Jian Jinan Runda Bank of Qingdao Co., Ltd. Jinan Branch 10,000,000.00 Guaranteed 2025/1/23 2026/1/23 Fulunda Medical, Li Jie, Li Jian Jinan Runda China Everbright Bank Co., Ltd. Jinan Branch 10,000,000.00 Guaranteed 2025/2/27 2026/2/26 No Runda Medical Jinan Runda Industrial Bank Co., Ltd. Jinan Branch 10,000,000.00 Guaranteed 2024/2/2 2025/2/1 Yes Runda Medical Jinan Runda Industrial Bank Co., Ltd. Jinan Branch 10,000,000.00 Guarantee 2025/5/30 2026/5/29 Fe Runda Medical, Li Jie, Li Jian Jinan Runda Qilu Bank Co., Ltd. Jinan Zhangzhuang Branch 30,000,000.00 Guarantee, mortgage 2024/11/27 2025/11/27 Shirunda Medical Qingdao Runda Industrial Bank Co., Ltd. Qingdao Branch 9,000,000.00 Guarantee 2024/5/13 2025/5/13 Shirunda Medical Qingdao Runda Industrial Bank Co., Ltd. Qingdao Branch 9,000,000.00 Guarantee 2025/6/19 2026/6/18 Norunda Medical Qingdao Runda Bank of Qingdao Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guaranteed 2024/7/23 2025/2/25 Yes Runda Medical Qingdao Runda Qingdao Bank Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guaranteed 2025/2/25 2025/9/25 Yes Runda Medical Qingdao Runda Bank of Qingdao Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guarantee 2025/8/4 2026/8/4 Norunda Medical Qingdao Runda Hua Xia Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/3/29 2025/3/29 Norunda Medical Qingdao Runda Hua Xia Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2025/6/9 2026/6/9 Runda Medical Qingdao Runda Qilu Bank Co., Ltd. Qingdao Shibei Branch 5,369,448.00 Guarantee 2024/10/22 2025/7/11 Runda Medical Qingdao Runda Qilu Bank Co., Ltd. Qingdao Shibei Branch 4,630,552.00 Guarantee 2025/2/13 2025/7/11 Yes Runda Medical Qingdao Runda Bank of Beijing Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2025/1/7 2025/11/11 Yes Runda Medical Qingdao Runda Bank of China Co., Ltd. Qingdao Shinan Branch 10,000,000.00 Guarantee 2024/6/26 2025/5/9 Yes Runda Medical Qingdao Runda Bank of China Co., Ltd. Qingdao Shinan Branch 10,000,000.00 Guarantee 2025/6/24 2026/6/23 No Runda Medical Qingdao Yixin Qingdao Branch of Bank of Beijing Co., Ltd. 10,000,000.00 Guarantee 2024/12/24 2025/12/24 Runda Medical Qingdao Yixin Qingdao Rural Commercial Bank Co., Ltd. Shibei Branch 10,000,000.00 Guarantee 2024/3/5 2025/3/3 Runda Medical Qingdao Yixin Qingdao Rural Commercial Bank Co., Ltd. Shibei Branch 15,000,000.00 Guarantee 2025/6/9 2026/6/8 Fulunda Medical Qingdao Yixin Bank of Qingdao Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guarantee, pledge 2024/9/3 2025/1/10 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Qingdao Yixin Cultural and Creative Branch of Bank of Qingdao Co., Ltd. 10,000,000.00 Guaranteed 2024/10/29 2025/4/29 Runda Medical Qingdao Yixin Cultural and Creative Branch of Bank of Qingdao Co., Ltd. 10,000,000.00 Guaranteed 2025/2/25 2025/6/26 Runda Medical Qingdao Yixin Cultural and Creative Branch of Bank of Qingdao Co., Ltd. 10,000,000.00 Guaranteed 2025/2/26 2025/8/26 Shirunda Medical Qingdao Yixin Cultural and Creative Branch of Bank of Qingdao Co., Ltd. 10,000,000.00 Guaranteed 2025/7/25 2026/1/25 Furunda Medical Qingdao Yixin China Everbright Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/5/10 2025/5/9 Yes Runda Medical Qingdao Yixin China Everbright Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/9/11 2025/3/28 Yes Runda Medical Qingdao Yixin China Everbright Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guaranteed 2025/8/22 2026/8/21 Frunda Medical Qingdao Yixin China Everbright Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guaranteed 2025/9/2 2026/9/1 Frunda Medical Qingdao Yixin China CITIC Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/6/12 2025/6/7 Runda Medical Qingdao Yixin China CITIC Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee, pledge 2025/7/23 2026/4/10 Frunda Medical Qingdao Yixin Qingdao Branch of Industrial Bank Co., Ltd. 10,000,000.00 Guarantee, pledge 2025/12/17 2026/12/14 Ferunda Medical Qingdao Yixin China Minsheng Banking Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/9/26 2025/3/6 Ferunda Medical Qingdao Yixin China Minsheng Banking Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee, pledge 2025/2/26 2025/8/26 Shirunda Medical Qingdao Yixin China Minsheng Banking Co., Ltd. Qingdao Branch 5,000,000.00 Guarantee, pledge 2025/6/5 2025/12/5 Shirunda Medical Qingdao Yixin Bank of China Co., Ltd. Qingdao Shinan Branch 10,000,000.00 Guarantee 2025/3/21 2026/3/21 Norunda Medical Qingdao Yixin Bank of Communications Co., Ltd. Qingdao Branch 3,000,000.00 Guarantee 2025/5/14 2025/11/14 Yesrunda Medical Qingdao Yixin Hua Xia Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/9/3 2025/2/3 Runda Medical Qingdao Yixin Hua Xia Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee, pledge 2025/8/7 2026/1/30 Runda Medical Runlan Biotech Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 10,000,000.00 Guaranteed 2024/6/11 2025/6/10 Yes Runda Medical Runlan Biotech Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 10,000,000.00 Guaranteed 2025/6/27 2026/6/26 No Runda Medical Shandong Xinhai Qingdao Rural Commercial Bank Co., Ltd. Shibei Branch 10,000,000.00 Guarantee 2024/3/5 2025/3/3 Yes Runda Medical Shandong Xinhai China Minsheng Banking Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2024/9/26 2025/3/5 Yes Runda Medical Shandong Xinhai Qingdao Branch of China Minsheng Banking Co., Ltd. 10,000,000.00 Guarantee 2025/6/6 2025/12/5 Runda Medical Shandong Xinhai Qingdao Branch of China Minsheng Banking Co., Ltd. 10,000,000.00 Guarantee, pledge 2025/12/9 2026/12/4 Runda Medical Shandong Xinhai Bank of Qingdao Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guaranteed 2024/9/19 2025/3/4 It is Runda Medical Shandong Xinhai Qingdao Bank Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guaranteed 2025/3/5 2025/9/5 It is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Shandong Xinhai Qingdao Bank Co., Ltd. Cultural and Creative Branch 10,000,000.00 Guaranteed 2025/8/4 2026/8/4 Ferunda Medical Shandong Xinhai China Everbright Bank Co., Ltd. Qingdao Branch 10,000,000.00 Guaranteed 2025/2/13 2025/10/9 Shirunda Medical Shandong Xinhai Bank of Beijing Co., Ltd. Qingdao Branch 10,000,000.00 Guarantee 2025/1/2 2025/7/29 Shirunda Medical Shandong Xinhai Industrial and Commercial Bank of China Co., Ltd. Qingdao Nanjing Road Guidu Branch 10,000,000.00 Guarantee 2024/7/3 2025/1/1 Shirunda Medical Shandong Xinhai Industrial and Commercial Bank of China Co., Ltd. Qingdao Aoyuan Branch 10,000,000.00 Guarantee 2025/2/21 2025/8/21 Shirunda Medical Shanghai Huizhong Biotech China Everbright Bank Co., Ltd. Shanghai Nanshi Branch 10,000,000.00 Guarantee 2024/3/26 2025/3/25 Shirunda Medical Shanghai Huizhong Biotech Shanghai Nanshi Branch of China Everbright Bank Co., Ltd. 10,000,000.00 Guaranteed 2025/11/4 2026/11/3 Shirunda Medical Shanghai Huizhong Biotech Bank of Jiangsu Co., Ltd. Shanghai Jing’an Branch 8,000,000.00 Guaranteed 2024/1/31 2025/1/14 Shirunda Medical Shanghai Huizhong Biotech Bank of Jiangsu Co., Ltd. Shanghai Jing'an Branch 8,000,000.00 Guaranteed 2025/1/13 2026/1/12 Verunda Medical Shanghai Huizhong Biotech Shanghai Rural Commercial Bank Co., Ltd. Xinhe Branch 10,000,000.00 Guaranteed 2024/3/14 2025/3/12 Runda Medical Shanghai Huizhong Biotech Xinhe Branch of Shanghai Rural Commercial Bank Co., Ltd. 10,000,000.00 Guaranteed 2025/3/11 2026/3/10 Runda Medical Shanghai Huizhong Biotech Bank of Shanghai Co., Ltd. Yangjing Branch 8,000,000.00 Guaranteed 2024/2/21 2025/2/18 Runda Medical Shanghai Huizhong Biotech Yangjing Branch of Bank of Shanghai Co., Ltd. 8,000,000.00 Guaranteed 2025/3/27 2026/3/17 Runda Medical Shanghai Huizhong Biotech Industrial Bank Co., Ltd. Shanghai Jing’an Branch 10,000,000.00 Guaranteed 2024/4/3 2025/4/2 Runda Medical Shanghai Huizhong Biotech Industrial Bank Co., Ltd. Shanghai Jing'an Branch 10,000,000.00 Guaranteed 2025/4/3 2026/4/2 Runda Medical Shanghai Huizhong Biotech Bank of Nanjing Co., Ltd. Shanghai Branch 10,000,000.00 Guaranteed 2024/9/19 2025/9/12 Runda Medical Shanghai Huizhong Biotech Shanghai Branch of Bank of Nanjing Co., Ltd. 10,000,000.00 Guaranteed 2025/9/30 2026/9/28 Runda Medical Shanghai Huizhong Bio Bohai Bank Co., Ltd. Shanghai Jing’an Branch 7,000,000.00 Guaranteed 2024/5/6 2025/5/5 Runda Medical Shanghai Huizhong Bio Shanghai Jing'an Branch of Bohai Bank Co., Ltd. 7,000,000.00 Guaranteed 2025/8/29 2026/8/28 Runda Medical Shanghai Huizhong Biotech Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 4,770,000.00 Guaranteed 2024/12/19 2025/12/18 Runda Medical Shanghai Huizhong Biotech Hongkou Branch of Shanghai Pudong Development Bank Co., Ltd. 300,000.00 Guaranteed 2025/3/10 2025/11/18 Runda Medical Shanghai Huizhong Biotech Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 3,200,000.00 Guaranteed 2025/3/10 2026/3/9 Runda Medical Shanghai Huizhong Biotech Hongkou Branch of Shanghai Pudong Development Bank Co., Ltd. 5,000,000.00 Guaranteed 2025/12/19 2026/12/10 Runda Medical Shanghai Huizhong Biotech Xiamen International Bank Co., Ltd. Shanghai Jing’an Branch 147,750.00 Guaranteed 2024/12/20 2025/6/20 Runda Medical Shanghai Huizhong Biotech Xiamen International Bank Co., Ltd. Shanghai Jing'an Branch 9,702,250.00 Guaranteed 2024/12/20 2025/12/19 Yes Runda Medical Shanghai Huizhong Biotech Xiamen International Bank Co., Ltd. Shanghai Jing'an Branch 9,702,250.00 Guaranteed 2025/12/12 2026/6/12 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Shanghai Huizhong Biotech Tianjin Bank Co., Ltd. Shanghai Lujiazui Branch 10,000,000.00 Guaranteed 2024/9/3 2025/9/2 Runda Medical Shanghai Huizhong Biotech Tianjin Bank Co., Ltd. Shanghai Lujiazui Branch 10,000,000.00 Guaranteed 2025/9/25 2026/9/24 No Runda Medical Shanghai Huizhong Biotech Shanghai Second Branch of China Construction Bank Co., Ltd. 15,000,000.00 Guarantee 2025/6/27 2026/6/26 Verunda Medical Shanghai Huizhong Biotech Bank of Beijing Co., Ltd. Shanghai Branch 20,000,000.00 Guarantee 2024/11/28 2025/11/28 Verunda Medical Shanghai Huizhong Biotech Bank of Beijing Co., Ltd. Shanghai Branch 20,000,000.00 Guarantee 2025/11/28 2026/11/28 Runda Medical Shanghai Huizhong Biotech Guangfa Bank Co., Ltd. Shanghai Changning Branch 300,000.00 Guarantee 2024/6/18 2025/6/18 Runda Medical Shanghai Huizhong Biotech Guangfa Bank Co., Ltd. Shanghai Changning Branch 9,400,000.00 Guaranteed 2024/6/18 2025/7/18 Runda Medical Shanghai Huizhong Biotech Guangfa Bank Co., Ltd. Shanghai Changning Branch 9,700,000.00 Guaranteed 2025/7/24 2026/8/24 Runda Medical Shanghai Huizhong Medical Bank of Jiangsu Co., Ltd. Shanghai Jing'an Branch 10,000,000.00 Guaranteed 2024/2/7 2025/1/31 Runda Medical Shanghai Huizhong Medical Bank of Jiangsu Co., Ltd. Shanghai Jing'an Branch 10,000,000.00 Guaranteed 2025/1/21 2026/1/20 Runda Medical Shanghai Huizhong Medical Bank of Shanghai Co., Ltd. Yangjing Branch 8,000,000.00 Guarantee 2024/2/28 2025/2/26 Runda Medical Shanghai Huizhong Medical Bank of Shanghai Co., Ltd. Yangjing Branch 8,000,000.00 Guarantee 2025/3/27 2026/3/18 Runda Medical Shanghai Huizhong Medical Shanghai Branch of Bank of Nanjing Co., Ltd. 10,000,000.00 Guarantee 2024/9/18 2025/9/12 Yes Runda Medical Shanghai Huizhong Medical Shanghai Branch of Bank of Nanjing Co., Ltd. 10,000,000.00 Guarantee 2025/9/30 2026/9/28 No Runda Medical Shanghai Huizhong Medical Shanghai Pudong Development Bank Co., Ltd. Liangcheng Road Branch 10,000,000.00 Guarantee 2024/9/30 2025/9/5 Runda Medical Shanghai Huizhong Medical Shanghai Pudong Development Bank Co., Ltd. Liangcheng Road Branch 10,000,000.00 Guarantee 2025/9/8 2026/3/20 Runda Medical Shanghai Huizhong Medical Shanghai Nanshi Branch of China Everbright Bank Co., Ltd. 10,000,000.00 Guarantee 2024/9/27 2025/9/26 Runda Medical Shanghai Huizhong Medical China Everbright Bank Co., Ltd. Shanghai Nanshi Branch 10,000,000.00 Guarantee 2025/9/24 2026/9/23 Runda Medical Shanghai Huizhong Medical Xiamen International Bank Co., Ltd., Shanghai Jing'an Branch 147,750.00 Guaranteed 2024/12/12 2025/6/12 Runda Medical Shanghai Huizhong Medical Xiamen International Bank Co., Ltd. Shanghai Jing'an Branch 9,702,250.00 Guaranteed 2025/12/12 2026/6/12 Runda Medical Shanghai Huizhong Medical Huaxia Bank Co., Ltd. Shanghai Putuo Branch 5,000,000.00 Guaranteed 2024/1/18 2025/1/18 Runda Medical Shanghai Huizhong Medical Hua Xia Bank Co., Ltd. Shanghai Putuo Branch 5,000,000.00 Guarantee 2024/12/10 2025/12/10 Yes Runda Medical Shanghai Huizhong Medical Hua Xia Bank Co., Ltd. Shanghai Putuo Branch 5,000,000.00 Guarantee 2025/1/20 2025/12/10 Yes Runda Medical Shanghai Huizhong Medical Hua Xia Bank Co., Ltd. Shanghai Putuo Branch 10,000,000.00 Guarantee 2025/12/9 2026/12/9 Fulunda Medical Shanghai Huizhong Medical Bank of Beijing Co., Ltd. Shanghai Branch 10,000,000.00 Guarantee 2024/11/28 2025/11/28 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Shanghai Huizhong Medical Bank of Beijing Co., Ltd. Shanghai Branch 10,000,000.00 Guarantee 2025/11/28 2026/11/28 Runda Medical Shanghai Huizhong Medical China Guangfa Bank Co., Ltd. Shanghai Branch 100,000.00 Guarantee 2025/5/6 2025/11/6 Yes Runda Medical Shanghai Huizhong Medical Shanghai Branch of China Guangfa Bank Co., Ltd. 4,890,000.00 Guaranteed 2025/5/6 2026/6/6 Furunda Medical Shanghai Huizhong Medical Guangfa Bank Co., Ltd. Shanghai Branch 2,170,000.00 Guaranteed 2025/7/7 2026/8/7 Furunda Medical Shanghai Huizhong Medical Guangfa Bank Co., Ltd. Shanghai Branch 1,340,000.00 Guaranteed 2025/7/24 2026/8/24 Fulunda Medical Shanghai Huizhong Medical Bohai Bank Co., Ltd. Shanghai Branch 5,000,000.00 Guaranteed 2025/1/15 2026/1/14 Fulunda Medical Shanghai Huizhong Medical Bohai Bank Co., Ltd. Shanghai Branch 2,000,000.00 Guaranteed 2025/6/27 2026/1/31 Fulunda Medical Shanghai Huizhong Medical Bank of Tianjin Co., Ltd. Shanghai Branch 10,000,000.00 Guaranteed 2025/1/17 2026/1/16 Fulunda Medical Shanghai Huizhong Medical Bank of China Baosteel Building Branch 3,000,000.00 Guaranteed 2025/7/31 2026/7/31 Fulunda Medical Shanghai Huizhong Medical Bank of China Baosteel Building Branch 7,000,000.00 Guaranteed 2025/8/22 2026/8/21 Fulunda Medical Shanghai Huizhong Medical China Construction Bank Co., Ltd. Shanghai Second Branch 5,000,000.00 Guarantee 2024/3/4 2025/3/3 Yes Runda Medical Shanghai Huizhong Medical Shanghai Second Branch of China Construction Bank Corporation 10,000,000.00 Guarantee 2024/7/19 2025/7/18 Yes Runda Medical Shanghai Huizhong Medical Shanghai Second Branch of China Construction Bank Corporation 5,000,000.00 Guarantee 2024/8/21 2025/8/20 Runda Medical Shanghai Huizhong Medical China Construction Bank Co., Ltd. Shanghai Second Branch 10,000,000.00 Guarantee 2024/8/26 2025/8/20 Runda Medical Shanghai Huizhong Medical China Construction Bank Co., Ltd. Shanghai Second Branch 5,000,000.00 Guaranteed 2025/3/12 2026/3/9 Fulunda Medical Shanghai Huizhong Medical Shanghai Second Branch of China Construction Bank Corporation 10,000,000.00 Guaranteed 2025/7/18 2026/7/17 Fulunda Medical Shanghai Huizhong Medical Shanghai Second Branch of China Construction Bank Corporation 5,000,000.00 Guaranteed 2025/8/22 2026/8/21 Fulunda Medical Shanghai Huizhong Medical China Construction Bank Co., Ltd. Shanghai Second Branch 10,000,000.00 Guaranteed 2025/9/11 2026/8/21 Fulunda Medical Shanghai Runda Rongjia Bohai Bank Co., Ltd. Shanghai Jing’an Branch 7,000,000.00 Guarantee 2024/4/25 2025/4/24 Yes Runda Medical Shanghai Runda Rongjia Bohai Bank Co., Ltd. Shanghai Jing’an Branch 7,000,000.00 Guarantee 2025/5/28 2026/5/27 No Runda Medical Shanghai Runda Rongjia Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 1,000,000.00 Guarantee 2024/9/30 2025/6/26 Yes Runda Medical Shanghai Runda Rongjia Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 9,000,000.00 Guarantee 2024/9/30 2025/9/5 Yes Runda Medical Shanghai Runda Rongjia Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 10,000,000.00 Guarantee 2025/9/8 2026/3/20 Frunda Medical Shanghai Runda Rongjia China Everbright Bank Co., Ltd. Shanghai Huaihai Branch 10,000,000.00 Guarantee 2024/7/23 2025/7/22 Runda Medical Shanghai Runda Rongjia China Everbright Bank Co., Ltd. Shanghai Huaihai Branch 5,000,000.00 Guaranteed 2025/9/3 2026/9/2 Runda Medical Shanghai Runda Rongjia China Everbright Bank Co., Ltd. Shanghai Huaihai Branch 5,000,000.00 Guaranteed 2025/9/18 2026/9/17 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Shanghai Runda Rongjia China Everbright Bank Co., Ltd. Shanghai Huaihai Branch 10,000,000.00 Guaranteed 2025/10/9 2026/10/8 Fe Runda Medical, Qian Xueqing Shanghai Runda Rongjia Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 19,090,000.00 Guaranteed 2024/5/27 2025/5/15 Runda Medical Shanghai Runda Rongjia Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 10,000,000.00 Guaranteed 2024/10/25 2025/10/25 Runda Medical Shanghai Runda Rongjia Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 19,090,000.00 Guaranteed 2025/5/19 2026/5/16 Ferunda Medical Shanghai Runda Rongjia Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 10,000,000.00 Guarantee 2025/8/26 2026/8/26 Ferunda Medical Shanghai Runda Rongjia Bank of China Co., Ltd. Shanghai Gonghexin Road Branch 10,000,000.00 Guarantee 2024/6/25 2025/6/25 Yes Runda Medical Shanghai Runda Rongjia Bank of China Co., Ltd. Shanghai Gonghexin Road Branch 10,000,000.00 Guarantee 2025/6/24 2026/6/23 No Runda Medical, Qian Xueqing Shanghai Runda Rongjia China Construction Bank Hongkou Branch 15,000,000.00 Guarantee 2025/10/30 2026/10/29 Runda Medical Shanghai Runda Rongjia Bank of Jiangsu Co., Ltd. Shanghai Baoshan Branch 15,000,000.00 Guarantee 2024/1/10 2025/1/9 Runda Medical Shanghai Runda Rongjia Bank of Jiangsu Co., Ltd. Shanghai Baoshan Branch 10,000,000.00 Guaranteed 2025/1/21 2026/1/20 No Runda Medical Shanghai Runda Rongjia Xiamen International Bank Co., Ltd. Shanghai Jing’an Branch 10,000,000.00 Guaranteed 2024/12/27 2025/4/30 No Runda Medical Shanghai Runda Rongjia Xiamen International Bank Co., Ltd. Shanghai Jing'an Branch 9,772,597.40 Guaranteed 2024/12/31 2025/4/29 Runda Medical Shanghai Runda Rongjia Xiamen International Bank Co., Ltd. Shanghai Jing'an Branch 150,000.00 Guaranteed 2025/6/27 2025/12/26 Runda Medical Shanghai Runda Rongjia Xiamen International Bank Co., Ltd. Shanghai Jing'an Branch 9,850,000.00 Guarantee 2025/6/27 2026/6/27 Runda Medical Shanghai Runda Rongjia Bank of Shanghai Co., Ltd. Baoshan Branch 10,000,000.00 Guarantee 2024/6/26 2025/6/25 Runda Medical Shanghai Runda Rongjia Bank of Shanghai Co., Ltd. Baoshan Branch 10,000,000.00 Guarantee 2025/6/24 2026/6/23 Runda Medical Shanghai Runda Rongjia Bank of Nanjing Co., Ltd. Shanghai Branch 10,000,000.00 Guarantee 2024/11/25 2025/11/14 Runda Medical Shanghai Runda Rongjia Bank of Nanjing Co., Ltd. Shanghai Branch 10,000,000.00 Guarantee 2025/12/15 2026/12/14 Runda Medical Shanghai Runda Rongjia Ningbo Commercial Bank Co., Ltd. Shanghai Branch 7,475,850.00 Guarantee 2024/3/20 2025/3/20 YesRunda Medical Shanghai Runda Rongjia Huaxia Bank Co., Ltd. Shanghai Putuo Branch 10,000,000.00 Guaranteed 2024/12/13 2025/12/12 YesRunda Medical Shanghai Runda Rongjia Huaxia Bank Co., Ltd. Shanghai Putuo Branch 10,000,000.00 Guaranteed 2025/12/11 2026/12/10 Fulunda Medical, Qian Xueqing Shanghai Runda Rongjia Ping An Bank Co., Ltd. Shanghai Jinke Road Branch 9,800,000.00 Guarantee 2025/6/20 2026/6/20 Fulunda Medical Shanghai Runda Rongjia Zheshang Bank Hangzhou Tiancheng Branch 20,000,000.00 Guarantee 2025/11/13 2026/11/12 No Runda Medical Shanghai Runda Rongjia Shanghai Rural Commercial Bank Co., Ltd. Gaojing Branch 20,000,000.00 Guarantee 2024/6/24 2025/6/16 Yes Runda Medical Shanghai Runda Rongjia Shanghai Rural Commercial Bank Co., Ltd. Gaojing Branch 10,000,000.00 Guaranteed 2025/6/20 2026/6/19 No Runda Medical Shanghai Runda Rongjia Tianjin Bank Co., Ltd. Shanghai Lujiazui Branch 10,000,000.00 Guaranteed 2024/6/28 2025/6/27 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Shanghai Runda Rongjia Bank of Tianjin Co., Ltd. Shanghai Lujiazui Branch 10,000,000.00 Guarantee 2025/6/27 2026/6/26 Runda Medical Shanghai Runda Rongjia Bank of Communications Co., Ltd. Shanghai Jing'an Branch 10,000,000.00 Guarantee 2025/1/14 2025/12/31 Yes Runda Medical Shanghai Runda Rongjia Bank of Communications Co., Ltd. Shanghai Jing’an Branch 10,000,000.00 Guaranteed 2025/11/20 2026/6/19 No Runda Medical Shanghai Runda Rongjia Industrial Bank Co., Ltd. Shanghai Jing’an Branch 10,000,000.00 Guaranteed 2024/3/8 2025/3/7 Yes Runda Medical Shanghai Runda Rongjia Industrial Bank Co., Ltd. Shanghai Jing’an Branch 10,000,000.00 Guaranteed 2025/4/29 2026/4/28 No Runda Medical Shanghai Runyi Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 10,000,000.00 Guaranteed 2024/6/5 2025/6/4 Yes Runda Medical Shanghai Runyi Bank of Beijing Co., Ltd. Shanghai Hongkou Branch 10,000,000.00 Guarantee 2025/6/11 2026/6/9 No Runda Medical Shanghai Runyi China Everbright Bank Co., Ltd. Shanghai Pengpu Branch 7,000,000.00 Guarantee 2024/5/16 2025/5/15 Yes Runda Medical Shanghai Runyi China Everbright Bank Co., Ltd. Shanghai Pengpu Branch 3,000,000.00 Guarantee 2024/8/16 2025/8/15 Yes Runda Medical Shanghai Runyi China Everbright Bank Co., Ltd. Shanghai Pengpu Branch 7,000,000.00 Guarantee 2025/5/9 2025/8/15 Yes Runda Medical Shanghai Runyi China Everbright Bank Co., Ltd. Shanghai Pengpu Branch 10,000,000.00 Guarantee 2025/8/20 2026/8/19 No Runda Medical Shanghai Runyi Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 5,000,000.00 Guarantee 2024/11/8 2025/11/7 Yes Runda Medical Shanghai Runyi Shanghai Pudong Development Bank Co., Ltd. Hongkou Branch 5,000,000.00 Guarantee 2025/12/16 2026/12/15 No Runda Medical Shanghai Runyi Shanghai Rural Commercial Bank Co., Ltd. Jiangwan Branch 10,000,000.00 Guarantee 2024/6/27 2025/6/25 Yes Runda Medical Shanghai Runyi Shanghai Rural Commercial Bank Co., Ltd. Jiangwan Branch 10,000,000.00 Guarantee 2025/6/17 2026/6/15 No Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Shanghai Pudong Development Bank Co., Ltd. Suzhou Branch 5,000,000.00 Guarantee 2024/11/29 2025/11/29 Yes Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Shanghai Pudong Development Bank Co., Ltd. Suzhou Branch 5,000,000.00 Guarantee 2025/12/3 2026/12/3 No Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 2,000,000.00 Guaranteed 2024/6/21 2025/6/19 Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 1,500,000.00 Guaranteed 2024/9/25 2025/9/24 Yes Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 1,500,000.00 Guaranteed 2025/3/27 2026/3/26 No Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 2,000,000.00 Guaranteed 2025/6/24 2026/6/19 Fulunda Medical, Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 1,500,000.00 Guarantee 2025/9/24 2026/9/24 Fulunda Medical, Zhang Xinming, Li Huabin Suzhou Runda China Merchants Bank Co., Ltd. Suzhou Ganjiang Road Branch 8,000,000.00 Guarantee 2024/5/24 2025/4/19 Yes Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda China Merchants Bank Co., Ltd. Suzhou Ganjiang Road Branch 2,000,000.00 Guarantee 2024/5/29 2025/4/19 Yes Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda China Construction Bank Co., Ltd. Suzhou Wuzhong Branch 5,000,000.00 Guarantee 2024/8/28 2025/8/27 Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda China Construction Bank Co., Ltd. Suzhou Wuzhong Branch 5,000,000.00 Guarantee 2025/6/25 2026/6/24 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda China Construction Bank Co., Ltd. Suzhou Wuzhong Branch 5,000,000.00 Guaranteed 2025/8/29 2026/8/27 Fu Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Suzhou Branch of Jiangsu Bank Co., Ltd. 3,000,000.00 Guaranteed 2024/3/25 2025/3/24 Yes Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Bank of Jiangsu Co., Ltd. Suzhou Branch 2,000,000.00 Guarantee 2024/12/27 2025/12/26 Yes Runda Medical, Zhang Xinming, Li Huabin Suzhou Runda Bank of Jiangsu Co., Ltd. Suzhou Branch 3,000,000.00 Guarantee 2025/3/21 2026/3/20 No Runda Medical Wuhan Runda Shangjian Industrial Bank Co., Ltd. Wuhan Branch 10,000,000.00 Guarantee 2024/9/6 2025/9/5 Yes Runda Medical Wuhan Runda Shangqian Industrial Bank Co., Ltd. Wuhan Branch 10,000,000.00 Guarantee 2025/9/9 2026/9/8 Forunda Medical, Chen Xinhua, Zeng Qing,

Yang Sanqi, Yang Zhimin, Hu Xiao, Gao Wuhan Runda Shangjian China Everbright Bank Co., Ltd. Wuhan Shucheng Road Branch 10,000,000.00 Guarantee 2024/1/12 2025/1/11 Shi Wen

Runda Medical, Chen Xinhua, Zeng Qing,

Yang Sanqi, Yang Zhimin, Hu Xiao, Gao Wuhan Runda Shangjian China Everbright Bank Co., Ltd. Wuhan Shucheng Road Branch 5,000,000.00 Guarantee 2025/9/18 2026/9/10 Fu Wen

Runda Medical, Chen Xinhua, Zeng Qing,

Yang Sanqi, Yang Zhimin, Hu Xiao, Gao Wuhan Runda Shangjian China Everbright Bank Co., Ltd. Wuhan Shucheng Road Branch 5,000,000.00 Guaranteed 2025/10/9 2026/9/10 Fu Wen

Runda Medical Wuhan Runda Shangjian China Merchants Bank Co., Ltd. Wuhan Branch 10,000,000.00 Guaranteed 2025/1/1 2026/1/1 Norunda Medical Wuhan Runda Shangqian Hua Xia Bank Co., Ltd. Wuhan Hanyang Branch 10,000,000.00 Guaranteed 2025/3/27 2026/3/26 Ferunda Medical Wuhan Runda Shangjian Hua Xia Bank Co., Ltd. Wuhan Hanyang Branch 10,000,000.00 Guarantee 2025/4/24 2026/4/23 Ferunda Medical Wuhan Runda Shangjian Hankou Bank Co., Ltd. Hongshan Branch 10,000,000.00 Guarantee 2024/4/12 2025/4/12 Shirunda Medical Wuhan Runda Shangqian Hankou Bank Co., Ltd. Hongshan Branch 10,000,000.00 Guarantee 2024/4/26 2025/4/26 Shirunda Medical Wuhan Runda Shangqian Hankou Bank Co., Ltd. Hongshan Branch 10,000,000.00 Guarantee 2025/12/24 2026/12/24 Norunda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 15,000,000.00 Guarantee 2024/4/22 2025/4/22 Runda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 8,000,000.00 Guarantee 2024/5/11 2025/5/11 Shirunda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 2,000,000.00 Guarantee 2024/10/23 2025/10/23 Shirunda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 5,000,000.00 Guarantee 2024/11/15 2025/5/14 Yes Runda Medical Wuhan Youke Liansheng Fubon China First Bank Co., Ltd. Wuhan Branch 6,000,000.00 Guarantee 2024/12/26 2025/6/24 Yes Runda Medical Wuhan Youke Liansheng Fubon China First Bank Co., Ltd. Wuhan Branch 3,365,000.00 Guarantee 2025/6/20 2025/12/17 is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 800,000.00 Guarantee 2025/6/24 2025/12/24 Runda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 3,700,000.00 Guarantee 2025/6/27 2025/12/26 Runda Medical Wuhan Youkeliansheng Fubon Huayi Bank Co., Ltd. Wuhan Branch 7,135,000.00 Guarantee 2025/7/17 2026/1/13 Frunda Medical Wuhan Youkeliansheng China Merchants Bank Co., Ltd. Wuhan Branch 15,000,000.00 Guarantee 2024/10/23 2025/10/23 Shirunda Medical Wuhan Youkeliansheng China Merchants Bank Co., Ltd. Wuhan Branch 10,000,000.00 Guarantee 2024/12/9 2025/12/9 Shirunda Medical Wuhan Youkeliansheng China Merchants Bank Co., Ltd. Wuhan Branch 10,000,000.00 Guarantee 2025/12/31 2026/12/31 Norunda Medical, Xiong Donghe Wuhan Youkeliansheng Bank of China Co., Ltd. Wuhan Guangbutun Branch 30,000,000.00 Guaranteed 2024/1/8 2025/1/8 Yesrunda Medical Wuhan Youukeliansheng Bank of China Co., Ltd. Wuhan Guangbutun Branch 30,000,000.00 Guaranteed 2024/8/9 2025/8/9 Runda Medical Wuhan Youkeliansheng Bank of China Co., Ltd. Wuhan Guangbutun Branch 18,000,000.00 Guaranteed 2025/1/10 2026/1/10 Furunda Medical Wuhan Youkeliansheng Bank of China Co., Ltd. Wuhan Guangbutun Branch 12,000,000.00 Guaranteed 2025/7/22 2026/7/22 Fulunda Medical Wuhan Youkeliansheng Bank of China Co., Ltd. Wuhan Guangbutun Branch 10,000,000.00 Guarantee 2025/12/26 2026/12/26 Fulunda Medical Wuhan Youkeliansheng China Everbright Bank Co., Ltd. Wuhan Shucheng Road Branch 20,000,000.00 Guarantee 2024/9/25 2025/9/24 Yes Runda Medical Wuhan Youke Liansheng China Everbright Bank Co., Ltd. Wuhan Shucheng Road Branch 20,000,000.00 Guarantee 2025/9/24 2026/9/23 No Runda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 2,106,475.00 Guaranteed 2024/3/18 2025/3/18 Runda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 2,000,000.00 Guaranteed 2024/8/9 2025/4/17 Runda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 768,851.22 Guaranteed 2024/9/19 2025/4/17 Runda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 1,200,000.00 Guaranteed 2024/10/12 2025/5/9 Shirunda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 1,036,607.99 Guaranteed 2024/10/25 2025/5/9 Shirunda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 1,421,006.17 Guaranteed 2024/12/3 2025/6/5 YesRunda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 2,000,000.00 Guaranteed 2024/12/11 2025/7/22 YesRunda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 936,114.00 Guaranteed 2024/12/27 2025/7/22 Yes Runda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 1,271,789.96 Guarantee 2025/7/4 2026/7/4 No Runda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 2,504,144.46 Guaranteed 2025/10/30 2026/8/16 Furunda Medical Yunnan Runda Kangtai China Merchants Bank Co., Ltd. Kunming Chenggong New District Branch 1,135,859.55 Guaranteed 2025/12/12 2026/8/16 Furunda Medical Yunnan Runda Kangtai Kunming Dongjin Branch of Hua Xia Bank Co., Ltd. 1,140,000.00 Guarantee 2024/8/14 2025/8/14 It is Runda Medical Yunnan Runda Kangtai Hua Xia Bank Co., Ltd. Kunming Dongjin Branch 975,000.00 Guarantee 2024/10/18 2025/4/8 It is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Yunnan Runda Kangtai Hua Xia Bank Co., Ltd. Kunming Dongjin Branch 2,850,000.00 Guarantee 2024/12/19 2025/4/8 Runda Medical Yunnan Runda Kangtai Hua Xia Bank Co., Ltd. Kunming Dongjin Branch 2,000,000.00 Guarantee 2024/12/31 2025/4/8 Shirunda Medical Yunnan Runda Kangtai Huaxia Bank Co., Ltd. Kunming Dongjin Branch 2,430,000.00 Guaranteed 2025/3/31 2025/10/24 Shirunda Medical Yunnan Runda Kangtai Huaxia Bank Co., Ltd. Kunming Dongjin Branch 1,550,000.00 Guaranteed 2025/4/15 2025/8/15 Yes Runda Medical Yunnan Runda Kangtai Hua Xia Bank Co., Ltd. Kunming Dongjin Branch 3,100,000.00 Guarantee 2025/5/13 2026/5/12 No Runda Medical Yunnan Runda Kangtai Hua Xia Bank Co., Ltd. Kunming Dongjin Branch 1,470,000.00 Guarantee 2025/6/6 2026/6/5 Fulunda Medical Yunnan Runda Kangtai Hua Xia Bank Co., Ltd. Kunming Dongjin Branch 980,000.00 Guaranteed 2025/6/23 2026/6/22 Fulunda Medical Yunnan Runda Kangtai Bank of Communications Co., Ltd. Kunming Anning Kungang Branch 3,904,808.27 Guaranteed 2024/9/14 2025/9/13 Yes Runda Medical Yunnan Runda Kangtai Bank of Communications Co., Ltd. Kunming Anning Kunming Steel Branch 2,184,479.44 Guaranteed 2024/9/29 2025/9/28 Yes Runda Medical Yunnan Runda Kangtai Bank of Communications Co., Ltd. Kunming Anning Kunming Steel Branch 1,884,513.84 Guaranteed 2024/10/14 2025/10/13 Yes Runda Medical Yunnan Runda Kangtai Bank of Communications Co., Ltd. Kunming Anning Kungang Branch 2,323,368.08 Guaranteed 2025/8/8 2026/2/28 No Runda Medical Yunnan Runda Kangtai Bank of Communications Co., Ltd. Kunming Anning Kungang Branch 2,745,046.20 Guarantee 2025/8/21 2026/2/28 No Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 2,000,000.00 Guarantee 2024/6/27 2025/1/3 Yes Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 4,000,000.00 Guarantee 2024/6/27 2025/2/7 Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 4,000,000.00 Guarantee 2024/6/27 2025/6/27 Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 1,953,357.00 Guarantee 2025/2/7 2025/12/20 Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 2,106,475.00 Guarantee 2025/3/17 2025/12/20 Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 1,940,168.00 Guarantee 2025/3/27 2025/12/20 Yes Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 2,275,478.00 Guarantee 2025/6/30 2026/6/30 No Runda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 1,672,558.00 Guaranteed 2025/7/28 2026/7/28 Fulunda Medical Yunnan Runda Kangtai Industrial Bank Co., Ltd. Kunming Branch 3,130,307.00 Guaranteed 2025/11/28 2026/11/28 Fulunda Medical Shanghai Runlin Bank of Beijing Co., Ltd. Shanghai Branch 10,000,000.00 Guarantee 2024/6/16 2025/6/14 Yes Runda Medical Shanghai Runlin Bank of Beijing Co., Ltd. Shanghai Branch 10,000,000.00 Guarantee 2025/6/16 2026/6/15 No Runda Medical Runda Supply Chain Hangzhou Industrial Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guarantee 2024/12/11 2025/12/10 Yes Runda Medical Runda Supply Chain Hangzhou Industrial Bank Co., Ltd. Hangzhou Branch 10,000,000.00 Guarantee 2025/10/23 2026/10/22 No Runda Medical Runda Supply Chain Hangzhou Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 10,000,000.00 Guarantee 2024/12/18 2025/12/15 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Runda Supply Chain Hangzhou Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 10,000,000.00 Guarantee 2025/12/15 2026/12/14 No Runda Medical Runda Supply Chain Hangzhou Bank of Beijing Co., Ltd. Hangzhou Linping Branch 10,000,000.00 Guarantee 2024/12/25 2025/12/24 Yes Runda Medical Runda Supply Chain Hangzhou Bank of Beijing Co., Ltd. Hangzhou Linping Branch 10,000,000.00 Guaranteed 2025/12/10 2026/12/9 No Runda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 200,000.00 Guaranteed 2025/5/26 2025/9/21 Yes Runda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 200,000.00 Guarantee 2025/5/26 2026/3/21 No Runda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 200,000.00 Guarantee 2025/5/26 2026/9/21 Norunda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 200,000.00 Guarantee 2025/5/26 2027/3/21 Norunda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 200,000.00 Guarantee 2025/5/26 2027/9/21 Fulunda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 200,000.00 Guaranteed 2025/5/26 2028/3/21 Fulunda Medical Runda Supply Chain Hangzhou Huaxia Bank Co., Ltd. Hangzhou Branch 17,800,000.00 Guaranteed 2025/5/26 2028/5/19 Norunda Medical Huizhong Rongjia Shanghai Rural Commercial Bank Co., Ltd. Baoshan Branch 500,000.00 Guarantee 2024/12/25 2025/6/22 Yes Runda Medical Huizhong Rongjia Shanghai Rural Commercial Bank Co., Ltd. Baoshan Branch 500,000.00 Guarantee 2024/12/25 2025/12/22 Runda Medical Huizhong Rongjia Shanghai Rural Commercial Bank Co., Ltd. Baoshan Branch 8,496,887.00 Guaranteed 2024/12/25 2029/12/22 Frunda Medical Huizhong Rongjia Xiamen International Bank Co., Ltd. Shanghai Branch 3,400,000.00 Guaranteed 2025/10/21 2026/10/21 Fulunda Medical Huizhong Rongjia Xiamen International Bank Co., Ltd. Shanghai Branch 1,600,000.00 Guarantee 2025/10/27 2026/10/27 Fulunda Medical, Zhang Min, Huang Liujin Chongqing Runda High-tech Branch of Bank of Chongqing Co., Ltd. 3,000,000.00 Guarantee 2025/8/28 2026/8/27 No Runda Medical, Tang Yong Hefei Sanli Huishang Bank Co., Ltd. Hefei Chenghuang Temple Branch 3,000,000.00 Guarantee 2025/12/15 2026/12/15 No Hefei State Control Construction Financing Guarantee Co., Ltd.

Company, Hou Zhong, Gong Yuying, Tang Yong, Hefei Sanli Hefei Science and Technology Rural Commercial Bank Co., Ltd. Binhu Branch 3,990,000.00 Guarantee 2024/6/13 2025/6/7 is Zhang Li

Hefei State Control Construction Financing Guarantee Co., Ltd.

Company, Hou Zhong, Gong Yuying, Tang Yong, Hefei Sanli Hefei Science and Technology Rural Commercial Bank Co., Ltd. Binhu Branch 3,000,000.00 Guarantee 2025/6/30 2026/6/27 No Zhang Li

Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 4,838,000.00 Guarantee, pledge 2024/9/9 2025/3/5 Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 990,000.00 Guarantee, pledge 2024/9/25 2025/1/28 It’s Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 2,460,000.00 Guarantee, pledge 2024/9/25 2025/3/29 It’s Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 372,000.00 Guarantee and pledge 2024/10/21 2025/2/22 is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,327,000.00 Guarantee, pledge 2024/10/21 2025/4/23 Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 601,000.00 Guarantee, pledge 2024/11/7 2025/3/11 It is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,165,000.00 Guarantee, pledge 2024/11/7 2025/5/10 It is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,925,000.00 Guarantee and pledge 2024/12/9 2025/4/11 Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,794,000.00 Guarantee and pledge 2024/12/9 2025/6/10 Are Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 871,000.00 Guarantee, pledge 2025/3/4 2025/6/3 Are Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 2,778,000.00 Guarantee, pledge 2025/3/4 2025/9/1 It is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,040,000.00 Guarantee, pledge 2025/4/2 2025/9/29 It is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,450,000.00 Guarantee and pledge 2025/5/23 2025/11/22 It is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 1,010,000.00 Guarantee and pledge 2025/6/9 2025/12/6 Yes Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd. 3,940,000.00 Guarantee, pledge 2025/10/14 2026/4/12 No Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 3,400,000.00 Guarantee, pledge 2024/8/16 2025/2/15 It’s Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 2,100,000.00 Guarantee, pledge 2024/9/2 2025/2/28 It’s Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 4,600,000.00 Guarantee, pledge 2024/9/9 2025/3/6 Yes Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,900,000.00 Guarantee, pledge 2024/11/15 2025/5/14 Yes Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 2,000,000.00 Guarantee, pledge 2025/1/21 2025/6/30 Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,400,000.00 Guarantee, pledge 2025/1/23 2025/6/30 is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 2,100,000.00 Guarantee, pledge 2025/3/3 2025/6/30 is Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 4,600,000.00 Guarantee, pledge 2025/3/14 2025/9/13 Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,900,000.00 Guarantee, pledge 2025/5/16 2025/11/15 Hou Zhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 6,500,000.00 Guarantee, pledge 2025/8/21 2026/2/20 Fu Houzhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,600,000.00 Guarantee, pledge 2025/9/1 2026/2/28 Fu Houzhong, Gong Yuying, Tang Yong Hefei Sanli Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,900,000.00 Guarantee, pledge 2025/9/19 2026/3/18 Fu Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 803,824.21 Guarantee, pledge 2024/3/12 2025/1/1 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,166,914.00 Guarantee, pledge 2024/3/12 2025/1/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,930,555.26 Guarantee and pledge 2024/3/12 2025/2/1 is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,972,046.15 Guarantee, pledge 2024/3/12 2025/2/1 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,171,968.62 Guarantee, pledge 2024/3/12 2025/2/1 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 568,786.13 Guarantee, pledge 2024/5/7 2025/3/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 941,749.70 Guarantee and pledge 2024/5/7 2025/3/7 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,041,814.00 Guarantee and pledge 2024/5/7 2025/4/1 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,029,820.00 Guarantee, pledge 2024/7/12 2025/5/1 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,960,062.28 Guarantee, pledge 2024/7/12 2025/5/1 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,282,036.67 Guarantee, pledge 2024/12/4 2025/9/5 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,306,481.02 Guarantee, pledge 2024/12/4 2025/9/5 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,337,515.00 Guarantee, pledge 2024/12/4 2025/9/5 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 7,397.40 Guarantee, pledge 2025/1/8 2025/6/27 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,947,522.68 Guarantee, pledge 2025/1/8 2025/10/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 53,537.70 Guarantee, pledge 2025/1/8 2025/10/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 8,724.80 Guarantee, pledge 2025/1/8 2025/4/16 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 374,746.37 Guarantee, pledge 2025/1/8 2025/10/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,094,868.05 Guarantee, pledge 2025/1/8 2025/10/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,597,570.52 Guarantee, pledge 2025/1/8 2025/10/6 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 4,367.00 Guarantee, pledge 2025/3/4 2025/4/16 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 156,782.25 Guarantee, pledge 2025/3/4 2025/12/5 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 36,322.46 Guarantee, pledge 2025/3/4 2025/12/8 It’s Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 452,352.81 Guarantee, pledge 2025/3/4 2026/2/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,721,168.10 Guarantee, pledge 2025/3/6 2025/12/3 Yes Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,132,496.00 Guarantee, pledge 2025/4/9 2026/3/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 633,374.00 Guarantee, pledge 2025/4/9 2025/12/26 Yes Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 280,568.00 Guarantee, pledge 2025/5/13 2026/4/6 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 56,848.62 Guarantee, pledge 2025/5/13 2026/3/1 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 419,999.28 Guarantee, pledge 2025/5/13 2026/4/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 298,460.30 Guarantee, pledge 2025/5/13 2026/3/2 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 157,578.40 Guarantee, pledge 2025/6/6 2025/7/14 Yes Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 809,255.04 Guarantee, pledge 2025/6/6 2026/3/9 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,854,944.00 Guarantee, pledge 2025/6/6 2026/4/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 134,204.00 Guarantee, pledge 2025/6/6 2025/7/22 Yes Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 137,376.00 Guarantee, pledge 2025/6/6 2026/6/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,325,800.00 Guarantee, pledge 2025/6/13 2026/6/1 Fu Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,027,158.40 Guarantee, pledge 2025/6/13 2026/6/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,100,000.00 Guarantee, pledge 2025/6/13 2026/6/4 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,800,000.00 Guarantee, pledge 2025/6/13 2026/6/4 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 2,321,684.99 Guarantee, pledge 2025/8/28 2026/7/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,739,661.54 Guarantee, pledge 2025/8/28 2026/6/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,488,383.24 Guarantee, pledge 2025/8/28 2026/6/7 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 7,003,268.72 Guarantee, pledge 2025/9/26 2026/9/1 Fu Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 197,630.40 Guarantee, pledge 2025/12/29 2026/10/5 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 222,501.05 Guarantee, pledge 2025/12/29 2026/10/5 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 631,449.76 Guarantee, pledge 2025/12/29 2026/12/1 No Qian Xueqing Shanghai Runda Rongjia Zhejiang Mintai Commercial Bank Co., Ltd. Shanghai Songjiang Branch 1,187,282.84 Guarantee, pledge 2025/12/29 2026/12/10 No Qian Xueqing Shanghai Runda Rongjia Ping An International Commercial Factoring (Tianjin) Co., Ltd. 5,599,999.99 Guarantee, pledge 2024/9/13 2025/3/13 It’s Qian Xueqing Shanghai Runda Rongjia Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,866,666.67 Guarantee, pledge 2025/3/18 2025/4/14 It’s Qian Xueqing Shanghai Runda Rongjia Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,866,666.67 Guarantee, pledge 2025/3/18 2025/5/14 It’s Qian Xueqing Shanghai Runda Rongjia Ping An International Commercial Factoring (Tianjin) Co., Ltd. 1,866,666.67 Guarantee, pledge 2025/3/18 2025/6/13 It’s Qian Xueqing Shanghai Runda Rongjia Ping An International Commercial Factoring (Tianjin) Co., Ltd. 5,599,999.99 Guarantee, pledge 2025/3/18 2025/10/14 Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 2,000,000.00 Guarantee 2024/6/21 2025/6/19 Is Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 1,500,000.00 Guarantee 2024/9/25 2025/9/24 Is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 1,500,000.00 Guaranteed 2025/3/27 2026/3/26 No Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 2,000,000.00 Guaranteed 2025/6/24 2026/6/19 No Zhang Xinming, Li Huabin Suzhou Runda Suzhou Bank Co., Ltd. Industrial Park Branch 1,500,000.00 Guarantee 2025/9/24 2026/9/24 No Ma Junsheng, Wang Ping Yunnan Runda Kangtai Ping An Dianchuang International Financial Leasing Co., Ltd. 800,000.00 Guarantee, pledge 2024/1/8 2025/1/8 Are Ma Junsheng and Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 420,000.00 Guarantee, pledge 2024/1/15 2025/1/15 Are Ma Junsheng and Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 400,000.00 Guarantee and pledge 2024/6/17 2025/1/17 Ma Junsheng and Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 400,000.00 Guarantee and pledge 2024/6/17 2025/2/17 Ma Junsheng and Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 400,000.00 Guarantee and pledge 2024/6/17 2025/3/17 They are Ma Junsheng and Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 400,000.00 Guarantee and pledge 2024/6/17 2025/4/17 They are Ma Junsheng and Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 400,000.00 Guarantee, pledge 2024/6/17 2025/5/17 Ma Junsheng, Wang Ping Yunnan Runda Kangtai Ping An International Commercial Factoring (Tianjin) Co., Ltd. 400,000.00 Guarantee, pledge 2024/6/17 2025/6/17 It is Shanghai Jinkai Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Ningbo Commercial Bank Co., Ltd. Shanghai Branch 5,000,000.00 Guarantee 2024/12/23 2025/6/23 Shi Si, Hu Chunying

Shanghai Xuhui Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of Communications Co., Ltd. Shanghai Tianyaoqiao Road Branch 3,000,000.00 Guarantee 2024/9/29 2025/9/25 Shi Si, Hu Chunying

Shanghai Xuhui Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of Communications Co., Ltd. Shanghai Tianyaoqiao Road Branch 2,000,000.00 Guarantee 2025/1/13 2026/1/13 Fu Si, Hu Chunying

Hu Chunying Shanghai Zhongke Laboratory China Merchants Bank Co., Ltd. Shanghai Oriental Branch 2,000,000.00 Guarantee 2024/3/29 2025/1/18 It’s Hu Chunying Shanghai Zhongke Laboratory Bank of Jiangsu Co., Ltd. Shanghai Yangpu Branch 3,000,000.00 Guarantee 2024/3/27 2025/3/15 It’s Hu Chunying Shanghai Zhongke Laboratory Xiamen International Bank Co., Ltd. Shanghai Branch 8,555,625.00 Guarantee 2024/2/21 2025/2/20 It is Shanghai Entrepreneurship Relay Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of Ningbo Co., Ltd. Shanghai Branch 2,000,000.00 Guarantee 2024/1/26 2025/1/25 Yes Company, Hu Chunying

Policy integration of small, medium and micro enterprises in Shanghai

Guarantee Fund Management Center, Hu Chun Shanghai Zhongke Laboratory Bank of Nanjing Co., Ltd. Shanghai Branch 2,000,000.00 Guarantee 2024/3/28 2025/3/27 Shiying

Policy integration of small, medium and micro enterprises in Shanghai

Guarantee Fund Management Center, Hu Chun Shanghai Zhongke Laboratory Bank of Nanjing Co., Ltd. Shanghai Branch 3,000,000.00 Guarantee 2025/6/27 2026/6/26 Fu Ying

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Shanghai Yangpu Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Industrial Bank Co., Ltd. Shanghai Huashan Branch 3,200,000.00 Guarantee 2024/2/28 2025/2/27 Shi Si, Hu Chunying

Hu Chunying Shanghai Zhongke Laboratory Industrial and Commercial Bank of China Jiangwan Branch 3,000,000.00 Guarantee 2025/7/1 2026/6/30 No Hu Chunying Shanghai Zhongke Laboratory China Construction Bank Shanghai Wujiaochang Branch 8,000,000.00 Guarantee 2025/9/15 2028/9/15 No Shanghai Pudong Technology Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of China Co., Ltd. Shanghai Zhabei Branch 5,000,000.00 Guarantee 2024/6/28 2025/6/27 Is the company

Shanghai Pudong Technology Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of China Co., Ltd. Shanghai Zhabei Branch 2,000,000.00 Guarantee 2024/7/4 2025/6/27 Is the company

Shanghai Pudong Technology Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of China Co., Ltd. Shanghai Zhabei Branch 3,000,000.00 Guarantee 2024/7/29 2025/6/27 Is the company

Shanghai Pudong Technology Financing Guarantee Co., Ltd.

Shanghai Zhongke Laboratory Bank of China Co., Ltd. Shanghai Hanzhong Road Branch 8,000,000.00 Guarantee 2025/6/24 2026/6/23 No Company, Hu Chunying

Policy integration of small, medium and micro enterprises in Shanghai

Capital Guarantee Fund Management Center, Hu Chun Shanghai Zhongke Precision Bank of China Shanghai Hanzhong Road Branch 1,000,000.00 Guarantee 2025/7/28 2026/7/24 Fu Ying

Policy integration of small, medium and micro enterprises in Shanghai

Capital Guarantee Fund Management Center, Hu Chun Shanghai Zhongke Precision Bank of China Shanghai Hanzhong Road Branch 1,000,000.00 Guarantee 2025/11/25 2026/11/23 Fu Ying

Policy integration of small, medium and micro enterprises in Shanghai

Shanghai Runli Bank of Shanghai Co., Ltd. Fumin Branch 3,000,000.00 Guarantee 2024/5/21 2025/5/20 Capital Guarantee Fund Management Center, Shi Ming

Policy integration of small, medium and micro enterprises in Shanghai

Shanghai Runli Bank of Shanghai Co., Ltd. Fumin Branch 3,000,000.00 Guarantee 2025/4/25 2026/4/24 Non-capital guarantee fund management center, Shi Ming

Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 87,589.79 Guarantee, pledge 2024/7/22 2025/1/24 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 111,189.38 Guarantee, pledge 2024/7/22 2025/4/30 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 40,118.93 Guarantee, pledge 2024/7/22 2025/2/28 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 35,900.35 Guarantee, pledge 2024/7/22 2025/2/28 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 135,571.15 Guarantee, pledge 2024/7/22 2025/2/28 It’s Yu Hongfei Zefen, Anhui China CITIC Bank Co., Ltd. Hefei Branch 164,520.00 Guarantee, pledge 2024/7/22 2025/7/22 It’s Yu Hongfei Zefen, Anhui China CITIC Bank Co., Ltd. Hefei Branch 173,821.65 Guarantee, pledge 2024/7/22 2025/3/28 It is Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 172,420.29 Guarantee, pledge 2024/7/22 2025/2/28 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 298,080.00 Guarantee, pledge 2024/7/22 2025/7/22 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 334,048.84 Guarantee, pledge 2024/7/22 2025/3/26 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 357,120.00 Guarantee, pledge 2024/7/22 2025/7/22 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 412,920.00 Guarantee and pledge 2024/7/22 2025/7/22 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 421,224.45 Guarantee and pledge 2024/7/22 2025/4/25 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 200,520.00 Guarantee, pledge 2024/7/22 2025/7/22 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 381,240.00 Guarantee, pledge 2024/7/22 2025/7/22 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 425,911.94 Guarantee, pledge 2024/10/22 2025/5/27 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 135,847.90 Guarantee, pledge 2024/10/24 2025/5/28 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 484,291.30 Guarantee, pledge 2024/10/22 2025/6/26 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 122,197.46 Guarantee, pledge 2024/10/22 2025/6/30 It’s Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 100,280.96 Guarantee, pledge 2024/10/22 2025/9/25 It’s Yu Hongfei, Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 439,465.06 Guarantee, pledge 2024/10/23 2025/9/25 It’s Yu Hongfei, Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 448,459.28 Guarantee, pledge 2024/11/22 2025/10/25 Yes Yu Hongfei Anhui Zefen China CITIC Bank Co., Ltd. Hefei Branch 52,100.06 Guarantee, pledge 2024/11/22 2025/10/25 Yes Runda Medical, Wang Chuangen Anhui Zefen Huishang Bank Co., Ltd. Hefei Chenghuangmiao Branch 24,200,000.00 Guaranteed 2025/6/20 2026/6/20 Ferunda Medical, Wang Chuangen Anhui Zefen Huishang Bank Co., Ltd. Hefei Chenghuangmiao Branch 5,800,000.00 Guaranteed 2025/6/25 2026/6/25 Fulunda Medical, Wang Chuangen Anhui Zefen Huishang Bank Co., Ltd. Hefei Chenghuangmiao Branch 15,000,000.00 Guaranteed 2025/9/29 2026/9/29 Fulunda Medical, Wang Chuangen Anhui Zefen China Everbright Bank Co., Ltd. Hefei Branch 10,000,000.00 Guaranteed 2025/10/9 2026/10/8 Fulunda Medical, Wang Chuangen Anhui Zefen Hua Xia Bank Hefei Luyang Branch 10,000,000.00 Guarantee 2025/11/18 2026/11/18 Fulunda Medical, Wang Chuangen Anhui Zefen Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 10,000,000.00 Guarantee 2025/11/26 2027/5/26 Fu Runda Medical, Wang Chuangen Anhui Zefen Shanghai Pudong Development Bank Co., Ltd. Hefei Branch 4,500,000.00 Guarantee, pledge 2025/12/15 2026/6/15 Fu Huang Liujin, Zhang Min Chongqing Runda Bank of China Co., Ltd. Chongqing Banan Branch 920,000.00 Guarantee, mortgage 2024/11/12 2025/10/15 It is Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/1/27 It’s Huang Liujin and Zhang Min

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/2/27 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/3/27 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/4/27 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/5/27 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/6/27 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/7/21 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/8/21 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/9/21 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/10/21 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/11/21 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 10,220.99 Guarantee, mortgage 2024/11/28 2025/12/21 It’s Huang Liujin and Zhang Min

Chongqing Tianan Cyber City Co., Ltd.,

Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 1,717,127.13 Guarantee, mortgage 2024/11/28 2039/11/27 No Huang Liujin, Zhang Min

Huang Liujin Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 50,000.00 Guarantee 2024/6/26 2025/3/28 It’s Huang Liujin Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 450,000.00 Guarantee 2024/6/26 2025/4/2 It’s Huang Liujin Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 700,000.00 Guarantee 2024/6/26 2025/5/30 Yes Huang Liujin Chongqing Runda Industrial Bank Co., Ltd. Chongqing Dadukou Branch 800,000.00 Guarantee 2024/6/26 2025/6/25 Yes Runda Medical Hangzhou Mingheyuan Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 10,000,000.00 Guaranteed 2025/1/22 2026/1/19 No Runda Medical Hangzhou Mingheyuan Bank of Jiangsu Co., Ltd. Hangzhou Branch 2,000,000.00 Guaranteed 2025/6/20 2026/6/19 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Whether the guarantee is the guarantor, the guaranteed party, the borrowing bank, the guarantee amount, related guarantee disclosure, the guarantee start date, the guarantee expiry date, has been fulfilled

Finished

Runda Medical Hangzhou Mingheyuan Bank of Jiangsu Co., Ltd. Hangzhou Branch 2,000,000.00 Guarantee 2025/6/23 2026/6/22 Fulunda Medical Hangzhou Mingheyuan Bank of Jiangsu Co., Ltd. Hangzhou Branch 1,000,000.00 Guarantee 2025/6/24 2026/6/23 Fulunda Medical Hangzhou Mingheyuan Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2025/6/23 2025/11/21 Yes Runda Medical Hangzhou Mingheyuan Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2025/6/23 2026/5/21 No Runda Medical Hangzhou Mingheyuan Hua Xia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2025/6/23 2026/11/21 Fulunda Medical Hangzhou Mingheyuan Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2025/6/23 2027/5/21 Fulunda Medical Hangzhou Mingheyuan Hua Xia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2025/6/23 2027/11/21 Fulunda Medical Hangzhou Mingheyuan Huaxia Bank Co., Ltd. Hangzhou Branch 100,000.00 Guarantee 2025/6/23 2028/5/21 Fulunda Medical Hangzhou Mingheyuan Hua Xia Bank Co., Ltd. Hangzhou Branch 9,400,000.00 Guaranteed 2025/6/23 2028/6/19 Ferunda Medical Zhongdingdako Bank of China Co., Ltd. Hangzhou Kaiyuan Branch 10,000,000.00 Guaranteed 2025/1/22 2026/1/19 Ferunda Medical Zhongdingdako Bank of Jiangsu Co., Ltd. Hangzhou Branch 2,000,000.00 Guarantee 2025/6/20 2026/6/19 Frunda Medical Zhongdingdako Bank of Jiangsu Co., Ltd. Hangzhou Branch 2,000,000.00 Guarantee 2025/6/23 2026/6/22 Frunda Medical Zhongdingdako Jiangsu Bank Co., Ltd. Hangzhou Branch 1,000,000.00 Guaranteed 2025/6/24 2026/6/23 Norunda Medical Zhongdingdaco Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/5/19 2025/9/21 Yesrunda Medical Zhongdingdaco Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/5/19 2026/3/21 Fulunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/5/19 2026/9/21 Ferunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/5/19 2027/3/21 Forunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/5/19 2027/9/21 Forunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/5/19 2028/3/21 Fulunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 4,700,000.00 Guarantee 2025/5/19 2028/5/16 Norunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guarantee 2025/6/12 2025/9/21 Yesrunda Medical Zhongdingdako Hua Xia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/6/12 2026/3/21 Verunda Medical Zhongding Dako Hua Xia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/6/12 2026/9/21 Verunda Medical Zhongding Daco Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/6/12 2027/3/21 Furunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/6/12 2027/9/21 Furunda Medical Zhongdingdako Huaxia Bank Co., Ltd. Hangzhou Branch 50,000.00 Guaranteed 2025/6/12 2028/3/21 No Runda Medical Zhongding Dako Hua Xia Bank Co., Ltd. Hangzhou Branch 4,700,000.00 Guarantee 2025/6/12 2028/6/12 No Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(5) Financial lease guarantee

1. The company signed a sale and leaseback agreement with Haitong Hengxin International Financial Leasing Co., Ltd. on January 10, 2023, and sold 227 instruments and equipment of the company to Haitong Hengxin International Financial Leasing Co., Ltd. for 90 million yuan, and then leased back the fixed assets through leasing. The lease deposit is 5.70 million yuan and the lease term is 24 months. As of December 31, 2025, all principal has been returned.

2. The company signed a sale and leaseback agreement with Haitong Hengxin International Financial Leasing Co., Ltd. on January 10, 2023, and sold 60 instruments and equipment of the company to Haitong Hengxin International Financial Leasing Co., Ltd. for 60 million yuan, and then leased back the fixed assets through leasing. The lease deposit is 1.80 million yuan and the lease term is 24 months. As of December 31, 2025, all principal has been returned.

3. The company signed a sale and leaseback agreement with Haitong Hengxin International Financial Leasing Co., Ltd. on December 10, 2023, and sold 183 instruments and equipment of the company to Haitong Hengxin International Financial Leasing Co., Ltd. for 65 million yuan, and then leased back the fixed assets through leasing. The lease deposit is 3.25 million yuan and the lease term is 36 months. As of December 31, 2025, the principal that has not been returned is 22.6326 million yuan.

4. The company signed a sale and leaseback agreement with Haitong Hengxin International Financial Leasing Co., Ltd. on December 10, 2024, and sold 82 instruments and equipment of the company to Haitong Hengxin International Financial Leasing Co., Ltd. for 49 million yuan, and then leased back the fixed assets through leasing. The lease deposit is 2.45 million yuan and the lease term is 36 months. As of December 31, 2025, the principal that has not been returned is 33.2912 million yuan.

5. The company signed a sale and leaseback agreement with Haitong Hengxin International Financial Leasing Co., Ltd. on July 4, 2025, and sold 208 instruments and equipment of the company to Haitong Hengxin International Financial Leasing Co., Ltd. for 118.00 million yuan, and then leased back the fixed assets through leasing. The lease deposit is 5.90 million yuan and the lease term is 36 months. As of December 31, 2025, the principal that has not been returned is 109.3055 million yuan.

6. The subsidiary Hefei Sanli signed a sale and leaseback contract with Haier Financial Leasing Co., Ltd. on June 19, 2024, and sold 7 instruments and equipment of Hefei Sanli to Haier Financial Leasing Co., Ltd. for 9.94 million yuan, and then leased them back with a lease deposit of 940,000 yuan and a lease period of 12 months. Tang Yong, Hou Zhong and Gong Yuying provided guarantees for the above matters. As of December 31, 2025, all principal has been returned.

7. The subsidiary Hefei Sanli signed a sale and leaseback contract with Haier Financial Leasing Co., Ltd. on June 19, 2024, and sold 8 instruments and equipment from Hefei Sanli to Haier Financial Leasing Co., Ltd. for 8.81 million yuan, and then leased them back with a lease period of 12 months. Tang Yong, Hou Zhong and Gong Yuying provided guarantees for the above matters. As of December 31, 2025, all principal has been returned.

8. The subsidiary Hefei Sanli signed a financial lease contract with Anhui Xingtai Financial Leasing Co., Ltd. on January 16, 2025, and sold 2 instruments and equipment of Hefei Sanli to Anhui Xingtai Financial Leasing Co., Ltd. for 5 million yuan, and then leased them back with a lease deposit of 250,000 yuan and a lease period of 12 months. Tang Yong, Hou Zhong and Gong Yuying provided guarantees for the above matters. As of December 31, 2025, the principal that has not been returned is 429,000 yuan.

9. The subsidiary Anhui Zefen signed a financial lease contract with Anhui Xingtai Financial Leasing Co., Ltd. on January 16, 2025, and sold two instruments and equipment from Anhui Zefen to Anhui Xingtai Financial Leasing Co., Ltd. for 5 million yuan, and then leased them back with a lease deposit of 250,000 yuan and a lease period of 12 months. Wang Chuangen provided guarantee for the above matters. As of December 31, 2025, the principal that has not been returned is 429,000 yuan.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

10. The subsidiary Hangzhou Runda signed a financial lease contract with Beiyin Financial Leasing Co., Ltd. on August 28, 2024, and sold 28 instruments and equipment of Hangzhou Runda to Beiyin Financial Leasing Co., Ltd. for 42 million yuan, and then leased them back with a lease term of 24 months. The above matters are guaranteed by our company. As of December 31, 2025, the principal that has not been returned is 18.7873 million yuan.

11. The subsidiary Hangzhou Runda signed a financial lease contract with Beiyin Financial Leasing Co., Ltd. on November 25, 2024, and sold 76 instruments and equipment of Hangzhou Runda to Beiyin Financial Leasing Co., Ltd. for 70 million yuan, and then leased them back with a lease term of 24 months. The above matters are guaranteed by our company. As of December 31, 2025, the principal that has not been returned is 35.2262 million yuan.

12. The subsidiary Hangzhou Runda signed a financial lease contract with Beiyin Financial Leasing Co., Ltd. on December 19, 2024, and sold 47 instruments and equipment of Hangzhou Runda to Beiyin Financial Leasing Co., Ltd. for 38 million yuan, and then leased them back with a lease term of 24 months. The above matters are guaranteed by our company. As of December 31, 2025, the principal that has not been repaid is 19.0444 million yuan.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(6) Fund lending by related parties

January 1, 2025 December 31, 2025 Interest payable this year

Fund lender Fund lender New loan principal this year Amount of interest incurred this year Repayment of loan principal this year Starting date Maturity date

Day Day Balance

Yunnan Thalys Biotech Shanghai Runda Medical Technology Stock

9,771,333.35 486,666.64 10,257,999.99 2,257,999.99 2023/12/23 2026/12/23 Technology Co., Ltd.

Wuhan Haijili Biotech Shanghai Runda Medical Technology Stock

1,872,534.24 75,000.00 1,947,534.24 447,534.24 2022/5/26 2026/12/31 Technology Co., Ltd. Co., Ltd.

Huang Liujin Chongqing Runda 2,144,845.76 1,800,000.00 -44,845.76 3,900,000.00 2025/7/29 2025/12/19 Yunnan Sailis Biotechnology Hangzhou Runda Medical Management Co., Ltd.

12,097,500.06 608,333.36 12,705,833.42 2,705,833.42 2021/12/23 2026/12/31 Technology Co., Ltd.

Shanghai Ruimei Computer Technology Co., Ltd.

Tang Jinhu 8,660,036.11 -660,036.11 8,000,000.00 2021/11/15 2025/12/31

Ltd.

Jiuyisanluling Medical Department Shanghai Runlin Medical Technology Co., Ltd.

5,090,000.00 5,090,000.00 2025/4/24 2025/7/15 Tech Nanjing Co., Ltd.

Shanghai Runda Rongjia Biotechnology Co., Ltd.

Qian Xueqing 500,000.00 500,000.00 2025/7/23 2025/8/4 Technology Co., Ltd.

total

34,546,249.52 7,390,000.00 465,118.13 17,490,000.00 24,911,367.65 5,411,367.65

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(7) Asset transfer and debt restructuring of related parties

Related parties Contents of related transactions Amount incurred in 2025 Amount incurred in 2024 Henan Runbaida Medical Equipment Co., Ltd. Disposal of fixed assets 80,437.17

Sichuan Runda Ruitai Biotechnology Co., Ltd. Disposal of fixed assets 22,389.38 Jiuyisanluling Medical Technology Nanjing Co., Ltd. Disposal of fixed assets 918,853.10 442,477.87 Shanghai Huihao Yisheng Information Technology Co., Ltd. Purchase of intangible assets

221,238.94

total

1,220,529.21 464,867.25

(8) Remuneration of key management personnel

(Unit: 10,000 yuan)

Item Amount incurred in 2025 Amount incurred in 2024

Remuneration of key management personnel 642.32 907.25

6. Accounts receivable and payable from related parties

(1) Items receivable

December 31, 2025 December 31, 2024 Project name

Book balance Bad debt provision Book balance Bad debt provision Accounts receivable:

Fujian Furui Medical Technology Co., Ltd. 13,055,853.69 12,080,050.23 7,099,905.42 4,940,066.74 Guizhou Runda Kangyi Medical Technology Co., Ltd. 19,085.68 285.04 34,701.88 438.27 Guorun Medical Supply Chain Service (Shanghai) Co., Ltd. 93,710,135.26 6,430,495.01 196,372,771.58 6,833,992.62 Harbin Runda Hongtai Medical Technology Co., Ltd. 62,036.87 50,636.87 50,036.87 25,018.44 Henan Runbaida Medical Equipment Co., Ltd. 2,797,636.40 558,658.73 9,512,011.88 475,600.59 Shanghai Anbaida Investment Management Consulting Co., Ltd. 121,426.06 116,740.12 121,426.06 113,928.56 Shanghai Xiangrun Medical Technology Co., Ltd. 75,441.58 50,749.41 1,046,981.21 78,715.68 Sichuan Runda Ruitai Biotechnology Co., Ltd. 1,012,999.99 258,620.00 225,700.00 225,700.00 Hefei Tianyuan Medical Equipment Co., Ltd. 886,339.63 63,334.61 634,215.39 18,244.24 Guangxi Liurun Medical Technology Co., Ltd. 2,747,000.00 136,270.00 72,000.00 720.00 Shanghai General Runda Medical Technology Co., Ltd. 330,252.79 49,108.00 347,400.27 13,117.26 Suzhou Runying Medical Equipment Co., Ltd. 2,137,981.73 21,379.82 772.20 772.20 Hebei Runda Kangtai Medical Technology Co., Ltd. 47,087,955.32 13,684,237.19 39,648,373.94 8,817,816.46 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 20,249,829.97 2,369,660.22 19,236,038.26 989,621.64 Yunnan Sailis Biotechnology Co., Ltd. 1,800,650.52 118,662.51 1,655,575.49 115,647.83 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2025 December 31, 2024 Project name

Book balance Bad debt provision Book balance Bad debt provision Hangzhou Runda Hongtai Medical Technology Co., Ltd. 30,129,980.61 14,824,893.30 34,939,477.46 6,668,309.63 Binzhou Runda Kangtai Medical Technology Co., Ltd. 175,869.44 35,173.89 175,869.44 8,793.47 Weiyan Medical Technology (Beijing) Co., Ltd. 208,905.05 10,445.25 5,736,176.07 142,783.08 Nanjing Zhongchen Medical Technology Co., Ltd. 4,947,048.14 985,063.41 2,928,115.41 415,099.12 Guangzhou Shiwei Technology R&D Co., Ltd. 143,430.40 33,731.10 20,824,974.16 3,560,138.74 Hangzhou Runda Shengtai Medical Technology Co., Ltd. 15,532,616.72 5,540,518.98 15,484,907.40 1,982,028.92 Zhejiang Qinggu Bioengineering Co., Ltd. 135,032.00 6,751.60 Sichuan Runda Hongwang Medical Technology Co., Ltd. 38,988.00 404.28 Xizhuo Medical Testing Laboratory (Dalian) Co., Ltd. 10,146,755.12 10,146,755.12 11,525,305.12 3,183,504.26 Sinopharm Holdings Guorun Medical Supply Chain Services (Anhui) has

231,144.22 9,199.44 2,989.00 149.45 Co., Ltd.

Shanghai Huihao Yisheng Information Technology Co., Ltd. 6,511,000.00 67,550.00

Zhejiang Provincial Medical and Health Group Hangzhou Medical Laboratory Laboratory

4,519,404.54 169,576.67

Ltd.

Shanghai Transdimensional Exosome Biomedicine Co., Ltd. 241,251.39 6,384.59

Total 258,882,031.12 67,818,179.51 367,849,744.51 38,617,363.08 Prepayments:

Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. 14,477.28 31,079.62

Sichuan Runda Ruitai Biotechnology Co., Ltd. 2,634.07

Wuhan Haijili Biotechnology Co., Ltd. 1,525,711.44

Sinopharm Holdings Guorun Medical Supply Chain Services (Anhui) has

24,634.16 250,499.89

Ltd.

Suzhou Runying Medical Equipment Co., Ltd. 1,225,929.04 1,412,478.40

Hebei Runda Kangtai Medical Technology Co., Ltd. 19,786,307.79 20,507,234.31

Henan Runbaida Medical Equipment Co., Ltd. 5,997,986.41

Shanghai Huihao Yisheng Information Technology Co., Ltd. 512,500.00 250,000.00

Hangzhou Runda Hongtai Medical Technology Co., Ltd. 755,867.90 27,284,314.12

Shanghai General Runda Medical Technology Co., Ltd. 17,372,436.00

Fujian Furui Medical Technology Co., Ltd. 0.01 5,440,000.00

Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 53,757,562.71 55,587,839.44

Total 77,602,990.33 134,136,502.26

Other receivables:

Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. 372,000.00 3,720.00 322,000.00 3,220.00 Hefei Tianyuan Medical Equipment Co., Ltd. 579,000.00 5,790.00 579,000.00 5,790.00 Hebei Runda Kangtai Medical Technology Co., Ltd. 1,020,800.00 11,040.00 1,000,000.00 10,000.00Shanghai Anbaida Investment Management Consulting Co., Ltd. 260,000.00 260,000.00 260,000.00 260,000.00Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2025 December 31, 2024 Project name

Book balance Bad debt provision Book balance Bad debt provision Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 3,126,906.71 1,492,320.00 Guangzhou Shiwei Technology R&D Co., Ltd. 11,556,823.95 2,311,364.79 Zhang Yanxue 19,348.71 19,348.71 19,348.71 19,348.71 Nanjing Zhongchen Medical Technology Co., Ltd. 153,000.00 150,150.00 150,000.00 75,000.00 Xizhuo Medical Testing Laboratory (Dalian) Co., Ltd. 666,450.00 133,290.00 Sichuan Runda Ruitai Biotechnology Co., Ltd. 51,000.00 510.00 76,300.00 1,775.00Hangzhou Gongshu State Investment Industrial Development Co., Ltd. 1,270,570.00 12,705.70 1,270,570.00 12,705.70Chen Linjun 1,181,242.59 236,248.52 1,181,242.59 59,062.13 Shanghai Lekang Technology Partnership (Limited Partnership) 3,271,133.32 163,556.67 3,271,133.32 163,556.67 Huang Liujin 39,025.68 390.26

Suzhou Runying Medical Equipment Co., Ltd. 185,000.00 9,250.00

Peng Huabing 32,640.00 1,632.00

Total 8,434,760.30 874,341.86 23,479,775.28 4,547,433.00 Long-term receivables:

Binzhou Runda Kangtai Medical Technology Co., Ltd. 55,365.11 10,633.65 54,124.22 3,761.24 Fujian Furui Medical Technology Co., Ltd. 200,000.00 156,000.00 200,000.00 119,500.00 Hebei Runda Kangtai Medical Technology Co., Ltd. 1,519,840.00 816,180.00 1,512,016.14 512,291.36 Guangxi Liurun Medical Technology Co., Ltd. 77,428.62 774.29 153,449.94 3,131.30

Total 1,852,633.73 983,587.94 1,919,590.30 638,683.90 Other receivables—dividends receivable:

Henan Runbaida Medical Equipment Co., Ltd. 1,126,647.24 1,126,647.24 1,126,647.24 1,126,647.24 Suzhou Runying Medical Equipment Co., Ltd. 17,500,000.00 175,000.00

Total 1,126,647.24 1,126,647.24 18,626,647.24 1,301,647.24 Notes receivable:

Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. 35,429,993.94 693,445.51

Total 35,429,993.94 693,445.51

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Payable items

Project name December 31, 2025 Accounts payable on December 31, 2024:

Guizhou Runda Kangyi Medical Technology Co., Ltd. 14,804,175.23 Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. 1,836,907.13 1,888,508.86 Jiangsu Yier Medical Equipment Co., Ltd. 1,147,364.00 1,947,900.00 Shanghai Anbaida Investment Management Consulting Co., Ltd. 213,543.79 66,649.81 Shanghai Xiangrun Medical Technology Co., Ltd. 169,811.32 169,811.32 Sichuan Runda Hongwang Medical Technology Co., Ltd. 26,408,819.57 38,046,225.85 Sichuan Runda Ruitai Biotechnology Co., Ltd. 6,346,425.65 13,137,556.54 Wuhan Haijili Biotechnology Co., Ltd. 1,354,647.07 Yunnan Sailis Biotechnology Co., Ltd. 48,992,398.63 16,401,121.91 Hefei Tianyuan Medical Equipment Co., Ltd. 457,204.66 444,865.03 Sinopharm Holdings Guorun Medical Supply Chain Services (Anhui) Co., Ltd. 199.11 19,424.22 Shanghai General Runda Medical Technology Co., Ltd. 55,491.71 6,035.00 Suzhou Runying Medical Equipment Co., Ltd. 96.18 96.18 Hangzhou Runda Hongtai Medical Technology Co., Ltd. 4,033,664.21 9,339,883.80 Zhejiang Qinggu Bioengineering Co., Ltd. 28,784.00 178,688.00 Weiyan Medical Technology (Beijing) Co., Ltd. 3,540.92 1,609,284.28 Nanjing Zhongchen Medical Technology Co., Ltd. 2,946,374.36 2,407,988.57 Hebei Runda Kangtai Medical Technology Co., Ltd. 332,925.75 7,969,934.52 Jiuyisanluling Medical Technology Nanjing Co., Ltd. 590,803.75 4,243,700.00 Fujian Furui Medical Technology Co., Ltd. 4,169.00 80,093.71 Beijing Weiyan Medical Equipment Co., Ltd. 834,000.00 288,000.00 Shanghai Huihao Yisheng Information Technology Co., Ltd. 1,690,314.57 2,252,212.39 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 892,507.86

Hangzhou Huihao Information Technology Co., Ltd. 1,335,472.00

Total 98,320,818.17 116,656,802.29 Advance payments:

Harbin Runda Hongtai Medical Technology Co., Ltd. 3,982.26 3,982.29 Sinopharm Holdings Guorun Medical Supply Chain Services (Anhui) Co., Ltd. 28,023.60 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 62,581.06 64,247.84 Fujian Furui Medical Technology Co., Ltd. 6,637.11 6,637.14 Zhejiang Medical and Health Group Hangzhou Medical Testing Laboratory Co., Ltd. 14,749.26

Total 87,949.69 102,890.87 Other payables:

Fujian Furui Medical Technology Co., Ltd. 560,000.00

Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 503,000.00 503,000.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Project name December 31, 2025 December 31, 2024 Henan Runbaida Medical Equipment Co., Ltd. 1,010,000.00 1,010,000.00 Shanghai Xiangrun Medical Technology Co., Ltd. 90,000.00 90,000.00 Sichuan Runda Ruitai Biotechnology Co., Ltd. 20,000.00 20,000.00 Yunnan Sailis Biotechnology Co., Ltd. 23,063,833.41 21,968,833.41 Suzhou Runying Medical Equipment Co., Ltd. 210,000.00 490,000.00 Wuhan Haijili Biotechnology Co., Ltd. 1,947,534.24 1,872,534.24 Nanjing Zhongchen Medical Technology Co., Ltd. 5,785,000.00 4,265,000.00 Huang Liujin 2,144,845.76 Shanghai General Runda Medical Technology Co., Ltd. 266,019.42

Hangzhou Huihao Information Technology Co., Ltd. 50,000.00 Tang Jinhu 8,660,036.11 Sichuan Runda Hongwang Medical Technology Co., Ltd. 30,000.00 30,000.00 Shanghai Huihao Lifespan Information Technology Co., Ltd. 592,000.00

Total 34,077,387.07 41,104,249.52 Other payables—dividends payable:

Tang Jianfeng 72,120.00 72,120.00 Yueshengda (Jinan) Investment Partnership (Limited Partnership) 3,000,000.00 3,000,000.00 Meng Fanyu 11,000,000.00 8,399,099.37 Deqing Hengyi Investment Management Partnership (Limited Partnership) 5,000,000.00 1,500,000.00

Total 19,072,120.00 12,971,219.37Contract liabilities:

Yunnan Sailis Biotechnology Co., Ltd. 12,752.21 0.02 Guizhou Runda Kangyi Medical Technology Co., Ltd. 88,495.58 88,495.58 Fujian Furui Medical Technology Co., Ltd. 4,968.34 Hefei Tianyuan Medical Equipment Co., Ltd. 885,388.20 41,073.34 Hebei Runda Kangtai Medical Technology Co., Ltd. 16,037.74

Suzhou Runying Medical Equipment Co., Ltd. 34,761.06 170,993.20 Henan Runbaida Medical Equipment Co., Ltd. 120,579.39 120,579.40 Sichuan Runda Ruitai Biotechnology Co., Ltd. 361,061.96 Zhenjiang Hanhe Medical Equipment Co., Ltd. 15,044.25 15,044.25 Nanjing Zhongchen Medical Technology Co., Ltd. 20,304.42 6,795.96 Jiangsu Yier Medical Equipment Co., Ltd. 19,572.19 58,717.04 Hangzhou Huihao Information Technology Co., Ltd. 183,962.26 183,962.26 Hangzhou Runda Hongtai Medical Technology Co., Ltd. 2,203,539.82 Shanghai Anbaida Investment Management Consulting Co., Ltd. 10,619.47

Total 1,407,516.77 3,255,231.17 Other current liabilities:

Yunnan Sailis Biotechnology Co., Ltd. 1,657.79

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Project name December 31, 2025 December 31, 2024 Guizhou Runda Kangyi Medical Technology Co., Ltd. 11,504.42 11,504.42 Fujian Furui Medical Technology Co., Ltd. 645.88 Hefei Tianyuan Medical Equipment Co., Ltd. 115,100.47 5,339.53 Hebei Runda Kangtai Medical Technology Co., Ltd. 962.26

Suzhou Runying Medical Equipment Co., Ltd. 4,518.94 22,229.11 Henan Runbaida Medical Equipment Co., Ltd. 7,420.61 7,420.60 Sichuan Runda Ruitai Biotechnology Co., Ltd. 46,938.05 Zhenjiang Hanhe Medical Equipment Co., Ltd. 1,955.75 1,955.75 Nanjing Zhongchen Medical Technology Co., Ltd. 2,639.58 824.04 Jiangsu Yier Medical Equipment Co., Ltd. 2,544.39 7,633.22 Hangzhou Runda Hongtai Medical Technology Co., Ltd. 286,460.18 Hangzhou Huihao Information Technology Co., Ltd. 11,037.74 11,037.74 Shanghai Anbaida Investment Management Consulting Co., Ltd. 1,380.53

Total 160,722.48 401,988.52

7. Related party commitments

For details of commitments resulting from related party guarantees, please refer to Note 10.5(4), Related Party Guarantees.

11. Share-based payment

There is no share-based payment in 2025.

12. Commitments and contingencies

1. Important commitments

(1) Operating lease commitment

As of the balance sheet date, the irrevocable short-term leases and low-value asset operating lease contracts signed by the Company are as follows:

Item December 31, 2025 Minimum lease payments for non-cancelable short-term leases and operating leases of low-value assets as of December 31, 2024

The first year after the balance sheet date 2,171,107.34 1,824,377.13 The second year after the balance sheet date 185,599.87 60,000.00 The third year after the balance sheet date 104,266.64 60,000.00 Years after 100,000.00

Total 2,560,973.85 1,944,377.13Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Mortgage and pledge

Project December 31, 2025

Book Value Restricted Type

Monetary funds 266,054,107.39 Pledge (Note 1)

65.00% equity of Hefei Sanli Medical Technology Co., Ltd. 109,551,180.04 pledged (Note 2)

Fixed assets 161,778,791.04 Mortgage (Note 3), sale and leaseback (Note 4) The Company’s accounts receivable 196,045,583.67 Pledge (Note 5)

Hefei Sanli Medical Technology Co., Ltd. Accounts receivable 10,187,666.45 Pledge (Note 6)

Anhui Zefen Biotechnology Co., Ltd. Accounts receivable 37,052,958.03 Pledge (Note 7)

Shanghai Runda Rongjia Biotechnology Co., Ltd. Accounts receivable 26,990,399.98 Pledge (Note 8)

Changchun Jinzerui Medical Technology Co., Ltd. Accounts receivable 7,465,527.30 Pledge (Note 9)

Total 815,126,213.90

Note 1: 1) On April 3, 2020, the company signed a comprehensive service procurement contract for the construction of the regional testing center of Shucheng County People's Hospital with Shucheng County People's Hospital, and issued a performance guarantee on April 7, 2020. The total amount of the guarantee is 2 million yuan. The beneficiary is Shucheng County People's Hospital. The guarantee is valid from April 7, 2020 to June 30, 2027.

2. On January 3, 2023, the company signed a purchase contract for the Longyan People's Hospital Regional Inspection Center with Longyan People's Hospital, and issued a performance guarantee on January 4, 2023. The total amount of the guarantee was RMB 600,000, and the beneficiary was Longyan People's Hospital. The guarantee is valid from January 4, 2023 to January 1, 2026.

3. On January 3, 2023, the company signed a purchase contract for the Longyan People's Hospital Regional Inspection Center with Longyan People's Hospital, and issued a performance guarantee on January 10, 2023. The total amount of the guarantee was 1.40 million yuan, and the beneficiary was Longyan People's Hospital. The guarantee is valid from January 10, 2023 to January 1, 2026.

4. On August 8, 2025, the company applied to the Lujiazui Branch of the Bank of Shanghai Co., Ltd. for the issuance of 3 bank acceptance bills totaling 30 million yuan. The bill issuance date is August 8, 2025, and the maturity date is February 8, 2026. The Company provided certificates of deposit worth RMB 30 million for pledge guarantee for the above notes.

5. On July 14, 2025, the company applied to the Bank of Tianjin Shanghai Branch for the issuance of 10 bank acceptance bills totaling 100 million yuan. The bill issuance date is July 14, 2025, and the maturity date is January 14, 2026. The company deposited a 30.00% margin for the above notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 30 million.

6. On July 2, 2025, the company applied to Bohai Bank Shanghai Jing'an Branch for the issuance of 7 bank acceptance bills totaling 71 million yuan. The bill issuance date is July 2, 2025, and the maturity date is January 2, 2026. The company deposited a 30.00% margin for the above-mentioned notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 21.30 million.

7. On September 4, 2025, the company applied to the Liangcheng Road Branch of Shanghai Pudong Development Bank Co., Ltd. for the issuance of 7 bank acceptance bills totaling 70 million yuan. The bill issuance date is September 4, 2025, and the maturity date is March 4, 2026. The company deposited a 30.00% margin for the above notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 21.00 million.

8. On October 15, 2025, the company applied to Bank of East Asia (China) Co., Ltd. Shanghai Branch for the issuance of 2 bank acceptance bills totaling 20 million yuan. The bill issuance date is October 15, 2025, and the maturity date is April 15, 2026. The company provided certificates of deposit worth RMB 20 million for pledge guarantee for the above notes.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

9. On December 5, 2025, the company applied to the Liangcheng Road Branch of Shanghai Pudong Development Bank Co., Ltd. for the issuance of 8 bank acceptance bills totaling 80 million yuan. The bill issuance date is December 5, 2025, and the maturity date is March 5, 2026. The company deposited a 30.00% margin for the above-mentioned notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 24.00 million.

10. On December 24, 2025, the company applied to Bohai Bank Shanghai Jing'an Branch for the issuance of a domestic letter of credit worth RMB 10,000.00. The issuance date of the letter of credit is December 24, 2025, and the expiration date is November 23, 2026. The company deposited a 30.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 30 million.

11. On December 11, 2025, the subsidiary Anhui Zefen applied to the Hefei Branch of Shanghai Pudong Development Bank Co., Ltd. for the issuance of a bank acceptance bill of 9 million yuan. The bill issuance date is December 15, 2025, and the expiry date is June 1, 2026. 5th; the above matters were guaranteed by the Company and Wang Chuangen. At the same time, Anhui Zefen deposited a 50.00% margin for the above notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was 4.50 million yuan.

12. On May 23, 2025, the subsidiary Hangzhou Runda applied for a letter of credit of RMB 10 million from the Dingqiao Branch of Hangzhou United Bank. The issuance date of the letter of credit is May 23, 2025, and the expiry date of the letter of credit is May 22, 2026. ; The above matters are guaranteed by the company, and Hangzhou Runda deposits a 10.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee is 1 million yuan.

13. On June 20, 2025, the subsidiary Hangzhou Runda applied for a letter of credit of 2.80 million yuan from Hangzhou United Bank Dingqiao Branch. The issuance date of the letter of credit is June 20, 2025, and the expiration date of the letter of credit is June 15, 2026. ; The above matters are guaranteed by the company, and Hangzhou Runda has deposited a 10.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee is 280,000 yuan.

14. On July 14, 2025, the subsidiary Hangzhou Runda applied for a letter of credit of RMB 11.5 million from the Dingqiao Branch of Hangzhou United Bank. The issuance date of the letter of credit is July 14, 2025, and the expiry date of the letter of credit is July 6, 2026. ; The above matters are guaranteed by the company, and Hangzhou Runda has deposited a 10.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee is 1.15 million yuan.

15. On August 21, 2025, the subsidiary Hangzhou Runda applied to Hangzhou United Bank Tongxie Branch for a letter of credit worth 11 million yuan. The issuance date of the letter of credit is August 21, 2025, and the expiration date of the letter of credit is July 6, 2026. ; The above matters are guaranteed by the company, and Hangzhou Runda has deposited a 10.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee is 1.10 million yuan.

16. On August 22, 2025, subsidiary Hangzhou Runda applied to the Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch for a letter of credit worth 53 million yuan. The issuance date of the letter of credit is August 22, 2025, and the expiration date of the letter of credit is February 2026. On December 16th; the Company provided guarantee for the above matters, and Hangzhou Runda deposited a 20.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 10.60 million.

17. On September 11, 2025, the subsidiary Hangzhou Runda applied to the Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch for a letter of credit worth 70 million yuan. The issuance date of the letter of credit is September 11, 2025, and the expiration date of the letter of credit is March 2026. On December 16th; the Company provided guarantee for the above matters, and Hangzhou Runda deposited a 20.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 14.00 million.

18. On September 15, 2025, the subsidiary Hangzhou Runda applied to Hangzhou United Bank Tongxie Branch for the issuance of a letter of credit worth 20 million yuan. The issuance date of the letter of credit is September 15, 2025, and the expiration date of the letter of credit is September 15, 2026. The above matters are guaranteed by the company, and Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

At the same time, Hangzhou Runda deposited a 10.00% margin for the above-mentioned letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 2 million.

19. On September 16, 2025, subsidiary Hangzhou Runda applied for a letter of credit of RMB 30 million from the Hangzhou Yan'an Road Branch of Agricultural Bank of China Co., Ltd. The issuance date of the letter of credit is September 16, 2025, and the expiration date of the letter of credit is 2026 March 19; The company provided guarantee for the above matters, and Hangzhou Runda deposited a 20.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was 6 million yuan.

20. On October 30, 2025, the subsidiary Hangzhou Runda applied for a letter of credit of RMB 20 million from the Agricultural Bank of China Co., Ltd. Hangzhou Yan'an Road Branch. The issuance date of the letter of credit is October 30, 2025, and the expiry date of the letter of credit is 2026 On April 27, 2020; the company provided guarantee for the above matters, and Hangzhou Runda deposited a 20.00% margin for the above letter of credit for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was RMB 4 million.

21. On November 20, 2025, the subsidiary Hangzhou Runda applied to the Hangzhou Branch of China Everbright Bank for the issuance of a bank acceptance bill of 38 million yuan. The bill issuance date is November 20, 2025, and the maturity date is May 20, 2026. ; The above matters are guaranteed by the company, and Hangzhou Runda has deposited a 30.00% margin for the above-mentioned notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee is 11.40 million yuan.

22. On December 1, 2025, the subsidiary Hangzhou Runda applied to the Hangzhou Branch of China Everbright Bank for the issuance of a bank acceptance bill of 33 million yuan. The bill issuance date is December 1, 2025, and the maturity date is June 1, 2026. The above matters are guaranteed by the company. At the same time, Hangzhou Runda deposited a 30.00% margin for the above notes for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee was 9.90 million yuan.

23. On March 21, 2024, the subsidiary Beijing Southeast Yueda and the Beijing Stomatological Hospital Affiliated to Capital Medical University signed a dental hospital start-up fee dental equipment and instrument procurement project contract, with a total price of 1.3925 million yuan. In 202 A bank performance guarantee was issued on June 26, 2024, with a total amount of 139,300 yuan. The beneficiary is the Beijing Stomatological Hospital Affiliated to Capital Medical University. The guarantee is valid from June 26, 2024 to March 21, 2026.

24. On July 30, 2024, the subsidiary Beijing Southeast Yueda and the Beijing Stomatological Hospital Affiliated to Capital Medical University signed a purchase project contract for oral equipment and instruments for the opening expenses of the dental hospital. The total price is 110,000 yuan. In 2024 A bank performance guarantee was issued on October 29, 2020, with a total amount of 11,000 yuan. The beneficiary is the Beijing Stomatological Hospital Affiliated to Capital Medical University. The guarantee is valid from October 29, 2024 to November 5, 2026.

25. On August 12, 2025, the subsidiary Beijing Southeast Yueda participated in the bidding negotiation for the fully automatic drug concentration analysis system of the Chinese People's Liberation Army General Hospital, and issued a bid guarantee on August 15, 2025. The guarantee deposit totaled 10,000 yuan. The beneficiary was the Chinese People's Liberation Army General Hospital. The guarantee was valid from August 15, 2025 to January 8, 2026.

26. On November 5, 2025, the subsidiary Beijing Southeast Yueda and Beijing Xiaotangshan Hospital signed a procurement contract for the 2025 Beijing Xiaotangshan Hospital medical equipment purchase project, with a total price of 850,000 yuan. A quality guarantee letter was issued on November 14, 2025, with a total amount of 85,000 yuan. The beneficiary is Beijing Xiaotangshan Hospital. The guarantee period is from November 14, 2025 to November 30, 2030.

27. The subsidiary Shanghai Huizhong Biotech provided a deposit of 38,500 yuan for the issuance of a letter of credit. The amount of the letter of credit is 656,000 yen, and the expiration date of the letter of credit is January 5, 2026. As of December 31, 2025, there is still a deposit of 38,500 yuan that has not been returned.

28. On May 20, 2025, the subsidiary Wuhan Youke Liansheng signed a medical equipment purchase and sales contract with Haikou Traditional Chinese Medicine Hospital, with a total price of 14,100 yuan, and issued a performance guarantee on May 27, 2025, with a total guarantee amount of 0.07 million yuan, the beneficiary is Haikou Traditional Chinese Medicine Hospital, and the guarantee is valid from May 20, 2025 to May 20, 2026.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

29. On September 4, 2025, the subsidiary Wuhan Youke Liansheng signed a medical equipment purchase and sales contract with Haikou Traditional Chinese Medicine Hospital, with a total price of 2,000 yuan, and issued a performance guarantee on September 17, 2025, with a total guarantee amount of 0,100 yuan. The beneficiary is Haikou Traditional Chinese Medicine Hospital, and the guarantee is valid from September 4, 2025 to September 3, 2026.

30. On January 13, 2025, the subsidiary Hangzhou Yidan signed an automated sample library purchase contract with the First Affiliated Hospital of Zhejiang University School of Medicine, with a total price of 16 million yuan. A performance guarantee was issued on March 7, 2025, with a total amount of 6.40 million yuan. The beneficiary is the First Affiliated Hospital of Zhejiang University School of Medicine. The guarantee is valid from March 7, 2025 to February 28, 2026.

31. On August 7, 2025, the subsidiary Qingdao Yixin applied to Hua Xia Bank Qingdao Branch for the issuance of a bank acceptance bill of 20 million yuan. The bank acceptance bill was issued on August 7, 2025, and the expiration date was January 30, 2026; the above The company provides a guarantee for the matter, and Qingdao Yixin deposits a 50.00% margin for the above-mentioned bank acceptance bill for pledge guarantee. As of December 31, 2025, the balance of the deposit for pledge guarantee is RMB 10 million.

32. On October 23, 2023, the subsidiary Ruimei Computer signed a purchase and sale contract with Yidu Cloud (Beijing) Technology Co., Ltd., and issued a performance guarantee on January 24, 2024. The total amount of the guarantee was 54,700 yuan, and the beneficiary was Yidu Cloud (Beijing) Technology Co., Ltd., and the guarantee was valid from January 16, 2024 to January 16, 2026.

33. On November 12, 2025, the subsidiary Ruimei Computer and the Jiangxi Branch of China Unicom Digital Technology Co., Ltd. signed a procurement contract for the Yingtan City Compact Medical Community Information Construction Project (Smart Hospital Core System Construction), and on 20 A performance guarantee was issued on December 26, 2025, with a total amount of 207,000 yuan. The beneficiary is the Jiangxi Branch of China Unicom Digital Technology Co., Ltd. The guarantee is valid from December 2, 2025 to December 2, 2028.

Note 2: On August 30, 2021, subsidiary Hangzhou Runda borrowed RMB 87 million from Shanghai Pudong Development Bank Hangzhou Jianguo Branch. The loan period is from August 31, 2021 to August 29, 2028. On April 14, 2022, subsidiary Hangzhou Runda borrowed 6 million yuan from Hangzhou Jianguo Branch of Shanghai Pudong Development Bank. The loan period is from April 14, 2022 to August 29, 2028. On August 17, 2022, the subsidiary Hangzhou Runda borrowed 3 million yuan from Hangzhou Jianguo Branch of Shanghai Pudong Development Bank. The loan period is from August 17, 2022 to August 29, 2028. The three loans are guaranteed by the company with the maximum amount, and at the same time, 65.00% of the equity of Hefei Sanli held by its subsidiary Hangzhou Runda is pledged as a guarantee. As of December 31, 2025, the principal balance of the three loans was 61.2472 million yuan.

Note 3: On November 28, 2024, the subsidiary Chongqing Runda signed a loan agreement with a maximum amount of 1.85 million yuan with the Chongqing Branch of Industrial Bank Co., Ltd., and the loan period is from November 28, 2024 to November 27, 2039. Huang Liujin and Zhang Min provided unlimited joint and several liability guarantees, and Chongqing Runda provided mortgage guarantees with the properties they held. As of December 31, 2025, a total of 1.85 million yuan in loans had been issued. The principal balance of the loan was 1.7171 million yuan. The book value of the collateral held by Chongqing Runda in fixed assets was 2.5453 million yuan.

Note 4: For details, please refer to Note 10.5(5), Financial Lease Guarantee.

Note 5: 1) On October 10, 2024, the company signed an accounts receivable factoring agreement (domestic factoring with recourse) with the Hongkou Branch of Shanghai Pudong Development Bank Co., Ltd. The factoring period is from January 1, 2024 to December 31, 2029. The company provides pledge guarantees for the accounts receivable of Inner Mongolia Baogang Hospital, Taizhou Second People's Hospital, Fudan University Zhongshan Hospital, Shanghai Putuo District Liqun Hospital, Shanghai First People's Hospital and Shanghai Sixth People's Hospital. As of December 31, 2025, the balance of accounts receivable in this part was 28.4192 million yuan.

2. On December 11, 2024, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd., with a factoring financing limit of 30 million yuan. The company provides pledge guarantee for the accounts receivable of Yingshang County People's Hospital and Wenchang People's Hospital (Wenchang People's Hospital Medical Community General Hospital). As of December 31, 2025, the balance of accounts receivable in this part was 9.1658 million yuan.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. On August 20, 2025, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd., with a factoring financing limit of 34 million yuan. The company provides pledge guarantee for the accounts receivable of Yingshang County People's Hospital, Haining People's Hospital, and Wenchang People's Hospital (Wenchang People's Hospital Medical Community General Hospital). As of December 31, 2025, the balance of accounts receivable in this part was 14.1219 million yuan.

4. On November 25, 2025, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd., with a factoring financing limit of RMB 48.80 million. The company provides pledge guarantee for the accounts receivable of Yingshang County People's Hospital, Pengzhou People's Hospital, Longyan People's Hospital, Qingdao Public Health Clinical Center, Haining People's Hospital, Wenchang People's Hospital (Wenchang People's Hospital Medical Community General Hospital). As of December 31, 2025, the balance of accounts receivable in this part was 39.9052 million yuan.

5. On December 28, 2024, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Ping An International Commercial Factoring (Tianjin) Co., Ltd., with a factoring financing limit of 65.5 million yuan. The company provides pledge guarantees for the accounts receivable of Chengfei Hospital, Hefei Second People's Hospital, Changxing County People's Hospital, Mianyang Third People's Hospital, Wuhan Wuchang Hospital, Haikou Traditional Chinese Medicine Hospital, Bahrain Right Banner Hospital, Bayannur City Linhe District Maternal and Child Health Hospital, and Horqin Right Front Banner People's Hospital. As of December 31, 2025, the balance of accounts receivable in this part was 14.129 million yuan.

6. On July 11, 2025, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Ping An International Commercial Factoring (Tianjin) Co., Ltd., with a factoring financing limit of RMB 60 million. The company provides pledge guarantee for the accounts receivable of Chengfei Hospital, Jieshou People's Hospital and Jingdezhen First People's Hospital. As of December 31, 2025, the balance of accounts receivable in this part was 29.1606 million yuan.

7. On September 12, 2025, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Ping An International Commercial Factoring (Tianjin) Co., Ltd., with a factoring financing limit of RMB 76 million. The company provides pledge guarantees for the accounts receivable of Fuyang Hospital Affiliated to Anhui Medical University, Hefei Second People's Hospital, Jieshou People's Hospital, Lianyungang First People's Hospital, Wuhan Wuchang Hospital, Horqin Right Front Banner People's Hospital, Yancheng Dafeng Traditional Chinese Medicine Hospital (Yancheng Dafeng District Geriatric Hospital), Anhui Medical University First Affiliated Hospital, Jingdezhen First People's Hospital, and Hengshui People's Hospital. As of December 31, 2025, the balance of this part of accounts receivable was 35.7887 million yuan.

8. On September 14, 2023, the company signed an accounts receivable factoring contract (domestic factoring with recourse) with Siemens Commercial Factoring Co., Ltd., with a factoring financing limit of 38.0258 million yuan. The company provides pledge guarantee for the accounts receivable of Longyan People's Hospital and Fuyang Hospital Affiliated to Anhui Medical University. As of December 31, 2025, the balance of accounts receivable in this part was 25.3552 million yuan.

Note 6: 1) On October 14, 2025, subsidiary Hefei Sanli signed an accounts receivable factoring contract (domestic factoring with recourse) with Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd., with a total contract amount of 3.94 million yuan. The loan was guaranteed by Hou Zhong, Gong Yuying and Tang Yong. At the same time, Hefei Sanli provides pledge guarantees with the accounts receivable of the First Affiliated Hospital of Bengbu Medical College, Lu'an Traditional Chinese Medicine Hospital, Yijishan Hospital of Wannan Medical College, Huangshan People's Hospital, and the Second Affiliated Hospital of Anhui Medical University. As of December 31, 2025, the balance of accounts receivable in this part was 4.9274 million yuan.

2. On October 9, 2024, subsidiary Hefei Sanli signed an accounts receivable factoring contract (with recourse) with Ping An International Commercial Factoring (Tianjin) Co., Ltd., with a factoring financing limit of 12 million yuan. The loan was guaranteed by Hou Zhong, Gong Yuying and Tang Yong. At the same time, Hefei Sanli provided pledge guarantees for its accounts receivable from the First Affiliated Hospital of Bengbu Medical College, Anhui Lujiang County People's Hospital, Huangshan People's Hospital, and the Second Affiliated Hospital of Anhui Medical University. As of December 31, 2025, the balance of accounts receivable in this part was 5.2602 million yuan.

Note 7: 1) From August 2025 to December 2025, subsidiary Anhui Zefen signed an accounts receivable factoring contract (domestic factoring with recourse) with Sinopharm Ronghui (Shanghai) Commercial Factoring Co., Ltd., with a total contract amount of 20.093 million yuan. Anhui Zefen relies on its management of Anhui Provincial Hospital (including the South District), the First Affiliated Hospital of Anhui Medical University (including the high-tech campus), the Second Affiliated Hospital of Anhui Medical University, the First Affiliated Hospital of Bengbu Medical College, Yijishan Hospital of Southern Anhui Medical College, Chizhou Second People's Hospital, Sinopharm Anhui Medical Equipment Co., Ltd., Huangshan People's Hospital, and Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Guangde Traditional Chinese Medicine Hospital, Anhui Lujiang County People's Hospital, and Wuhu Jiuzhoutong Pharmaceutical Sales Co., Ltd. provide pledge guarantees for their accounts receivable. As of December 31, 2025, the balance of this part of accounts receivable was 25.053 million yuan.

2. On October 9, 2024, subsidiary Anhui Zefen signed an accounts receivable factoring contract (with recourse) with Ping An International Commercial Factoring (Tianjin) Co., Ltd., with a factoring financing limit of 12 million yuan. Anhui Zefen provides pledge guarantee for the accounts receivable of the First Affiliated Hospital of Anhui Medical University (including the High-tech Campus) and the Second Affiliated Hospital of Anhui Medical University. As of December 31, 2025, the balance of this part of accounts receivable was RMB 12 million.

Note 8: On May 30, 2025, subsidiary Runda Rongjia signed a maximum credit agreement with the Shanghai Songjiang Branch of Zhejiang Mintai Commercial Bank Co., Ltd., with a total credit amount of 30 million yuan, and the credit period is from May 28, 2025 to December 20, 2026. Subsidiary Runda Rongjia provides the highest amount of pledge guarantee with its accounts receivable and deposit of 10.00% for Tianjin Medical University General Hospital, Hefu (China) Medical Technology Co., Ltd. and Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. Qian Xueqing provides the highest joint liability guarantee. As of December 31, 2025, the balance of accounts receivable in this part was 26.9904 million yuan, and the balance of the deposit used for pledge guarantee was 2.8779 million yuan.

Note 9: 1) On December 15, 2025, the subsidiary Changchun Jinzerui signed an accounts receivable factoring business contract (domestic factoring with recourse) with the Industrial and Commercial Bank of China Huludao Lianshan Branch, with a factoring financing limit of 6.3358 million yuan. Changchun Jinzerui provided pledge guarantee for its accounts receivable from Huludao Central Hospital. As of December 31, 2025, the balance of accounts receivable in this part was 6.3358 million yuan.

2. On December 3, 2025, the subsidiary Changchun Jinzerui signed an accounts receivable factoring contract (factoring with recourse) with the Jixi Branch of China Construction Bank Corporation, with a factoring financing limit of 578,800 yuan. Changchun Jinzerui provided pledge guarantee for its accounts receivable from Jixi People's Hospital. As of December 31, 2025, the balance of this part of accounts receivable was 578,800 yuan.

3. On December 23, 2025, the subsidiary Changchun Jinzerui signed an accounts receivable factoring contract (factoring with recourse) with the Daqing Branch of China Minsheng Banking Corporation, with a factoring financing limit of 551,000 yuan. Changchun Jinzerui provided pledge guarantee for its accounts receivable from Daqing Oilfield General Hospital. As of December 31, 2025, the balance of accounts receivable in this part was 551,000 yuan.

(3) Unconfirmed commitments related to joint venture investments:

None in 2025.

(4) The company’s commitment to the industrial investment fund priority fund partners and their managers:

None in 2025.

(5) Other commitments:

As of December 31, 2025, the Company has no other major commitments that need to be disclosed.

2. Contingencies

The Company has no important contingencies that need to be disclosed.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

13. Events after the balance sheet date

As of the date when the financial report is approved for issuance, the Company has no other major post-balance sheet events that should be disclosed but have not been disclosed.

14. Other important matters

As of December 31, 2025, the company has no other important matters.

15. Notes on main items of the parent company’s financial statements

1. Accounts receivable

(1) Accounts receivable are disclosed based on aging:

Aging December 31, 2025 Within 1 year on December 31, 2024

Including: Within the credit period 394,362,466.20 438,916,950.19

Credit period expires within 1 year 227,017,973.25 411,379,298.50 Subtotal within 1 year 621,380,439.45 850,296,248.69 1 to 2 years 298,794,316.95 221,978,479.68 2 to 3 years 145,440,431.20 81,527,875.30 More than 3 years 99,704,133.39 68,515,670.57

Subtotal 1,165,319,320.99 1,222,318,274.24 Less: Bad debt provision 161,515,652.41 116,313,109.23 Total 1,003,803,668.58 1,106,005,165.01

(2) Accounts receivable are classified and disclosed according to the bad debt accrual method:

December 31, 2025

Book balance Bad debt provision

Category

Provision ratio Book value amount Ratio (%) Amount

(%)

Receivables with provision for bad debts based on individual items

Accounts

Among them:

The individual amount is significant and has been separately accrued

Provision for bad debts

The individual amounts are not significant and have been calculated separately

Provision for bad debts

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2025

Book balance Bad debt provision

Category

Provision ratio Book value amount Ratio (%) Amount

(%)

Receivables with provision for bad debts on a group basis

1,165,319,320.99 100.00 161,515,652.41 13.86 1,003,803,668.58 Accounts

Among them:

Credit period and aging combination 925,848,365.55 79.45 161,515,652.41 17.45 764,332,713.14 Related party combination (within the scope of consolidation) 239,470,955.44 20.55 239,470,955.44 Total 1,165,319,320.99 161,515,652.41 1,003,803,668.58

December 31, 2024

Book balance Bad debt provision

Category

Provision ratio Book value amount Ratio (%) Amount

(%)

Receivables with provision for bad debts based on individual items

Accounts

Among them:

The individual amount is significant and has been separately accrued

Provision for bad debts

The individual amounts are not significant and have been calculated separately

Provision for bad debts

Receivables with provision for bad debts on a group basis

1,222,318,274.24 100.00 116,313,109.23 9.52 1,106,005,165.01 Account

Among them:

Credit period and aging combination 945,117,994.95 77.32 116,313,109.23 12.31 828,804,885.72 Related party combination (within the scope of consolidation) 277,200,279.29 22.68 277,200,279.29 Total 1,222,318,274.24 116,313,109.23 1,106,005,165.01

1. Accounts receivable for which bad debt provisions are made based on credit period and aging combination:

December 31, 2025

Aging

Book balance of accounts receivable Bad debt provision Provision ratio (%) Within the credit period 393,503,866.20 3,935,038.66 1.00 The credit period expires to 1 year (including 1 year) 126,220,798.67 6,311,039.93 5.00 1 to 2 years (including 2 years) 264,232,313.33 52,846,462.67 20.00 2 to 3 years (including 3 years) 86,936,552.40 43,468,276.20 50.00 More than 3 years 54,954,834.95 54,954,834.95 100.00

Total 925,848,365.55 161,515,652.41

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2024

Aging

Book balance of accounts receivable Bad debt provision Provision ratio (%) Within the credit period 438,246,570.19 4,382,465.70 1.00 The credit period expires to 1 year (including 1 year) 262,183,856.25 13,109,192.81 5.00 1 to 2 years (including 2 years) 144,161,707.27 28,832,341.45 20.00 2 to 3 years (including 3 years) 61,073,503.94 30,536,751.97 50.00 More than 3 years 39,452,357.30 39,452,357.30 100.00Total 945,117,994.95 116,313,109.23

(3) Bad debt provisions for accounts receivable accrued, recovered or reversed in the current period:

Amount of changes in the current period

Category: Write-off on December 31, 2024 or Provision on December 31, 2025, Recovery or transfer Other

Write off

Accounts receivable

116,313,109.23 45,202,543.18 161,515,652.41 Bad debt provision

Total 116,313,109.23 45,202,543.18 161,515,652.41

(4) The top five accounts receivable at the end of the period based on debtors:

December 31, 2025

Unit name

Closing balance Proportion of total accounts receivable (%) Bad debt provision closing balance No. 1 80,113,954.76 6.87 14,076,599.47 No. 2 63,438,831.32 5.44

Third place 52,013,291.64 4.46 18,965,267.29 Fourth place 48,507,885.84 4.16 5,183,544.69 Fifth place 44,704,398.18 3.84 6,675,546.60

Total 288,778,361.74 24.77 44,900,958.05Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

2. Other receivables

(1) Classification of other receivables:

Project December 31, 2025 December 31, 2024

interest receivable

Dividends receivable 70,729,825.68 55,429,825.68 Other receivables 308,562,447.34 315,835,460.76

Subtotal 379,292,273.02 371,265,286.44 Less: Bad debt provision 18,886,317.47 15,654,200.32 Total 360,405,955.55 355,611,086.12

(2) Interest receivable

As of December 31, 2025, there is no interest receivable.

(3) Dividends receivable

1. Dividends receivable:

Project (or invested unit) December 31, 2025 December 31, 2024 Henan Runbaida Medical Equipment Co., Ltd. 1,126,647.24 1,126,647.24 Jinan Runda Biotechnology Co., Ltd. 7,000,000.00 7,000,000.00 Wuhan Youkeliansheng Technology and Trade Co., Ltd. 15,300,000.00

Shanghai Ruimei Computer Technology Co., Ltd. 43,272,000.00 43,272,000.00 Runlan (Shanghai) Biotechnology Co., Ltd. 4,031,178.44 4,031,178.44

Subtotal 70,729,825.68 55,429,825.68 Less: Bad debt provision 1,126,647.24 1,126,647.24 Total 69,603,178.44 54,303,178.44

2. Important dividends receivable aged more than 1 year:

Project (or investee) December 31, 2025 Aging Bad debt provision amount Shanghai Ruimei Computer Technology Co., Ltd. 43,272,000.00 More than 3 years

Jinan Runda Biotechnology Co., Ltd. 7,000,000.00 More than 3 years

Henan Runbaida Medical Equipment Co., Ltd. 1,126,647.24 More than 3 years 1,126,647.24

Total 51,398,647.24 1,126,647.24Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. Provision for bad debts is made in accordance with the general model of credit losses:

The first stage The second stage The third stage

Lifetime expectations Lifetime expectations

Provision for bad debts Estimated total credit losses (unincurred) in the next 12 months Credit losses (incurred

period credit loss

credit impairment) credit impairment)

Balance on December 31, 2024 1,126,647.24 1,126,647.24 Balance on December 31, 2024

This issue

--Transfer to the second stage

--Transfer to the third stage

--Return to the second stage

--Return to the first stage

Provision for this period

Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance as of December 31, 2025 1,126,647.24 1,126,647.24

4. Bad debt provisions accrued, recovered or reversed in the current period:

Amount of changes in the current period

Category: Recovery or resale on December 31, 2024 or Provision on December 31, 2025 Other

transfer write-off

Dividends receivable 1,126,647.24 1,126,647.24 Total 1,126,647.24 1,126,647.24

(4) Other receivables

1. Classification of other receivables according to nature of payment:

Nature of funds December 31, 2025 Loans and current accounts on December 31, 2024 281,320,069.76 289,911,405.16 Deposits and guarantees 27,054,284.95 25,724,541.76 Reserve funds 177,663.04 Advance payment of 193,000.00 10,429.59 6,513.84

Subtotal 308,562,447.34 315,835,460.76 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Nature of payment December 31, 2025 December 31, 2024 Less: bad debt provision 17,759,670.23 14,527,553.08 Total 290,802,777.11 301,307,907.68

2. Provision for bad debt provisions for other receivables:

The first stage The second stage The third stage

Lifetime expectations letter Lifetime forecast letter

Provision for bad debts Expected total losses in the next 12 months (no credit losses have occurred (credit losses have occurred)

credit loss

Use impairment) Use impairment)

Balance on December 31, 2024 188,740.56 871,541.54 13,467,270.98 14,527,553.08 Balance on December 31, 2024

This issue

--Transfer to the second stage

--Transfer to the third stage -472,370.00 472,370.00

--Return to the second stage

--Return to the first stage

Provision in this period 14,183.22 -298,530.07 3,516,464.00 3,232,117.15 Transferred in this period

Sales in this period

Write-off in this period

Other changes

Balance on December 31, 2025 202,923.78 100,641.47 17,456,104.98 17,759,670.23

3. Disclosure of other receivables based on aging:

Aging December 31, 2025 December 31, 2024

Within 1 year 70,730,362.69 123,980,339.55 1 to 2 years 54,289,873.61 148,518,613.79 2 to 3 years 148,009,812.97 11,896,654.68 More than 3 years 35,532,398.07 31,439,852.74

Subtotal 308,562,447.34 315,835,460.76 Less: bad debt provision 17,759,670.23 14,527,553.08

Total 290,802,777.11 301,307,907.68 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

4. Bad debt provisions for other receivables accrued, recovered or reversed in the current period:

Amount of changes in the current period

Category Recovery on December 31, 2024 or Provision on December 31, 2025 Write-off or write-off

turn back to him

Other receivables 14,527,553.08 3,232,117.15 17,759,670.23 Total 14,527,553.08 3,232,117.15 17,759,670.23

5. Other receivables with the top five closing balances based on debtors:

Accounting for the closing balance of other receivables Name of the unit during the bad debt provision period Nature of the payment December 31, 2025 Aging

Proportion of the total amount (%) The final balance of Hangzhou Huizhong Diagnostic Technology is 1-2 years, 2-3 years,

Loans and current accounts 128,385,359.03 41.61 Co., Ltd. More than 3 years

Jinan Runda Biotechnology has within 1 year, 1-2

Loans and current accounts 63,801,321.63 20.68 Co., Ltd. Years, more than 3 years

Hangzhou Runda Medical Management Co., Ltd.

Loans and current accounts 13,884,522.00 2-3 years 4.50 Co., Ltd.

Within 1 year, 1-2

Taizhou Second People's Hospital Loans and current accounts 10,221,600.00 3.31 3,827,940.00

Years, 2-3 years

Shanghai Runda Rongjia Biotechnology Loans and current payments, deposits within 1 year, 1-2

10,210,000.00 3.31 Technology Co., Ltd. and deposit year, more than 3 years

Total 226,502,802.66 73.41 3,827,940.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

3. Long-term equity investment

December 31, 2025 December 31, 2024

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Investment in subsidiaries 3,640,221,538.20 50,327,394.03 3,589,894,144.17 3,649,821,538.20 3,649,821,538.20 Investment in associates and joint ventures 1,200,154,692.67 1,200,154,692.67 1,197,776,720.66 1,197,776,720.66Total 4,840,376,230.87 50,327,394.03 4,790,048,836.84 4,847,598,258.86 4,847,598,258.86

(1) Investment in subsidiaries:

December 31, 2024 Impairment provision Impairment accrued in the current period December 31, 2025 Impairment provision period Investee Additional investment Decrease investment

Day (book value) Opening balance Provision Day (book value) Closing balance Shanghai Runda Industrial Development Co., Ltd. 8,600,000.00 8,600,000.00 Hangzhou Huizhong Diagnostic Technology Co., Ltd. 166,676,344.36 166,676,344.36 Shanghai Rui Rui Information Technology Co., Ltd. 350,000.00 350,000.00 Beijing Southeast Yueda Medical Equipment Co., Ltd. 313,260,000.00 313,260,000.00 Runlan (Shanghai) Biotechnology Co., Ltd. 3,938,759.64 3,938,759.64 Shanghai Runhao Medical Technology Co., Ltd. 10,000.00 10,000.00 Shanghai Kangxia Medical Technology Co., Ltd. 360,000.00 360,000.00 Shanghai Runda Rongjia Biotechnology Co., Ltd. 10,200,000.00 10,200,000.00 Harbin Runda Kangtai Biotechnology Co., Ltd. 222,000,000.00 222,000,000.00 Changchun Jinzerui Medical Technology Co., Ltd. 860,484,400.00 860,484,400.00 Heilongjiang Runda Taixin Biotechnology Co., Ltd. 5,100,000.00 5,100,000.00 Suzhou Runda Huichang Biotechnology Co., Ltd. 1,530,000.00 1,530,000.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2024 Impairment provision Impairment accrued in the current period December 31, 2025 Impairment provision period Investee Additional investment Decrease investment

Day (book value) Opening balance Provision Day (book value) Closing balance Nanjing Runda Qianghan Medical Technology Co., Ltd. (Note 1) 10,000,000.00 10,000,000.00

Qingdao Yixin Medical Technology Co., Ltd. 102,990,735.17 102,990,735.17 Jinan Runda Biotechnology Co., Ltd. 51,275,000.00 51,275,000.00 Shandong Xinhai Runbang Medical Supplies Distribution Co., Ltd. 260,000,000.00 260,000,000.00 Hangzhou Yidan Biotechnology Co., Ltd. 291,840,000.00 291,840,000.00 Hangzhou Runda Medical Management Co., Ltd. 500,000,000.00 500,000,000.00 Zhejiang Runhui Diagnostic Technology Co., Ltd. (Note 2)

Hefei Runda Wantong Medical Technology Co., Ltd. 63,340,000.00 63,340,000.00 Shanghai Zhongke Runda Precision Medical Testing Co., Ltd. 28,000,000.00 28,000,000.00 Shanghai Ruimei Computer Technology Co., Ltd. 137,235,009.48 137,235,009.48 Yunnan Runda Kangtai Medical Technology Co., Ltd. 28,754,423.17 28,754,423.17 Wuhan Runda Shangqian Medical Technology Co., Ltd. 250,827,650.04 50,327,394.03 200,500,256.01 50,327,394.03 Wuhan Youkeliansheng Technology and Trade Co., Ltd. 165,600,000.00 165,600,000.00 Guangdong Runda Medical Diagnostic Technology Co., Ltd. 26,210,001.00 26,210,001.00 Chongqing Runda Kangtai Medical Equipment Co., Ltd. 6,078,510.27 6,078,510.27 1077801B.C.LTD 118,705,705.07 118,705,705.07 Hainan Runda Medical Technology Co., Ltd.

Runda Medical Supply Chain Management (Hangzhou) Co., Ltd. 4,000,000.00 4,000,000.00 Zhejiang Zhongdingdako Biotechnology Co., Ltd. 5,000,000.00 5,000,000.00 Hangzhou Mingheyuan Medical Technology Co., Ltd. 500,000.00 500,000.00 Anhui Zefen Biotechnology Co., Ltd. 455,000.00 455,000.00 Zhejiang Hangrun Private Equity Fund Management Co., Ltd. 6,500,000.00 6,500,000.00 Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

December 31, 2024 Impairment provision Impairment accrued in the current period December 31, 2025 Impairment provision period Investee Additional investment Decrease investment

Day (book value) Opening balance Provision Day (book value) Closing balance Hangzhou Runda Jiafu Medical Technology Co., Ltd.

Fuyang Runda Medical Technology Co., Ltd. (Note 3) 400,000.00 400,000.00 Hangzhou Runyi Smart Technology Co., Ltd. (Note 4) 500,000.00 500,000.00 Total 3,649,821,538.20 900,000.00 10,500,000.00 50,327,394.03 3,589,894,144.17 50,327,394.03 Note 1: In 2025, the company will cancel Nanjing Runda Qianghan Medical Technology Co., Ltd.

Note 2: In 2025, the company will cancel Zhejiang Runhui Diagnostic Technology Co., Ltd.

Note 3: In 2025, the company invested RMB 400,000 in Fuyang Runda Medical Technology Co., Ltd. and incorporated it into the company's consolidation scope.

Note 4: In 2025, the company will cancel Hangzhou Runyi Smart Technology Co., Ltd.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

(2) Investment in associates and joint ventures:

Increases and decreases in the current period

Impairment as of December 31, 2024 Other comprehensive provision December 31, 2025 Investment unit Other equity recognized under the equity method Announcement of cash distribution Its balance at the end of the provision period Additional investment Decrease in investment Combined income Impairment Daily balance Investment gains and losses Changes in dividends or profits Other balance

Adjustment Preparation

1. Joint ventures

Subtotal

2. Joint ventures

Sinopharm Holding Runda Medical Equipment

461,993,084.84 78,075,018.60 24,896,324.00 515,171,779.44 Development (Shanghai) Co., Ltd.

Yunnan Sailis Biotechnology Co., Ltd.

125,238,462.33 4,508,706.28 129,747,168.61 Co., Ltd.

Shanghai Runda Shenghu Investment Management

21,829,737.65 -19,793,977.93 2,035,759.72 Center (limited partnership)

Shanghai Runqi Investment Management Center

9,868,551.06 300,000.00 -9,018,571.01 549,980.05 (limited partnership)

Shanghai Runhu Investment Management Center

19,463,561.07 -19,463,561.07

(limited partnership)

Shanghai Runbo Investment Management Center

40,677,920.09 -13,466,624.90 27,211,295.19 (limited partnership)

Wuhu Runjie Investment Management Center

63,289,232.92 -276,108.00 63,013,124.92 (limited partnership)

Fujian Furui Medical Technology Co., Ltd.

29,513,031.05 -2,611,931.47 26,901,099.58 Co., Ltd.

Guangxi Liurun Medical Technology Co., Ltd.

72,165,681.14 2,160,081.37 74,325,762.51 Company

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Increases and decreases in the current period

Impairment as of December 31, 2024 Other comprehensive provision December 31, 2025 Investment unit Other equity recognized under the equity method Announcement of cash distribution Its balance at the end of the provision period Additional investment Decrease in investment Combined income Impairment Daily balance Investment gains and losses Changes in dividends or profits Other balance

Adjustment Preparation

Sichuan Runda Hongwang Medical Technology

4,004,812.19 3,651.09 4,008,463.28 Co., Ltd.

Guizhou Runda Kangyi Medical Technology

5,402,176.32 191,815.39 5,593,991.71 Co., Ltd.

Sichuan Runda Ruitai Biotechnology

62,647,135.37 1,804,754.96 64,451,890.33 Co., Ltd.

Henan Runbaida Medical Equipment Co., Ltd.

10,665,004.86 20,846.89 10,685,851.75 Co., Ltd.

Hefei Tianyuan Medical Equipment Co., Ltd.

4,593,728.67 119,196.36 1,309.77 137,200.00 4,577,034.80 Co., Ltd.

Hebei Runda Kangtai Medical Technology

6,811,086.38 443,523.06 7,254,609.44 Co., Ltd.

Runda Rongmai (Hangzhou) Medical

4,555,473.13 -28,437.13 4,527,036.00 Technology Co., Ltd.

Shanghai GM Runda Medical Technology

36,826,182.71 -5,265,826.62 31,560,356.09 Co., Ltd.

Hangzhou Xinxiaomei Health Technology Co., Ltd.

1,250,020.83 -922,260.67 327,760.16 Co., Ltd.

Anhui Runkang Lianchuang Biotechnology

17,480,342.91 -864,864.04 16,615,478.87 Limited liability company

Hangzhou Runshi Equity Investment Partnership

199,501,495.14 -2,057,540.45 197,443,954.69 Enterprise (limited partnership)

Hangzhou Runda Hongtai Medical Technology

Ltd.

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Increases and decreases in the current period

Impairment as of December 31, 2024 Other comprehensive provision December 31, 2025 Investment unit Other equity recognized under the equity method Announcement of cash distribution Its balance at the end of the provision period Additional investment Decrease in investment Combined income Impairment Daily balance Investment gains and losses Changes in dividends or profits Other balance

Adjustment Preparation

Fuzhou new investment leads Kairuikang to start a business

Investment fund partnership (12,062,498.07 -63,647.01 11,998,851.06 limited partnership)

Guangzhou Xiangxue Smart Traditional Chinese Medicine Co., Ltd.

1,960,000.00 -427,437.16 1,532,562.84Company

Beijing Xiangyue Huibai Medical Technology

666,667.00 -45,785.37 620,881.63 Co., Ltd.

Total 1,197,776,720.66 14,689,165.07 300,000.00 13,021,021.17 1,309.77 25,033,524.00 1,200,154,692.67Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

4. Operating income and operating costs

2025 2024

Project

Revenue Cost Revenue Cost Main business 1,428,922,916.98 1,328,450,806.97 1,711,577,375.04 1,529,093,987.19 Other businesses

Total 1,428,922,916.98 1,328,450,806.97 1,711,577,375.04 1,529,093,987.19

5. Investment income

Project 2025 2024

Dividend income from long-term equity investments in subsidiaries 181,973,370.69 139,153,598.43 Income from long-term equity investments accounted for by the equity method 13,021,021.17 93,782,948.34 Investment income from disposal of long-term equity investments -8,356,653.15 461,863.24 Income from entrusted loans or financial management 1,334,889.94 2,502,249.06

Total 187,972,628.65 235,900,659.07

16. Supplementary information

1. Detailed statement of non-recurring gains and losses

Item 2025 Profit and loss from disposal of non-current assets in 2024, including the write-off part of the provision for asset impairment -451,972.67 7,377,738.88 Ultra-viral approval or no formal approval document, or occasional tax refund or reduction

Government subsidies included in the current profit and loss, but closely related to the company's normal business operations and in compliance with national regulations,

27,988,819.84 26,834,113.26 Except for government subsidies that are enjoyed according to determined standards and have a lasting impact on the company’s profits and losses.

In addition to the effective hedging business related to the company's normal operating business, it holds trading financial assets,

Gains and losses from changes in fair value of trading financial liabilities, as well as investment income from the disposal of trading financial assets, trading financial liabilities and available-for-sale financial assets

Fund occupation fees charged to non-financial enterprises included in current profits and losses

Gains and losses from entrusting others to invest or manage assets

Profit and loss from external entrusted loans

Provisions for impairment of various assets due to force majeure factors, such as natural disasters

In addition to the effective hedging business related to the company's normal operating business, it holds trading financial assets,

Gains and losses from changes in fair value of derivative financial assets, trading financial liabilities, and derivative financial liabilities,

and the disposal of trading financial assets, derivative financial assets, trading financial liabilities, and derivative financial liabilities.

and investment income from other bond investments

Reversal of impairment provision for accounts receivable that has been individually tested for impairment

Profit and loss from external entrusted loans

The investment cost of an enterprise in acquiring subsidiaries, associated enterprises and joint ventures is less than the amount of the investment it should enjoy when acquiring the investment.

2,944.80 Income generated from the fair value of the identifiable net assets of the investment unit

Shanghai Runda Medical Technology Co., Ltd.

Notes to the 2025 Financial Statements

(Unless otherwise specified, the unit of amount is RMB)

Item 2025: Current net profit and loss from the beginning of the period to the date of merger of subsidiaries resulting from business mergers under common control in 2024

Gains and losses on non-monetary asset exchanges

Debt restructuring gains and losses

One-time expenses incurred by the enterprise due to the cessation of relevant business activities, such as expenses for relocating employees, etc.

One-time impact on current profit and loss due to tax, accounting and other legal adjustments

One-time confirmation of share support expenses due to cancellation or modification of equity incentive plan

For cash-settled share-based payment, the change in fair value of employee compensation payable after the vesting date

Profit and loss incurred

Gains and losses arising from changes in the fair value of investment properties that are subsequently measured using the fair value model

Gains from transactions where the transaction price appears to be unfair

Profit and loss arising from contingencies unrelated to the company's normal business operations

Custody fee income from entrusted operations

Other non-operating income and expenses other than the above items -7,123,067.69 -3,603,849.79 Other profit and loss items that meet the definition of non-recurring gains and losses

Subtotal 22,230,313.70 31,050,528.92 Less: Impact on income tax -251,158.57 387,947.42 Amount of impact on minority shareholders’ profits and losses for the current period (after tax) 5,052,902.15 6,838,472.83

Total 17,428,570.12 23,824,108.67 Note: The number “+” in non-recurring profit and loss items represents income and income, and “-” represents loss or expense.

2. Return on equity and earnings per share

Weighted average net assets Earnings per share

Profit for the 2025 reporting period

Yield (%) Basic earnings per share (yuan/share) Diluted earnings per share (yuan/share) Net profit attributable to the company’s ordinary shareholders -13.48 -0.91 -0.91 After deducting non-recurring gains and losses, net profit attributable to the company’s ordinary shareholders

-13.91 -0.94 -0.94 net profit for shareholders